DDI-MedLine.d190.s1	To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).
adeno-associated virus-2	drug_n	145-168	AAV2	drug_n	171-174	false

DDI-MedLine.d190.s2	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase.
AAV2	drug_n	0-3	collagenase	drug_n	214-224	false
AAV2	drug_n	0-3	hyaluronan lyase	drug_n	227-242	false
AAV2	drug_n	0-3	heparinase III	drug_n	245-258	false
AAV2	drug_n	0-3	chondroitin ABC lyase	drug_n	264-284	false
collagenase	drug_n	214-224	hyaluronan lyase	drug_n	227-242	false
collagenase	drug_n	214-224	heparinase III	drug_n	245-258	false
collagenase	drug_n	214-224	chondroitin ABC lyase	drug_n	264-284	false
hyaluronan lyase	drug_n	227-242	heparinase III	drug_n	245-258	false
hyaluronan lyase	drug_n	227-242	chondroitin ABC lyase	drug_n	264-284	false
heparinase III	drug_n	245-258	chondroitin ABC lyase	drug_n	264-284	false

DDI-MedLine.d190.s5	The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina.
heparinase III	drug_n	16-29	chondroitin ABC lyase	drug_n	34-54	false

DDI-MedLine.d190.s6	Hyaluronan lyase had a limited effect and collagenase was ineffective.
Hyaluronan lyase	drug_n	0-15	collagenase	drug_n	42-52	false

DDI-MedLine.d190.s7	Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction.
heparinase III	drug_n	58-71	chondroitin ABC lyase	drug_n	77-97	false

DDI-MedLine.d190.s8	AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase.
AAV2	drug_n	0-3	heparinase III	drug_n	66-79	effect
AAV2	drug_n	0-3	chondroitin ABC lyase	drug_n	84-104	effect
heparinase III	drug_n	66-79	chondroitin ABC lyase	drug_n	84-104	false

DDI-MedLine.d180.s1	The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia.
3-Deazaneplanocin A	drug_n	4-22	DZNep	drug_n	25-29	false

DDI-MedLine.d180.s10	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.
DZNep	drug_n	46-50	DZNep	drug_n	92-96	false
DZNep	drug_n	46-50	ABT-737	drug_n	102-108	false
DZNep	drug_n	46-50	DZNep	drug_n	195-199	false
DZNep	drug_n	92-96	ABT-737	drug_n	102-108	effect
DZNep	drug_n	92-96	DZNep	drug_n	195-199	false
ABT-737	drug_n	102-108	DZNep	drug_n	195-199	false

DDI-MedLine.d180.s12	In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis.
DZNep	drug_n	13-17	ABT-737	drug_n	106-112	false
DZNep	drug_n	13-17	DZNep	drug_n	118-122	false
ABT-737	drug_n	106-112	DZNep	drug_n	118-122	effect

DDI-MedLine.d204.s0	Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa.
piperacillin	drug	31-42	methylglyoxal	drug_n	48-60	false

DDI-MedLine.d204.s7	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels.
piperacillin	drug	84-95	carbenicillin	drug	98-110	false
piperacillin	drug	84-95	amikacin	drug	113-120	false
piperacillin	drug	84-95	ciprofloxacin	drug	126-138	false
carbenicillin	drug	98-110	amikacin	drug	113-120	false
carbenicillin	drug	98-110	ciprofloxacin	drug	126-138	false
amikacin	drug	113-120	ciprofloxacin	drug	126-138	false

DDI-MedLine.d204.s9	Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects.
methylglyoxal	drug_n	70-82	piperacillin	drug	88-99	effect

DDI-MedLine.d204.s11	Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.
methylglyoxal	drug_n	30-42	carbenicillin	drug	62-74	effect
methylglyoxal	drug_n	30-42	amikacin	drug	80-87	effect
carbenicillin	drug	62-74	amikacin	drug	80-87	false

DDI-MedLine.d214.s0	[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
hemantane	drug_n	14-22	doxycycline	drug	28-38	false

DDI-MedLine.d214.s1	The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.)
anti-parkinsonian drug	group	15-36	hemantane	drug_n	38-46	false
anti-parkinsonian drug	group	15-36	(2-adamantyl)hexamethylenimine	drug_n	49-78	false
hemantane	drug_n	38-46	(2-adamantyl)hexamethylenimine	drug_n	49-78	false

DDI-MedLine.d214.s2	and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.)
antibiotic drug	group	7-21	doxycycline	drug	23-33	false
antibiotic drug	group	7-21	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	drug_n	85-128	false
antibiotic drug	group	7-21	MPTP	drug_n	131-134	false
doxycycline	drug	23-33	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	drug_n	85-128	false
doxycycline	drug	23-33	MPTP	drug_n	131-134	false
1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	drug_n	85-128	MPTP	drug_n	131-134	false

DDI-MedLine.d214.s5	Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity.
hemantane	drug_n	24-32	doxycycline	drug	37-47	effect

DDI-MedLine.d189.s3	The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors.
1-aminobenzotriazole	drug_n	94-113	ABT	drug_n	116-118	false

DDI-MedLine.d189.s7	ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.
ABT	drug_n	0-2	precocene I	drug_n	30-40	effect

DDI-MedLine.d189.s8	Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1.
precocene I	drug_n	67-77	tranylcypromine	drug	104-118	false

DDI-MedLine.d189.s9	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole.
ABT	drug_n	71-73	diethyldithiocarbamate	drug_n	75-96	false
ABT	drug_n	71-73	tranylcypromine	drug	98-112	false
ABT	drug_n	71-73	ketoconazole	drug	114-125	false
diethyldithiocarbamate	drug_n	75-96	tranylcypromine	drug	98-112	false
diethyldithiocarbamate	drug_n	75-96	ketoconazole	drug	114-125	false
tranylcypromine	drug	98-112	ketoconazole	drug	114-125	false

DDI-MedLine.d189.s10	Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity.
Furafylline	drug_n	0-10	sulfaphenazole	drug_n	16-29	false
Furafylline	drug_n	0-10	quinidine	drug	52-60	false
Furafylline	drug_n	0-10	precocene I	drug_n	82-92	false
sulfaphenazole	drug_n	16-29	quinidine	drug	52-60	false
sulfaphenazole	drug_n	16-29	precocene I	drug_n	82-92	false
quinidine	drug	52-60	precocene I	drug_n	82-92	effect

DDI-MedLine.d189.s11	These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism.
precocene I	drug_n	103-113	precocene I	drug_n	165-175	false

DDI-MedLine.d184.s0	Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.
Amphetamine	drug	0-10	quinpirole	drug_n	128-137	false

DDI-MedLine.d184.s2	The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures.
quinpirole	drug_n	53-62	amphetamine	drug	88-98	false

DDI-MedLine.d184.s5	In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.
quinpirole	drug_n	25-34	amphetamine	drug	55-65	effect
quinpirole	drug_n	25-34	quinpirole	drug_n	105-114	false
quinpirole	drug_n	25-34	amphetamine	drug	144-154	false
amphetamine	drug	55-65	quinpirole	drug_n	105-114	false
amphetamine	drug	55-65	amphetamine	drug	144-154	false
quinpirole	drug_n	105-114	amphetamine	drug	144-154	false

DDI-MedLine.d184.s6	Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole.
amphetamine	drug	40-50	quinpirole	drug_n	136-145	false

DDI-MedLine.d184.s8	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.
quinpirole	drug_n	27-36	amphetamine	drug	65-75	false
quinpirole	drug_n	27-36	quinpirole	drug_n	106-115	false
quinpirole	drug_n	27-36	amphetamine	drug	148-158	false
quinpirole	drug_n	27-36	amphetamine	drug	203-213	false
amphetamine	drug	65-75	quinpirole	drug_n	106-115	false
amphetamine	drug	65-75	amphetamine	drug	148-158	false
amphetamine	drug	65-75	amphetamine	drug	203-213	false
quinpirole	drug_n	106-115	amphetamine	drug	148-158	false
quinpirole	drug_n	106-115	amphetamine	drug	203-213	false
amphetamine	drug	148-158	amphetamine	drug	203-213	false

DDI-MedLine.d143.s0	[Interaction between clopidogrel and proton pump inhibitors].
clopidogrel	drug	21-31	proton pump inhibitors	group	37-58	false

DDI-MedLine.d143.s1	The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years.
proton pump inhibitors	group	29-50	clopidogrel	drug	56-66	false

DDI-MedLine.d143.s2	Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature.
proton pump inhibitors	group	46-67	clopidogrel	drug	119-129	false

DDI-MedLine.d143.s3	Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.
omeprazole	drug	19-28	clopidogrel	drug	34-44	mechanism
omeprazole	drug	19-28	omeprazole	drug	203-212	false
clopidogrel	drug	34-44	omeprazole	drug	203-212	false

DDI-MedLine.d143.s4	Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use.
Pantoprazole	drug	0-11	clopidogrel	drug	41-51	mechanism

DDI-MedLine.d143.s5	The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies.
proton pump inhibitors	group	27-48	clopidogrel	drug	80-90	false

DDI-MedLine.d143.s6	Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided.
clopidogrel	drug	50-60	omeprazole	drug	89-98	advise
clopidogrel	drug	50-60	esomeprazole	drug	104-115	advise
omeprazole	drug	89-98	esomeprazole	drug	104-115	false

DDI-MedLine.d143.s7	To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.
proton pump inhibitors	group	97-118	clopidogrel	drug	124-134	false

DDI-MedLine.d213.s0	In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
cyclosporine	drug	49-60	tacrolimus	drug	87-96	false

DDI-MedLine.d213.s1	In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors.
cyclosporine	drug	33-44	tacrolimus	drug	50-59	false

DDI-MedLine.d213.s3	Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).
midazolam	drug	27-35	cyclosporine	drug	181-192	mechanism
midazolam	drug	27-35	tacrolimus	drug	236-245	false
cyclosporine	drug	181-192	tacrolimus	drug	236-245	false

DDI-MedLine.d213.s4	The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6).
midazolam	drug	21-29	tacrolimus	drug	95-104	false
midazolam	drug	21-29	calcineurin inhibitor	group	168-188	false
tacrolimus	drug	95-104	calcineurin inhibitor	group	168-188	false

DDI-MedLine.d213.s5	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.
cyclosporine	drug	112-123	tacrolimus	drug	149-158	false
cyclosporine	drug	112-123	cyclosporine	drug	228-239	false
tacrolimus	drug	149-158	cyclosporine	drug	228-239	false

DDI-MedLine.d154.s0	Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.
avian influenza vaccines	group	77-100	ginseng stem-and-leaf saponins	drug_n	128-157	false

DDI-MedLine.d154.s2	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines.
ginseng stem-and-leaf saponins	drug_n	81-110	GSLS	drug_n	113-116	false
ginseng stem-and-leaf saponins	drug_n	81-110	inactivated ND vaccines	drug	166-179;188-195	false
ginseng stem-and-leaf saponins	drug_n	81-110	inactivated AI vaccines	drug	166-176;185-186;188-195	false
GSLS	drug_n	113-116	inactivated ND vaccines	drug	166-179;188-195	false
GSLS	drug_n	113-116	inactivated AI vaccines	drug	166-176;185-186;188-195	false
inactivated ND vaccines	drug	166-179;188-195	inactivated AI vaccines	drug	166-176;185-186;188-195	false

DDI-MedLine.d154.s3	In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated.
GSLS	drug_n	40-43	inactivated ND vaccine	drug	145-166	false

DDI-MedLine.d154.s5	In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed.
GSLS	drug_n	37-40	inactivated AI vaccines	drug	87-109	effect

DDI-MedLine.d154.s6	Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.
GSLS	drug_n	26-29	GSLS	drug_n	96-99	false

DDI-MedLine.d161.s3	In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	106-153	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	281-324	false

DDI-MedLine.d161.s4	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	21-64	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	150-197	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	21-64	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	321-364	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	21-64	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	366-413	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	21-64	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	422-465	false
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	150-197	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	321-364	false
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	150-197	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	366-413	false
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	150-197	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	422-465	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	321-364	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	366-413	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	321-364	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	422-465	false
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	366-413	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	422-465	false

DDI-MedLine.d161.s5	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	18-61	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	78-121	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	18-61	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	200-243	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	18-61	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	245-292	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	78-121	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	200-243	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	78-121	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	245-292	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	200-243	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	245-292	effect

DDI-MedLine.d161.s6	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	349-392	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	394-441	effect
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	349-392	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	467-510	false
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	394-441	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	467-510	false

DDI-MedLine.d161.s7	The 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine treatment also had a significant effect on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups.
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	4-51	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	100-143	effect

DDI-MedLine.d161.s8	In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	3-46	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	283-326	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	3-46	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	328-375	false
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	283-326	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	328-375	effect

DDI-MedLine.d161.s9	Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine, significantly reduces 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.
3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	drug_n	99-146	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	drug_n	171-214	effect

DDI-MedLine.d217.s0	Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
celecoxib	drug	15-23	anti-cancer drugs	group	40-56	effect

DDI-MedLine.d217.s2	This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents.
cyclooxygenase-2 inhibitors	group	39-65	chemotherapeutic agents	group	120-142	false

DDI-MedLine.d217.s4	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.
5-FU	drug	130-133	cisplatin	drug	136-144	false
5-FU	drug	130-133	doxorubicin	drug	147-157	false
5-FU	drug	130-133	etoposide	drug	163-171	false
5-FU	drug	130-133	celecoxib	drug	175-183	false
cisplatin	drug	136-144	doxorubicin	drug	147-157	false
cisplatin	drug	136-144	etoposide	drug	163-171	false
cisplatin	drug	136-144	celecoxib	drug	175-183	false
doxorubicin	drug	147-157	etoposide	drug	163-171	false
doxorubicin	drug	147-157	celecoxib	drug	175-183	false
etoposide	drug	163-171	celecoxib	drug	175-183	false

DDI-MedLine.d217.s5	We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells.
celecoxib	drug	28-36	celecoxib	drug	136-144	false
celecoxib	drug	28-36	doxorubicin	drug	150-160	false
celecoxib	drug	136-144	doxorubicin	drug	150-160	effect

DDI-MedLine.d217.s11	These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers.
celecoxib	drug	51-59	doxorubicin	drug	121-131	false

DDI-MedLine.d218.s0	Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.
Antidepressant	group	0-13	warfarin	drug	15-22	false

DDI-MedLine.d218.s3	We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.
antidepressant	group	47-60	warfarin	drug	133-140	false

DDI-MedLine.d218.s5	In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use.
warfarin	drug	18-25	warfarin	drug	69-76	false

DDI-MedLine.d218.s8	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]).
Warfarin	drug	0-7	citalopram	drug	91-100	effect
Warfarin	drug	0-7	fluoxetine	drug	139-148	effect
Warfarin	drug	0-7	paroxetine	drug	187-196	effect
Warfarin	drug	0-7	amitriptyline	drug	235-247	effect
citalopram	drug	91-100	fluoxetine	drug	139-148	false
citalopram	drug	91-100	paroxetine	drug	187-196	false
citalopram	drug	91-100	amitriptyline	drug	235-247	false
fluoxetine	drug	139-148	paroxetine	drug	187-196	false
fluoxetine	drug	139-148	amitriptyline	drug	235-247	false
paroxetine	drug	187-196	amitriptyline	drug	235-247	false

DDI-MedLine.d218.s9	Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]).
mirtazapine	drug	5-15	warfarin	drug	57-64	effect

DDI-MedLine.d218.s10	Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.
Warfarin	drug	0-7	citalopram	drug	29-38	effect
Warfarin	drug	0-7	fluoxetine	drug	41-50	effect
Warfarin	drug	0-7	paroxetine	drug	53-62	effect
Warfarin	drug	0-7	amitriptyline	drug	65-77	effect
Warfarin	drug	0-7	mirtazapine	drug	83-93	effect
citalopram	drug	29-38	fluoxetine	drug	41-50	false
citalopram	drug	29-38	paroxetine	drug	53-62	false
citalopram	drug	29-38	amitriptyline	drug	65-77	false
citalopram	drug	29-38	mirtazapine	drug	83-93	false
fluoxetine	drug	41-50	paroxetine	drug	53-62	false
fluoxetine	drug	41-50	amitriptyline	drug	65-77	false
fluoxetine	drug	41-50	mirtazapine	drug	83-93	false
paroxetine	drug	53-62	amitriptyline	drug	65-77	false
paroxetine	drug	53-62	mirtazapine	drug	83-93	false
amitriptyline	drug	65-77	mirtazapine	drug	83-93	false

DDI-MedLine.d208.s0	Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.
Implanon	brand	0-7	antiretroviral	group	47-60	effect

DDI-MedLine.d208.s3	We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.
antiretroviral	group	59-72	Implanon	brand	138-145	effect

DDI-MedLine.d163.s0	In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
minocycline	drug	21-31	fosfomycin	drug	47-56	false
minocycline	drug	21-31	methicillin	drug	87-97	false
fosfomycin	drug	47-56	methicillin	drug	87-97	false

DDI-MedLine.d163.s1	This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA).
minocycline	drug	54-64	fosfomycin	drug	80-89	false
minocycline	drug	54-64	methicillin	drug	111-121	false
fosfomycin	drug	80-89	methicillin	drug	111-121	false

DDI-MedLine.d163.s4	The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria.
minocycline	drug	31-41	fosfomycin	drug	47-56	false

DDI-MedLine.d163.s7	The combination of minocycline and fosfomycin can be synergistic against MRSA.
minocycline	drug	19-29	fosfomycin	drug	35-44	effect

DDI-MedLine.d169.s0	Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.
Calcium	drug	0-6	nonheme iron	drug	59-65;75-78	false
Calcium	drug	0-6	heme iron	drug	70-78	false
nonheme iron	drug	59-65;75-78	heme iron	drug	70-78	false

DDI-MedLine.d169.s1	Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron.
Calcium	drug	0-6	nonheme iron	drug	83-89;100-103	mechanism
Calcium	drug	0-6	heme iron	drug	95-103	mechanism
nonheme iron	drug	83-89;100-103	heme iron	drug	95-103	false

DDI-MedLine.d169.s2	However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.
calcium	drug	28-34	iron	drug	46-49	mechanism
calcium	drug	28-34	calcium	drug	123-129	false
iron	drug	46-49	calcium	drug	123-129	false

DDI-MedLine.d169.s3	Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal.
calcium	drug	52-58	nonheme iron	drug	77-83;94-97	false
calcium	drug	52-58	heme iron	drug	89-97	false
nonheme iron	drug	77-83;94-97	heme iron	drug	89-97	false

DDI-MedLine.d169.s5	We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate).
calcium	drug	28-34	nonheme iron	drug	88-99	false
calcium	drug	28-34	ferrous sulfate	drug	105-119	false
nonheme iron	drug	88-99	ferrous sulfate	drug	105-119	false

DDI-MedLine.d169.s6	We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)].
calcium	drug	33-39	heme iron	drug	92-100	false

DDI-MedLine.d169.s7	Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach.
Calcium	drug	0-6	calcium chloride	drug	28-43	false
Calcium	drug	0-6	minerals	group	64-71	false
calcium chloride	drug	28-43	minerals	group	64-71	false

DDI-MedLine.d169.s8	Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.
Calcium	drug	0-6	nonheme iron	drug	35-46	mechanism

DDI-MedLine.d169.s9	A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%.
calcium	drug	2-8	heme iron	drug	55-63	mechanism

DDI-MedLine.d169.s10	In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron.
calcium	drug	53-59	nonheme iron	drug	117-123;157-160	mechanism
calcium	drug	53-59	heme iron	drug	142-145;157-160	mechanism
nonheme iron	drug	117-123;157-160	heme iron	drug	142-145;157-160	false

DDI-MedLine.d166.s0	Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
cinacalcet	drug	40-49	darbepoetin	drug	83-93	false

DDI-MedLine.d166.s1	Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance.
erythropoietin	drug	75-88	EPO	drug	91-93	false

DDI-MedLine.d166.s2	Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown.
cinacalcet	drug	23-32	darbepoetin	drug	118-128	false

DDI-MedLine.d166.s6	The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy.
darbepoetin	drug	70-80	cinacalcet	drug	127-136	false

DDI-MedLine.d166.s17	Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement.
cinacalcet	drug	20-29	darbepoetin	drug	64-74	effect

DDI-MedLine.d179.s0	Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
sunitinib	drug	32-40	docetaxel	drug	46-54	int

DDI-MedLine.d179.s2	This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.
sunitinib	drug	66-74	sunitinib	drug	131-139	false
sunitinib	drug	66-74	docetaxel	drug	145-153	false
sunitinib	drug	131-139	docetaxel	drug	145-153	false

DDI-MedLine.d179.s3	NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations.
sunitinib	drug	84-92	docetaxel	drug	97-105	false

DDI-MedLine.d179.s5	Sunitinib exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas docetaxel arrested at S phase.
Sunitinib	drug	0-8	docetaxel	drug	118-126	false

DDI-MedLine.d179.s6	Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.
sunitinib	drug	37-45	docetaxel	drug	51-59	effect

DDI-MedLine.d179.s7	When cells were exposed to docetaxel followed by sunitinib, synergism was observed.
docetaxel	drug	27-35	sunitinib	drug	49-57	effect

DDI-MedLine.d179.s8	The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib.
docetaxel	drug	102-110	sunitinib	drug	179-187	effect

DDI-MedLine.d179.s10	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.
Sunitinib	drug	0-8	docetaxel	drug	166-174	false
Sunitinib	drug	0-8	sunitinib	drug	188-196	false
Sunitinib	drug	0-8	sunitinib	drug	213-221	false
Sunitinib	drug	0-8	docetaxel	drug	235-243	false
docetaxel	drug	166-174	sunitinib	drug	188-196	effect
docetaxel	drug	166-174	sunitinib	drug	213-221	false
docetaxel	drug	166-174	docetaxel	drug	235-243	false
sunitinib	drug	188-196	sunitinib	drug	213-221	false
sunitinib	drug	188-196	docetaxel	drug	235-243	false
sunitinib	drug	213-221	docetaxel	drug	235-243	false

DDI-MedLine.d194.s0	The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
dasatinib	drug	25-33	paclitaxel	drug	44-53	effect

DDI-MedLine.d194.s4	The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts.
dasatinib	drug	14-22	paclitaxel	drug	65-74	false

DDI-MedLine.d194.s5	The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry.
dasatinib	drug	64-72	paclitaxel	drug	78-87	false

DDI-MedLine.d194.s9	HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone.
dasatinib	drug	23-31	paclitaxel	drug	38-47	effect

DDI-MedLine.d194.s10	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);
dasatinib	drug	45-53	paclitaxel	drug	60-69	effect
dasatinib	drug	45-53	dasatinib	drug	171-179	false
dasatinib	drug	45-53	paclitaxel	drug	183-192	false
dasatinib	drug	45-53	paclitaxel	drug	197-206	false
paclitaxel	drug	60-69	dasatinib	drug	171-179	false
paclitaxel	drug	60-69	paclitaxel	drug	183-192	false
paclitaxel	drug	60-69	paclitaxel	drug	197-206	false
dasatinib	drug	171-179	paclitaxel	drug	183-192	false
dasatinib	drug	171-179	paclitaxel	drug	197-206	false
paclitaxel	drug	183-192	paclitaxel	drug	197-206	false

DDI-MedLine.d194.s11	dasatinib + paclitaxel vs.
dasatinib	drug	0-8	paclitaxel	drug	12-21	false

DDI-MedLine.d194.s15	The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017).
dasatinib	drug	43-51	paclitaxel	drug	58-67	false

DDI-MedLine.d194.s16	Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.
dasatinib	drug	82-90	paclitaxel	drug	133-142	effect

DDI-MedLine.d194.s17	Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.
dasatinib	drug	63-71	paclitaxel	drug	82-91	effect

DDI-MedLine.d159.s0	Protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.
acetyl-l-carnitine	drug	21-38	alpha lipoic acid	drug_n	45-61	false

DDI-MedLine.d159.s6	(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.
acetyl-l-carnitine	drug	5-22	alpha-lipoic acid	drug	115-131	effect

DDI-MedLine.d211.s0	Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
lenalidomide	drug	17-28	CCI-779	drug	34-40	false
lenalidomide	drug	17-28	lenalidomide	drug	99-110	false
lenalidomide	drug	17-28	CCI-779	drug	112-118	false
CCI-779	drug	34-40	lenalidomide	drug	99-110	false
CCI-779	drug	34-40	CCI-779	drug	112-118	false
lenalidomide	drug	99-110	CCI-779	drug	112-118	false

DDI-MedLine.d211.s2	The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.
lenalidomide	drug	31-42	CCI-779	drug	68-74	effect

DDI-MedLine.d185.s0	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor.
ketoconazole	drug	10-21	panobinostat	drug	82-93	false
ketoconazole	drug	10-21	LBH589	drug	96-101	false
ketoconazole	drug	10-21	histone deacetylase inhibitor	group	122-150	false
panobinostat	drug	82-93	LBH589	drug	96-101	false
panobinostat	drug	82-93	histone deacetylase inhibitor	group	122-150	false
LBH589	drug	96-101	histone deacetylase inhibitor	group	122-150	false

DDI-MedLine.d185.s2	This study evaluated the effect of a potent CYP3A inhibitor, ketoconazole, on the pharmacokinetics and safety of panobinostat.
ketoconazole	drug	61-72	panobinostat	drug	113-124	false

DDI-MedLine.d185.s5	On day 8, a single panobinostat dose was co-administered with ketoconazole.
panobinostat	drug	19-30	ketoconazole	drug	62-73	false

DDI-MedLine.d185.s7	In the presence of ketoconazole, there was 1.6- and 1.8-fold increase in C (max) and AUC of panobinostat, respectively.
ketoconazole	drug	19-30	panobinostat	drug	92-103	mechanism

DDI-MedLine.d185.s12	Co-administration of panobinostat with CYP3A inhibitors is feasible as the observed increase in panobinostat PK parameters was not considered clinically relevant.
panobinostat	drug	21-32	panobinostat	drug	96-107	false

DDI-MedLine.d185.s13	Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of panobinostat was not studied with CYP3A inhibitors, close monitoring of panobinostat-related adverse events is necessary.
panobinostat	drug	104-115	panobinostat	drug	176-187	false

DDI-MedLine.d231.s0	Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.
moxifloxacin	drug	21-32	lomefloxacin	drug	38-49	false

DDI-MedLine.d231.s1	Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.
Moxifloxacin	drug	0-11	lomefloxacin	drug	17-28	false
Moxifloxacin	drug	0-11	fluoroquinolone antibiotics	group	34-60	false
lomefloxacin	drug	17-28	fluoroquinolone antibiotics	group	34-60	false

DDI-MedLine.d231.s3	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.
moxifloxacin	drug	6-17	fluoroquinolones	group	36-51	false
moxifloxacin	drug	6-17	sucralfate	drug	99-108	false
moxifloxacin	drug	6-17	gelusil	brand	111-117	false
moxifloxacin	drug	6-17	erythromycin	drug	120-131	false
moxifloxacin	drug	6-17	multi minerals	group	137-150	false
fluoroquinolones	group	36-51	sucralfate	drug	99-108	false
fluoroquinolones	group	36-51	gelusil	brand	111-117	false
fluoroquinolones	group	36-51	erythromycin	drug	120-131	false
fluoroquinolones	group	36-51	multi minerals	group	137-150	false
sucralfate	drug	99-108	gelusil	brand	111-117	false
sucralfate	drug	99-108	erythromycin	drug	120-131	false
sucralfate	drug	99-108	multi minerals	group	137-150	false
gelusil	brand	111-117	erythromycin	drug	120-131	false
gelusil	brand	111-117	multi minerals	group	137-150	false
erythromycin	drug	120-131	multi minerals	group	137-150	false

DDI-MedLine.d231.s6	The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector.
moxifloxacin	drug	16-27	lomefloxacin	drug	33-44	false

DDI-MedLine.d231.s8	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.
Moxifloxacin	drug	0-11	Lomefloxacin	drug	17-28	false
Moxifloxacin	drug	0-11	sucralfate	drug	49-58	mechanism
Moxifloxacin	drug	0-11	gelusil	brand	64-70	mechanism
Moxifloxacin	drug	0-11	erythromycin	drug	101-112	mechanism
Moxifloxacin	drug	0-11	multi-minerals	group	133-146	mechanism
Lomefloxacin	drug	17-28	sucralfate	drug	49-58	mechanism
Lomefloxacin	drug	17-28	gelusil	brand	64-70	mechanism
Lomefloxacin	drug	17-28	erythromycin	drug	101-112	mechanism
Lomefloxacin	drug	17-28	multi-minerals	group	133-146	mechanism
sucralfate	drug	49-58	gelusil	brand	64-70	false
sucralfate	drug	49-58	erythromycin	drug	101-112	false
sucralfate	drug	49-58	multi-minerals	group	133-146	false
gelusil	brand	64-70	erythromycin	drug	101-112	false
gelusil	brand	64-70	multi-minerals	group	133-146	false
erythromycin	drug	101-112	multi-minerals	group	133-146	false

DDI-MedLine.d201.s4	The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, cross-reacting material 197 (CRM197).
cross-reacting material 197	drug_n	180-206	CRM197	drug_n	209-214	false

DDI-MedLine.d201.s5	We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent.
CRM197	drug_n	88-93	anticancer agent	group	139-154	false

DDI-MedLine.d201.s9	CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line.
CRM197	drug_n	0-5	CRM197	drug_n	62-67	false
CRM197	drug_n	0-5	doxorubicin	drug	74-84	false
CRM197	drug_n	62-67	doxorubicin	drug	74-84	effect

DDI-MedLine.d200.s0	[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease]
amlodipine	drug	31-40	valsartan	drug	42-50	false

DDI-MedLine.d200.s1	Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology.
amlodipine	drug	35-44	valsartan	drug	46-54	false

DDI-MedLine.d200.s2	All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43).
amlodipine	drug	106-115	valsartan	drug	117-125	false

DDI-MedLine.d200.s7	Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%).
amlodipine	drug	56-65	valsartan	drug	67-75	false

DDI-MedLine.d200.s8	But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).
amlodipine	drug	33-42	valsartan	drug	44-52	effect
amlodipine	drug	33-42	antihypertensive drugs	group	247-268	false
valsartan	drug	44-52	antihypertensive drugs	group	247-268	false

DDI-MedLine.d200.s10	We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.
amlodipine	drug	75-84	valsartan	drug	86-94	effect
amlodipine	drug	75-84	antihypertensive drugs	group	192-213	false
valsartan	drug	86-94	antihypertensive drugs	group	192-213	false

DDI-MedLine.d209.s1	Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer.
Tamoxifen	drug	0-8	estrogen antagonist	group	14-32	false

DDI-MedLine.d209.s5	Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%.
Paroxetine	drug	0-9	fluoxetine	drug	15-24	false
Paroxetine	drug	0-9	endoxifen	drug_n	61-69	mechanism
fluoxetine	drug	15-24	endoxifen	drug_n	61-69	mechanism

DDI-MedLine.d209.s9	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine.
tamoxifen	drug	85-93	SSRI antidepressants	group	125-144	advise
tamoxifen	drug	85-93	paroxetine	drug	154-163	advise
tamoxifen	drug	85-93	fluoxetine	drug	169-178	advise
SSRI antidepressants	group	125-144	paroxetine	drug	154-163	false
SSRI antidepressants	group	125-144	fluoxetine	drug	169-178	false
paroxetine	drug	154-163	fluoxetine	drug	169-178	false

DDI-MedLine.d209.s10	Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause.
antidepressant drug	group	35-53	antidepressants	group	68-82	false

DDI-MedLine.d209.s11	If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.
antidepressant	group	24-37	tamoxifen	drug	95-103	advise
antidepressant	group	24-37	anastrozole	drug	110-120	false
tamoxifen	drug	95-103	anastrozole	drug	110-120	false

DDI-MedLine.d195.s0	Influence of piperine on ibuprofen induced antinociception and its pharmacokinetics.
piperine	drug_n	13-20	ibuprofen	drug	25-33	false

DDI-MedLine.d195.s4	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.
piperine	drug_n	21-28	ibuprofen	drug	112-120	effect
piperine	drug_n	21-28	acetic acid	drug	140-150	false
piperine	drug_n	21-28	ibuprofen	drug	210-218	false
ibuprofen	drug	112-120	acetic acid	drug	140-150	false
ibuprofen	drug	112-120	ibuprofen	drug	210-218	false
acetic acid	drug	140-150	ibuprofen	drug	210-218	false

DDI-MedLine.d195.s5	Ibuprofen plasma concentration was also increased when it was administered with piperine.
Ibuprofen	drug	0-8	piperine	drug_n	80-87	mechanism

DDI-MedLine.d195.s6	The synergistic antinociception activity of ibuprofen when administered with piperine can be attributed to increased plasma concentration of ibuprofen.
ibuprofen	drug	44-52	piperine	drug_n	77-84	mechanism
ibuprofen	drug	44-52	ibuprofen	drug	141-149	false
piperine	drug_n	77-84	ibuprofen	drug	141-149	false

DDI-MedLine.d195.s7	From this study it can be concluded that piperine can be used as a bioenhancer along with ibuprofen.
piperine	drug_n	41-48	ibuprofen	drug	90-98	effect

DDI-MedLine.d147.s0	Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
dacarbazine	drug	15-25	imexon	drug_n	31-36	false

DDI-MedLine.d147.s1	We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.
dacarbazine	drug	67-77	DTIC	drug	80-83	false
dacarbazine	drug	67-77	imexon	drug	107-112	false
DTIC	drug	80-83	imexon	drug	107-112	false

DDI-MedLine.d147.s2	The effect of DTIC and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay).
DTIC	drug	14-17	imexon	drug	23-28	false

DDI-MedLine.d147.s6	There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC.
imexon	drug	69-74	DTIC	drug	84-87	false

DDI-MedLine.d147.s8	Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.
Imexon	drug	0-5	dacarbazine	drug	11-21	effect

DDI-MedLine.d193.s0	Ticagrelor (Brilinta)--better than clopidogrel (Plavix)
Ticagrelor	drug	0-9	Brilinta	brand	12-19	false
Ticagrelor	drug	0-9	clopidogrel	drug	35-45	false
Ticagrelor	drug	0-9	Plavix	brand	48-53	false
Brilinta	brand	12-19	clopidogrel	drug	35-45	false
Brilinta	brand	12-19	Plavix	brand	48-53	false
clopidogrel	drug	35-45	Plavix	brand	48-53	false

DDI-MedLine.d193.s1	The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).
ticagrelor	drug	21-30	Brilinta	brand	33-40	false
ticagrelor	drug	21-30	antiplatelet drug	group	64-80	false
ticagrelor	drug	21-30	aspirin	brand	105-111	effect
Brilinta	brand	33-40	antiplatelet drug	group	64-80	false
Brilinta	brand	33-40	aspirin	brand	105-111	effect
antiplatelet drug	group	64-80	aspirin	brand	105-111	false

DDI-MedLine.d193.s2	It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use.
clopidogrel	drug	21-31	Plavix	brand	34-39	false
clopidogrel	drug	21-31	prasugrel	drug	46-54	false
clopidogrel	drug	21-31	Effient	brand	57-63	false
Plavix	brand	34-39	prasugrel	drug	46-54	false
Plavix	brand	34-39	Effient	brand	57-63	false
prasugrel	drug	46-54	Effient	brand	57-63	false

DDI-MedLine.d181.s4	The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone.
levothyroxine	drug	85-97	simeticone	drug	148-157	int

DDI-MedLine.d181.s6	Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine.
Infacol	brand	42-48	levothyroxine	drug	78-90	false

DDI-MedLine.d181.s8	Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children.
thyroxine	drug	20-28	simeticone	drug	35-44	false

DDI-MedLine.d227.s0	Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
Ephedrine	drug	0-8	dexmedetomidine	drug	49-63	effect

DDI-MedLine.d227.s2	The purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.
ephedrine	drug	75-83	dexmedetomidine	drug	103-117	false

DDI-MedLine.d227.s6	saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.
ephedrine	drug	17-25	dexmedetomidine	drug	59-73	false
ephedrine	drug	17-25	ephedrine	drug	93-101	false
ephedrine	drug	17-25	dexmedetomidine	drug	118-132	false
dexmedetomidine	drug	59-73	ephedrine	drug	93-101	false
dexmedetomidine	drug	59-73	dexmedetomidine	drug	118-132	false
ephedrine	drug	93-101	dexmedetomidine	drug	118-132	false

DDI-MedLine.d227.s7	In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.
dexmedetomidine	drug	64-78	ephedrine	drug	96-104	effect
dexmedetomidine	drug	64-78	dexmedetomidine	drug	205-219	false
ephedrine	drug	96-104	dexmedetomidine	drug	205-219	false

DDI-MedLine.d227.s8	At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine.
dexmedetomidine	drug	53-67	ephedrine	drug	89-97	effect

DDI-MedLine.d227.s9	We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.
dexmedetomidine	drug	49-63	ephedrine	drug	70-78	effect
dexmedetomidine	drug	49-63	dexmedetomidine	drug	183-197	false
dexmedetomidine	drug	49-63	analgesic	group	205-213	false
ephedrine	drug	70-78	dexmedetomidine	drug	183-197	false
ephedrine	drug	70-78	analgesic	group	205-213	false
dexmedetomidine	drug	183-197	analgesic	group	205-213	false

DrugDDI.d21928724.s0	Evaluation of antidepressant like activity of curcumin and its combination with fluoxetine and imipramine: an acute and chronic study.
curcumin	drug_n	46-53	fluoxetine	drug	80-89	false
curcumin	drug_n	46-53	imipramine	drug	95-104	false
fluoxetine	drug	80-89	imipramine	drug	95-104	false

DrugDDI.d21928724.s2	In the present study, the antidepressant like activity of curcumin and its combination with fluoxetine and imipramine was studied in acute model (three doses 24, 5 and 1 h before test) of forced swimming test (FST) in glass jar and tail suspension test (TST) in mice and in chronic model (14 day study) of FST with water wheel in rats.
curcumin	drug_n	58-65	fluoxetine	drug	92-101	false
curcumin	drug_n	58-65	imipramine	drug	107-116	false
fluoxetine	drug	92-101	imipramine	drug	107-116	false

DrugDDI.d21928724.s3	All the tests were carried out in the following seven groups (n = 6 in each group), drugs being given orally (doses for mice): Group 1 (vehicle), group 2 (curcumin 50 mg/kg), group 3 (curcumin 100 mg/kg), group 4 (fluoxetine 20 mg/kg), group 5 (imipramine 15 mg/kg), group 6 (curcumin 100 mg/kg plus fluoxetine 20 mg/kg) and group 7 (curcumin 100 mg/kg plus imipramine 15 mg/kg).
curcumin	drug_n	155-162	curcumin	drug_n	184-191	false
curcumin	drug_n	155-162	fluoxetine	drug	214-223	false
curcumin	drug_n	155-162	imipramine	drug	245-254	false
curcumin	drug_n	155-162	curcumin	drug_n	276-283	false
curcumin	drug_n	155-162	fluoxetine	drug	300-309	false
curcumin	drug_n	155-162	curcumin	drug_n	334-341	false
curcumin	drug_n	155-162	imipramine	drug	358-367	false
curcumin	drug_n	184-191	fluoxetine	drug	214-223	false
curcumin	drug_n	184-191	imipramine	drug	245-254	false
curcumin	drug_n	184-191	curcumin	drug_n	276-283	false
curcumin	drug_n	184-191	fluoxetine	drug	300-309	false
curcumin	drug_n	184-191	curcumin	drug_n	334-341	false
curcumin	drug_n	184-191	imipramine	drug	358-367	false
fluoxetine	drug	214-223	imipramine	drug	245-254	false
fluoxetine	drug	214-223	curcumin	drug_n	276-283	false
fluoxetine	drug	214-223	fluoxetine	drug	300-309	false
fluoxetine	drug	214-223	curcumin	drug_n	334-341	false
fluoxetine	drug	214-223	imipramine	drug	358-367	false
imipramine	drug	245-254	curcumin	drug_n	276-283	false
imipramine	drug	245-254	fluoxetine	drug	300-309	false
imipramine	drug	245-254	curcumin	drug_n	334-341	false
imipramine	drug	245-254	imipramine	drug	358-367	false
curcumin	drug_n	276-283	fluoxetine	drug	300-309	false
curcumin	drug_n	276-283	curcumin	drug_n	334-341	false
curcumin	drug_n	276-283	imipramine	drug	358-367	false
fluoxetine	drug	300-309	curcumin	drug_n	334-341	false
fluoxetine	drug	300-309	imipramine	drug	358-367	false
curcumin	drug_n	334-341	imipramine	drug	358-367	false

DrugDDI.d21928724.s6	The effect of curcumin (100 mg/kg) was similar to that of fluoxetine and imipramine (p > 0.05) but its addition to fluoxetine and imipramine did not improve their antidepressant activity (p > 0.05).
curcumin	drug_n	14-21	fluoxetine	drug	58-67	false
curcumin	drug_n	14-21	imipramine	drug	73-82	false
curcumin	drug_n	14-21	fluoxetine	drug	115-124	false
curcumin	drug_n	14-21	imipramine	drug	130-139	false
fluoxetine	drug	58-67	imipramine	drug	73-82	false
fluoxetine	drug	58-67	fluoxetine	drug	115-124	false
fluoxetine	drug	58-67	imipramine	drug	130-139	false
imipramine	drug	73-82	fluoxetine	drug	115-124	false
imipramine	drug	73-82	imipramine	drug	130-139	false
fluoxetine	drug	115-124	imipramine	drug	130-139	false

DrugDDI.d21928724.s8	Curcumin can be a useful antidepressant especially in cases which respond to drugs having mixed effects on serotonin and catecholamines levels in the brain.
Curcumin	drug_n	0-7	antidepressant	group	25-38	false

DDI-MedLine.d199.s0	Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.
ketamine	drug	71-78	propofol	drug	84-91	false

DDI-MedLine.d199.s2	We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.
ketamine	drug	95-102	propofol	drug	124-131	false

DDI-MedLine.d199.s3	EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol.
propofol	drug	61-68	ketamine	drug	161-168	false
propofol	drug	61-68	propofol	drug	183-190	false
ketamine	drug	161-168	propofol	drug	183-190	false

DDI-MedLine.d199.s4	Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.
ketamine	drug	51-58	propofol	drug	69-76	effect
ketamine	drug	51-58	propofol	drug	156-163	false
propofol	drug	69-76	propofol	drug	156-163	false

DDI-MedLine.d164.s0	Lapatinib enhances herceptin-mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
Lapatinib	drug	0-8	herceptin	brand	19-27	effect

DDI-MedLine.d164.s1	Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
lapatinib	drug	41-49	Herceptin	brand	65-73	effect
lapatinib	drug	41-49	lapatinib	drug	133-141	false
lapatinib	drug	41-49	Herceptin	brand	167-175	false
Herceptin	brand	65-73	lapatinib	drug	133-141	false
Herceptin	brand	65-73	Herceptin	brand	167-175	false
lapatinib	drug	133-141	Herceptin	brand	167-175	false

DDI-MedLine.d164.s2	We evaluated how lapatinib interacts with Herceptin in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC).
lapatinib	drug	17-25	Herceptin	brand	42-50	false
lapatinib	drug	17-25	Herceptin	brand	111-119	false
Herceptin	brand	42-50	Herceptin	brand	111-119	false

DDI-MedLine.d164.s3	In an in vitro assay, lapatinib induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of Herceptin-mediated ADCC.
lapatinib	drug	22-30	Herceptin	brand	149-157	effect

DDI-MedLine.d164.s4	Furthermore, we present a case report in which a second Herceptin treatment following lapatinib resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer.
Herceptin	brand	56-64	lapatinib	drug	86-94	effect

DDI-MedLine.d164.s5	Lapatinib may have the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
Lapatinib	drug	0-8	Herceptin	brand	44-52	false
Lapatinib	drug	0-8	Herceptin	brand	68-76	false
Herceptin	brand	44-52	Herceptin	brand	68-76	false

DDI-MedLine.d216.s0	Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
S-ketamine	drug	17-26	itraconazole	drug	45-56	false
S-ketamine	drug	17-26	ticlopidine	drug	83-93	effect
itraconazole	drug	45-56	ticlopidine	drug	83-93	false

DDI-MedLine.d216.s1	This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole.
S-ketamine	drug	51-60	ticlopidine	drug	107-117	false
S-ketamine	drug	51-60	itraconazole	drug	143-154	false
ticlopidine	drug	107-117	itraconazole	drug	143-154	false

DDI-MedLine.d216.s2	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.
S-ketamine	drug	87-96	ticlopidine	drug	128-138	false
S-ketamine	drug	87-96	itraconazole	drug	162-173	false
ticlopidine	drug	128-138	itraconazole	drug	162-173	false

DDI-MedLine.d216.s3	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine.
Ticlopidine	drug	0-10	ketamine	drug	134-141	mechanism
Ticlopidine	drug	0-10	itraconazole	drug	164-175	false
Ticlopidine	drug	0-10	S-ketamine	drug	220-229	false
ketamine	drug	134-141	itraconazole	drug	164-175	false
ketamine	drug	134-141	S-ketamine	drug	220-229	false
itraconazole	drug	164-175	S-ketamine	drug	220-229	false

DDI-MedLine.d216.s4	The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.
norketamine	drug_n	13-23	ketamine	drug	39-46	false
norketamine	drug_n	13-23	ticlopidine	drug	94-104	false
norketamine	drug_n	13-23	itraconazole	drug	125-136	false
ketamine	drug	39-46	ticlopidine	drug	94-104	false
ketamine	drug	39-46	itraconazole	drug	125-136	false
ticlopidine	drug	94-104	itraconazole	drug	125-136	false

DDI-MedLine.d216.s5	In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05).
ticlopidine	drug	7-17	itraconazole	drug	23-34	false

DDI-MedLine.d216.s6	The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.
S-ketamine	drug	40-49	ticlopidine	drug	91-101	advise

DDI-DrugBank.d744.s0	Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.
insulin	drug	63-69	hypoglycemic	group	83-94	false
insulin	drug	63-69	SOMAVERT	brand	196-203	advise
hypoglycemic	group	83-94	SOMAVERT	brand	196-203	advise

DDI-DrugBank.d744.s1	In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.
opioids	group	33-39	pegvisomant	drug	67-77	mechanism
opioids	group	33-39	opioids	group	172-178	false
pegvisomant	drug	67-77	opioids	group	172-178	false

DDI-DrugBank.d689.s0	Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
Vasopressors	group	0-11	metaraminol	drug	27-37	false
Vasopressors	group	0-11	halothane	drug	85-93	effect
metaraminol	drug	27-37	halothane	drug	85-93	effect

DDI-DrugBank.d689.s1	MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
MAO Inhibitors	group	0-13	sympathomimetic pressor amines	group	39-68	false
MAO Inhibitors	group	0-13	monoamine oxidase inhibitors	group	116-143	false
MAO Inhibitors	group	0-13	MAOI	group	146-149	false
sympathomimetic pressor amines	group	39-68	monoamine oxidase inhibitors	group	116-143	effect
sympathomimetic pressor amines	group	39-68	MAOI	group	146-149	effect
monoamine oxidase inhibitors	group	116-143	MAOI	group	146-149	false

DDI-DrugBank.d689.s3	The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
adrenergic agents	group	24-40	tricyclic antidepressants	group	69-93	effect

DDI-DrugBank.d702.s1	These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.
sympathomimetic bronchodilators	group	14-44	methylxanthines	group	47-61	false
sympathomimetic bronchodilators	group	14-44	steroids	group	85-92	false
methylxanthines	group	47-61	steroids	group	85-92	false

DDI-DrugBank.d702.s2	However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.
SPIRIVA	brand	36-42	anticholinergic	group	55-69	advise
SPIRIVA	brand	36-42	ipratropium	drug	97-107	advise
anticholinergic	group	55-69	ipratropium	drug	97-107	false

DDI-DrugBank.d679.s0	Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.
cimetidine	drug	35-44	mebendazole	drug	55-65	mechanism
cimetidine	drug	35-44	mebendazole	drug	136-146	false
mebendazole	drug	55-65	mebendazole	drug	136-146	false

DDI-DrugBank.d775.s0	Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied.
MIVACRON	brand	9-16	MIVACRON	brand	165-172	false
MIVACRON	brand	9-16	succinylcholine	drug	178-192	false
MIVACRON	brand	165-172	succinylcholine	drug	178-192	false

DDI-DrugBank.d775.s1	Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents.
succinylcholine	drug	24-38	nondepolarizing agents	group	93-114	effect

DDI-DrugBank.d775.s2	Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON.
succinylcholine	drug	38-52	MIVACRON	brand	102-109	advise

DDI-DrugBank.d775.s3	The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied.
MIVACRON	brand	11-18	succinylcholine	drug	27-41	false
MIVACRON	brand	11-18	succinylcholine	drug	84-98	false
succinylcholine	drug	27-41	succinylcholine	drug	84-98	false

DDI-DrugBank.d775.s4	There are no clinical data on the use of MIVACRON with other nondepolarizing neuromuscular blocking agents.
MIVACRON	brand	41-48	nondepolarizing neuromuscular blocking agents	group	61-105	false

DDI-DrugBank.d775.s5	Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C.
Isoflurane	drug	0-9	enflurane	drug	15-23	false
Isoflurane	drug	0-9	nitrous oxide	drug	44-56	false
Isoflurane	drug	0-9	oxygen	drug	58-63	false
enflurane	drug	15-23	nitrous oxide	drug	44-56	false
enflurane	drug	15-23	oxygen	drug	58-63	false
nitrous oxide	drug	44-56	oxygen	drug	58-63	false

DDI-DrugBank.d775.s8	A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane.
MIVACRON	brand	64-71	enflurane	drug	119-127	false
MIVACRON	brand	64-71	isoflurane	drug	132-141	false
enflurane	drug	119-127	isoflurane	drug	132-141	false

DDI-DrugBank.d775.s10	Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
nondepolarizing agents	drug	67-88	MIVACRON	brand	98-105	false
nondepolarizing agents	drug	67-88	antibiotics	group	123-133	int
nondepolarizing agents	drug	67-88	aminoglycosides	group	142-156	int
nondepolarizing agents	drug	67-88	tetracyclines	group	159-171	int
nondepolarizing agents	drug	67-88	bacitracin	drug	174-183	int
nondepolarizing agents	drug	67-88	polymyxins	group	186-195	int
nondepolarizing agents	drug	67-88	lincomycin	drug	198-207	int
nondepolarizing agents	drug	67-88	clindamycin	drug	210-220	int
nondepolarizing agents	drug	67-88	colistin	drug	223-230	int
nondepolarizing agents	drug	67-88	sodium colistimethate	drug	237-257	int
nondepolarizing agents	drug	67-88	magnesium	group	261-269	int
nondepolarizing agents	drug	67-88	lithium	drug	278-284	int
nondepolarizing agents	drug	67-88	anesthetics	group	293-303	int
nondepolarizing agents	drug	67-88	procainamide	drug	306-317	int
nondepolarizing agents	drug	67-88	quinidine	drug	324-332	int
MIVACRON	brand	98-105	antibiotics	group	123-133	int
MIVACRON	brand	98-105	aminoglycosides	group	142-156	int
MIVACRON	brand	98-105	tetracyclines	group	159-171	int
MIVACRON	brand	98-105	bacitracin	drug	174-183	int
MIVACRON	brand	98-105	polymyxins	group	186-195	int
MIVACRON	brand	98-105	lincomycin	drug	198-207	int
MIVACRON	brand	98-105	clindamycin	drug	210-220	int
MIVACRON	brand	98-105	colistin	drug	223-230	int
MIVACRON	brand	98-105	sodium colistimethate	drug	237-257	int
MIVACRON	brand	98-105	magnesium	group	261-269	int
MIVACRON	brand	98-105	lithium	drug	278-284	int
MIVACRON	brand	98-105	anesthetics	group	293-303	int
MIVACRON	brand	98-105	procainamide	drug	306-317	int
MIVACRON	brand	98-105	quinidine	drug	324-332	int
antibiotics	group	123-133	aminoglycosides	group	142-156	false
antibiotics	group	123-133	tetracyclines	group	159-171	false
antibiotics	group	123-133	bacitracin	drug	174-183	false
antibiotics	group	123-133	polymyxins	group	186-195	false
antibiotics	group	123-133	lincomycin	drug	198-207	false
antibiotics	group	123-133	clindamycin	drug	210-220	false
antibiotics	group	123-133	colistin	drug	223-230	false
antibiotics	group	123-133	sodium colistimethate	drug	237-257	false
antibiotics	group	123-133	magnesium	group	261-269	false
antibiotics	group	123-133	lithium	drug	278-284	false
antibiotics	group	123-133	anesthetics	group	293-303	false
antibiotics	group	123-133	procainamide	drug	306-317	false
antibiotics	group	123-133	quinidine	drug	324-332	false
aminoglycosides	group	142-156	tetracyclines	group	159-171	false
aminoglycosides	group	142-156	bacitracin	drug	174-183	false
aminoglycosides	group	142-156	polymyxins	group	186-195	false
aminoglycosides	group	142-156	lincomycin	drug	198-207	false
aminoglycosides	group	142-156	clindamycin	drug	210-220	false
aminoglycosides	group	142-156	colistin	drug	223-230	false
aminoglycosides	group	142-156	sodium colistimethate	drug	237-257	false
aminoglycosides	group	142-156	magnesium	group	261-269	false
aminoglycosides	group	142-156	lithium	drug	278-284	false
aminoglycosides	group	142-156	anesthetics	group	293-303	false
aminoglycosides	group	142-156	procainamide	drug	306-317	false
aminoglycosides	group	142-156	quinidine	drug	324-332	false
tetracyclines	group	159-171	bacitracin	drug	174-183	false
tetracyclines	group	159-171	polymyxins	group	186-195	false
tetracyclines	group	159-171	lincomycin	drug	198-207	false
tetracyclines	group	159-171	clindamycin	drug	210-220	false
tetracyclines	group	159-171	colistin	drug	223-230	false
tetracyclines	group	159-171	sodium colistimethate	drug	237-257	false
tetracyclines	group	159-171	magnesium	group	261-269	false
tetracyclines	group	159-171	lithium	drug	278-284	false
tetracyclines	group	159-171	anesthetics	group	293-303	false
tetracyclines	group	159-171	procainamide	drug	306-317	false
tetracyclines	group	159-171	quinidine	drug	324-332	false
bacitracin	drug	174-183	polymyxins	group	186-195	false
bacitracin	drug	174-183	lincomycin	drug	198-207	false
bacitracin	drug	174-183	clindamycin	drug	210-220	false
bacitracin	drug	174-183	colistin	drug	223-230	false
bacitracin	drug	174-183	sodium colistimethate	drug	237-257	false
bacitracin	drug	174-183	magnesium	group	261-269	false
bacitracin	drug	174-183	lithium	drug	278-284	false
bacitracin	drug	174-183	anesthetics	group	293-303	false
bacitracin	drug	174-183	procainamide	drug	306-317	false
bacitracin	drug	174-183	quinidine	drug	324-332	false
polymyxins	group	186-195	lincomycin	drug	198-207	false
polymyxins	group	186-195	clindamycin	drug	210-220	false
polymyxins	group	186-195	colistin	drug	223-230	false
polymyxins	group	186-195	sodium colistimethate	drug	237-257	false
polymyxins	group	186-195	magnesium	group	261-269	false
polymyxins	group	186-195	lithium	drug	278-284	false
polymyxins	group	186-195	anesthetics	group	293-303	false
polymyxins	group	186-195	procainamide	drug	306-317	false
polymyxins	group	186-195	quinidine	drug	324-332	false
lincomycin	drug	198-207	clindamycin	drug	210-220	false
lincomycin	drug	198-207	colistin	drug	223-230	false
lincomycin	drug	198-207	sodium colistimethate	drug	237-257	false
lincomycin	drug	198-207	magnesium	group	261-269	false
lincomycin	drug	198-207	lithium	drug	278-284	false
lincomycin	drug	198-207	anesthetics	group	293-303	false
lincomycin	drug	198-207	procainamide	drug	306-317	false
lincomycin	drug	198-207	quinidine	drug	324-332	false
clindamycin	drug	210-220	colistin	drug	223-230	false
clindamycin	drug	210-220	sodium colistimethate	drug	237-257	false
clindamycin	drug	210-220	magnesium	group	261-269	false
clindamycin	drug	210-220	lithium	drug	278-284	false
clindamycin	drug	210-220	anesthetics	group	293-303	false
clindamycin	drug	210-220	procainamide	drug	306-317	false
clindamycin	drug	210-220	quinidine	drug	324-332	false
colistin	drug	223-230	sodium colistimethate	drug	237-257	false
colistin	drug	223-230	magnesium	group	261-269	false
colistin	drug	223-230	lithium	drug	278-284	false
colistin	drug	223-230	anesthetics	group	293-303	false
colistin	drug	223-230	procainamide	drug	306-317	false
colistin	drug	223-230	quinidine	drug	324-332	false
sodium colistimethate	drug	237-257	magnesium	group	261-269	false
sodium colistimethate	drug	237-257	lithium	drug	278-284	false
sodium colistimethate	drug	237-257	anesthetics	group	293-303	false
sodium colistimethate	drug	237-257	procainamide	drug	306-317	false
sodium colistimethate	drug	237-257	quinidine	drug	324-332	false
magnesium	group	261-269	lithium	drug	278-284	false
magnesium	group	261-269	anesthetics	group	293-303	false
magnesium	group	261-269	procainamide	drug	306-317	false
magnesium	group	261-269	quinidine	drug	324-332	false
lithium	drug	278-284	anesthetics	group	293-303	false
lithium	drug	278-284	procainamide	drug	306-317	false
lithium	drug	278-284	quinidine	drug	324-332	false
anesthetics	group	293-303	procainamide	drug	306-317	false
anesthetics	group	293-303	quinidine	drug	324-332	false
procainamide	drug	306-317	quinidine	drug	324-332	false

DDI-DrugBank.d775.s11	The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.
MIVACRON	brand	37-44	contraceptives	group	151-164	effect
MIVACRON	brand	37-44	glucocorticoids	group	167-181	effect
MIVACRON	brand	37-44	monoamine oxidase inhibitors	group	195-222	effect
MIVACRON	brand	37-44	neuromuscular blocking agents	group	354-382	false
MIVACRON	brand	37-44	phenytoin	drug	443-451	false
MIVACRON	brand	37-44	carbamazepine	drug	456-468	false
contraceptives	group	151-164	glucocorticoids	group	167-181	false
contraceptives	group	151-164	monoamine oxidase inhibitors	group	195-222	false
contraceptives	group	151-164	neuromuscular blocking agents	group	354-382	false
contraceptives	group	151-164	phenytoin	drug	443-451	false
contraceptives	group	151-164	carbamazepine	drug	456-468	false
glucocorticoids	group	167-181	monoamine oxidase inhibitors	group	195-222	false
glucocorticoids	group	167-181	neuromuscular blocking agents	group	354-382	false
glucocorticoids	group	167-181	phenytoin	drug	443-451	false
glucocorticoids	group	167-181	carbamazepine	drug	456-468	false
monoamine oxidase inhibitors	group	195-222	neuromuscular blocking agents	group	354-382	false
monoamine oxidase inhibitors	group	195-222	phenytoin	drug	443-451	false
monoamine oxidase inhibitors	group	195-222	carbamazepine	drug	456-468	false
neuromuscular blocking agents	group	354-382	phenytoin	drug	443-451	effect
neuromuscular blocking agents	group	354-382	carbamazepine	drug	456-468	effect
phenytoin	drug	443-451	carbamazepine	drug	456-468	false

DDI-DrugBank.d775.s12	While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.
phenytoin	drug	29-37	carbamazepine	drug	42-54	false
phenytoin	drug	29-37	MIVACRON	brand	81-88	effect
carbamazepine	drug	42-54	MIVACRON	brand	81-88	effect

DDI-DrugBank.d775.s13	Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants
corticosteroids	group	53-67	phenytoin	drug	176-184	false
corticosteroids	group	53-67	carbamazepine	drug	189-201	false
corticosteroids	group	53-67	antibiotics	group	213-223	false
corticosteroids	group	53-67	cisplatin	drug	246-254	false
corticosteroids	group	53-67	edrophonium	drug	258-268	false
corticosteroids	group	53-67	neostigmine	drug	272-282	false
corticosteroids	group	53-67	polymyxin B	drug	286-296	false
corticosteroids	group	53-67	bacitracin	drug	301-310	false
corticosteroids	group	53-67	anesthetics	group	320-330	false
corticosteroids	group	53-67	procaine	drug	340-347	false
corticosteroids	group	53-67	anesthetics	group	359-369	false
corticosteroids	group	53-67	succinylcholine	drug	373-387	false
corticosteroids	group	53-67	muscle relaxants	group	398-413	false
phenytoin	drug	176-184	carbamazepine	drug	189-201	false
phenytoin	drug	176-184	antibiotics	group	213-223	false
phenytoin	drug	176-184	cisplatin	drug	246-254	false
phenytoin	drug	176-184	edrophonium	drug	258-268	false
phenytoin	drug	176-184	neostigmine	drug	272-282	false
phenytoin	drug	176-184	polymyxin B	drug	286-296	false
phenytoin	drug	176-184	bacitracin	drug	301-310	false
phenytoin	drug	176-184	anesthetics	group	320-330	false
phenytoin	drug	176-184	procaine	drug	340-347	false
phenytoin	drug	176-184	anesthetics	group	359-369	false
phenytoin	drug	176-184	succinylcholine	drug	373-387	false
phenytoin	drug	176-184	muscle relaxants	group	398-413	false
carbamazepine	drug	189-201	antibiotics	group	213-223	false
carbamazepine	drug	189-201	cisplatin	drug	246-254	false
carbamazepine	drug	189-201	edrophonium	drug	258-268	false
carbamazepine	drug	189-201	neostigmine	drug	272-282	false
carbamazepine	drug	189-201	polymyxin B	drug	286-296	false
carbamazepine	drug	189-201	bacitracin	drug	301-310	false
carbamazepine	drug	189-201	anesthetics	group	320-330	false
carbamazepine	drug	189-201	procaine	drug	340-347	false
carbamazepine	drug	189-201	anesthetics	group	359-369	false
carbamazepine	drug	189-201	succinylcholine	drug	373-387	false
carbamazepine	drug	189-201	muscle relaxants	group	398-413	false
antibiotics	group	213-223	cisplatin	drug	246-254	false
antibiotics	group	213-223	edrophonium	drug	258-268	false
antibiotics	group	213-223	neostigmine	drug	272-282	false
antibiotics	group	213-223	polymyxin B	drug	286-296	false
antibiotics	group	213-223	bacitracin	drug	301-310	false
antibiotics	group	213-223	anesthetics	group	320-330	false
antibiotics	group	213-223	procaine	drug	340-347	false
antibiotics	group	213-223	anesthetics	group	359-369	false
antibiotics	group	213-223	succinylcholine	drug	373-387	false
antibiotics	group	213-223	muscle relaxants	group	398-413	false
cisplatin	drug	246-254	edrophonium	drug	258-268	false
cisplatin	drug	246-254	neostigmine	drug	272-282	false
cisplatin	drug	246-254	polymyxin B	drug	286-296	false
cisplatin	drug	246-254	bacitracin	drug	301-310	false
cisplatin	drug	246-254	anesthetics	group	320-330	false
cisplatin	drug	246-254	procaine	drug	340-347	false
cisplatin	drug	246-254	anesthetics	group	359-369	false
cisplatin	drug	246-254	succinylcholine	drug	373-387	false
cisplatin	drug	246-254	muscle relaxants	group	398-413	false
edrophonium	drug	258-268	neostigmine	drug	272-282	false
edrophonium	drug	258-268	polymyxin B	drug	286-296	false
edrophonium	drug	258-268	bacitracin	drug	301-310	false
edrophonium	drug	258-268	anesthetics	group	320-330	false
edrophonium	drug	258-268	procaine	drug	340-347	false
edrophonium	drug	258-268	anesthetics	group	359-369	false
edrophonium	drug	258-268	succinylcholine	drug	373-387	false
edrophonium	drug	258-268	muscle relaxants	group	398-413	false
neostigmine	drug	272-282	polymyxin B	drug	286-296	false
neostigmine	drug	272-282	bacitracin	drug	301-310	false
neostigmine	drug	272-282	anesthetics	group	320-330	false
neostigmine	drug	272-282	procaine	drug	340-347	false
neostigmine	drug	272-282	anesthetics	group	359-369	false
neostigmine	drug	272-282	succinylcholine	drug	373-387	false
neostigmine	drug	272-282	muscle relaxants	group	398-413	false
polymyxin B	drug	286-296	bacitracin	drug	301-310	false
polymyxin B	drug	286-296	anesthetics	group	320-330	false
polymyxin B	drug	286-296	procaine	drug	340-347	false
polymyxin B	drug	286-296	anesthetics	group	359-369	false
polymyxin B	drug	286-296	succinylcholine	drug	373-387	false
polymyxin B	drug	286-296	muscle relaxants	group	398-413	false
bacitracin	drug	301-310	anesthetics	group	320-330	false
bacitracin	drug	301-310	procaine	drug	340-347	false
bacitracin	drug	301-310	anesthetics	group	359-369	false
bacitracin	drug	301-310	succinylcholine	drug	373-387	false
bacitracin	drug	301-310	muscle relaxants	group	398-413	false
anesthetics	group	320-330	procaine	drug	340-347	false
anesthetics	group	320-330	anesthetics	group	359-369	false
anesthetics	group	320-330	succinylcholine	drug	373-387	false
anesthetics	group	320-330	muscle relaxants	group	398-413	false
procaine	drug	340-347	anesthetics	group	359-369	false
procaine	drug	340-347	succinylcholine	drug	373-387	false
procaine	drug	340-347	muscle relaxants	group	398-413	false
anesthetics	group	359-369	succinylcholine	drug	373-387	false
anesthetics	group	359-369	muscle relaxants	group	398-413	false
succinylcholine	drug	373-387	muscle relaxants	group	398-413	false

DDI-DrugBank.d732.s0	CHEMET is not known to interact with other drugs including iron supplements;
CHEMET	brand	0-5	iron	drug	59-62	false

DDI-DrugBank.d732.s2	Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended.
CHEMET	brand	30-35	CaNa 2 EDTA	drug	75-85	advise

DDI-DrugBank.d678.s1	The metabolism of Metopirone is accelerated by phenytoin;
Metopirone	brand	18-27	phenytoin	drug	47-55	mechanism

DDI-DrugBank.d678.s4	Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.
Metopirone	brand	0-9	acetaminophen	drug	43-55	mechanism
Metopirone	brand	0-9	acetaminophen	drug	87-99	effect
acetaminophen	drug	43-55	acetaminophen	drug	87-99	false

DDI-DrugBank.d758.s0	The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..
oxycodone hydrochloride	drug	30-52	CNS depressants	group	89-103	effect

DDI-DrugBank.d606.s0	MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine.
MAO inhibitors	group	0-13	beta adrenergic blockers	group	19-42	false
MAO inhibitors	group	0-13	pseudoephedrine	drug	68-82	effect
beta adrenergic blockers	group	19-42	pseudoephedrine	drug	68-82	effect

DDI-DrugBank.d606.s1	Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.
Sympathomimetics	group	0-15	methyldopa	drug	60-69	effect
Sympathomimetics	group	0-15	mecamylamine	drug	72-83	effect
Sympathomimetics	group	0-15	reserpine	drug	86-94	effect
Sympathomimetics	group	0-15	veratrum alkaloids	group	100-117	effect
methyldopa	drug	60-69	mecamylamine	drug	72-83	false
methyldopa	drug	60-69	reserpine	drug	86-94	false
methyldopa	drug	60-69	veratrum alkaloids	group	100-117	false
mecamylamine	drug	72-83	reserpine	drug	86-94	false
mecamylamine	drug	72-83	veratrum alkaloids	group	100-117	false
reserpine	drug	86-94	veratrum alkaloids	group	100-117	false

DDI-DrugBank.d777.s0	The interaction of Streptase, Streptokinase, with other drugs has not been well studied.
Streptase	brand	19-27	Streptokinase	drug	30-42	false

DDI-DrugBank.d777.s1	Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.
Anticoagulants	group	7-20	Antiplatelet Agents	group	26-44	false
Anticoagulants	group	7-20	Streptase	brand	49-57	false
Anticoagulants	group	7-20	Streptokinase	drug	60-72	false
Anticoagulants	group	7-20	antiplatelet agents	group	104-122	false
Anticoagulants	group	7-20	anticoagulants	group	128-141	false
Antiplatelet Agents	group	26-44	Streptase	brand	49-57	false
Antiplatelet Agents	group	26-44	Streptokinase	drug	60-72	false
Antiplatelet Agents	group	26-44	antiplatelet agents	group	104-122	false
Antiplatelet Agents	group	26-44	anticoagulants	group	128-141	false
Streptase	brand	49-57	Streptokinase	drug	60-72	false
Streptase	brand	49-57	antiplatelet agents	group	104-122	effect
Streptase	brand	49-57	anticoagulants	group	128-141	effect
Streptokinase	drug	60-72	antiplatelet agents	group	104-122	effect
Streptokinase	drug	60-72	anticoagulants	group	128-141	effect
antiplatelet agents	group	104-122	anticoagulants	group	128-141	false

DDI-DrugBank.d777.s3	In the treatment of acute MI, aspirin, when not otherwise contraindicated, should be administered with Streptokinase ( see below ).
aspirin	brand	30-36	Streptokinase	drug	103-115	false

DDI-DrugBank.d777.s4	Anticoagulation and Antiplatelets After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of aspirin has been shown to reduce the incidence of reinfarction and stroke.
Antiplatelets	group	20-32	aspirin	brand	139-145	false

DDI-DrugBank.d777.s5	The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see
aspirin	brand	16-22	Streptokinase	drug	27-39	effect

DDI-DrugBank.d654.s0	Co-administration of oral ketoconazole 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.
ketoconazole	drug	26-37	retapamulin	drug	68-78	false
ketoconazole	drug	26-37	retapamulin	drug	150-160	mechanism
retapamulin	drug	68-78	retapamulin	drug	150-160	false

DDI-DrugBank.d654.s1	Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as ketoconazole.
retapamulin	drug	32-42	retapamulin	drug	110-120	false
retapamulin	drug	32-42	ketoconazole	drug	191-202	false
retapamulin	drug	110-120	ketoconazole	drug	191-202	false

DDI-DrugBank.d654.s2	Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of ALTABAX, retapamulin is unlikely to affect the metabolism of other P450 substrates.
ALTABAX	brand	114-120	retapamulin	drug	123-133	false

DDI-DrugBank.d710.s0	Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known.
Cimetidine	drug	0-9	cimetidine	drug	35-44	false
Cimetidine	drug	0-9	rimantadine	drug	71-81	false
cimetidine	drug	35-44	rimantadine	drug	71-81	false

DDI-DrugBank.d710.s1	When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).
rimantadine HCl	drug	29-43	Cimetidine	drug	95-104	mechanism
rimantadine HCl	drug	29-43	rimantadine	drug	152-162	false
rimantadine HCl	drug	29-43	rimantadine	drug	270-280	false
rimantadine HCl	drug	29-43	cimetidine	drug	331-340	false
Cimetidine	drug	95-104	rimantadine	drug	152-162	false
Cimetidine	drug	95-104	rimantadine	drug	270-280	false
Cimetidine	drug	95-104	cimetidine	drug	331-340	false
rimantadine	drug	152-162	rimantadine	drug	270-280	false
rimantadine	drug	152-162	cimetidine	drug	331-340	false
rimantadine	drug	270-280	cimetidine	drug	331-340	false

DDI-DrugBank.d710.s2	Acetaminophen: Rimantadine HCl, 100 mg, was given twice daily for 13 days to 12 healthy volunteers.
Acetaminophen	drug	0-12	Rimantadine HCl	drug	15-29	false

DDI-DrugBank.d710.s5	Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%.
acetaminophen	drug	22-34	rimantadine	drug	86-96	mechanism

DDI-DrugBank.d710.s6	Aspirin: Rimantadine HCl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers.
Aspirin	brand	0-6	Rimantadine HCl	drug	9-23	false

DDI-DrugBank.d710.s9	Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.
rimantadine	drug	38-48	aspirin	brand	100-106	mechanism

DDI-DrugBank.d661.s0	Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.
ZEMURON	brand	30-36	rocuronium bromide	drug	42-59	false
ZEMURON	brand	30-36	succinylcholine	drug	79-93	false
ZEMURON	brand	30-36	succinylcholine	drug	155-169	false
rocuronium bromide	drug	42-59	succinylcholine	drug	79-93	false
rocuronium bromide	drug	42-59	succinylcholine	drug	155-169	false
succinylcholine	drug	79-93	succinylcholine	drug	155-169	false

DDI-DrugBank.d661.s1	If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed.
ZEMURON	brand	3-9	succinylcholine	drug	58-72	advise
ZEMURON	brand	3-9	succinylcholine	drug	118-132	false
succinylcholine	drug	58-72	succinylcholine	drug	118-132	false

DDI-DrugBank.d661.s2	The median duration of action of ZEMURON    0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs.
ZEMURON	brand	33-39	succinylcholine	drug	91-105	false

DDI-DrugBank.d661.s4	There are no controlled studies documenting the use of ZEMURON    before or after other nondepolarizing muscle relaxants.
ZEMURON	brand	55-61	nondepolarizing muscle relaxants	group	88-119	false

DDI-DrugBank.d709.s1	Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.
Terfenadine	drug	48-58	astemizole	drug	64-73	false
Terfenadine	drug	48-58	macrolides	group	84-93	false
Terfenadine	drug	48-58	terfenadine	drug	109-119	false
Terfenadine	drug	48-58	astemizole	drug	125-134	false
astemizole	drug	64-73	macrolides	group	84-93	false
astemizole	drug	64-73	terfenadine	drug	109-119	false
astemizole	drug	64-73	astemizole	drug	125-134	false
macrolides	group	84-93	terfenadine	drug	109-119	int
macrolides	group	84-93	astemizole	drug	125-134	int
terfenadine	drug	109-119	astemizole	drug	125-134	false

DDI-DrugBank.d709.s3	Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended.
roxithromycin	drug	56-68	roxithromycin	drug	101-113	false
roxithromycin	drug	56-68	terfenadine	drug	120-130	false
roxithromycin	drug	56-68	astemizole	drug	135-144	false
roxithromycin	drug	101-113	terfenadine	drug	120-130	advise
roxithromycin	drug	101-113	astemizole	drug	135-144	advise
terfenadine	drug	120-130	astemizole	drug	135-144	false

DDI-DrugBank.d709.s4	- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.
Cisapride	drug	2-10	pimozide	drug	13-20	false
Cisapride	drug	2-10	cisapride	drug	43-51	false
Cisapride	drug	2-10	pimozide	drug	56-63	false
Cisapride	drug	2-10	macrolide antibacterials	group	352-375	false
pimozide	drug	13-20	cisapride	drug	43-51	false
pimozide	drug	13-20	pimozide	drug	56-63	false
pimozide	drug	13-20	macrolide antibacterials	group	352-375	mechanism
cisapride	drug	43-51	pimozide	drug	56-63	false
cisapride	drug	43-51	macrolide antibacterials	group	352-375	mechanism
pimozide	drug	56-63	macrolide antibacterials	group	352-375	false

DDI-DrugBank.d709.s5	Although such a risk is not verified for roxithromycin, combination of roxithromycin with such drugs is not recommended.
roxithromycin	drug	41-53	roxithromycin	drug	71-83	false

DDI-DrugBank.d676.s0	To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, hypotensive agents or phenothiazines should be used with caution.
barbiturates	group	54-65	antihistamines	group	68-81	false
barbiturates	group	54-65	narcotics	group	84-92	false
barbiturates	group	54-65	hypotensive agents	group	95-112	false
barbiturates	group	54-65	phenothiazines	group	117-130	false
antihistamines	group	68-81	narcotics	group	84-92	false
antihistamines	group	68-81	hypotensive agents	group	95-112	false
antihistamines	group	68-81	phenothiazines	group	117-130	false
narcotics	group	84-92	hypotensive agents	group	95-112	false
narcotics	group	84-92	phenothiazines	group	117-130	false
hypotensive agents	group	95-112	phenothiazines	group	117-130	false

DDI-DrugBank.d676.s2	Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.
Matulane	brand	8-15	sympathomimetic drugs	group	70-90	advise
Matulane	brand	8-15	tricyclic antidepressant	group	93-116	advise
Matulane	brand	8-15	amitriptyline HCl	drug	131-147	advise
Matulane	brand	8-15	imipramine HCl	drug	150-163	advise
Matulane	brand	8-15	tyramine	drug_n	208-215	advise
sympathomimetic drugs	group	70-90	tricyclic antidepressant	group	93-116	false
sympathomimetic drugs	group	70-90	amitriptyline HCl	drug	131-147	false
sympathomimetic drugs	group	70-90	imipramine HCl	drug	150-163	false
sympathomimetic drugs	group	70-90	tyramine	drug_n	208-215	false
tricyclic antidepressant	group	93-116	amitriptyline HCl	drug	131-147	false
tricyclic antidepressant	group	93-116	imipramine HCl	drug	150-163	false
tricyclic antidepressant	group	93-116	tyramine	drug_n	208-215	false
amitriptyline HCl	drug	131-147	imipramine HCl	drug	150-163	false
amitriptyline HCl	drug	131-147	tyramine	drug_n	208-215	false
imipramine HCl	drug	150-163	tyramine	drug_n	208-215	false

DDI-DrugBank.d676.s4	No cross-resistance with other chemotherapeutic agents, radiotherapy or steroids has been demonstrated.
chemotherapeutic agents	group	31-53	steroids	group	72-79	false

DDI-DrugBank.d712.s1	Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.
paclitaxel	drug	18-27	HERCEPTIN	brand	49-57	mechanism
paclitaxel	drug	18-27	HERCEPTIN	brand	94-102	false
paclitaxel	drug	18-27	HERCEPTIN	brand	173-181	false
HERCEPTIN	brand	49-57	HERCEPTIN	brand	94-102	false
HERCEPTIN	brand	49-57	HERCEPTIN	brand	173-181	false
HERCEPTIN	brand	94-102	HERCEPTIN	brand	173-181	false

DDI-DrugBank.d598.s0	Trimethoprim may inhibit the hepatic metabolism of phenytoin.
Trimethoprim	drug	0-11	phenytoin	drug	51-59	mechanism

DDI-DrugBank.d598.s1	Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.
Trimethoprim	drug	0-11	phenytoin	drug	63-71	mechanism
Trimethoprim	drug	0-11	phenytoin	drug	108-116	mechanism
phenytoin	drug	63-71	phenytoin	drug	108-116	false

DDI-DrugBank.d616.s1	Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs.
ZADAXIN	brand	47-53	immunomodulating drugs	group	89-110	advise

DDI-DrugBank.d618.s1	In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase    therapy.
heparin	drug	40-46	vitamin K antagonists	group	52-72	false
heparin	drug	40-46	aspirin	brand	119-125	false
heparin	drug	40-46	dipyridamole	drug	128-139	false
heparin	drug	40-46	abciximab	drug	146-154	false
heparin	drug	40-46	Retavase	brand	225-232	effect
vitamin K antagonists	group	52-72	aspirin	brand	119-125	false
vitamin K antagonists	group	52-72	dipyridamole	drug	128-139	false
vitamin K antagonists	group	52-72	abciximab	drug	146-154	false
vitamin K antagonists	group	52-72	Retavase	brand	225-232	effect
aspirin	brand	119-125	dipyridamole	drug	128-139	false
aspirin	brand	119-125	abciximab	drug	146-154	false
aspirin	brand	119-125	Retavase	brand	225-232	effect
dipyridamole	drug	128-139	abciximab	drug	146-154	false
dipyridamole	drug	128-139	Retavase	brand	225-232	effect
abciximab	drug	146-154	Retavase	brand	225-232	effect

DDI-DrugBank.d635.s0	Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.
short-acting beta adrenergic aerosol bronchodilators	group	6-57	MAXAIR AUTOHALER	brand	97-112	advise

DDI-DrugBank.d697.s0	Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants
Vitamin B1	drug	17-26	Thiamine	drug	29-36	false
Vitamin B1	drug	17-26	Loop Diuretics	group	41-54	int
Vitamin B1	drug	17-26	Contraceptives	group	62-75	int
Vitamin B1	drug	17-26	Stavudine	drug	78-86	int
Vitamin B1	drug	17-26	Tricyclic Antidepressants	group	89-113	int
Thiamine	drug	29-36	Loop Diuretics	group	41-54	int
Thiamine	drug	29-36	Contraceptives	group	62-75	int
Thiamine	drug	29-36	Stavudine	drug	78-86	int
Thiamine	drug	29-36	Tricyclic Antidepressants	group	89-113	int
Loop Diuretics	group	41-54	Contraceptives	group	62-75	false
Loop Diuretics	group	41-54	Stavudine	drug	78-86	false
Loop Diuretics	group	41-54	Tricyclic Antidepressants	group	89-113	false
Contraceptives	group	62-75	Stavudine	drug	78-86	false
Contraceptives	group	62-75	Tricyclic Antidepressants	group	89-113	false
Stavudine	drug	78-86	Tricyclic Antidepressants	group	89-113	false

DDI-DrugBank.d782.s0	Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine
Vindesine	drug	0-8	Phenytoin	drug	310-318	int
Vindesine	drug	0-8	Live virus vaccines	group	353-371	int
Vindesine	drug	0-8	vaccine	drug	412-418	false
Vindesine	drug	0-8	Mitomycin-C	drug	526-536	int
Vindesine	drug	0-8	Killed virus vaccines	group	588-608	int
Vindesine	drug	0-8	vaccine	group	650-656	false
Phenytoin	drug	310-318	Live virus vaccines	group	353-371	false
Phenytoin	drug	310-318	vaccine	drug	412-418	false
Phenytoin	drug	310-318	Mitomycin-C	drug	526-536	false
Phenytoin	drug	310-318	Killed virus vaccines	group	588-608	false
Phenytoin	drug	310-318	vaccine	group	650-656	false
Live virus vaccines	group	353-371	vaccine	drug	412-418	false
Live virus vaccines	group	353-371	Mitomycin-C	drug	526-536	false
Live virus vaccines	group	353-371	Killed virus vaccines	group	588-608	false
Live virus vaccines	group	353-371	vaccine	group	650-656	false
vaccine	drug	412-418	Mitomycin-C	drug	526-536	false
vaccine	drug	412-418	Killed virus vaccines	group	588-608	false
vaccine	drug	412-418	vaccine	group	650-656	false
Mitomycin-C	drug	526-536	Killed virus vaccines	group	588-608	false
Mitomycin-C	drug	526-536	vaccine	group	650-656	false
Killed virus vaccines	group	588-608	vaccine	group	650-656	false

DDI-DrugBank.d759.s0	Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.
ascorbic acid	drug	31-43	bishydroxycoumarin	drug	99-116	mechanism

DDI-DrugBank.d591.s0	Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.
Ropivacaine	drug	0-10	anesthetics	group	74-84	advise
Ropivacaine	drug	0-10	amide-type local anesthetics	group	120-147	false
anesthetics	group	74-84	amide-type local anesthetics	group	120-147	false

DDI-DrugBank.d591.s2	In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.
ropivacaine	drug	33-43	fluvoxamine	drug	91-101	mechanism

DDI-DrugBank.d591.s3	Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels.
fluvoxamine	drug	54-64	Ropivacaine	drug	112-122	int
fluvoxamine	drug	54-64	Ropivacaine	drug	143-153	false
fluvoxamine	drug	54-64	ropivacaine	drug	176-186	false
Ropivacaine	drug	112-122	Ropivacaine	drug	143-153	false
Ropivacaine	drug	112-122	ropivacaine	drug	176-186	false
Ropivacaine	drug	143-153	ropivacaine	drug	176-186	false

DDI-DrugBank.d591.s5	Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur.
theophylline	drug	102-113	imipramine	drug	119-128	false

DDI-DrugBank.d591.s6	Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.
ketoconazole	drug	64-75	ropivacaine	drug	105-115	false
ketoconazole	drug	64-75	ketoconazole	drug	152-163	false
ketoconazole	drug	64-75	ropivacaine	drug	220-230	mechanism
ropivacaine	drug	105-115	ketoconazole	drug	152-163	false
ropivacaine	drug	105-115	ropivacaine	drug	220-230	false
ketoconazole	drug	152-163	ropivacaine	drug	220-230	false

DDI-DrugBank.d632.s0	Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).
SYMLIN	brand	40-45	anticholinergic agents	group	150-171	advise
SYMLIN	brand	40-45	atropine	drug	181-188	advise
SYMLIN	brand	40-45	alpha glucosidase inhibitors	group	258-285	advise
anticholinergic agents	group	150-171	atropine	drug	181-188	false
anticholinergic agents	group	150-171	alpha glucosidase inhibitors	group	258-285	false
atropine	drug	181-188	alpha glucosidase inhibitors	group	258-285	false

DDI-DrugBank.d632.s3	When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as analgesics), the agent should be administered at least 1 hour prior to or 2 hours after SYMLIN injection.
analgesics	group	116-125	SYMLIN	brand	204-209	advise

DDI-DrugBank.d632.s4	In clinical trials, the concomitant use of sulfonylureas or biguanides did not alter the adverse event profile of SYMLIN.
sulfonylureas	group	43-55	biguanides	group	60-69	false
sulfonylureas	group	43-55	SYMLIN	brand	114-119	false
biguanides	group	60-69	SYMLIN	brand	114-119	false

DDI-DrugBank.d632.s5	No formal interaction studies have been performed to assess the effect of SYMLIN on the kinetics of oral antidiabetic agents.
SYMLIN	brand	74-79	antidiabetic agents	group	105-123	false

DDI-DrugBank.d632.s6	Mixing SYMLIN and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.
SYMLIN	brand	7-12	Insulin	drug	18-24	false
SYMLIN	brand	7-12	SYMLIN	brand	60-65	false
SYMLIN	brand	7-12	human insulin	drug	157-169	false
Insulin	drug	18-24	SYMLIN	brand	60-65	false
Insulin	drug	18-24	human insulin	drug	157-169	false
SYMLIN	brand	60-65	human insulin	drug	157-169	mechanism

DDI-DrugBank.d632.s7	Thus, SYMLIN and insulin should not be mixed and must be administered separately.
SYMLIN	brand	6-11	insulin	drug	17-23	false

DDI-DrugBank.d763.s1	Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron.
ondansetron	drug	8-18	ondansetron	drug	209-219	false

DDI-DrugBank.d763.s3	Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
Phenytoin	drug	0-8	Carbamazepine	drug	11-23	false
Phenytoin	drug	0-8	Rifampicin	drug	30-39	false
Phenytoin	drug	0-8	phenytoin	drug	100-108	false
Phenytoin	drug	0-8	carbamazepine	drug	111-123	false
Phenytoin	drug	0-8	rifampicin	drug	130-139	false
Phenytoin	drug	0-8	ondansetron	drug	160-170	false
Phenytoin	drug	0-8	ondansetron	drug	204-214	false
Carbamazepine	drug	11-23	Rifampicin	drug	30-39	false
Carbamazepine	drug	11-23	phenytoin	drug	100-108	false
Carbamazepine	drug	11-23	carbamazepine	drug	111-123	false
Carbamazepine	drug	11-23	rifampicin	drug	130-139	false
Carbamazepine	drug	11-23	ondansetron	drug	160-170	false
Carbamazepine	drug	11-23	ondansetron	drug	204-214	false
Rifampicin	drug	30-39	phenytoin	drug	100-108	false
Rifampicin	drug	30-39	carbamazepine	drug	111-123	false
Rifampicin	drug	30-39	rifampicin	drug	130-139	false
Rifampicin	drug	30-39	ondansetron	drug	160-170	false
Rifampicin	drug	30-39	ondansetron	drug	204-214	false
phenytoin	drug	100-108	carbamazepine	drug	111-123	false
phenytoin	drug	100-108	rifampicin	drug	130-139	false
phenytoin	drug	100-108	ondansetron	drug	160-170	mechanism
phenytoin	drug	100-108	ondansetron	drug	204-214	mechanism
carbamazepine	drug	111-123	rifampicin	drug	130-139	false
carbamazepine	drug	111-123	ondansetron	drug	160-170	mechanism
carbamazepine	drug	111-123	ondansetron	drug	204-214	mechanism
rifampicin	drug	130-139	ondansetron	drug	160-170	mechanism
rifampicin	drug	130-139	ondansetron	drug	204-214	mechanism
ondansetron	drug	160-170	ondansetron	drug	204-214	false

DDI-DrugBank.d763.s4	However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.
ondansetron	drug	66-76	Tramadol	drug	126-133	false
ondansetron	drug	66-76	ondansetron	drug	189-199	false
ondansetron	drug	66-76	tramadol	drug	205-212	false
ondansetron	drug	66-76	ondansetron	drug	273-283	false
ondansetron	drug	66-76	tramadol	drug	360-367	false
ondansetron	drug	66-76	ondansetron	drug	472-482	false
Tramadol	drug	126-133	ondansetron	drug	189-199	false
Tramadol	drug	126-133	tramadol	drug	205-212	false
Tramadol	drug	126-133	ondansetron	drug	273-283	false
Tramadol	drug	126-133	tramadol	drug	360-367	false
Tramadol	drug	126-133	ondansetron	drug	472-482	false
ondansetron	drug	189-199	tramadol	drug	205-212	false
ondansetron	drug	189-199	ondansetron	drug	273-283	false
ondansetron	drug	189-199	tramadol	drug	360-367	false
ondansetron	drug	189-199	ondansetron	drug	472-482	false
tramadol	drug	205-212	ondansetron	drug	273-283	false
tramadol	drug	205-212	tramadol	drug	360-367	false
tramadol	drug	205-212	ondansetron	drug	472-482	false
ondansetron	drug	273-283	tramadol	drug	360-367	effect
ondansetron	drug	273-283	ondansetron	drug	472-482	false
tramadol	drug	360-367	ondansetron	drug	472-482	false

DDI-DrugBank.d763.s5	In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.
carmustine	drug	11-20	etoposide	drug	23-31	false
carmustine	drug	11-20	cisplatin	drug	38-46	false
carmustine	drug	11-20	ondansetron	drug	86-96	false
etoposide	drug	23-31	cisplatin	drug	38-46	false
etoposide	drug	23-31	ondansetron	drug	86-96	false
cisplatin	drug	38-46	ondansetron	drug	86-96	false

DDI-DrugBank.d763.s7	ondansetron did not increase blood levels of high-dose methotrexate.
ondansetron	drug	0-10	methotrexate	drug	55-66	false

DDI-DrugBank.d638.s0	Ritalin may decrease the hypotensive effect of guanethidine.
Ritalin	brand	0-6	guanethidine	drug	47-58	effect

DDI-DrugBank.d638.s2	Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).
Ritalin	brand	44-50	coumarin anticoagulants	group	82-104	mechanism
Ritalin	brand	44-50	anticonvulsants	group	107-121	mechanism
Ritalin	brand	44-50	phenobarbital	drug	124-136	mechanism
Ritalin	brand	44-50	diphenylhydantoin	drug	139-155	mechanism
Ritalin	brand	44-50	primidone	drug	158-166	mechanism
Ritalin	brand	44-50	phenylbutazone	drug	170-183	mechanism
Ritalin	brand	44-50	tricyclic drugs	group	190-204	mechanism
Ritalin	brand	44-50	imipramine	drug	207-216	mechanism
Ritalin	brand	44-50	clomipramine	drug	219-230	mechanism
Ritalin	brand	44-50	desipramine	drug	233-243	mechanism
coumarin anticoagulants	group	82-104	anticonvulsants	group	107-121	false
coumarin anticoagulants	group	82-104	phenobarbital	drug	124-136	false
coumarin anticoagulants	group	82-104	diphenylhydantoin	drug	139-155	false
coumarin anticoagulants	group	82-104	primidone	drug	158-166	false
coumarin anticoagulants	group	82-104	phenylbutazone	drug	170-183	false
coumarin anticoagulants	group	82-104	tricyclic drugs	group	190-204	false
coumarin anticoagulants	group	82-104	imipramine	drug	207-216	false
coumarin anticoagulants	group	82-104	clomipramine	drug	219-230	false
coumarin anticoagulants	group	82-104	desipramine	drug	233-243	false
anticonvulsants	group	107-121	phenobarbital	drug	124-136	false
anticonvulsants	group	107-121	diphenylhydantoin	drug	139-155	false
anticonvulsants	group	107-121	primidone	drug	158-166	false
anticonvulsants	group	107-121	phenylbutazone	drug	170-183	false
anticonvulsants	group	107-121	tricyclic drugs	group	190-204	false
anticonvulsants	group	107-121	imipramine	drug	207-216	false
anticonvulsants	group	107-121	clomipramine	drug	219-230	false
anticonvulsants	group	107-121	desipramine	drug	233-243	false
phenobarbital	drug	124-136	diphenylhydantoin	drug	139-155	false
phenobarbital	drug	124-136	primidone	drug	158-166	false
phenobarbital	drug	124-136	phenylbutazone	drug	170-183	false
phenobarbital	drug	124-136	tricyclic drugs	group	190-204	false
phenobarbital	drug	124-136	imipramine	drug	207-216	false
phenobarbital	drug	124-136	clomipramine	drug	219-230	false
phenobarbital	drug	124-136	desipramine	drug	233-243	false
diphenylhydantoin	drug	139-155	primidone	drug	158-166	false
diphenylhydantoin	drug	139-155	phenylbutazone	drug	170-183	false
diphenylhydantoin	drug	139-155	tricyclic drugs	group	190-204	false
diphenylhydantoin	drug	139-155	imipramine	drug	207-216	false
diphenylhydantoin	drug	139-155	clomipramine	drug	219-230	false
diphenylhydantoin	drug	139-155	desipramine	drug	233-243	false
primidone	drug	158-166	phenylbutazone	drug	170-183	false
primidone	drug	158-166	tricyclic drugs	group	190-204	false
primidone	drug	158-166	imipramine	drug	207-216	false
primidone	drug	158-166	clomipramine	drug	219-230	false
primidone	drug	158-166	desipramine	drug	233-243	false
phenylbutazone	drug	170-183	tricyclic drugs	group	190-204	false
phenylbutazone	drug	170-183	imipramine	drug	207-216	false
phenylbutazone	drug	170-183	clomipramine	drug	219-230	false
phenylbutazone	drug	170-183	desipramine	drug	233-243	false
tricyclic drugs	group	190-204	imipramine	drug	207-216	false
tricyclic drugs	group	190-204	clomipramine	drug	219-230	false
tricyclic drugs	group	190-204	desipramine	drug	233-243	false
imipramine	drug	207-216	clomipramine	drug	219-230	false
imipramine	drug	207-216	desipramine	drug	233-243	false
clomipramine	drug	219-230	desipramine	drug	233-243	false

DDI-DrugBank.d638.s5	The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.
methylphenidate	drug	20-34	clonidine	drug	56-64	false
methylphenidate	drug	20-34	alpha-2 agonists	group	92-107	false
clonidine	drug	56-64	alpha-2 agonists	group	92-107	false

DDI-DrugBank.d783.s0	Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants.
Posicor	brand	0-6	terfenadine	drug	78-88	mechanism
Posicor	brand	0-6	astemizole	drug	91-100	mechanism
Posicor	brand	0-6	cisapride	drug	103-111	mechanism
Posicor	brand	0-6	cyclosporine	drug	114-125	mechanism
Posicor	brand	0-6	tricyclic antidepressants	group	132-156	mechanism
terfenadine	drug	78-88	astemizole	drug	91-100	false
terfenadine	drug	78-88	cisapride	drug	103-111	false
terfenadine	drug	78-88	cyclosporine	drug	114-125	false
terfenadine	drug	78-88	tricyclic antidepressants	group	132-156	false
astemizole	drug	91-100	cisapride	drug	103-111	false
astemizole	drug	91-100	cyclosporine	drug	114-125	false
astemizole	drug	91-100	tricyclic antidepressants	group	132-156	false
cisapride	drug	103-111	cyclosporine	drug	114-125	false
cisapride	drug	103-111	tricyclic antidepressants	group	132-156	false
cyclosporine	drug	114-125	tricyclic antidepressants	group	132-156	false

DDI-DrugBank.d624.s0	In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.
TOBI	brand	23-26	TOBI	brand	45-48	false
TOBI	brand	23-26	dornase alfa	drug	69-80	false
TOBI	brand	23-26	PULMOZYME	brand	83-91	false
TOBI	brand	23-26	(beta)-agonists	group	109-123	false
TOBI	brand	23-26	corticosteroids	group	134-148	false
TOBI	brand	23-26	anti-pseudomonal antibiotics	group	157-184	false
TOBI	brand	23-26	aminoglycosides	group	201-215	false
TOBI	brand	45-48	dornase alfa	drug	69-80	effect
TOBI	brand	45-48	PULMOZYME	brand	83-91	effect
TOBI	brand	45-48	(beta)-agonists	group	109-123	effect
TOBI	brand	45-48	corticosteroids	group	134-148	effect
TOBI	brand	45-48	anti-pseudomonal antibiotics	group	157-184	effect
TOBI	brand	45-48	aminoglycosides	group	201-215	effect
dornase alfa	drug	69-80	PULMOZYME	brand	83-91	false
dornase alfa	drug	69-80	(beta)-agonists	group	109-123	false
dornase alfa	drug	69-80	corticosteroids	group	134-148	false
dornase alfa	drug	69-80	anti-pseudomonal antibiotics	group	157-184	false
dornase alfa	drug	69-80	aminoglycosides	group	201-215	false
PULMOZYME	brand	83-91	(beta)-agonists	group	109-123	false
PULMOZYME	brand	83-91	corticosteroids	group	134-148	false
PULMOZYME	brand	83-91	anti-pseudomonal antibiotics	group	157-184	false
PULMOZYME	brand	83-91	aminoglycosides	group	201-215	false
(beta)-agonists	group	109-123	corticosteroids	group	134-148	false
(beta)-agonists	group	109-123	anti-pseudomonal antibiotics	group	157-184	false
(beta)-agonists	group	109-123	aminoglycosides	group	201-215	false
corticosteroids	group	134-148	anti-pseudomonal antibiotics	group	157-184	false
corticosteroids	group	134-148	aminoglycosides	group	201-215	false
anti-pseudomonal antibiotics	group	157-184	aminoglycosides	group	201-215	false

DDI-DrugBank.d624.s2	Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue.
diuretics	group	5-13	aminoglycoside	group	27-40	effect
diuretics	group	5-13	antibiotic	group	63-72	false
aminoglycoside	group	27-40	antibiotic	group	63-72	false

DDI-DrugBank.d624.s3	TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.
TOBI	brand	0-3	ethacrynic acid	drug	51-65	advise
TOBI	brand	0-3	furosemide	drug	68-77	advise
TOBI	brand	0-3	urea	drug	80-83	advise
TOBI	brand	0-3	mannitol	drug	89-96	advise
ethacrynic acid	drug	51-65	furosemide	drug	68-77	false
ethacrynic acid	drug	51-65	urea	drug	80-83	false
ethacrynic acid	drug	51-65	mannitol	drug	89-96	false
furosemide	drug	68-77	urea	drug	80-83	false
furosemide	drug	68-77	mannitol	drug	89-96	false
urea	drug	80-83	mannitol	drug	89-96	false

DDI-DrugBank.d637.s0	Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.
Central Nervous System Depressants	group	15-48	morphine	drug	77-84	false
Central Nervous System Depressants	group	15-48	CNS depressants	group	127-141	false
Central Nervous System Depressants	group	15-48	alcohol	drug	151-157	false
Central Nervous System Depressants	group	15-48	sedatives	group	160-168	false
Central Nervous System Depressants	group	15-48	antihistaminics	group	171-185	false
Central Nervous System Depressants	group	15-48	psychotropic drugs	group	191-208	false
morphine	drug	77-84	CNS depressants	group	127-141	effect
morphine	drug	77-84	alcohol	drug	151-157	effect
morphine	drug	77-84	sedatives	group	160-168	effect
morphine	drug	77-84	antihistaminics	group	171-185	effect
morphine	drug	77-84	psychotropic drugs	group	191-208	effect
CNS depressants	group	127-141	alcohol	drug	151-157	false
CNS depressants	group	127-141	sedatives	group	160-168	false
CNS depressants	group	127-141	antihistaminics	group	171-185	false
CNS depressants	group	127-141	psychotropic drugs	group	191-208	false
alcohol	drug	151-157	sedatives	group	160-168	false
alcohol	drug	151-157	antihistaminics	group	171-185	false
alcohol	drug	151-157	psychotropic drugs	group	191-208	false
sedatives	group	160-168	antihistaminics	group	171-185	false
sedatives	group	160-168	psychotropic drugs	group	191-208	false
antihistaminics	group	171-185	psychotropic drugs	group	191-208	false

DDI-DrugBank.d637.s1	Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma.
neuroleptics	group	7-18	morphine	drug	45-52	effect

DDI-DrugBank.d637.s2	Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.
Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	Agonist/antagonist analgesics	group	61-89	false
Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	pentazocine	drug	98-108	false
Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	nalbuphine	drug	111-120	false
Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	butorphanol	drug	123-133	false
Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	buprenorphine	drug	139-151	false
Mixed Agonist/Antagonist Opioid Analgesics	group	17-58	opioid agonist analgesic	group	261-284	false
Agonist/antagonist analgesics	group	61-89	pentazocine	drug	98-108	false
Agonist/antagonist analgesics	group	61-89	nalbuphine	drug	111-120	false
Agonist/antagonist analgesics	group	61-89	butorphanol	drug	123-133	false
Agonist/antagonist analgesics	group	61-89	buprenorphine	drug	139-151	false
Agonist/antagonist analgesics	group	61-89	opioid agonist analgesic	group	261-284	advise
pentazocine	drug	98-108	nalbuphine	drug	111-120	false
pentazocine	drug	98-108	butorphanol	drug	123-133	false
pentazocine	drug	98-108	buprenorphine	drug	139-151	false
pentazocine	drug	98-108	opioid agonist analgesic	group	261-284	advise
nalbuphine	drug	111-120	butorphanol	drug	123-133	false
nalbuphine	drug	111-120	buprenorphine	drug	139-151	false
nalbuphine	drug	111-120	opioid agonist analgesic	group	261-284	advise
butorphanol	drug	123-133	buprenorphine	drug	139-151	false
butorphanol	drug	123-133	opioid agonist analgesic	group	261-284	advise
buprenorphine	drug	139-151	opioid agonist analgesic	group	261-284	advise

DDI-DrugBank.d633.s0	Since MEXITIL is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations.
MEXITIL	brand	6-12	mexiletine	drug	171-180	false

DDI-DrugBank.d633.s1	In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2.
mexiletine	drug	74-83	fluvoxamine	drug	140-150	mechanism

DDI-DrugBank.d633.s2	In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group.
propafenone	drug	101-111	mexiletine	drug	143-152	false

DDI-DrugBank.d633.s4	In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine.
propafenone	drug	62-72	mexiletine	drug	137-146	false

DDI-DrugBank.d633.s5	Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone.
mexiletine	drug	12-21	propafenone	drug	26-36	false
mexiletine	drug	12-21	propafenone	drug	141-151	false
propafenone	drug	26-36	propafenone	drug	141-151	false

DDI-DrugBank.d633.s6	When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect.
mexiletine	drug	66-75	mexiletine	drug	103-112	false

DDI-DrugBank.d633.s7	In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions.
Mexitil	brand	37-43	antihypertensive	group	111-126	false
Mexitil	brand	37-43	anticoagulant drugs	group	133-151	false
antihypertensive	group	111-126	anticoagulant drugs	group	133-151	false

DDI-DrugBank.d633.s8	A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy.
antiarrhythmics	group	13-27	quinidine	drug	37-45	false
antiarrhythmics	group	13-27	propranolol	drug	50-60	false
quinidine	drug	37-45	propranolol	drug	50-60	false

DDI-DrugBank.d633.s9	When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported.
phenytoin	drug	5-13	rifampin	drug	56-63	false
phenytoin	drug	5-13	phenobarbital	drug	69-81	false
phenytoin	drug	5-13	Mexitil	brand	117-123	mechanism
phenytoin	drug	5-13	Mexitil	brand	137-143	false
rifampin	drug	56-63	phenobarbital	drug	69-81	false
rifampin	drug	56-63	Mexitil	brand	117-123	mechanism
rifampin	drug	56-63	Mexitil	brand	137-143	false
phenobarbital	drug	69-81	Mexitil	brand	117-123	mechanism
phenobarbital	drug	69-81	Mexitil	brand	137-143	false
Mexitil	brand	117-123	Mexitil	brand	137-143	false

DDI-DrugBank.d633.s11	In a formal study, benzodiazepines were shown not to affect Mexitil    plasma concentrations.
benzodiazepines	group	19-33	Mexitil	brand	60-66	false

DDI-DrugBank.d633.s12	ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol.
Mexitil	brand	64-70	digoxin	drug	79-85	false
Mexitil	brand	64-70	diuretics	group	88-96	false
Mexitil	brand	64-70	propranolol	drug	102-112	false
digoxin	drug	79-85	diuretics	group	88-96	false
digoxin	drug	79-85	propranolol	drug	102-112	false
diuretics	group	88-96	propranolol	drug	102-112	false

DDI-DrugBank.d633.s13	Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels;
cimetidine	drug	29-38	Mexitil	brand	44-50	mechanism
cimetidine	drug	29-38	Mexitil	brand	115-121	false
Mexitil	brand	44-50	Mexitil	brand	115-121	false

DDI-DrugBank.d633.s15	Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels.
Mexitil	brand	0-6	digoxin	drug	32-38	false
Mexitil	brand	0-6	magnesium-aluminum hydroxide	drug	51-78	false
Mexitil	brand	0-6	Mexitil	brand	133-139	false
Mexitil	brand	0-6	digoxin	drug	178-184	false
digoxin	drug	32-38	magnesium-aluminum hydroxide	drug	51-78	false
digoxin	drug	32-38	Mexitil	brand	133-139	false
digoxin	drug	32-38	digoxin	drug	178-184	false
magnesium-aluminum hydroxide	drug	51-78	Mexitil	brand	133-139	false
magnesium-aluminum hydroxide	drug	51-78	digoxin	drug	178-184	mechanism
Mexitil	brand	133-139	digoxin	drug	178-184	false

DDI-DrugBank.d633.s16	Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels.
Mexitil	brand	18-24	theophylline	drug	33-44	mechanism
Mexitil	brand	18-24	theophylline	drug	75-86	false
theophylline	drug	33-44	theophylline	drug	75-86	false

DDI-DrugBank.d633.s18	This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed.
Mexitil	brand	91-97	Theophylline	drug	103-114	false
Mexitil	brand	91-97	Mexitil	brand	146-152	false
Mexitil	brand	91-97	Mexitil	brand	200-206	false
Mexitil	brand	91-97	Mexitil	brand	215-221	false
Mexitil	brand	91-97	theophylline	drug	227-238	false
Mexitil	brand	91-97	theophylline	drug	269-280	false
Mexitil	brand	91-97	Mexitil	brand	338-344	false
Theophylline	drug	103-114	Mexitil	brand	146-152	false
Theophylline	drug	103-114	Mexitil	brand	200-206	mechanism
Theophylline	drug	103-114	Mexitil	brand	215-221	false
Theophylline	drug	103-114	theophylline	drug	227-238	false
Theophylline	drug	103-114	theophylline	drug	269-280	false
Theophylline	drug	103-114	Mexitil	brand	338-344	false
Mexitil	brand	146-152	Mexitil	brand	200-206	false
Mexitil	brand	146-152	Mexitil	brand	215-221	false
Mexitil	brand	146-152	theophylline	drug	227-238	false
Mexitil	brand	146-152	theophylline	drug	269-280	false
Mexitil	brand	146-152	Mexitil	brand	338-344	false
Mexitil	brand	200-206	Mexitil	brand	215-221	false
Mexitil	brand	200-206	theophylline	drug	227-238	false
Mexitil	brand	200-206	theophylline	drug	269-280	false
Mexitil	brand	200-206	Mexitil	brand	338-344	false
Mexitil	brand	215-221	theophylline	drug	227-238	advise
Mexitil	brand	215-221	theophylline	drug	269-280	false
Mexitil	brand	215-221	Mexitil	brand	338-344	false
theophylline	drug	227-238	theophylline	drug	269-280	false
theophylline	drug	227-238	Mexitil	brand	338-344	false
theophylline	drug	269-280	Mexitil	brand	338-344	false

DDI-DrugBank.d633.s20	Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .
caffeine	drug	99-106	Mexitil	brand	158-164	mechanism

DDI-DrugBank.d747.s0	Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.
Tetracycline	group	0-11	antibiotic	group	31-40	false
Tetracycline	group	0-11	penicillin	drug	85-94	effect
antibiotic	group	31-40	penicillin	drug	85-94	false

DDI-DrugBank.d686.s0	Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.
Thiabendazole	drug	0-12	theophylline	drug	52-63	mechanism

DDI-DrugBank.d686.s1	Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.
thiabendazole	drug	35-47	xanthine derivatives	group	53-72	advise

DDI-DrugBank.d599.s4	If glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted.
glucocorticoid	group	3-16	glucocorticoid	group	47-60	false

DDI-DrugBank.d599.s6	Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man.
GH	drug	37-38	antipyrine	drug	93-102	mechanism

DDI-DrugBank.d599.s7	These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin).
GH	drug	24-25	corticosteroids	group	133-147	mechanism
GH	drug	24-25	sex steroids	group	150-161	mechanism
GH	drug	24-25	anticonvulsants	group	164-178	mechanism
GH	drug	24-25	cyclosporin	drug	181-191	mechanism
corticosteroids	group	133-147	sex steroids	group	150-161	false
corticosteroids	group	133-147	anticonvulsants	group	164-178	false
corticosteroids	group	133-147	cyclosporin	drug	181-191	false
sex steroids	group	150-161	anticonvulsants	group	164-178	false
sex steroids	group	150-161	cyclosporin	drug	181-191	false
anticonvulsants	group	164-178	cyclosporin	drug	181-191	false

DDI-DrugBank.d698.s0	Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin
Vitamin B2	drug	17-26	Riboflavin	drug	29-38	false
Vitamin B2	drug	17-26	Alcohol	drug	43-49	false
Vitamin B2	drug	17-26	riboflavin	drug	90-99	false
Riboflavin	drug	29-38	Alcohol	drug	43-49	false
Riboflavin	drug	29-38	riboflavin	drug	90-99	false
Alcohol	drug	43-49	riboflavin	drug	90-99	mechanism

DDI-DrugBank.d698.s1	Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin;
Probenecid	drug	0-9	riboflavin	drug	69-78	mechanism

DDI-DrugBank.d698.s2	requirements for riboflavin may be increased in patients receiving probenecid.
riboflavin	drug	17-26	probenecid	drug	67-76	effect

DDI-DrugBank.d576.s1	ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.
ASPIRIN	brand	0-6	SALICYLATE DRUGS	group	18-33	false
ASPIRIN	brand	0-6	DISALCID	brand	55-62	effect
ASPIRIN	brand	0-6	SALICYLIC ACID	drug	106-119	false
SALICYLATE DRUGS	group	18-33	DISALCID	brand	55-62	effect
SALICYLATE DRUGS	group	18-33	SALICYLIC ACID	drug	106-119	false
DISALCID	brand	55-62	SALICYLIC ACID	drug	106-119	false

DDI-DrugBank.d576.s4	Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding.
Salicylates	group	0-10	anticoagulant drugs	group	37-55	effect

DDI-DrugBank.d576.s5	Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class.
Salicylates	group	0-10	antidiabetic drugs	group	56-73	effect

DDI-DrugBank.d576.s6	Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.
Salicylate	group	0-9	penicillin	drug	78-87	mechanism
Salicylate	group	0-9	thiopental	drug	90-99	mechanism
Salicylate	group	0-9	thyroxine	drug	102-110	mechanism
Salicylate	group	0-9	triiodothyronine	drug	113-128	mechanism
Salicylate	group	0-9	phenytoin	drug	131-139	mechanism
Salicylate	group	0-9	sulfinpyrazone	drug	142-155	mechanism
Salicylate	group	0-9	naproxen	drug	158-165	mechanism
Salicylate	group	0-9	warfarin	drug	168-175	mechanism
Salicylate	group	0-9	methotrexate	drug	178-189	mechanism
Salicylate	group	0-9	corticosteroids	group	205-219	mechanism
penicillin	drug	78-87	thiopental	drug	90-99	false
penicillin	drug	78-87	thyroxine	drug	102-110	false
penicillin	drug	78-87	triiodothyronine	drug	113-128	false
penicillin	drug	78-87	phenytoin	drug	131-139	false
penicillin	drug	78-87	sulfinpyrazone	drug	142-155	false
penicillin	drug	78-87	naproxen	drug	158-165	false
penicillin	drug	78-87	warfarin	drug	168-175	false
penicillin	drug	78-87	methotrexate	drug	178-189	false
penicillin	drug	78-87	corticosteroids	group	205-219	false
thiopental	drug	90-99	thyroxine	drug	102-110	false
thiopental	drug	90-99	triiodothyronine	drug	113-128	false
thiopental	drug	90-99	phenytoin	drug	131-139	false
thiopental	drug	90-99	sulfinpyrazone	drug	142-155	false
thiopental	drug	90-99	naproxen	drug	158-165	false
thiopental	drug	90-99	warfarin	drug	168-175	false
thiopental	drug	90-99	methotrexate	drug	178-189	false
thiopental	drug	90-99	corticosteroids	group	205-219	false
thyroxine	drug	102-110	triiodothyronine	drug	113-128	false
thyroxine	drug	102-110	phenytoin	drug	131-139	false
thyroxine	drug	102-110	sulfinpyrazone	drug	142-155	false
thyroxine	drug	102-110	naproxen	drug	158-165	false
thyroxine	drug	102-110	warfarin	drug	168-175	false
thyroxine	drug	102-110	methotrexate	drug	178-189	false
thyroxine	drug	102-110	corticosteroids	group	205-219	false
triiodothyronine	drug	113-128	phenytoin	drug	131-139	false
triiodothyronine	drug	113-128	sulfinpyrazone	drug	142-155	false
triiodothyronine	drug	113-128	naproxen	drug	158-165	false
triiodothyronine	drug	113-128	warfarin	drug	168-175	false
triiodothyronine	drug	113-128	methotrexate	drug	178-189	false
triiodothyronine	drug	113-128	corticosteroids	group	205-219	false
phenytoin	drug	131-139	sulfinpyrazone	drug	142-155	false
phenytoin	drug	131-139	naproxen	drug	158-165	false
phenytoin	drug	131-139	warfarin	drug	168-175	false
phenytoin	drug	131-139	methotrexate	drug	178-189	false
phenytoin	drug	131-139	corticosteroids	group	205-219	false
sulfinpyrazone	drug	142-155	naproxen	drug	158-165	false
sulfinpyrazone	drug	142-155	warfarin	drug	168-175	false
sulfinpyrazone	drug	142-155	methotrexate	drug	178-189	false
sulfinpyrazone	drug	142-155	corticosteroids	group	205-219	false
naproxen	drug	158-165	warfarin	drug	168-175	false
naproxen	drug	158-165	methotrexate	drug	178-189	false
naproxen	drug	158-165	corticosteroids	group	205-219	false
warfarin	drug	168-175	methotrexate	drug	178-189	false
warfarin	drug	168-175	corticosteroids	group	205-219	false
methotrexate	drug	178-189	corticosteroids	group	205-219	false

DDI-DrugBank.d639.s0	Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.
SUTENT	brand	21-26	ketoconazole	drug	79-90	mechanism
SUTENT	brand	21-26	itraconazole	drug	93-104	mechanism
SUTENT	brand	21-26	clarithromycin	drug	107-120	mechanism
SUTENT	brand	21-26	atazanavir	drug	123-132	mechanism
SUTENT	brand	21-26	indinavir	drug	135-143	mechanism
SUTENT	brand	21-26	nefazodone	drug	146-155	mechanism
SUTENT	brand	21-26	nelfinavir	drug	158-167	mechanism
SUTENT	brand	21-26	ritonavir	drug	170-178	mechanism
SUTENT	brand	21-26	saquinavir	drug	181-190	mechanism
SUTENT	brand	21-26	telithromycin	drug	193-205	mechanism
SUTENT	brand	21-26	voriconizole	drug	208-219	mechanism
SUTENT	brand	21-26	sunitinib	drug	236-244	false
ketoconazole	drug	79-90	itraconazole	drug	93-104	false
ketoconazole	drug	79-90	clarithromycin	drug	107-120	false
ketoconazole	drug	79-90	atazanavir	drug	123-132	false
ketoconazole	drug	79-90	indinavir	drug	135-143	false
ketoconazole	drug	79-90	nefazodone	drug	146-155	false
ketoconazole	drug	79-90	nelfinavir	drug	158-167	false
ketoconazole	drug	79-90	ritonavir	drug	170-178	false
ketoconazole	drug	79-90	saquinavir	drug	181-190	false
ketoconazole	drug	79-90	telithromycin	drug	193-205	false
ketoconazole	drug	79-90	voriconizole	drug	208-219	false
ketoconazole	drug	79-90	sunitinib	drug	236-244	false
itraconazole	drug	93-104	clarithromycin	drug	107-120	false
itraconazole	drug	93-104	atazanavir	drug	123-132	false
itraconazole	drug	93-104	indinavir	drug	135-143	false
itraconazole	drug	93-104	nefazodone	drug	146-155	false
itraconazole	drug	93-104	nelfinavir	drug	158-167	false
itraconazole	drug	93-104	ritonavir	drug	170-178	false
itraconazole	drug	93-104	saquinavir	drug	181-190	false
itraconazole	drug	93-104	telithromycin	drug	193-205	false
itraconazole	drug	93-104	voriconizole	drug	208-219	false
itraconazole	drug	93-104	sunitinib	drug	236-244	false
clarithromycin	drug	107-120	atazanavir	drug	123-132	false
clarithromycin	drug	107-120	indinavir	drug	135-143	false
clarithromycin	drug	107-120	nefazodone	drug	146-155	false
clarithromycin	drug	107-120	nelfinavir	drug	158-167	false
clarithromycin	drug	107-120	ritonavir	drug	170-178	false
clarithromycin	drug	107-120	saquinavir	drug	181-190	false
clarithromycin	drug	107-120	telithromycin	drug	193-205	false
clarithromycin	drug	107-120	voriconizole	drug	208-219	false
clarithromycin	drug	107-120	sunitinib	drug	236-244	false
atazanavir	drug	123-132	indinavir	drug	135-143	false
atazanavir	drug	123-132	nefazodone	drug	146-155	false
atazanavir	drug	123-132	nelfinavir	drug	158-167	false
atazanavir	drug	123-132	ritonavir	drug	170-178	false
atazanavir	drug	123-132	saquinavir	drug	181-190	false
atazanavir	drug	123-132	telithromycin	drug	193-205	false
atazanavir	drug	123-132	voriconizole	drug	208-219	false
atazanavir	drug	123-132	sunitinib	drug	236-244	false
indinavir	drug	135-143	nefazodone	drug	146-155	false
indinavir	drug	135-143	nelfinavir	drug	158-167	false
indinavir	drug	135-143	ritonavir	drug	170-178	false
indinavir	drug	135-143	saquinavir	drug	181-190	false
indinavir	drug	135-143	telithromycin	drug	193-205	false
indinavir	drug	135-143	voriconizole	drug	208-219	false
indinavir	drug	135-143	sunitinib	drug	236-244	false
nefazodone	drug	146-155	nelfinavir	drug	158-167	false
nefazodone	drug	146-155	ritonavir	drug	170-178	false
nefazodone	drug	146-155	saquinavir	drug	181-190	false
nefazodone	drug	146-155	telithromycin	drug	193-205	false
nefazodone	drug	146-155	voriconizole	drug	208-219	false
nefazodone	drug	146-155	sunitinib	drug	236-244	false
nelfinavir	drug	158-167	ritonavir	drug	170-178	false
nelfinavir	drug	158-167	saquinavir	drug	181-190	false
nelfinavir	drug	158-167	telithromycin	drug	193-205	false
nelfinavir	drug	158-167	voriconizole	drug	208-219	false
nelfinavir	drug	158-167	sunitinib	drug	236-244	false
ritonavir	drug	170-178	saquinavir	drug	181-190	false
ritonavir	drug	170-178	telithromycin	drug	193-205	false
ritonavir	drug	170-178	voriconizole	drug	208-219	false
ritonavir	drug	170-178	sunitinib	drug	236-244	false
saquinavir	drug	181-190	telithromycin	drug	193-205	false
saquinavir	drug	181-190	voriconizole	drug	208-219	false
saquinavir	drug	181-190	sunitinib	drug	236-244	false
telithromycin	drug	193-205	voriconizole	drug	208-219	false
telithromycin	drug	193-205	sunitinib	drug	236-244	false
voriconizole	drug	208-219	sunitinib	drug	236-244	false

DDI-DrugBank.d639.s2	Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.
SUTENT	brand	21-26	dexamethasone	drug	70-82	mechanism
SUTENT	brand	21-26	phenytoin	drug	85-93	mechanism
SUTENT	brand	21-26	carbamazepine	drug	96-108	mechanism
SUTENT	brand	21-26	rifampin	drug	111-118	mechanism
SUTENT	brand	21-26	rifabutin	drug	121-129	mechanism
SUTENT	brand	21-26	rifapentin	drug	132-141	mechanism
SUTENT	brand	21-26	phenobarbital	drug	144-156	mechanism
SUTENT	brand	21-26	sunitinib	drug	188-196	false
dexamethasone	drug	70-82	phenytoin	drug	85-93	false
dexamethasone	drug	70-82	carbamazepine	drug	96-108	false
dexamethasone	drug	70-82	rifampin	drug	111-118	false
dexamethasone	drug	70-82	rifabutin	drug	121-129	false
dexamethasone	drug	70-82	rifapentin	drug	132-141	false
dexamethasone	drug	70-82	phenobarbital	drug	144-156	false
dexamethasone	drug	70-82	sunitinib	drug	188-196	false
phenytoin	drug	85-93	carbamazepine	drug	96-108	false
phenytoin	drug	85-93	rifampin	drug	111-118	false
phenytoin	drug	85-93	rifabutin	drug	121-129	false
phenytoin	drug	85-93	rifapentin	drug	132-141	false
phenytoin	drug	85-93	phenobarbital	drug	144-156	false
phenytoin	drug	85-93	sunitinib	drug	188-196	false
carbamazepine	drug	96-108	rifampin	drug	111-118	false
carbamazepine	drug	96-108	rifabutin	drug	121-129	false
carbamazepine	drug	96-108	rifapentin	drug	132-141	false
carbamazepine	drug	96-108	phenobarbital	drug	144-156	false
carbamazepine	drug	96-108	sunitinib	drug	188-196	false
rifampin	drug	111-118	rifabutin	drug	121-129	false
rifampin	drug	111-118	rifapentin	drug	132-141	false
rifampin	drug	111-118	phenobarbital	drug	144-156	false
rifampin	drug	111-118	sunitinib	drug	188-196	false
rifabutin	drug	121-129	rifapentin	drug	132-141	false
rifabutin	drug	121-129	phenobarbital	drug	144-156	false
rifabutin	drug	121-129	sunitinib	drug	188-196	false
rifapentin	drug	132-141	phenobarbital	drug	144-156	false
rifapentin	drug	132-141	sunitinib	drug	188-196	false
phenobarbital	drug	144-156	sunitinib	drug	188-196	false

DDI-DrugBank.d656.s1	Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.
coumarin-type anticoagulants	group	56-83	coumarin-type anticoagulants	group	104-131	false
coumarin-type anticoagulants	group	56-83	FELDENE	brand	157-163	false
coumarin-type anticoagulants	group	56-83	FELDENE	brand	291-297	false
coumarin-type anticoagulants	group	56-83	coumarin-type anticoagulants	group	314-341	false
coumarin-type anticoagulants	group	104-131	FELDENE	brand	157-163	int
coumarin-type anticoagulants	group	104-131	FELDENE	brand	291-297	false
coumarin-type anticoagulants	group	104-131	coumarin-type anticoagulants	group	314-341	false
FELDENE	brand	157-163	FELDENE	brand	291-297	false
FELDENE	brand	157-163	coumarin-type anticoagulants	group	314-341	false
FELDENE	brand	291-297	coumarin-type anticoagulants	group	314-341	advise

DDI-DrugBank.d656.s2	Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.
piroxicam	drug	17-25	FELDENE	brand	90-96	false
piroxicam	drug	17-25	aspirin	brand	134-140	false
piroxicam	drug	17-25	antacids	group	191-198	false
piroxicam	drug	17-25	piroxicam	drug	217-225	false
piroxicam	drug	17-25	Nonsteroidal anti-inflammatory agents	group	243-279	false
piroxicam	drug	17-25	FELDENE	brand	292-298	false
piroxicam	drug	17-25	lithium	drug	352-358	false
FELDENE	brand	90-96	aspirin	brand	134-140	mechanism
FELDENE	brand	90-96	antacids	group	191-198	false
FELDENE	brand	90-96	piroxicam	drug	217-225	false
FELDENE	brand	90-96	Nonsteroidal anti-inflammatory agents	group	243-279	false
FELDENE	brand	90-96	FELDENE	brand	292-298	false
FELDENE	brand	90-96	lithium	drug	352-358	false
aspirin	brand	134-140	antacids	group	191-198	false
aspirin	brand	134-140	piroxicam	drug	217-225	false
aspirin	brand	134-140	Nonsteroidal anti-inflammatory agents	group	243-279	false
aspirin	brand	134-140	FELDENE	brand	292-298	false
aspirin	brand	134-140	lithium	drug	352-358	false
antacids	group	191-198	piroxicam	drug	217-225	false
antacids	group	191-198	Nonsteroidal anti-inflammatory agents	group	243-279	false
antacids	group	191-198	FELDENE	brand	292-298	false
antacids	group	191-198	lithium	drug	352-358	false
piroxicam	drug	217-225	Nonsteroidal anti-inflammatory agents	group	243-279	false
piroxicam	drug	217-225	FELDENE	brand	292-298	false
piroxicam	drug	217-225	lithium	drug	352-358	false
Nonsteroidal anti-inflammatory agents	group	243-279	FELDENE	brand	292-298	false
Nonsteroidal anti-inflammatory agents	group	243-279	lithium	drug	352-358	mechanism
FELDENE	brand	292-298	lithium	drug	352-358	mechanism

DDI-DrugBank.d656.s3	It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.
lithium	drug	30-36	FELDENE	brand	103-109	advise

DDI-DrugBank.d669.s0	Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions.
vancomycin	drug	30-39	anesthetic agents	group	45-61	effect

DDI-DrugBank.d669.s1	Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.
amphotericin B	drug	119-132	aminoglycosides	group	135-149	false
amphotericin B	drug	119-132	bacitracin	drug	152-161	false
amphotericin B	drug	119-132	polymyxin B	drug	164-174	false
amphotericin B	drug	119-132	colistin	drug	177-184	false
amphotericin B	drug	119-132	viomycin	drug	187-194	false
amphotericin B	drug	119-132	cisplatin	drug	200-208	false
aminoglycosides	group	135-149	bacitracin	drug	152-161	false
aminoglycosides	group	135-149	polymyxin B	drug	164-174	false
aminoglycosides	group	135-149	colistin	drug	177-184	false
aminoglycosides	group	135-149	viomycin	drug	187-194	false
aminoglycosides	group	135-149	cisplatin	drug	200-208	false
bacitracin	drug	152-161	polymyxin B	drug	164-174	false
bacitracin	drug	152-161	colistin	drug	177-184	false
bacitracin	drug	152-161	viomycin	drug	187-194	false
bacitracin	drug	152-161	cisplatin	drug	200-208	false
polymyxin B	drug	164-174	colistin	drug	177-184	false
polymyxin B	drug	164-174	viomycin	drug	187-194	false
polymyxin B	drug	164-174	cisplatin	drug	200-208	false
colistin	drug	177-184	viomycin	drug	187-194	false
colistin	drug	177-184	cisplatin	drug	200-208	false
viomycin	drug	187-194	cisplatin	drug	200-208	false

DDI-DrugBank.d608.s0	The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers.
warfarin	drug	24-31	tolmetin	drug	75-82	false
warfarin	drug	24-31	tolmetin	drug	89-96	false
tolmetin	drug	75-82	tolmetin	drug	89-96	false

DDI-DrugBank.d608.s1	However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy.
TOLECTIN	brand	95-102	warfarin	drug	108-115	effect

DDI-DrugBank.d608.s2	Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants.
TOLECTIN	brand	58-65	anticoagulants	group	82-95	advise

DDI-DrugBank.d608.s3	In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents.
sulfonylureas	group	55-67	insulin	drug	72-78	false
sulfonylureas	group	55-67	TOLECTIN	brand	133-140	false
sulfonylureas	group	55-67	hypoglycemic agents	group	149-167	false
insulin	drug	72-78	TOLECTIN	brand	133-140	false
insulin	drug	72-78	hypoglycemic agents	group	149-167	false
TOLECTIN	brand	133-140	hypoglycemic agents	group	149-167	false

DDI-DrugBank.d608.s4	Caution should be used if TOLECTIN is administered concomitantly with methotrexate.
TOLECTIN	brand	26-33	methotrexate	drug	70-81	advise

DDI-DrugBank.d608.s5	TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.
TOLECTIN	brand	0-7	nonsteroidal anti-inflammatory drugs	group	19-54	false
TOLECTIN	brand	0-7	methotrexate	drug	110-121	mechanism
TOLECTIN	brand	0-7	methotrexate	drug	178-189	false
nonsteroidal anti-inflammatory drugs	group	19-54	methotrexate	drug	110-121	mechanism
nonsteroidal anti-inflammatory drugs	group	19-54	methotrexate	drug	178-189	false
methotrexate	drug	110-121	methotrexate	drug	178-189	false

DDI-DrugBank.d699.s0	Mequitazine can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and alcohol.
Mequitazine	drug	0-10	CNS depressant	group	30-43	int
Mequitazine	drug	0-10	antichlolinergic	group	46-61	int
Mequitazine	drug	0-10	TCA	group	64-66	int
Mequitazine	drug	0-10	MAOIs	group	69-73	int
Mequitazine	drug	0-10	alcohol	drug	80-86	int
CNS depressant	group	30-43	antichlolinergic	group	46-61	false
CNS depressant	group	30-43	TCA	group	64-66	false
CNS depressant	group	30-43	MAOIs	group	69-73	false
CNS depressant	group	30-43	alcohol	drug	80-86	false
antichlolinergic	group	46-61	TCA	group	64-66	false
antichlolinergic	group	46-61	MAOIs	group	69-73	false
antichlolinergic	group	46-61	alcohol	drug	80-86	false
TCA	group	64-66	MAOIs	group	69-73	false
TCA	group	64-66	alcohol	drug	80-86	false
MAOIs	group	69-73	alcohol	drug	80-86	false

DDI-DrugBank.d619.s0	The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine.
selegiline	drug	152-161	meperidine	drug	167-176	effect

DDI-DrugBank.d619.s2	This is typical of the interaction of meperidine and MAOIs.
meperidine	drug	38-47	MAOIs	group	53-57	int

DDI-DrugBank.d619.s4	Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and selective serotonin reuptake inhibitors and ELDEPRYL.
tricyclic antidepressants	group	80-104	ELDEPRYL	brand	110-117	effect
tricyclic antidepressants	group	80-104	selective serotonin reuptake inhibitors	group	123-161	false
tricyclic antidepressants	group	80-104	ELDEPRYL	brand	167-174	false
ELDEPRYL	brand	110-117	selective serotonin reuptake inhibitors	group	123-161	false
ELDEPRYL	brand	110-117	ELDEPRYL	brand	167-174	false
selective serotonin reuptake inhibitors	group	123-161	ELDEPRYL	brand	167-174	effect

DDI-DrugBank.d619.s5	One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).
selegiline	drug	95-104	sympathomimetic medication	group	112-137	effect
selegiline	drug	95-104	ephedrine	drug	140-148	effect
sympathomimetic medication	group	112-137	ephedrine	drug	140-148	false

DDI-DrugBank.d587.s0	Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
Celontin	brand	6-13	methsuximide	drug	16-27	false
Celontin	brand	6-13	antiepileptic drugs	group	74-92	advise
Celontin	brand	6-13	methsuximide	drug	167-178	false
Celontin	brand	6-13	phenytoin	drug	222-230	false
Celontin	brand	6-13	phenobarbital	drug	236-248	false
methsuximide	drug	16-27	antiepileptic drugs	group	74-92	advise
methsuximide	drug	16-27	methsuximide	drug	167-178	false
methsuximide	drug	16-27	phenytoin	drug	222-230	false
methsuximide	drug	16-27	phenobarbital	drug	236-248	false
antiepileptic drugs	group	74-92	methsuximide	drug	167-178	false
antiepileptic drugs	group	74-92	phenytoin	drug	222-230	false
antiepileptic drugs	group	74-92	phenobarbital	drug	236-248	false
methsuximide	drug	167-178	phenytoin	drug	222-230	mechanism
methsuximide	drug	167-178	phenobarbital	drug	236-248	mechanism
phenytoin	drug	222-230	phenobarbital	drug	236-248	false

DDI-DrugBank.d585.s0	The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.
anticholinergic drugs	group	69-89	amantadine	drug	92-101	effect
anticholinergic drugs	group	69-89	antiarrhythmic agents of class I	group	104-135	effect
anticholinergic drugs	group	69-89	quinidine	drug	144-152	effect
anticholinergic drugs	group	69-89	antihistamines	group	156-169	effect
anticholinergic drugs	group	69-89	antipsychotic agents	group	172-191	effect
anticholinergic drugs	group	69-89	phenothiazines	group	200-213	effect
anticholinergic drugs	group	69-89	benzodiazepines	group	217-231	effect
anticholinergic drugs	group	69-89	MAO inhibitors	group	234-247	effect
anticholinergic drugs	group	69-89	narcotic analgesics	group	250-268	effect
anticholinergic drugs	group	69-89	meperidine	drug	277-286	effect
anticholinergic drugs	group	69-89	nitrates	group	290-297	effect
anticholinergic drugs	group	69-89	nitrites	group	303-310	effect
anticholinergic drugs	group	69-89	sympathomimetic agents	group	313-334	effect
anticholinergic drugs	group	69-89	tricyclic antidepressants	group	337-361	effect
amantadine	drug	92-101	antiarrhythmic agents of class I	group	104-135	false
amantadine	drug	92-101	quinidine	drug	144-152	false
amantadine	drug	92-101	antihistamines	group	156-169	false
amantadine	drug	92-101	antipsychotic agents	group	172-191	false
amantadine	drug	92-101	phenothiazines	group	200-213	false
amantadine	drug	92-101	benzodiazepines	group	217-231	false
amantadine	drug	92-101	MAO inhibitors	group	234-247	false
amantadine	drug	92-101	narcotic analgesics	group	250-268	false
amantadine	drug	92-101	meperidine	drug	277-286	false
amantadine	drug	92-101	nitrates	group	290-297	false
amantadine	drug	92-101	nitrites	group	303-310	false
amantadine	drug	92-101	sympathomimetic agents	group	313-334	false
amantadine	drug	92-101	tricyclic antidepressants	group	337-361	false
antiarrhythmic agents of class I	group	104-135	quinidine	drug	144-152	false
antiarrhythmic agents of class I	group	104-135	antihistamines	group	156-169	false
antiarrhythmic agents of class I	group	104-135	antipsychotic agents	group	172-191	false
antiarrhythmic agents of class I	group	104-135	phenothiazines	group	200-213	false
antiarrhythmic agents of class I	group	104-135	benzodiazepines	group	217-231	false
antiarrhythmic agents of class I	group	104-135	MAO inhibitors	group	234-247	false
antiarrhythmic agents of class I	group	104-135	narcotic analgesics	group	250-268	false
antiarrhythmic agents of class I	group	104-135	meperidine	drug	277-286	false
antiarrhythmic agents of class I	group	104-135	nitrates	group	290-297	false
antiarrhythmic agents of class I	group	104-135	nitrites	group	303-310	false
antiarrhythmic agents of class I	group	104-135	sympathomimetic agents	group	313-334	false
antiarrhythmic agents of class I	group	104-135	tricyclic antidepressants	group	337-361	false
quinidine	drug	144-152	antihistamines	group	156-169	false
quinidine	drug	144-152	antipsychotic agents	group	172-191	false
quinidine	drug	144-152	phenothiazines	group	200-213	false
quinidine	drug	144-152	benzodiazepines	group	217-231	false
quinidine	drug	144-152	MAO inhibitors	group	234-247	false
quinidine	drug	144-152	narcotic analgesics	group	250-268	false
quinidine	drug	144-152	meperidine	drug	277-286	false
quinidine	drug	144-152	nitrates	group	290-297	false
quinidine	drug	144-152	nitrites	group	303-310	false
quinidine	drug	144-152	sympathomimetic agents	group	313-334	false
quinidine	drug	144-152	tricyclic antidepressants	group	337-361	false
antihistamines	group	156-169	antipsychotic agents	group	172-191	false
antihistamines	group	156-169	phenothiazines	group	200-213	false
antihistamines	group	156-169	benzodiazepines	group	217-231	false
antihistamines	group	156-169	MAO inhibitors	group	234-247	false
antihistamines	group	156-169	narcotic analgesics	group	250-268	false
antihistamines	group	156-169	meperidine	drug	277-286	false
antihistamines	group	156-169	nitrates	group	290-297	false
antihistamines	group	156-169	nitrites	group	303-310	false
antihistamines	group	156-169	sympathomimetic agents	group	313-334	false
antihistamines	group	156-169	tricyclic antidepressants	group	337-361	false
antipsychotic agents	group	172-191	phenothiazines	group	200-213	false
antipsychotic agents	group	172-191	benzodiazepines	group	217-231	false
antipsychotic agents	group	172-191	MAO inhibitors	group	234-247	false
antipsychotic agents	group	172-191	narcotic analgesics	group	250-268	false
antipsychotic agents	group	172-191	meperidine	drug	277-286	false
antipsychotic agents	group	172-191	nitrates	group	290-297	false
antipsychotic agents	group	172-191	nitrites	group	303-310	false
antipsychotic agents	group	172-191	sympathomimetic agents	group	313-334	false
antipsychotic agents	group	172-191	tricyclic antidepressants	group	337-361	false
phenothiazines	group	200-213	benzodiazepines	group	217-231	false
phenothiazines	group	200-213	MAO inhibitors	group	234-247	false
phenothiazines	group	200-213	narcotic analgesics	group	250-268	false
phenothiazines	group	200-213	meperidine	drug	277-286	false
phenothiazines	group	200-213	nitrates	group	290-297	false
phenothiazines	group	200-213	nitrites	group	303-310	false
phenothiazines	group	200-213	sympathomimetic agents	group	313-334	false
phenothiazines	group	200-213	tricyclic antidepressants	group	337-361	false
benzodiazepines	group	217-231	MAO inhibitors	group	234-247	false
benzodiazepines	group	217-231	narcotic analgesics	group	250-268	false
benzodiazepines	group	217-231	meperidine	drug	277-286	false
benzodiazepines	group	217-231	nitrates	group	290-297	false
benzodiazepines	group	217-231	nitrites	group	303-310	false
benzodiazepines	group	217-231	sympathomimetic agents	group	313-334	false
benzodiazepines	group	217-231	tricyclic antidepressants	group	337-361	false
MAO inhibitors	group	234-247	narcotic analgesics	group	250-268	false
MAO inhibitors	group	234-247	meperidine	drug	277-286	false
MAO inhibitors	group	234-247	nitrates	group	290-297	false
MAO inhibitors	group	234-247	nitrites	group	303-310	false
MAO inhibitors	group	234-247	sympathomimetic agents	group	313-334	false
MAO inhibitors	group	234-247	tricyclic antidepressants	group	337-361	false
narcotic analgesics	group	250-268	meperidine	drug	277-286	false
narcotic analgesics	group	250-268	nitrates	group	290-297	false
narcotic analgesics	group	250-268	nitrites	group	303-310	false
narcotic analgesics	group	250-268	sympathomimetic agents	group	313-334	false
narcotic analgesics	group	250-268	tricyclic antidepressants	group	337-361	false
meperidine	drug	277-286	nitrates	group	290-297	false
meperidine	drug	277-286	nitrites	group	303-310	false
meperidine	drug	277-286	sympathomimetic agents	group	313-334	false
meperidine	drug	277-286	tricyclic antidepressants	group	337-361	false
nitrates	group	290-297	nitrites	group	303-310	false
nitrates	group	290-297	sympathomimetic agents	group	313-334	false
nitrates	group	290-297	tricyclic antidepressants	group	337-361	false
nitrites	group	303-310	sympathomimetic agents	group	313-334	false
nitrites	group	303-310	tricyclic antidepressants	group	337-361	false
sympathomimetic agents	group	313-334	tricyclic antidepressants	group	337-361	false

DDI-DrugBank.d585.s1	Anticholinergics antagonize the effects of antiglaucoma agents.
Anticholinergics	group	0-15	antiglaucoma agents	group	43-61	effect

DDI-DrugBank.d585.s2	Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids.
Anticholinergic drugs	group	0-20	corticosteroids	group	133-147	effect

DDI-DrugBank.d585.s3	Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin;
Anticholinergic agents	group	0-21	digoxin	drug	122-128	mechanism

DDI-DrugBank.d585.s5	Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide.
Anticholinergic drugs	group	0-20	metoclopramide	drug	104-117	effect

DDI-DrugBank.d585.s6	Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided.
antacids	group	8-15	anticholinergic agents	group	54-75	mechanism

DDI-DrugBank.d738.s0	Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors.
VESIcare	brand	35-42	ketoconazole	drug	88-99	advise

DDI-DrugBank.d738.s1	Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose.
solifenacin	drug	81-91	solifenacin	drug	177-187	false
solifenacin	drug	81-91	solifenacin	drug	273-283	false
solifenacin	drug	81-91	moxifloxacin	drug	347-358	false
solifenacin	drug	177-187	solifenacin	drug	273-283	false
solifenacin	drug	177-187	moxifloxacin	drug	347-358	false
solifenacin	drug	273-283	moxifloxacin	drug	347-358	false

DDI-DrugBank.d666.s0	Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
reserpine	drug	37-45	beta-blocking agents	group	92-111	effect

DDI-DrugBank.d666.s2	Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.
Pindolol	drug	0-7	antihypertensive agents	group	41-63	false
Pindolol	drug	0-7	hydrochlorothiazide	drug	76-94	false
Pindolol	drug	0-7	hydralazine	drug	97-107	false
Pindolol	drug	0-7	guanethidine	drug	114-125	false
antihypertensive agents	group	41-63	hydrochlorothiazide	drug	76-94	false
antihypertensive agents	group	41-63	hydralazine	drug	97-107	false
antihypertensive agents	group	41-63	guanethidine	drug	114-125	false
hydrochlorothiazide	drug	76-94	hydralazine	drug	97-107	false
hydrochlorothiazide	drug	76-94	guanethidine	drug	114-125	false
hydralazine	drug	97-107	guanethidine	drug	114-125	false

DDI-DrugBank.d666.s3	Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered.
Pindolol	drug	0-7	thioridazine	drug	42-53	mechanism

DDI-DrugBank.d597.s0	ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors.
ACE inhibitors	group	0-13	NSAIDs	group	36-41	false
ACE inhibitors	group	0-13	angiotensin-converting enzyme (ACE) inhibitors	group	87-132	false
NSAIDs	group	36-41	angiotensin-converting enzyme (ACE) inhibitors	group	87-132	effect

DDI-DrugBank.d597.s1	This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors.
NSAIDs	group	66-71	ACE inhibitors	group	92-105	advise

DDI-DrugBank.d597.s2	Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam.
Aspirin	brand	0-6	aspirin	brand	39-45	false
Aspirin	brand	0-6	meloxicam	drug	134-142	false
aspirin	brand	39-45	meloxicam	drug	134-142	mechanism

DDI-DrugBank.d597.s4	however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects.
NSAIDs	group	23-28	meloxicam	drug	61-69	false
NSAIDs	group	23-28	aspirin	brand	75-81	advise
meloxicam	drug	61-69	aspirin	brand	75-81	advise

DDI-DrugBank.d597.s5	Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.
aspirin	brand	39-45	MOBIC	brand	52-56	effect
aspirin	brand	39-45	MOBIC	brand	150-154	false
MOBIC	brand	52-56	MOBIC	brand	150-154	false

DDI-DrugBank.d597.s6	MOBIC is not a substitute for aspirin for cardiovascular prophylaxis.
MOBIC	brand	0-4	aspirin	brand	30-36	false

DDI-DrugBank.d597.s7	Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%.
Cholestyramine	drug	0-13	cholestyramine	drug	48-61	false
Cholestyramine	drug	0-13	meloxicam	drug	104-112	false
cholestyramine	drug	48-61	meloxicam	drug	104-112	mechanism

DDI-DrugBank.d597.s11	Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam.
Cimetidine	drug	0-9	cimetidine	drug	49-58	false
Cimetidine	drug	0-9	meloxicam	drug	120-128	false
cimetidine	drug	49-58	meloxicam	drug	120-128	false

DDI-DrugBank.d597.s12	Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses.
Digoxin	drug	0-6	Meloxicam	drug	9-17	false
Digoxin	drug	0-6	digoxin	drug	97-103	false
Meloxicam	drug	9-17	digoxin	drug	97-103	false

DDI-DrugBank.d597.s13	In vitro testing found no protein binding drug interaction between digoxin and meloxicam.
digoxin	drug	67-73	meloxicam	drug	79-87	false

DDI-DrugBank.d597.s14	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.
Furosemide	drug	0-9	NSAIDs	group	86-91	false
Furosemide	drug	0-9	furosemide	drug	130-139	false
Furosemide	drug	0-9	thiazide diuretics	group	145-162	false
NSAIDs	group	86-91	furosemide	drug	130-139	effect
NSAIDs	group	86-91	thiazide diuretics	group	145-162	effect
furosemide	drug	130-139	thiazide diuretics	group	145-162	false

DDI-DrugBank.d597.s16	Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect.
furosemide	drug	13-22	meloxicam	drug	35-43	false

DDI-DrugBank.d597.s17	Furosemide: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam.
Furosemide	drug	0-9	meloxicam	drug	113-121	false

DDI-DrugBank.d597.s18	Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.
furosemide	drug	46-55	MOBIC	brand	61-65	advise

DDI-DrugBank.d597.s19	Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.
Lithium	drug	0-6	NSAIDs	group	29-34	false
Lithium	drug	0-6	lithium	drug	73-79	false
Lithium	drug	0-6	lithium	drug	113-119	false
NSAIDs	group	29-34	lithium	drug	73-79	mechanism
NSAIDs	group	29-34	lithium	drug	113-119	false
lithium	drug	73-79	lithium	drug	113-119	false

DDI-DrugBank.d597.s20	In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone.
lithium	drug	56-62	lithium	drug	130-136	false
lithium	drug	56-62	meloxicam	drug	181-189	false
lithium	drug	56-62	lithium	drug	234-240	false
lithium	drug	130-136	meloxicam	drug	181-189	mechanism
lithium	drug	130-136	lithium	drug	234-240	false
meloxicam	drug	181-189	lithium	drug	234-240	false

DDI-DrugBank.d597.s22	Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn.
lithium	drug	12-18	MOBIC	brand	63-67	advise

DDI-DrugBank.d597.s23	Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly.
Methotrexate	drug	0-11	meloxicam	drug	106-114	false
Methotrexate	drug	0-11	methotrexate	drug	143-154	false
meloxicam	drug	106-114	methotrexate	drug	143-154	false

DDI-DrugBank.d597.s24	Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate.
Meloxicam	drug	0-8	methotrexate	drug	87-98	false

DDI-DrugBank.d597.s25	In vitro, methotrexate did not displace meloxicam from its human serum binding sites.
methotrexate	drug	10-21	meloxicam	drug	40-48	false

DDI-DrugBank.d597.s26	Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.
Warfarin	drug	0-7	MOBIC	brand	118-122	false
Warfarin	drug	0-7	warfarin	drug	154-161	false
MOBIC	brand	118-122	warfarin	drug	154-161	advise

DDI-DrugBank.d597.s27	The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8.
meloxicam	drug	14-22	warfarin	drug	55-62	false
meloxicam	drug	14-22	warfarin	drug	132-139	false
warfarin	drug	55-62	warfarin	drug	132-139	false

DDI-DrugBank.d597.s28	In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.
meloxicam	drug	19-27	warfarin	drug	43-50	false
meloxicam	drug	19-27	warfarin	drug	109-116	false
warfarin	drug	43-50	warfarin	drug	109-116	false

DDI-DrugBank.d597.s30	Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.
MOBIC	brand	42-46	warfarin	drug	53-60	advise
MOBIC	brand	42-46	warfarin	drug	80-87	false
warfarin	drug	53-60	warfarin	drug	80-87	false

DDI-DrugBank.d741.s0	In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with PEG-Intron once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;
methadone	drug	86-94	PEG-Intron	brand	112-121	mechanism
methadone	drug	86-94	methadone	drug	193-201	false
PEG-Intron	brand	112-121	methadone	drug	193-201	false

DDI-DrugBank.d580.s1	However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.
ketoconazole	drug	9-20	mometasone furoate	drug	96-113	mechanism

DDI-DrugBank.d603.s0	When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V.
ProAmatine	brand	37-46	cardiac glycosides	group	52-69	effect

DDI-DrugBank.d603.s2	The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction.
phenylephrine	drug	66-78	pseudoephedrine	drug	81-95	false
phenylephrine	drug	66-78	ephedrine	drug	98-106	false
phenylephrine	drug	66-78	phenylpropanolamine	drug	109-127	false
phenylephrine	drug	66-78	dihydroergotamine	drug	132-148	false
phenylephrine	drug	66-78	ProAmatine	brand	200-209	effect
phenylephrine	drug	66-78	ProAmatine	brand	254-263	false
pseudoephedrine	drug	81-95	ephedrine	drug	98-106	false
pseudoephedrine	drug	81-95	phenylpropanolamine	drug	109-127	false
pseudoephedrine	drug	81-95	dihydroergotamine	drug	132-148	false
pseudoephedrine	drug	81-95	ProAmatine	brand	200-209	effect
pseudoephedrine	drug	81-95	ProAmatine	brand	254-263	false
ephedrine	drug	98-106	phenylpropanolamine	drug	109-127	false
ephedrine	drug	98-106	dihydroergotamine	drug	132-148	false
ephedrine	drug	98-106	ProAmatine	brand	200-209	effect
ephedrine	drug	98-106	ProAmatine	brand	254-263	false
phenylpropanolamine	drug	109-127	dihydroergotamine	drug	132-148	false
phenylpropanolamine	drug	109-127	ProAmatine	brand	200-209	effect
phenylpropanolamine	drug	109-127	ProAmatine	brand	254-263	false
dihydroergotamine	drug	132-148	ProAmatine	brand	200-209	effect
dihydroergotamine	drug	132-148	ProAmatine	brand	254-263	false
ProAmatine	brand	200-209	ProAmatine	brand	254-263	false

DDI-DrugBank.d603.s3	ProAmatine    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation.
ProAmatine	brand	0-9	fludrocortisone acetate	drug	105-127	false

DDI-DrugBank.d603.s5	ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.
ProAmatine	brand	0-9	Alpha-adrenergic blocking agents	group	12-43	false
ProAmatine	brand	0-9	prazosin	drug	54-61	false
ProAmatine	brand	0-9	terazosin	drug	64-72	false
ProAmatine	brand	0-9	doxazosin	drug	79-87	false
ProAmatine	brand	0-9	ProAmatine	brand	120-129	false
ProAmatine	brand	0-9	desglymidodrine	drug_n	274-288	false
ProAmatine	brand	0-9	metformin	drug	415-423	false
ProAmatine	brand	0-9	cimetidine	drug	426-435	false
ProAmatine	brand	0-9	ranitidine	drug	438-447	false
ProAmatine	brand	0-9	procainamide	drug	450-461	false
ProAmatine	brand	0-9	triamterene	drug	464-474	false
ProAmatine	brand	0-9	flecainide	drug	477-486	false
ProAmatine	brand	0-9	quinidine	drug	493-501	false
Alpha-adrenergic blocking agents	group	12-43	prazosin	drug	54-61	false
Alpha-adrenergic blocking agents	group	12-43	terazosin	drug	64-72	false
Alpha-adrenergic blocking agents	group	12-43	doxazosin	drug	79-87	false
Alpha-adrenergic blocking agents	group	12-43	ProAmatine	brand	120-129	effect
Alpha-adrenergic blocking agents	group	12-43	desglymidodrine	drug_n	274-288	false
Alpha-adrenergic blocking agents	group	12-43	metformin	drug	415-423	false
Alpha-adrenergic blocking agents	group	12-43	cimetidine	drug	426-435	false
Alpha-adrenergic blocking agents	group	12-43	ranitidine	drug	438-447	false
Alpha-adrenergic blocking agents	group	12-43	procainamide	drug	450-461	false
Alpha-adrenergic blocking agents	group	12-43	triamterene	drug	464-474	false
Alpha-adrenergic blocking agents	group	12-43	flecainide	drug	477-486	false
Alpha-adrenergic blocking agents	group	12-43	quinidine	drug	493-501	false
prazosin	drug	54-61	terazosin	drug	64-72	false
prazosin	drug	54-61	doxazosin	drug	79-87	false
prazosin	drug	54-61	ProAmatine	brand	120-129	effect
prazosin	drug	54-61	desglymidodrine	drug_n	274-288	false
prazosin	drug	54-61	metformin	drug	415-423	false
prazosin	drug	54-61	cimetidine	drug	426-435	false
prazosin	drug	54-61	ranitidine	drug	438-447	false
prazosin	drug	54-61	procainamide	drug	450-461	false
prazosin	drug	54-61	triamterene	drug	464-474	false
prazosin	drug	54-61	flecainide	drug	477-486	false
prazosin	drug	54-61	quinidine	drug	493-501	false
terazosin	drug	64-72	doxazosin	drug	79-87	false
terazosin	drug	64-72	ProAmatine	brand	120-129	effect
terazosin	drug	64-72	desglymidodrine	drug_n	274-288	false
terazosin	drug	64-72	metformin	drug	415-423	false
terazosin	drug	64-72	cimetidine	drug	426-435	false
terazosin	drug	64-72	ranitidine	drug	438-447	false
terazosin	drug	64-72	procainamide	drug	450-461	false
terazosin	drug	64-72	triamterene	drug	464-474	false
terazosin	drug	64-72	flecainide	drug	477-486	false
terazosin	drug	64-72	quinidine	drug	493-501	false
doxazosin	drug	79-87	ProAmatine	brand	120-129	effect
doxazosin	drug	79-87	desglymidodrine	drug_n	274-288	false
doxazosin	drug	79-87	metformin	drug	415-423	false
doxazosin	drug	79-87	cimetidine	drug	426-435	false
doxazosin	drug	79-87	ranitidine	drug	438-447	false
doxazosin	drug	79-87	procainamide	drug	450-461	false
doxazosin	drug	79-87	triamterene	drug	464-474	false
doxazosin	drug	79-87	flecainide	drug	477-486	false
doxazosin	drug	79-87	quinidine	drug	493-501	false
ProAmatine	brand	120-129	desglymidodrine	drug_n	274-288	false
ProAmatine	brand	120-129	metformin	drug	415-423	false
ProAmatine	brand	120-129	cimetidine	drug	426-435	false
ProAmatine	brand	120-129	ranitidine	drug	438-447	false
ProAmatine	brand	120-129	procainamide	drug	450-461	false
ProAmatine	brand	120-129	triamterene	drug	464-474	false
ProAmatine	brand	120-129	flecainide	drug	477-486	false
ProAmatine	brand	120-129	quinidine	drug	493-501	false
desglymidodrine	drug_n	274-288	metformin	drug	415-423	mechanism
desglymidodrine	drug_n	274-288	cimetidine	drug	426-435	mechanism
desglymidodrine	drug_n	274-288	ranitidine	drug	438-447	mechanism
desglymidodrine	drug_n	274-288	procainamide	drug	450-461	mechanism
desglymidodrine	drug_n	274-288	triamterene	drug	464-474	mechanism
desglymidodrine	drug_n	274-288	flecainide	drug	477-486	mechanism
desglymidodrine	drug_n	274-288	quinidine	drug	493-501	mechanism
metformin	drug	415-423	cimetidine	drug	426-435	false
metformin	drug	415-423	ranitidine	drug	438-447	false
metformin	drug	415-423	procainamide	drug	450-461	false
metformin	drug	415-423	triamterene	drug	464-474	false
metformin	drug	415-423	flecainide	drug	477-486	false
metformin	drug	415-423	quinidine	drug	493-501	false
cimetidine	drug	426-435	ranitidine	drug	438-447	false
cimetidine	drug	426-435	procainamide	drug	450-461	false
cimetidine	drug	426-435	triamterene	drug	464-474	false
cimetidine	drug	426-435	flecainide	drug	477-486	false
cimetidine	drug	426-435	quinidine	drug	493-501	false
ranitidine	drug	438-447	procainamide	drug	450-461	false
ranitidine	drug	438-447	triamterene	drug	464-474	false
ranitidine	drug	438-447	flecainide	drug	477-486	false
ranitidine	drug	438-447	quinidine	drug	493-501	false
procainamide	drug	450-461	triamterene	drug	464-474	false
procainamide	drug	450-461	flecainide	drug	477-486	false
procainamide	drug	450-461	quinidine	drug	493-501	false
triamterene	drug	464-474	flecainide	drug	477-486	false
triamterene	drug	464-474	quinidine	drug	493-501	false
flecainide	drug	477-486	quinidine	drug	493-501	false

DDI-DrugBank.d704.s0	Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined.
FLOMAX	brand	85-90	alpha-adrenergic blocking agents	group	111-142	false

DDI-DrugBank.d704.s1	However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents.
FLOMAX	brand	42-47	alpha-adrenergic blocking agents	group	103-134	advise

DDI-DrugBank.d704.s2	The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated.
cimetidine	drug	40-49	FLOMAX	brand	55-60	false

DDI-DrugBank.d704.s4	Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg.
FLOMAX	brand	11-16	cimetidine	drug	75-84	advise

DDI-DrugBank.d704.s5	Results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin HCI and warfarin are inconclusive.
tamsulosin HCI	drug	80-93	warfarin	drug	99-106	false

DDI-DrugBank.d704.s6	Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.
warfarin	drug	74-81	FLOMAX	brand	87-92	advise

DDI-DrugBank.d628.s0	The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.)
DIPRIVAN	brand	35-42	narcotics	group	158-166	effect
DIPRIVAN	brand	35-42	morphine	drug	173-180	effect
DIPRIVAN	brand	35-42	meperidine	drug	183-192	effect
DIPRIVAN	brand	35-42	fentanyl	drug	199-206	effect
narcotics	group	158-166	morphine	drug	173-180	false
narcotics	group	158-166	meperidine	drug	183-192	false
narcotics	group	158-166	fentanyl	drug	199-206	false
morphine	drug	173-180	meperidine	drug	183-192	false
morphine	drug	173-180	fentanyl	drug	199-206	false
meperidine	drug	183-192	fentanyl	drug	199-206	false

DDI-DrugBank.d628.s1	and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).
opioids	group	20-26	sedatives	group	32-40	false
opioids	group	20-26	benzodiazepines	group	47-61	false
opioids	group	20-26	barbiturates	group	64-75	false
opioids	group	20-26	chloral hydrate	drug	78-92	false
opioids	group	20-26	droperidol	drug	95-104	false
sedatives	group	32-40	benzodiazepines	group	47-61	false
sedatives	group	32-40	barbiturates	group	64-75	false
sedatives	group	32-40	chloral hydrate	drug	78-92	false
sedatives	group	32-40	droperidol	drug	95-104	false
benzodiazepines	group	47-61	barbiturates	group	64-75	false
benzodiazepines	group	47-61	chloral hydrate	drug	78-92	false
benzodiazepines	group	47-61	droperidol	drug	95-104	false
barbiturates	group	64-75	chloral hydrate	drug	78-92	false
barbiturates	group	64-75	droperidol	drug	95-104	false
chloral hydrate	drug	78-92	droperidol	drug	95-104	false

DDI-DrugBank.d628.s3	During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids).
DIPRIVAN	brand	58-65	analgesic agents	group	229-244	advise
DIPRIVAN	brand	58-65	nitrous oxide	drug	251-263	advise
DIPRIVAN	brand	58-65	opioids	group	268-274	advise
analgesic agents	group	229-244	nitrous oxide	drug	251-263	false
analgesic agents	group	229-244	opioids	group	268-274	false
nitrous oxide	drug	251-263	opioids	group	268-274	false

DDI-DrugBank.d628.s4	The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.
isoflurane	drug	65-74	enflurane	drug	77-85	false
isoflurane	drug	65-74	halothane	drug	92-100	false
isoflurane	drug	65-74	DIPRIVAN	brand	127-134	false
enflurane	drug	77-85	halothane	drug	92-100	false
enflurane	drug	77-85	DIPRIVAN	brand	127-134	false
halothane	drug	92-100	DIPRIVAN	brand	127-134	false

DDI-DrugBank.d628.s6	DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants).
DIPRIVAN	brand	0-7	neuromuscular blocking agents	group	140-168	false
DIPRIVAN	brand	0-7	succinylcholine	drug	175-189	false
DIPRIVAN	brand	0-7	nondepolarizing muscle relaxants	group	195-226	false
neuromuscular blocking agents	group	140-168	succinylcholine	drug	175-189	false
neuromuscular blocking agents	group	140-168	nondepolarizing muscle relaxants	group	195-226	false
succinylcholine	drug	175-189	nondepolarizing muscle relaxants	group	195-226	false

DDI-DrugBank.d628.s7	No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.
muscle relaxants	group	136-151	analgesic agents	group	175-190	false
muscle relaxants	group	136-151	anesthetic agents	group	203-219	false
analgesic agents	group	175-190	anesthetic agents	group	203-219	false

DDI-DrugBank.d761.s0	Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.
Alcohol	drug	0-6	XENICAL	brand	84-90	false
Alcohol	drug	0-6	alcohol	drug	108-114	false
Alcohol	drug	0-6	alcohol	drug	188-194	false
Alcohol	drug	0-6	orlistat	drug	214-221	false
Alcohol	drug	0-6	orlistat	drug	287-294	false
XENICAL	brand	84-90	alcohol	drug	108-114	false
XENICAL	brand	84-90	alcohol	drug	188-194	false
XENICAL	brand	84-90	orlistat	drug	214-221	false
XENICAL	brand	84-90	orlistat	drug	287-294	false
alcohol	drug	108-114	alcohol	drug	188-194	false
alcohol	drug	108-114	orlistat	drug	214-221	false
alcohol	drug	108-114	orlistat	drug	287-294	false
alcohol	drug	188-194	orlistat	drug	214-221	false
alcohol	drug	188-194	orlistat	drug	287-294	false
orlistat	drug	214-221	orlistat	drug	287-294	false

DDI-DrugBank.d761.s1	Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.
Cyclosporine	drug	0-11	XENICAL	brand	38-44	false
Cyclosporine	drug	0-11	cyclosporine	drug	50-61	false
Cyclosporine	drug	0-11	cyclosporine	drug	110-121	false
Cyclosporine	drug	0-11	XENICAL	brand	142-148	false
Cyclosporine	drug	0-11	cyclosporine	drug	174-185	false
XENICAL	brand	38-44	cyclosporine	drug	50-61	false
XENICAL	brand	38-44	cyclosporine	drug	110-121	false
XENICAL	brand	38-44	XENICAL	brand	142-148	false
XENICAL	brand	38-44	cyclosporine	drug	174-185	false
cyclosporine	drug	50-61	cyclosporine	drug	110-121	false
cyclosporine	drug	50-61	XENICAL	brand	142-148	false
cyclosporine	drug	50-61	cyclosporine	drug	174-185	false
cyclosporine	drug	110-121	XENICAL	brand	142-148	false
cyclosporine	drug	110-121	cyclosporine	drug	174-185	false
XENICAL	brand	142-148	cyclosporine	drug	174-185	mechanism

DDI-DrugBank.d761.s2	Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin.
Digoxin	drug	0-6	XENICAL	brand	48-54	false
Digoxin	drug	0-6	XENICAL	brand	93-99	false
Digoxin	drug	0-6	digoxin	drug	156-162	false
XENICAL	brand	48-54	XENICAL	brand	93-99	false
XENICAL	brand	48-54	digoxin	drug	156-162	false
XENICAL	brand	93-99	digoxin	drug	156-162	false

DDI-DrugBank.d761.s3	Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL.
Fat-soluble Vitamin Supplements	group	0-30	beta-carotene	drug	109-121	false
Fat-soluble Vitamin Supplements	group	0-30	XENICAL	brand	182-188	false
beta-carotene	drug	109-121	XENICAL	brand	182-188	mechanism

DDI-DrugBank.d761.s4	XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%.
XENICAL	brand	0-6	vitamin E acetate	drug	34-50	mechanism

DDI-DrugBank.d761.s5	The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time.
orlistat	drug	14-21	vitamin D	group	57-65	false
orlistat	drug	14-21	vitamin A	group	68-76	false
orlistat	drug	14-21	vitamin K	group	105-113	false
vitamin D	group	57-65	vitamin A	group	68-76	false
vitamin D	group	57-65	vitamin K	group	105-113	false
vitamin A	group	68-76	vitamin K	group	105-113	false

DDI-DrugBank.d761.s6	Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.
Glyburide	drug	0-8	orlistat	drug	50-57	false
Glyburide	drug	0-8	orlistat	drug	95-102	false
Glyburide	drug	0-8	glyburide	drug	187-195	false
orlistat	drug	50-57	orlistat	drug	95-102	false
orlistat	drug	50-57	glyburide	drug	187-195	false
orlistat	drug	95-102	glyburide	drug	187-195	false

DDI-DrugBank.d761.s7	Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets).
Nifedipine	drug	0-9	XENICAL	brand	78-84	false
Nifedipine	drug	0-9	XENICAL	brand	123-129	false
Nifedipine	drug	0-9	nifedipine	drug	168-177	false
XENICAL	brand	78-84	XENICAL	brand	123-129	false
XENICAL	brand	78-84	nifedipine	drug	168-177	false
XENICAL	brand	123-129	nifedipine	drug	168-177	false

DDI-DrugBank.d761.s8	Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.
Contraceptives	group	5-18	XENICAL	brand	75-81	false
Contraceptives	group	5-18	contraceptives	group	187-200	false
XENICAL	brand	75-81	contraceptives	group	187-200	false

DDI-DrugBank.d761.s9	Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.
Phenytoin	drug	0-8	XENICAL	brand	50-56	false
Phenytoin	drug	0-8	XENICAL	brand	95-101	false
Phenytoin	drug	0-8	phenytoin	drug	165-173	false
XENICAL	brand	50-56	XENICAL	brand	95-101	false
XENICAL	brand	50-56	phenytoin	drug	165-173	false
XENICAL	brand	95-101	phenytoin	drug	165-173	false

DDI-DrugBank.d761.s10	Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin.
Pravastatin	drug	0-10	XENICAL	brand	108-114	false
Pravastatin	drug	0-10	XENICAL	brand	153-159	false
Pravastatin	drug	0-10	pravastatin	drug	200-210	false
XENICAL	brand	108-114	XENICAL	brand	153-159	false
XENICAL	brand	108-114	pravastatin	drug	200-210	false
XENICAL	brand	153-159	pravastatin	drug	200-210	false

DDI-DrugBank.d761.s11	Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).
Warfarin	drug	0-7	XENICAL	brand	58-64	false
Warfarin	drug	0-7	warfarin	drug	142-149	false
XENICAL	brand	58-64	warfarin	drug	142-149	false

DDI-DrugBank.d761.s12	Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with XENICAL administration, vitamin K levels tended to decline in subjects taking XENICAL.
XENICAL	brand	101-107	XENICAL	brand	179-185	false

DDI-DrugBank.d761.s13	Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.
vitamin K	group	14-22	XENICAL	brand	57-63	mechanism
vitamin K	group	14-22	warfarin	drug	102-109	false
vitamin K	group	14-22	XENICAL	brand	130-136	false
XENICAL	brand	57-63	warfarin	drug	102-109	false
XENICAL	brand	57-63	XENICAL	brand	130-136	false
warfarin	drug	102-109	XENICAL	brand	130-136	advise

DDI-DrugBank.d650.s0	Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);
Dopamine antagonists	group	0-19	neuroleptics	group	34-45	false
Dopamine antagonists	group	0-19	phenothiazines	group	48-61	false
Dopamine antagonists	group	0-19	butyrophenones	group	64-77	false
Dopamine antagonists	group	0-19	thioxanthines	group	80-92	false
Dopamine antagonists	group	0-19	metoclopramide	drug	99-112	false
Dopamine antagonists	group	0-19	Permax	brand	171-176	advise
Dopamine antagonists	group	0-19	dopamine agonist	group	181-196	false
neuroleptics	group	34-45	phenothiazines	group	48-61	false
neuroleptics	group	34-45	butyrophenones	group	64-77	false
neuroleptics	group	34-45	thioxanthines	group	80-92	false
neuroleptics	group	34-45	metoclopramide	drug	99-112	false
neuroleptics	group	34-45	Permax	brand	171-176	advise
neuroleptics	group	34-45	dopamine agonist	group	181-196	false
phenothiazines	group	48-61	butyrophenones	group	64-77	false
phenothiazines	group	48-61	thioxanthines	group	80-92	false
phenothiazines	group	48-61	metoclopramide	drug	99-112	false
phenothiazines	group	48-61	Permax	brand	171-176	advise
phenothiazines	group	48-61	dopamine agonist	group	181-196	false
butyrophenones	group	64-77	thioxanthines	group	80-92	false
butyrophenones	group	64-77	metoclopramide	drug	99-112	false
butyrophenones	group	64-77	Permax	brand	171-176	advise
butyrophenones	group	64-77	dopamine agonist	group	181-196	false
thioxanthines	group	80-92	metoclopramide	drug	99-112	false
thioxanthines	group	80-92	Permax	brand	171-176	advise
thioxanthines	group	80-92	dopamine agonist	group	181-196	false
metoclopramide	drug	99-112	Permax	brand	171-176	advise
metoclopramide	drug	99-112	dopamine agonist	group	181-196	false
Permax	brand	171-176	dopamine agonist	group	181-196	false

DDI-DrugBank.d650.s2	Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.
pergolide mesylate	drug	8-25	pergolide mesylate	drug	105-122	false

DDI-DrugBank.d623.s1	Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA.
Aminoglutethimide	drug	0-16	depo-subQ provera 104	brand	50-70	mechanism
Aminoglutethimide	drug	0-16	MPA	drug	127-129	false
depo-subQ provera 104	brand	50-70	MPA	drug	127-129	false

DDI-DrugBank.d690.s0	The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol.
propoxyphene	drug	29-40	CNS depressants	group	73-87	effect
propoxyphene	drug	29-40	alcohol	drug	100-106	effect
CNS depressants	group	73-87	alcohol	drug	100-106	false

DDI-DrugBank.d690.s3	Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs.
propoxyphene	drug	41-52	antidepressants	group	86-100	false
propoxyphene	drug	41-52	anticonvulsants	group	103-117	false
propoxyphene	drug	41-52	warfarin	drug	123-130	false
antidepressants	group	86-100	anticonvulsants	group	103-117	false
antidepressants	group	86-100	warfarin	drug	123-130	false
anticonvulsants	group	103-117	warfarin	drug	123-130	false

DDI-DrugBank.d722.s0	There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine.
PURINETHOL	brand	51-60	mercaptopurine	drug	63-76	false
PURINETHOL	brand	51-60	TABLOID	brand	83-89	effect
PURINETHOL	brand	51-60	Thioguanine	drug	97-107	effect
mercaptopurine	drug	63-76	TABLOID	brand	83-89	effect
mercaptopurine	drug	63-76	Thioguanine	drug	97-107	effect
TABLOID	brand	83-89	Thioguanine	drug	97-107	false

DDI-DrugBank.d722.s1	As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.
aminosalicylate derivatives	group	35-61	olsalazine	drug	70-79	false
aminosalicylate derivatives	group	35-61	mesalazine	drug	82-91	false
aminosalicylate derivatives	group	35-61	sulphasalazine	drug	97-110	false
aminosalicylate derivatives	group	35-61	thioguanine	drug	212-222	mechanism
olsalazine	drug	70-79	mesalazine	drug	82-91	false
olsalazine	drug	70-79	sulphasalazine	drug	97-110	false
olsalazine	drug	70-79	thioguanine	drug	212-222	mechanism
mesalazine	drug	82-91	sulphasalazine	drug	97-110	false
mesalazine	drug	82-91	thioguanine	drug	212-222	mechanism
sulphasalazine	drug	97-110	thioguanine	drug	212-222	mechanism

DDI-DrugBank.d575.s0	In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.
tolbutamide	drug	95-105	sodium salicylate	drug	108-124	false
tolbutamide	drug	95-105	sulfamethizole	drug	130-143	false
tolbutamide	drug	95-105	teniposide	drug	169-178	mechanism
sodium salicylate	drug	108-124	sulfamethizole	drug	130-143	false
sodium salicylate	drug	108-124	teniposide	drug	169-178	mechanism
sulfamethizole	drug	130-143	teniposide	drug	169-178	mechanism

DDI-DrugBank.d575.s2	Therefore, caution should be used in administering VUMON (teniposide injection) to patients receiving these other agents.
VUMON	brand	51-55	teniposide	drug	58-67	false

DDI-DrugBank.d575.s3	There was no change in the plasma kinetics of teniposide when coadministered with methotrexate.
teniposide	drug	46-55	methotrexate	drug	82-93	false

DDI-DrugBank.d575.s5	An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.
methotrexate	drug	39-50	teniposide	drug	93-102	mechanism

DDI-DrugBank.d776.s2	These are described in greater detail below:  Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines,  Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;
hypoglycemics	group	51-63	Coumarin-type anticoagulants	group	66-93	false
hypoglycemics	group	51-63	Phenytoin	drug	96-104	false
hypoglycemics	group	51-63	Cyclosporine	drug	107-118	false
hypoglycemics	group	51-63	Rifampin	drug	121-128	false
hypoglycemics	group	51-63	Theophylline	drug	131-142	false
hypoglycemics	group	51-63	Terfenadine	drug	145-155	false
hypoglycemics	group	51-63	Cisapride	drug	158-166	false
hypoglycemics	group	51-63	Astemizole	drug	169-178	false
hypoglycemics	group	51-63	Rifabutin	drug	181-189	false
hypoglycemics	group	51-63	Tacrolimus	drug	192-201	false
hypoglycemics	group	51-63	Short-acting benzodiazepines	group	204-231	false
hypoglycemics	group	51-63	hypoglycemics	group	240-252	false
hypoglycemics	group	51-63	DIFLUCAN	brand	325-332	false
hypoglycemics	group	51-63	hypoglycemic agents	group	344-362	false
Coumarin-type anticoagulants	group	66-93	Phenytoin	drug	96-104	false
Coumarin-type anticoagulants	group	66-93	Cyclosporine	drug	107-118	false
Coumarin-type anticoagulants	group	66-93	Rifampin	drug	121-128	false
Coumarin-type anticoagulants	group	66-93	Theophylline	drug	131-142	false
Coumarin-type anticoagulants	group	66-93	Terfenadine	drug	145-155	false
Coumarin-type anticoagulants	group	66-93	Cisapride	drug	158-166	false
Coumarin-type anticoagulants	group	66-93	Astemizole	drug	169-178	false
Coumarin-type anticoagulants	group	66-93	Rifabutin	drug	181-189	false
Coumarin-type anticoagulants	group	66-93	Tacrolimus	drug	192-201	false
Coumarin-type anticoagulants	group	66-93	Short-acting benzodiazepines	group	204-231	false
Coumarin-type anticoagulants	group	66-93	hypoglycemics	group	240-252	false
Coumarin-type anticoagulants	group	66-93	DIFLUCAN	brand	325-332	false
Coumarin-type anticoagulants	group	66-93	hypoglycemic agents	group	344-362	false
Phenytoin	drug	96-104	Cyclosporine	drug	107-118	false
Phenytoin	drug	96-104	Rifampin	drug	121-128	false
Phenytoin	drug	96-104	Theophylline	drug	131-142	false
Phenytoin	drug	96-104	Terfenadine	drug	145-155	false
Phenytoin	drug	96-104	Cisapride	drug	158-166	false
Phenytoin	drug	96-104	Astemizole	drug	169-178	false
Phenytoin	drug	96-104	Rifabutin	drug	181-189	false
Phenytoin	drug	96-104	Tacrolimus	drug	192-201	false
Phenytoin	drug	96-104	Short-acting benzodiazepines	group	204-231	false
Phenytoin	drug	96-104	hypoglycemics	group	240-252	false
Phenytoin	drug	96-104	DIFLUCAN	brand	325-332	false
Phenytoin	drug	96-104	hypoglycemic agents	group	344-362	false
Cyclosporine	drug	107-118	Rifampin	drug	121-128	false
Cyclosporine	drug	107-118	Theophylline	drug	131-142	false
Cyclosporine	drug	107-118	Terfenadine	drug	145-155	false
Cyclosporine	drug	107-118	Cisapride	drug	158-166	false
Cyclosporine	drug	107-118	Astemizole	drug	169-178	false
Cyclosporine	drug	107-118	Rifabutin	drug	181-189	false
Cyclosporine	drug	107-118	Tacrolimus	drug	192-201	false
Cyclosporine	drug	107-118	Short-acting benzodiazepines	group	204-231	false
Cyclosporine	drug	107-118	hypoglycemics	group	240-252	false
Cyclosporine	drug	107-118	DIFLUCAN	brand	325-332	false
Cyclosporine	drug	107-118	hypoglycemic agents	group	344-362	false
Rifampin	drug	121-128	Theophylline	drug	131-142	false
Rifampin	drug	121-128	Terfenadine	drug	145-155	false
Rifampin	drug	121-128	Cisapride	drug	158-166	false
Rifampin	drug	121-128	Astemizole	drug	169-178	false
Rifampin	drug	121-128	Rifabutin	drug	181-189	false
Rifampin	drug	121-128	Tacrolimus	drug	192-201	false
Rifampin	drug	121-128	Short-acting benzodiazepines	group	204-231	false
Rifampin	drug	121-128	hypoglycemics	group	240-252	false
Rifampin	drug	121-128	DIFLUCAN	brand	325-332	false
Rifampin	drug	121-128	hypoglycemic agents	group	344-362	false
Theophylline	drug	131-142	Terfenadine	drug	145-155	false
Theophylline	drug	131-142	Cisapride	drug	158-166	false
Theophylline	drug	131-142	Astemizole	drug	169-178	false
Theophylline	drug	131-142	Rifabutin	drug	181-189	false
Theophylline	drug	131-142	Tacrolimus	drug	192-201	false
Theophylline	drug	131-142	Short-acting benzodiazepines	group	204-231	false
Theophylline	drug	131-142	hypoglycemics	group	240-252	false
Theophylline	drug	131-142	DIFLUCAN	brand	325-332	false
Theophylline	drug	131-142	hypoglycemic agents	group	344-362	false
Terfenadine	drug	145-155	Cisapride	drug	158-166	false
Terfenadine	drug	145-155	Astemizole	drug	169-178	false
Terfenadine	drug	145-155	Rifabutin	drug	181-189	false
Terfenadine	drug	145-155	Tacrolimus	drug	192-201	false
Terfenadine	drug	145-155	Short-acting benzodiazepines	group	204-231	false
Terfenadine	drug	145-155	hypoglycemics	group	240-252	false
Terfenadine	drug	145-155	DIFLUCAN	brand	325-332	false
Terfenadine	drug	145-155	hypoglycemic agents	group	344-362	false
Cisapride	drug	158-166	Astemizole	drug	169-178	false
Cisapride	drug	158-166	Rifabutin	drug	181-189	false
Cisapride	drug	158-166	Tacrolimus	drug	192-201	false
Cisapride	drug	158-166	Short-acting benzodiazepines	group	204-231	false
Cisapride	drug	158-166	hypoglycemics	group	240-252	false
Cisapride	drug	158-166	DIFLUCAN	brand	325-332	false
Cisapride	drug	158-166	hypoglycemic agents	group	344-362	false
Astemizole	drug	169-178	Rifabutin	drug	181-189	false
Astemizole	drug	169-178	Tacrolimus	drug	192-201	false
Astemizole	drug	169-178	Short-acting benzodiazepines	group	204-231	false
Astemizole	drug	169-178	hypoglycemics	group	240-252	false
Astemizole	drug	169-178	DIFLUCAN	brand	325-332	false
Astemizole	drug	169-178	hypoglycemic agents	group	344-362	false
Rifabutin	drug	181-189	Tacrolimus	drug	192-201	false
Rifabutin	drug	181-189	Short-acting benzodiazepines	group	204-231	false
Rifabutin	drug	181-189	hypoglycemics	group	240-252	false
Rifabutin	drug	181-189	DIFLUCAN	brand	325-332	false
Rifabutin	drug	181-189	hypoglycemic agents	group	344-362	false
Tacrolimus	drug	192-201	Short-acting benzodiazepines	group	204-231	false
Tacrolimus	drug	192-201	hypoglycemics	group	240-252	false
Tacrolimus	drug	192-201	DIFLUCAN	brand	325-332	false
Tacrolimus	drug	192-201	hypoglycemic agents	group	344-362	false
Short-acting benzodiazepines	group	204-231	hypoglycemics	group	240-252	false
Short-acting benzodiazepines	group	204-231	DIFLUCAN	brand	325-332	false
Short-acting benzodiazepines	group	204-231	hypoglycemic agents	group	344-362	false
hypoglycemics	group	240-252	DIFLUCAN	brand	325-332	false
hypoglycemics	group	240-252	hypoglycemic agents	group	344-362	false
DIFLUCAN	brand	325-332	hypoglycemic agents	group	344-362	effect

DDI-DrugBank.d776.s3	one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use.
DIFLUCAN	brand	78-85	glyburide	drug	91-99	effect

DDI-DrugBank.d776.s4	DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents.
DIFLUCAN	brand	0-7	tolbutamide	drug	35-45	mechanism
DIFLUCAN	brand	0-7	glyburide	drug	48-56	mechanism
DIFLUCAN	brand	0-7	glipizide	drug	63-71	mechanism
tolbutamide	drug	35-45	glyburide	drug	48-56	false
tolbutamide	drug	35-45	glipizide	drug	63-71	false
glyburide	drug	48-56	glipizide	drug	63-71	false

DDI-DrugBank.d776.s5	When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.
DIFLUCAN	brand	5-12	sulfonylurea oral hypoglycemic agents	group	56-92	advise
DIFLUCAN	brand	5-12	sulfonylurea	group	174-185	false
sulfonylurea oral hypoglycemic agents	group	56-92	sulfonylurea	group	174-185	false

DDI-DrugBank.d776.s6	Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants.
Coumarin-type anticoagulants	group	0-27	DIFLUCAN	brand	98-105	false
Coumarin-type anticoagulants	group	0-27	coumarin-type anticoagulants	group	111-138	false
DIFLUCAN	brand	98-105	coumarin-type anticoagulants	group	111-138	effect

DDI-DrugBank.d776.s7	In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin.
azole antifungals	group	44-60	fluconazole	drug	242-252	false
azole antifungals	group	44-60	warfarin	drug	272-279	false
fluconazole	drug	242-252	warfarin	drug	272-279	effect

DDI-DrugBank.d776.s8	Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended.
DIFLUCAN	brand	61-68	coumarin-type anticoagulants	group	74-101	advise

DDI-DrugBank.d776.s10	Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin.
Phenytoin	drug	0-8	DIFLUCAN	brand	11-18	false
Phenytoin	drug	0-8	phenytoin	drug	59-67	false
DIFLUCAN	brand	11-18	phenytoin	drug	59-67	mechanism

DDI-DrugBank.d776.s11	Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended.
phenytoin	drug	22-30	DIFLUCAN	brand	69-76	false
phenytoin	drug	22-30	phenytoin	drug	82-90	false
DIFLUCAN	brand	69-76	phenytoin	drug	82-90	advise

DDI-DrugBank.d776.s13	Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.
Cyclosporine	drug	0-11	DIFLUCAN	brand	14-21	false
Cyclosporine	drug	0-11	cyclosporine	drug	50-61	false
DIFLUCAN	brand	14-21	cyclosporine	drug	50-61	mechanism

DDI-DrugBank.d776.s14	Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine.
cyclosporine	drug	22-33	DIFLUCAN	brand	108-115	false
cyclosporine	drug	22-33	cyclosporine	drug	121-132	false
DIFLUCAN	brand	108-115	cyclosporine	drug	121-132	advise

DDI-DrugBank.d776.s16	Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN.
Rifampin	drug	0-7	Rifampin	drug	10-17	false
Rifampin	drug	0-7	DIFLUCAN	brand	72-79	false
Rifampin	drug	10-17	DIFLUCAN	brand	72-79	mechanism

DDI-DrugBank.d776.s17	Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin.
DIFLUCAN	brand	93-100	rifampin	drug	131-138	advise

DDI-DrugBank.d776.s18	Theophylline: DIFLUCAN increases the serum concentrations of theophylline.
Theophylline	drug	0-11	DIFLUCAN	brand	14-21	false
Theophylline	drug	0-11	theophylline	drug	61-72	false
DIFLUCAN	brand	14-21	theophylline	drug	61-72	mechanism

DDI-DrugBank.d776.s19	Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended.
theophylline	drug	28-39	DIFLUCAN	brand	78-85	false
theophylline	drug	28-39	theophylline	drug	91-102	false
DIFLUCAN	brand	78-85	theophylline	drug	91-102	advise

DDI-DrugBank.d776.s20	Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed.
Terfenadine	drug	0-10	azole antifungals	group	139-155	false
Terfenadine	drug	0-10	terfenadine	drug	177-187	false
azole antifungals	group	139-155	terfenadine	drug	177-187	effect

DDI-DrugBank.d776.s22	Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.
fluconazole	drug	51-61	DIFLUCAN	brand	81-88	false
fluconazole	drug	51-61	terfenadine	drug	175-185	false
DIFLUCAN	brand	81-88	terfenadine	drug	175-185	mechanism

DDI-DrugBank.d776.s23	The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated.
fluconazole	drug	20-30	terfenadine	drug	67-77	advise

DDI-DrugBank.d776.s24	The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.
fluconazole	drug	24-34	terfenadine	drug	72-82	advise

DDI-DrugBank.d776.s25	Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered.
Cisapride	drug	0-8	fluconazole	drug	103-113	false
Cisapride	drug	0-8	cisapride	drug	119-127	false
fluconazole	drug	103-113	cisapride	drug	119-127	effect

DDI-DrugBank.d776.s26	A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.
fluconazole	drug	42-52	cisapride	drug	76-84	mechanism
fluconazole	drug	42-52	cisapride	drug	143-151	false
cisapride	drug	76-84	cisapride	drug	143-151	false

DDI-DrugBank.d776.s27	The combined use of fluconazole with cisapride is contraindicated.
fluconazole	drug	20-30	cisapride	drug	37-45	advise

DDI-DrugBank.d776.s28	Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.
Astemizole	drug	0-9	fluconazole	drug	23-33	false
Astemizole	drug	0-9	astemizole	drug	67-76	false
fluconazole	drug	23-33	astemizole	drug	67-76	mechanism

DDI-DrugBank.d776.s31	Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered.
Rifabutin	drug	0-8	fluconazole	drug	66-76	false
Rifabutin	drug	0-8	rifabutin	drug	82-90	false
fluconazole	drug	66-76	rifabutin	drug	82-90	effect

DDI-DrugBank.d776.s32	Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.
rifabutin	drug	19-27	fluconazole	drug	33-43	advise

DDI-DrugBank.d776.s33	Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered.
Tacrolimus	drug	0-9	fluconazole	drug	74-84	false
Tacrolimus	drug	0-9	tacrolimus	drug	90-99	false
fluconazole	drug	74-84	tacrolimus	drug	90-99	effect

DDI-DrugBank.d776.s34	Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored.
tacrolimus	drug	19-28	fluconazole	drug	34-44	advise

DDI-DrugBank.d776.s35	Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.
Short-acting Benzodiazepines	group	0-27	midazolam	drug	63-71	false
Short-acting Benzodiazepines	group	0-27	fluconazole	drug	74-84	false
Short-acting Benzodiazepines	group	0-27	midazolam	drug	123-131	false
midazolam	drug	63-71	fluconazole	drug	74-84	mechanism
midazolam	drug	63-71	midazolam	drug	123-131	false
fluconazole	drug	74-84	midazolam	drug	123-131	false

DDI-DrugBank.d776.s36	This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously.
midazolam	drug	15-23	fluconazole	drug	88-98	effect
midazolam	drug	15-23	fluconazole	drug	110-120	false
fluconazole	drug	88-98	fluconazole	drug	110-120	false

DDI-DrugBank.d776.s37	If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.
short-acting benzodiazepines	group	3-30	fluconazole	drug	122-132	advise
short-acting benzodiazepines	group	3-30	benzodiazepine	group	183-196	false
fluconazole	drug	122-132	benzodiazepine	group	183-196	false

DDI-DrugBank.d776.s38	Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;
Fluconazole	drug	0-10	ethinyl estradiol	drug	40-56	mechanism
Fluconazole	drug	0-10	levonorgestrel	drug	63-76	mechanism
Fluconazole	drug	0-10	contraceptives	group	94-107	false
Fluconazole	drug	0-10	ethinyl estradiol	drug	146-162	false
Fluconazole	drug	0-10	levonorgestrel	drug	168-181	false
ethinyl estradiol	drug	40-56	levonorgestrel	drug	63-76	false
ethinyl estradiol	drug	40-56	contraceptives	group	94-107	false
ethinyl estradiol	drug	40-56	ethinyl estradiol	drug	146-162	false
ethinyl estradiol	drug	40-56	levonorgestrel	drug	168-181	false
levonorgestrel	drug	63-76	contraceptives	group	94-107	false
levonorgestrel	drug	63-76	ethinyl estradiol	drug	146-162	false
levonorgestrel	drug	63-76	levonorgestrel	drug	168-181	false
contraceptives	group	94-107	ethinyl estradiol	drug	146-162	false
contraceptives	group	94-107	levonorgestrel	drug	168-181	false
ethinyl estradiol	drug	146-162	levonorgestrel	drug	168-181	false

DDI-DrugBank.d776.s39	however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels.
ethinyl estradiol	drug	68-84	levonorgestrel	drug	90-103	false

DDI-DrugBank.d776.s40	The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation.
ethinyl estradiol	drug	76-92	levonorgestrel	drug	98-111	false
ethinyl estradiol	drug	76-92	fluconazole	drug	129-139	false
levonorgestrel	drug	98-111	fluconazole	drug	129-139	false

DDI-DrugBank.d776.s41	While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.
fluconazole	drug	29-39	ethinyl estradiol	drug	71-87	mechanism
fluconazole	drug	29-39	levonorgestrel	drug	93-106	mechanism
fluconazole	drug	29-39	fluconazole	drug	135-145	false
fluconazole	drug	29-39	ethinyl estradiol	drug	167-183	false
fluconazole	drug	29-39	levonorgestrel	drug	188-201	false
ethinyl estradiol	drug	71-87	levonorgestrel	drug	93-106	false
ethinyl estradiol	drug	71-87	fluconazole	drug	135-145	false
ethinyl estradiol	drug	71-87	ethinyl estradiol	drug	167-183	false
ethinyl estradiol	drug	71-87	levonorgestrel	drug	188-201	false
levonorgestrel	drug	93-106	fluconazole	drug	135-145	false
levonorgestrel	drug	93-106	ethinyl estradiol	drug	167-183	false
levonorgestrel	drug	93-106	levonorgestrel	drug	188-201	false
fluconazole	drug	135-145	ethinyl estradiol	drug	167-183	false
fluconazole	drug	135-145	levonorgestrel	drug	188-201	false
ethinyl estradiol	drug	167-183	levonorgestrel	drug	188-201	false

DDI-DrugBank.d625.s0	DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.
ALKERAN	brand	71-77	live organism vaccines	group	98-119	false
ALKERAN	brand	71-77	Nalidixic acid	drug	175-188	false
ALKERAN	brand	71-77	melphalan	drug	226-234	false
live organism vaccines	group	98-119	Nalidixic acid	drug	175-188	false
live organism vaccines	group	98-119	melphalan	drug	226-234	false
Nalidixic acid	drug	175-188	melphalan	drug	226-234	effect

DDI-DrugBank.d625.s1	Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease
melphalan	drug	126-134	cyclosporin	drug	166-176	effect

DDI-DrugBank.d600.s1	Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.
alcohol	drug	18-24	CNS depression-producing drugs	group	36-65	false
alcohol	drug	18-24	methyprylon	drug	110-120	effect
CNS depression-producing drugs	group	36-65	methyprylon	drug	110-120	effect

DDI-DrugBank.d577.s0	In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported.
diuretics	group	51-59	thiazides	group	72-80	false

DDI-DrugBank.d577.s1	It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin.
sulfamethoxazole	drug	26-41	anticoagulant	group	110-122	false
sulfamethoxazole	drug	26-41	warfarin	drug	124-131	effect
anticoagulant	group	110-122	warfarin	drug	124-131	false

DDI-DrugBank.d577.s3	Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin.
Sulfamethoxazole	drug	0-15	phenytoin	drug	55-63	mechanism

DDI-DrugBank.d577.s4	At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate.
sulfamethoxazole	drug	17-32	phenytoin	drug	97-105	mechanism

DDI-DrugBank.d577.s6	Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations.
Sulfonamides	group	0-11	methotrexate	drug	31-42	mechanism
Sulfonamides	group	0-11	methotrexate	drug	100-111	false
methotrexate	drug	31-42	methotrexate	drug	100-111	false

DDI-DrugBank.d653.s1	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
phenobarbital	drug	42-54	phenytoin	drug	57-65	false
phenobarbital	drug	42-54	rifampin	drug	71-78	false
phenobarbital	drug	42-54	corticosteroids	group	110-124	mechanism
phenobarbital	drug	42-54	corticosteroid	group	155-168	mechanism
phenytoin	drug	57-65	rifampin	drug	71-78	false
phenytoin	drug	57-65	corticosteroids	group	110-124	mechanism
phenytoin	drug	57-65	corticosteroid	group	155-168	mechanism
rifampin	drug	71-78	corticosteroids	group	110-124	mechanism
rifampin	drug	71-78	corticosteroid	group	155-168	mechanism
corticosteroids	group	110-124	corticosteroid	group	155-168	false

DDI-DrugBank.d653.s2	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance.
troleandomycin	drug	14-27	ketoconazole	drug	33-44	false
troleandomycin	drug	14-27	corticosteroids	group	76-90	mechanism
ketoconazole	drug	33-44	corticosteroids	group	76-90	mechanism

DDI-DrugBank.d653.s4	Corticosteroids may increase the clearance of chronic high dose aspirin.
Corticosteroids	group	0-14	aspirin	brand	64-70	mechanism

DDI-DrugBank.d653.s5	This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn.
salicylate	group	29-38	salicylate	group	77-86	false
salicylate	group	29-38	corticosteroid	group	102-115	false
salicylate	group	77-86	corticosteroid	group	102-115	effect

DDI-DrugBank.d653.s6	Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
Aspirin	brand	0-6	corticosteroids	group	54-68	advise

DDI-DrugBank.d653.s7	The effect of corticosteroids on oral anticoagulants is variable.
corticosteroids	group	14-28	anticoagulants	group	38-51	effect

DDI-DrugBank.d653.s8	There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids.
anticoagulants	group	63-76	corticosteroids	group	107-121	effect

DDI-DrugBank.d770.s4	however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.
diphosphonate	group	48-60	Calcitonin (salmon)	drug	116-134	effect

DDI-DrugBank.d779.s0	When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur.
methyldopa	drug	5-14	antihypertensive drugs	group	35-56	effect

DDI-DrugBank.d779.s2	Patients may require reduced doses of anesthetics when on methyldopa.
anesthetics	group	38-48	methyldopa	drug	58-67	advise

DDI-DrugBank.d779.s5	When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.
methyldopa	drug	5-14	lithium	drug	20-26	advise
methyldopa	drug	5-14	lithium	drug	110-116	false
lithium	drug	20-26	lithium	drug	110-116	false

DDI-DrugBank.d779.s7	Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate.
methyldopa	drug	65-74	ferrous sulfate	drug	101-115	mechanism
methyldopa	drug	65-74	ferrous gluconate	drug	120-136	mechanism
ferrous sulfate	drug	101-115	ferrous gluconate	drug	120-136	false

DDI-DrugBank.d779.s9	Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended.
methyldopa	drug	20-29	ferrous sulfate	drug	36-50	advise
methyldopa	drug	20-29	ferrous gluconate	drug	55-71	advise
ferrous sulfate	drug	36-50	ferrous gluconate	drug	55-71	false

DDI-DrugBank.d779.s16	Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin.
Methyldopa	drug	0-9	VMA	drug_n	50-52	false
Methyldopa	drug	0-9	vanillylmandelic acid	drug_n	55-75	false
Methyldopa	drug	0-9	VMA	drug_n	139-141	false
Methyldopa	drug	0-9	vanillin	drug_n	146-153	false
VMA	drug_n	50-52	vanillylmandelic acid	drug_n	55-75	false
VMA	drug_n	50-52	VMA	drug_n	139-141	false
VMA	drug_n	50-52	vanillin	drug_n	146-153	false
vanillylmandelic acid	drug_n	55-75	VMA	drug_n	139-141	false
vanillylmandelic acid	drug_n	55-75	vanillin	drug_n	146-153	false
VMA	drug_n	139-141	vanillin	drug_n	146-153	false

DDI-DrugBank.d651.s0	Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.
contraceptives	group	33-46	vitamin A	group	92-100	mechanism

DDI-DrugBank.d601.s0	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.
Barbiturates	group	0-11	contraceptives	group	52-65	int
Barbiturates	group	0-11	antibiotics	group	76-86	int
Barbiturates	group	0-11	quinidine	group	89-97	int
Barbiturates	group	0-11	theophylline	drug	100-111	int
Barbiturates	group	0-11	corticosteroids	group	114-128	int
Barbiturates	group	0-11	anticoagulants	group	131-144	int
Barbiturates	group	0-11	beta blockers	group	151-163	int
contraceptives	group	52-65	antibiotics	group	76-86	false
contraceptives	group	52-65	quinidine	group	89-97	false
contraceptives	group	52-65	theophylline	drug	100-111	false
contraceptives	group	52-65	corticosteroids	group	114-128	false
contraceptives	group	52-65	anticoagulants	group	131-144	false
contraceptives	group	52-65	beta blockers	group	151-163	false
antibiotics	group	76-86	quinidine	group	89-97	false
antibiotics	group	76-86	theophylline	drug	100-111	false
antibiotics	group	76-86	corticosteroids	group	114-128	false
antibiotics	group	76-86	anticoagulants	group	131-144	false
antibiotics	group	76-86	beta blockers	group	151-163	false
quinidine	group	89-97	theophylline	drug	100-111	false
quinidine	group	89-97	corticosteroids	group	114-128	false
quinidine	group	89-97	anticoagulants	group	131-144	false
quinidine	group	89-97	beta blockers	group	151-163	false
theophylline	drug	100-111	corticosteroids	group	114-128	false
theophylline	drug	100-111	anticoagulants	group	131-144	false
theophylline	drug	100-111	beta blockers	group	151-163	false
corticosteroids	group	114-128	anticoagulants	group	131-144	false
corticosteroids	group	114-128	beta blockers	group	151-163	false
anticoagulants	group	131-144	beta blockers	group	151-163	false

DDI-DrugBank.d723.s0	Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.
acetylcholine chloride	drug	39-60	Miochol	brand	63-69	false
acetylcholine chloride	drug	39-60	carbachol	drug	76-84	false
acetylcholine chloride	drug	39-60	Carboptic	brand	87-95	false
acetylcholine chloride	drug	39-60	Isopto Carbachol	brand	98-113	false
acetylcholine chloride	drug	39-60	suprofen	drug	144-151	effect
Miochol	brand	63-69	carbachol	drug	76-84	false
Miochol	brand	63-69	Carboptic	brand	87-95	false
Miochol	brand	63-69	Isopto Carbachol	brand	98-113	false
Miochol	brand	63-69	suprofen	drug	144-151	effect
carbachol	drug	76-84	Carboptic	brand	87-95	false
carbachol	drug	76-84	Isopto Carbachol	brand	98-113	false
carbachol	drug	76-84	suprofen	drug	144-151	effect
Carboptic	brand	87-95	Isopto Carbachol	brand	98-113	false
Carboptic	brand	87-95	suprofen	drug	144-151	effect
Isopto Carbachol	brand	98-113	suprofen	drug	144-151	effect

DDI-DrugBank.d742.s2	Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of REMERON SolTab    (mirtazapine) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes.
REMERON SolTab	brand	74-87	mirtazapine	drug	93-103	false

DDI-DrugBank.d742.s5	While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied.
mirtazapine	drug	39-49	mirtazapine	drug	121-131	false
mirtazapine	drug	39-49	REMERON SolTab	brand	309-322	false
mirtazapine	drug	121-131	REMERON SolTab	brand	309-322	false

DDI-DrugBank.d742.s7	Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.
Alcohol	drug	0-6	alcohol	drug	39-45	false
Alcohol	drug	0-6	mirtazapine	drug	109-119	false
alcohol	drug	39-45	mirtazapine	drug	109-119	mechanism

DDI-DrugBank.d742.s8	However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol.
REMERON	brand	66-72	alcohol	drug	126-132	effect

DDI-DrugBank.d742.s9	Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
alcohol	drug	49-55	REMERON SolTab	brand	70-83	advise
alcohol	drug	49-55	Diazepam	drug	86-93	false
alcohol	drug	49-55	diazepam	drug	126-133	false
alcohol	drug	49-55	mirtazapine	drug	184-194	false
REMERON SolTab	brand	70-83	Diazepam	drug	86-93	false
REMERON SolTab	brand	70-83	diazepam	drug	126-133	false
REMERON SolTab	brand	70-83	mirtazapine	drug	184-194	false
Diazepam	drug	86-93	diazepam	drug	126-133	false
Diazepam	drug	86-93	mirtazapine	drug	184-194	false
diazepam	drug	126-133	mirtazapine	drug	184-194	mechanism

DDI-DrugBank.d742.s10	However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam.
REMERON	brand	52-58	diazepam	drug	111-118	effect

DDI-DrugBank.d742.s11	Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.
diazepam	drug	49-56	REMERON SolTab	brand	95-108	advise

DDI-DrugBank.d643.s0	Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).
Melatonin	drug	0-8	aspirin	brand	49-55	int
Melatonin	drug	0-8	NSAIDs	group	67-72	int
Melatonin	drug	0-8	melatonin	drug	85-93	false
Melatonin	drug	0-8	fluvoxamine	drug	104-114	int
Melatonin	drug	0-8	melatonin	drug	141-149	false
Melatonin	drug	0-8	beta blockers	group	188-200	int
Melatonin	drug	0-8	melatonin	drug	216-224	false
Melatonin	drug	0-8	fluoxetine	drug	235-244	int
Melatonin	drug	0-8	progestin	group	299-307	int
Melatonin	drug	0-8	melatonin	drug	330-338	false
Melatonin	drug	0-8	progestin	group	345-353	false
Melatonin	drug	0-8	benzodiazepenes	group	395-409	int
Melatonin	drug	0-8	corticosteroids	group	521-535	int
Melatonin	drug	0-8	melatonin	drug	558-566	false
Melatonin	drug	0-8	corticosteroids	group	572-586	false
Melatonin	drug	0-8	corticosteroids	group	627-641	false
aspirin	brand	49-55	NSAIDs	group	67-72	false
aspirin	brand	49-55	melatonin	drug	85-93	false
aspirin	brand	49-55	fluvoxamine	drug	104-114	false
aspirin	brand	49-55	melatonin	drug	141-149	false
aspirin	brand	49-55	beta blockers	group	188-200	false
aspirin	brand	49-55	melatonin	drug	216-224	false
aspirin	brand	49-55	fluoxetine	drug	235-244	false
aspirin	brand	49-55	progestin	group	299-307	false
aspirin	brand	49-55	melatonin	drug	330-338	false
aspirin	brand	49-55	progestin	group	345-353	false
aspirin	brand	49-55	benzodiazepenes	group	395-409	false
aspirin	brand	49-55	corticosteroids	group	521-535	false
aspirin	brand	49-55	melatonin	drug	558-566	false
aspirin	brand	49-55	corticosteroids	group	572-586	false
aspirin	brand	49-55	corticosteroids	group	627-641	false
NSAIDs	group	67-72	melatonin	drug	85-93	false
NSAIDs	group	67-72	fluvoxamine	drug	104-114	false
NSAIDs	group	67-72	melatonin	drug	141-149	false
NSAIDs	group	67-72	beta blockers	group	188-200	false
NSAIDs	group	67-72	melatonin	drug	216-224	false
NSAIDs	group	67-72	fluoxetine	drug	235-244	false
NSAIDs	group	67-72	progestin	group	299-307	false
NSAIDs	group	67-72	melatonin	drug	330-338	false
NSAIDs	group	67-72	progestin	group	345-353	false
NSAIDs	group	67-72	benzodiazepenes	group	395-409	false
NSAIDs	group	67-72	corticosteroids	group	521-535	false
NSAIDs	group	67-72	melatonin	drug	558-566	false
NSAIDs	group	67-72	corticosteroids	group	572-586	false
NSAIDs	group	67-72	corticosteroids	group	627-641	false
melatonin	drug	85-93	fluvoxamine	drug	104-114	false
melatonin	drug	85-93	melatonin	drug	141-149	false
melatonin	drug	85-93	beta blockers	group	188-200	false
melatonin	drug	85-93	melatonin	drug	216-224	false
melatonin	drug	85-93	fluoxetine	drug	235-244	false
melatonin	drug	85-93	progestin	group	299-307	false
melatonin	drug	85-93	melatonin	drug	330-338	false
melatonin	drug	85-93	progestin	group	345-353	false
melatonin	drug	85-93	benzodiazepenes	group	395-409	false
melatonin	drug	85-93	corticosteroids	group	521-535	false
melatonin	drug	85-93	melatonin	drug	558-566	false
melatonin	drug	85-93	corticosteroids	group	572-586	false
melatonin	drug	85-93	corticosteroids	group	627-641	false
fluvoxamine	drug	104-114	melatonin	drug	141-149	false
fluvoxamine	drug	104-114	beta blockers	group	188-200	false
fluvoxamine	drug	104-114	melatonin	drug	216-224	false
fluvoxamine	drug	104-114	fluoxetine	drug	235-244	false
fluvoxamine	drug	104-114	progestin	group	299-307	false
fluvoxamine	drug	104-114	melatonin	drug	330-338	false
fluvoxamine	drug	104-114	progestin	group	345-353	false
fluvoxamine	drug	104-114	benzodiazepenes	group	395-409	false
fluvoxamine	drug	104-114	corticosteroids	group	521-535	false
fluvoxamine	drug	104-114	melatonin	drug	558-566	false
fluvoxamine	drug	104-114	corticosteroids	group	572-586	false
fluvoxamine	drug	104-114	corticosteroids	group	627-641	false
melatonin	drug	141-149	beta blockers	group	188-200	false
melatonin	drug	141-149	melatonin	drug	216-224	false
melatonin	drug	141-149	fluoxetine	drug	235-244	false
melatonin	drug	141-149	progestin	group	299-307	false
melatonin	drug	141-149	melatonin	drug	330-338	false
melatonin	drug	141-149	progestin	group	345-353	false
melatonin	drug	141-149	benzodiazepenes	group	395-409	false
melatonin	drug	141-149	corticosteroids	group	521-535	false
melatonin	drug	141-149	melatonin	drug	558-566	false
melatonin	drug	141-149	corticosteroids	group	572-586	false
melatonin	drug	141-149	corticosteroids	group	627-641	false
beta blockers	group	188-200	melatonin	drug	216-224	false
beta blockers	group	188-200	fluoxetine	drug	235-244	false
beta blockers	group	188-200	progestin	group	299-307	false
beta blockers	group	188-200	melatonin	drug	330-338	false
beta blockers	group	188-200	progestin	group	345-353	false
beta blockers	group	188-200	benzodiazepenes	group	395-409	false
beta blockers	group	188-200	corticosteroids	group	521-535	false
beta blockers	group	188-200	melatonin	drug	558-566	false
beta blockers	group	188-200	corticosteroids	group	572-586	false
beta blockers	group	188-200	corticosteroids	group	627-641	false
melatonin	drug	216-224	fluoxetine	drug	235-244	false
melatonin	drug	216-224	progestin	group	299-307	false
melatonin	drug	216-224	melatonin	drug	330-338	false
melatonin	drug	216-224	progestin	group	345-353	false
melatonin	drug	216-224	benzodiazepenes	group	395-409	false
melatonin	drug	216-224	corticosteroids	group	521-535	false
melatonin	drug	216-224	melatonin	drug	558-566	false
melatonin	drug	216-224	corticosteroids	group	572-586	false
melatonin	drug	216-224	corticosteroids	group	627-641	false
fluoxetine	drug	235-244	progestin	group	299-307	false
fluoxetine	drug	235-244	melatonin	drug	330-338	false
fluoxetine	drug	235-244	progestin	group	345-353	false
fluoxetine	drug	235-244	benzodiazepenes	group	395-409	false
fluoxetine	drug	235-244	corticosteroids	group	521-535	false
fluoxetine	drug	235-244	melatonin	drug	558-566	false
fluoxetine	drug	235-244	corticosteroids	group	572-586	false
fluoxetine	drug	235-244	corticosteroids	group	627-641	false
progestin	group	299-307	melatonin	drug	330-338	false
progestin	group	299-307	progestin	group	345-353	false
progestin	group	299-307	benzodiazepenes	group	395-409	false
progestin	group	299-307	corticosteroids	group	521-535	false
progestin	group	299-307	melatonin	drug	558-566	false
progestin	group	299-307	corticosteroids	group	572-586	false
progestin	group	299-307	corticosteroids	group	627-641	false
melatonin	drug	330-338	progestin	group	345-353	effect
melatonin	drug	330-338	benzodiazepenes	group	395-409	false
melatonin	drug	330-338	corticosteroids	group	521-535	false
melatonin	drug	330-338	melatonin	drug	558-566	false
melatonin	drug	330-338	corticosteroids	group	572-586	false
melatonin	drug	330-338	corticosteroids	group	627-641	false
progestin	group	345-353	benzodiazepenes	group	395-409	false
progestin	group	345-353	corticosteroids	group	521-535	false
progestin	group	345-353	melatonin	drug	558-566	false
progestin	group	345-353	corticosteroids	group	572-586	false
progestin	group	345-353	corticosteroids	group	627-641	false
benzodiazepenes	group	395-409	corticosteroids	group	521-535	false
benzodiazepenes	group	395-409	melatonin	drug	558-566	false
benzodiazepenes	group	395-409	corticosteroids	group	572-586	false
benzodiazepenes	group	395-409	corticosteroids	group	627-641	false
corticosteroids	group	521-535	melatonin	drug	558-566	false
corticosteroids	group	521-535	corticosteroids	group	572-586	false
corticosteroids	group	521-535	corticosteroids	group	627-641	false
melatonin	drug	558-566	corticosteroids	group	572-586	effect
melatonin	drug	558-566	corticosteroids	group	627-641	false
corticosteroids	group	572-586	corticosteroids	group	627-641	false

DDI-DrugBank.d781.s0	Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy.
Diuretics	group	0-8	diuretics	group	23-31	false
Diuretics	group	0-8	ACEON	brand	162-166	false
diuretics	group	23-31	ACEON	brand	162-166	effect

DDI-DrugBank.d781.s1	The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril.
diuretic	group	84-91	perindopril	drug	161-171	effect

DDI-DrugBank.d781.s2	If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour.
diuretics	group	3-11	ACEON	brand	104-108	advise

DDI-DrugBank.d781.s3	The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics.
perindopril	drug	23-33	diuretics	group	94-102	false

DDI-DrugBank.d781.s4	The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition.
perindoprilat	drug_n	23-35	diuretics	group	52-60	false

DDI-DrugBank.d781.s5	Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production.
Potassium	drug	0-8	Potassium-Sparing Diuretics	group	26-52	false
Potassium	drug	0-8	ACEON	brand	55-59	false
Potassium-Sparing Diuretics	group	26-52	ACEON	brand	55-59	false

DDI-DrugBank.d781.s6	Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
potassium-sparing diuretics	group	7-33	spironolactone	drug	36-49	false
potassium-sparing diuretics	group	7-33	amiloride	drug	52-60	false
potassium-sparing diuretics	group	7-33	triamterene	drug	63-73	false
potassium-sparing diuretics	group	7-33	potassium	drug	88-96	false
potassium-sparing diuretics	group	7-33	indomethacin	drug	164-175	false
potassium-sparing diuretics	group	7-33	heparin	drug	178-184	false
potassium-sparing diuretics	group	7-33	cyclosporine	drug	187-198	false
spironolactone	drug	36-49	amiloride	drug	52-60	false
spironolactone	drug	36-49	triamterene	drug	63-73	false
spironolactone	drug	36-49	potassium	drug	88-96	false
spironolactone	drug	36-49	indomethacin	drug	164-175	false
spironolactone	drug	36-49	heparin	drug	178-184	false
spironolactone	drug	36-49	cyclosporine	drug	187-198	false
amiloride	drug	52-60	triamterene	drug	63-73	false
amiloride	drug	52-60	potassium	drug	88-96	false
amiloride	drug	52-60	indomethacin	drug	164-175	false
amiloride	drug	52-60	heparin	drug	178-184	false
amiloride	drug	52-60	cyclosporine	drug	187-198	false
triamterene	drug	63-73	potassium	drug	88-96	false
triamterene	drug	63-73	indomethacin	drug	164-175	false
triamterene	drug	63-73	heparin	drug	178-184	false
triamterene	drug	63-73	cyclosporine	drug	187-198	false
potassium	drug	88-96	indomethacin	drug	164-175	false
potassium	drug	88-96	heparin	drug	178-184	false
potassium	drug	88-96	cyclosporine	drug	187-198	false
indomethacin	drug	164-175	heparin	drug	178-184	false
indomethacin	drug	164-175	cyclosporine	drug	187-198	false
heparin	drug	178-184	cyclosporine	drug	187-198	false

DDI-DrugBank.d781.s8	Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.
Lithium	drug	0-6	lithium	drug	25-31	false
Lithium	drug	0-6	lithium	drug	49-55	false
Lithium	drug	0-6	lithium	drug	119-125	false
lithium	drug	25-31	lithium	drug	49-55	false
lithium	drug	25-31	lithium	drug	119-125	false
lithium	drug	49-55	lithium	drug	119-125	false

DDI-DrugBank.d781.s10	Use of a diuretic may further increase the risk of lithium toxicity.
diuretic	group	9-16	lithium	drug	51-57	false

DDI-DrugBank.d781.s11	Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.
Digoxin	drug	0-6	digoxin	drug	74-80	false
Digoxin	drug	0-6	ACEON	brand	122-126	false
Digoxin	drug	0-6	digoxin	drug	157-163	false
Digoxin	drug	0-6	perindopril	drug	196-206	false
Digoxin	drug	0-6	perindoprilat	drug_n	208-220	false
digoxin	drug	74-80	ACEON	brand	122-126	false
digoxin	drug	74-80	digoxin	drug	157-163	false
digoxin	drug	74-80	perindopril	drug	196-206	false
digoxin	drug	74-80	perindoprilat	drug_n	208-220	false
ACEON	brand	122-126	digoxin	drug	157-163	false
ACEON	brand	122-126	perindopril	drug	196-206	false
ACEON	brand	122-126	perindoprilat	drug_n	208-220	false
digoxin	drug	157-163	perindopril	drug	196-206	mechanism
digoxin	drug	157-163	perindoprilat	drug_n	208-220	mechanism
perindopril	drug	196-206	perindoprilat	drug_n	208-220	false

DDI-DrugBank.d781.s12	Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin.
Gentamicin	drug	0-9	perindopril	drug	78-88	false
Gentamicin	drug	0-9	gentamicin	drug	94-103	false
perindopril	drug	78-88	gentamicin	drug	94-103	int

DDI-DrugBank.d781.s15	Food Interaction: Oral administration of ACEON    Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state.
ACEON	brand	41-45	perindopril	drug	119-129	false

DDI-DrugBank.d781.s16	However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant.
perindopril	drug	44-54	perindoprilat	drug_n	82-94	false

DDI-DrugBank.d659.s0	Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors.
TRENTAL	brand	152-158	anticoagulants	group	177-190	effect
TRENTAL	brand	152-158	platelet aggregation inhibitors	group	195-225	effect
anticoagulants	group	177-190	platelet aggregation inhibitors	group	195-225	false

DDI-DrugBank.d659.s2	Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.
TRENTAL	brand	30-36	theophylline	drug	42-53	mechanism
TRENTAL	brand	30-36	theophylline	drug	91-102	false
TRENTAL	brand	30-36	theophylline	drug	115-126	false
theophylline	drug	42-53	theophylline	drug	91-102	false
theophylline	drug	42-53	theophylline	drug	115-126	false
theophylline	drug	91-102	theophylline	drug	115-126	false

DDI-DrugBank.d659.s4	TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.
TRENTAL	brand	0-6	antihypertensive drugs	group	40-61	false
TRENTAL	brand	0-6	beta blockers	group	64-76	false
TRENTAL	brand	0-6	digitalis	group	79-87	false
TRENTAL	brand	0-6	diuretics	group	90-98	false
TRENTAL	brand	0-6	antidiabetic agents	group	101-119	false
TRENTAL	brand	0-6	antiarrhythmics	group	126-140	false
antihypertensive drugs	group	40-61	beta blockers	group	64-76	false
antihypertensive drugs	group	40-61	digitalis	group	79-87	false
antihypertensive drugs	group	40-61	diuretics	group	90-98	false
antihypertensive drugs	group	40-61	antidiabetic agents	group	101-119	false
antihypertensive drugs	group	40-61	antiarrhythmics	group	126-140	false
beta blockers	group	64-76	digitalis	group	79-87	false
beta blockers	group	64-76	diuretics	group	90-98	false
beta blockers	group	64-76	antidiabetic agents	group	101-119	false
beta blockers	group	64-76	antiarrhythmics	group	126-140	false
digitalis	group	79-87	diuretics	group	90-98	false
digitalis	group	79-87	antidiabetic agents	group	101-119	false
digitalis	group	79-87	antiarrhythmics	group	126-140	false
diuretics	group	90-98	antidiabetic agents	group	101-119	false
diuretics	group	90-98	antiarrhythmics	group	126-140	false
antidiabetic agents	group	101-119	antiarrhythmics	group	126-140	false

DDI-DrugBank.d634.s0	Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.
Anticoagulants	group	0-13	anticoagulants	group	44-57	false
Anticoagulants	group	0-13	methimazole	drug	119-129	false
anticoagulants	group	44-57	methimazole	drug	119-129	effect

DDI-DrugBank.d634.s3	Digitalis glycosides: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid;
Digitalis glycosides	group	0-19	digitalis glycoside	group	101-119	false

DDI-DrugBank.d634.s5	Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid;
Theophylline	drug	0-11	Theophylline	drug	14-25	false
Theophylline	drug	0-11	theophylline	drug	89-100	false
Theophylline	drug	14-25	theophylline	drug	89-100	false

DDI-DrugBank.d737.s0	Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).
Carbidopa	drug	0-8	Levodopa	drug	10-17	false
Carbidopa	drug	0-8	Carbidopa	drug	20-28	false
Carbidopa	drug	0-8	Levodopa	drug	30-37	false
Carbidopa	drug	0-8	pramipexole	drug	82-92	false
Levodopa	drug	10-17	Carbidopa	drug	20-28	false
Levodopa	drug	10-17	Levodopa	drug	30-37	false
Levodopa	drug	10-17	pramipexole	drug	82-92	false
Carbidopa	drug	20-28	Levodopa	drug	30-37	false
Carbidopa	drug	20-28	pramipexole	drug	82-92	false
Levodopa	drug	30-37	pramipexole	drug	82-92	false

DDI-DrugBank.d737.s2	Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole.
Selegiline	drug	0-9	selegiline	drug	43-52	false
Selegiline	drug	0-9	pramipexole	drug	96-106	false
selegiline	drug	43-52	pramipexole	drug	96-106	false

DDI-DrugBank.d737.s3	Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54).
Amantadine	drug	0-9	amantadine	drug	62-71	false
Amantadine	drug	0-9	pramipexole	drug	116-126	false
amantadine	drug	62-71	pramipexole	drug	116-126	false

DDI-DrugBank.d737.s4	Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12).
Cimetidine	drug	0-9	Cimetidine	drug	12-21	false
Cimetidine	drug	0-9	pramipexole	drug	146-156	false
Cimetidine	drug	12-21	pramipexole	drug	146-156	mechanism

DDI-DrugBank.d737.s5	Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12).
Probenecid	drug	0-9	Probenecid	drug	12-21	false
Probenecid	drug	0-9	pramipexole	drug	144-154	false
Probenecid	drug	12-21	pramipexole	drug	144-154	false

DDI-DrugBank.d737.s6	Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.
cimetidine	drug	178-187	ranitidine	drug	190-199	false
cimetidine	drug	178-187	diltiazem	drug	202-210	false
cimetidine	drug	178-187	triamterene	drug	213-223	false
cimetidine	drug	178-187	verapamil	drug	226-234	false
cimetidine	drug	178-187	quinidine	drug	237-245	false
cimetidine	drug	178-187	quinine	drug	252-258	false
cimetidine	drug	178-187	pramipexole	drug	293-303	mechanism
cimetidine	drug	178-187	cephalosporins	group	379-392	false
cimetidine	drug	178-187	penicillins	group	395-405	false
cimetidine	drug	178-187	indomethacin	drug	408-419	false
cimetidine	drug	178-187	hydrochlorothiazide	drug	422-440	false
cimetidine	drug	178-187	chlorpropamide	drug	447-460	false
cimetidine	drug	178-187	pramipexole	drug	521-531	false
ranitidine	drug	190-199	diltiazem	drug	202-210	false
ranitidine	drug	190-199	triamterene	drug	213-223	false
ranitidine	drug	190-199	verapamil	drug	226-234	false
ranitidine	drug	190-199	quinidine	drug	237-245	false
ranitidine	drug	190-199	quinine	drug	252-258	false
ranitidine	drug	190-199	pramipexole	drug	293-303	mechanism
ranitidine	drug	190-199	cephalosporins	group	379-392	false
ranitidine	drug	190-199	penicillins	group	395-405	false
ranitidine	drug	190-199	indomethacin	drug	408-419	false
ranitidine	drug	190-199	hydrochlorothiazide	drug	422-440	false
ranitidine	drug	190-199	chlorpropamide	drug	447-460	false
ranitidine	drug	190-199	pramipexole	drug	521-531	false
diltiazem	drug	202-210	triamterene	drug	213-223	false
diltiazem	drug	202-210	verapamil	drug	226-234	false
diltiazem	drug	202-210	quinidine	drug	237-245	false
diltiazem	drug	202-210	quinine	drug	252-258	false
diltiazem	drug	202-210	pramipexole	drug	293-303	mechanism
diltiazem	drug	202-210	cephalosporins	group	379-392	false
diltiazem	drug	202-210	penicillins	group	395-405	false
diltiazem	drug	202-210	indomethacin	drug	408-419	false
diltiazem	drug	202-210	hydrochlorothiazide	drug	422-440	false
diltiazem	drug	202-210	chlorpropamide	drug	447-460	false
diltiazem	drug	202-210	pramipexole	drug	521-531	false
triamterene	drug	213-223	verapamil	drug	226-234	false
triamterene	drug	213-223	quinidine	drug	237-245	false
triamterene	drug	213-223	quinine	drug	252-258	false
triamterene	drug	213-223	pramipexole	drug	293-303	mechanism
triamterene	drug	213-223	cephalosporins	group	379-392	false
triamterene	drug	213-223	penicillins	group	395-405	false
triamterene	drug	213-223	indomethacin	drug	408-419	false
triamterene	drug	213-223	hydrochlorothiazide	drug	422-440	false
triamterene	drug	213-223	chlorpropamide	drug	447-460	false
triamterene	drug	213-223	pramipexole	drug	521-531	false
verapamil	drug	226-234	quinidine	drug	237-245	false
verapamil	drug	226-234	quinine	drug	252-258	false
verapamil	drug	226-234	pramipexole	drug	293-303	mechanism
verapamil	drug	226-234	cephalosporins	group	379-392	false
verapamil	drug	226-234	penicillins	group	395-405	false
verapamil	drug	226-234	indomethacin	drug	408-419	false
verapamil	drug	226-234	hydrochlorothiazide	drug	422-440	false
verapamil	drug	226-234	chlorpropamide	drug	447-460	false
verapamil	drug	226-234	pramipexole	drug	521-531	false
quinidine	drug	237-245	quinine	drug	252-258	false
quinidine	drug	237-245	pramipexole	drug	293-303	mechanism
quinidine	drug	237-245	cephalosporins	group	379-392	false
quinidine	drug	237-245	penicillins	group	395-405	false
quinidine	drug	237-245	indomethacin	drug	408-419	false
quinidine	drug	237-245	hydrochlorothiazide	drug	422-440	false
quinidine	drug	237-245	chlorpropamide	drug	447-460	false
quinidine	drug	237-245	pramipexole	drug	521-531	false
quinine	drug	252-258	pramipexole	drug	293-303	mechanism
quinine	drug	252-258	cephalosporins	group	379-392	false
quinine	drug	252-258	penicillins	group	395-405	false
quinine	drug	252-258	indomethacin	drug	408-419	false
quinine	drug	252-258	hydrochlorothiazide	drug	422-440	false
quinine	drug	252-258	chlorpropamide	drug	447-460	false
quinine	drug	252-258	pramipexole	drug	521-531	false
pramipexole	drug	293-303	cephalosporins	group	379-392	false
pramipexole	drug	293-303	penicillins	group	395-405	false
pramipexole	drug	293-303	indomethacin	drug	408-419	false
pramipexole	drug	293-303	hydrochlorothiazide	drug	422-440	false
pramipexole	drug	293-303	chlorpropamide	drug	447-460	false
pramipexole	drug	293-303	pramipexole	drug	521-531	false
cephalosporins	group	379-392	penicillins	group	395-405	false
cephalosporins	group	379-392	indomethacin	drug	408-419	false
cephalosporins	group	379-392	hydrochlorothiazide	drug	422-440	false
cephalosporins	group	379-392	chlorpropamide	drug	447-460	false
cephalosporins	group	379-392	pramipexole	drug	521-531	mechanism
penicillins	group	395-405	indomethacin	drug	408-419	false
penicillins	group	395-405	hydrochlorothiazide	drug	422-440	false
penicillins	group	395-405	chlorpropamide	drug	447-460	false
penicillins	group	395-405	pramipexole	drug	521-531	mechanism
indomethacin	drug	408-419	hydrochlorothiazide	drug	422-440	false
indomethacin	drug	408-419	chlorpropamide	drug	447-460	false
indomethacin	drug	408-419	pramipexole	drug	521-531	mechanism
hydrochlorothiazide	drug	422-440	chlorpropamide	drug	447-460	false
hydrochlorothiazide	drug	422-440	pramipexole	drug	521-531	mechanism
chlorpropamide	drug	447-460	pramipexole	drug	521-531	mechanism

DDI-DrugBank.d737.s7	CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro.
pramipexole	drug	88-98	pramipexole	drug	120-130	false

DDI-DrugBank.d737.s10	Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.
Dopamine antagonists	group	0-19	pramipexole	drug	28-38	false
Dopamine antagonists	group	0-19	dopamine agonist	group	45-60	false
Dopamine antagonists	group	0-19	dopamine antagonists	group	83-102	false
Dopamine antagonists	group	0-19	neuroleptics	group	117-128	false
Dopamine antagonists	group	0-19	phenothiazines	group	131-144	false
Dopamine antagonists	group	0-19	butyrophenones	group	147-160	false
Dopamine antagonists	group	0-19	thioxanthenes	group	163-175	false
Dopamine antagonists	group	0-19	metoclopramide	group	181-194	false
Dopamine antagonists	group	0-19	MIRAPEX	brand	231-237	false
pramipexole	drug	28-38	dopamine agonist	group	45-60	false
pramipexole	drug	28-38	dopamine antagonists	group	83-102	false
pramipexole	drug	28-38	neuroleptics	group	117-128	false
pramipexole	drug	28-38	phenothiazines	group	131-144	false
pramipexole	drug	28-38	butyrophenones	group	147-160	false
pramipexole	drug	28-38	thioxanthenes	group	163-175	false
pramipexole	drug	28-38	metoclopramide	group	181-194	false
pramipexole	drug	28-38	MIRAPEX	brand	231-237	false
dopamine agonist	group	45-60	dopamine antagonists	group	83-102	false
dopamine agonist	group	45-60	neuroleptics	group	117-128	false
dopamine agonist	group	45-60	phenothiazines	group	131-144	false
dopamine agonist	group	45-60	butyrophenones	group	147-160	false
dopamine agonist	group	45-60	thioxanthenes	group	163-175	false
dopamine agonist	group	45-60	metoclopramide	group	181-194	false
dopamine agonist	group	45-60	MIRAPEX	brand	231-237	false
dopamine antagonists	group	83-102	neuroleptics	group	117-128	false
dopamine antagonists	group	83-102	phenothiazines	group	131-144	false
dopamine antagonists	group	83-102	butyrophenones	group	147-160	false
dopamine antagonists	group	83-102	thioxanthenes	group	163-175	false
dopamine antagonists	group	83-102	metoclopramide	group	181-194	false
dopamine antagonists	group	83-102	MIRAPEX	brand	231-237	effect
neuroleptics	group	117-128	phenothiazines	group	131-144	false
neuroleptics	group	117-128	butyrophenones	group	147-160	false
neuroleptics	group	117-128	thioxanthenes	group	163-175	false
neuroleptics	group	117-128	metoclopramide	group	181-194	false
neuroleptics	group	117-128	MIRAPEX	brand	231-237	effect
phenothiazines	group	131-144	butyrophenones	group	147-160	false
phenothiazines	group	131-144	thioxanthenes	group	163-175	false
phenothiazines	group	131-144	metoclopramide	group	181-194	false
phenothiazines	group	131-144	MIRAPEX	brand	231-237	effect
butyrophenones	group	147-160	thioxanthenes	group	163-175	false
butyrophenones	group	147-160	metoclopramide	group	181-194	false
butyrophenones	group	147-160	MIRAPEX	brand	231-237	effect
thioxanthenes	group	163-175	metoclopramide	group	181-194	false
thioxanthenes	group	163-175	MIRAPEX	brand	231-237	effect
metoclopramide	group	181-194	MIRAPEX	brand	231-237	effect

DDI-DrugBank.d752.s0	Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics).
midazolam	drug	74-82	azole antimycotics	group	228-245	advise
midazolam	drug	74-82	protease inhibitors	group	248-266	advise
midazolam	drug	74-82	calcium channel antagonists	group	269-295	advise
midazolam	drug	74-82	macrolide antibiotics	group	302-322	advise
azole antimycotics	group	228-245	protease inhibitors	group	248-266	false
azole antimycotics	group	228-245	calcium channel antagonists	group	269-295	false
azole antimycotics	group	228-245	macrolide antibiotics	group	302-322	false
protease inhibitors	group	248-266	calcium channel antagonists	group	269-295	false
protease inhibitors	group	248-266	macrolide antibiotics	group	302-322	false
calcium channel antagonists	group	269-295	macrolide antibiotics	group	302-322	false

DDI-DrugBank.d752.s1	Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.
erythromycin	drug	14-25	diltiazem	drug	28-36	false
erythromycin	drug	14-25	verapamil	drug	39-47	false
erythromycin	drug	14-25	ketoconazole	drug	50-61	false
erythromycin	drug	14-25	fluconazole	drug	64-74	false
erythromycin	drug	14-25	itraconazole	drug	80-91	false
erythromycin	drug	14-25	midazolam	drug	171-179	mechanism
diltiazem	drug	28-36	verapamil	drug	39-47	false
diltiazem	drug	28-36	ketoconazole	drug	50-61	false
diltiazem	drug	28-36	fluconazole	drug	64-74	false
diltiazem	drug	28-36	itraconazole	drug	80-91	false
diltiazem	drug	28-36	midazolam	drug	171-179	mechanism
verapamil	drug	39-47	ketoconazole	drug	50-61	false
verapamil	drug	39-47	fluconazole	drug	64-74	false
verapamil	drug	39-47	itraconazole	drug	80-91	false
verapamil	drug	39-47	midazolam	drug	171-179	mechanism
ketoconazole	drug	50-61	fluconazole	drug	64-74	false
ketoconazole	drug	50-61	itraconazole	drug	80-91	false
ketoconazole	drug	50-61	midazolam	drug	171-179	mechanism
fluconazole	drug	64-74	itraconazole	drug	80-91	false
fluconazole	drug	64-74	midazolam	drug	171-179	mechanism
itraconazole	drug	80-91	midazolam	drug	171-179	mechanism

DDI-DrugBank.d752.s3	Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.
ritonavir	drug	64-72	nelfinavir	drug	78-87	false
ritonavir	drug	64-72	midazolam	drug	198-206	mechanism
nelfinavir	drug	78-87	midazolam	drug	198-206	mechanism

DDI-DrugBank.d752.s6	Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.
rifampin	drug	63-70	carbamazepine	drug	73-85	false
rifampin	drug	63-70	phenytoin	drug	92-100	false
rifampin	drug	63-70	midazolam	drug	175-183	mechanism
carbamazepine	drug	73-85	phenytoin	drug	92-100	false
carbamazepine	drug	73-85	midazolam	drug	175-183	mechanism
phenytoin	drug	92-100	midazolam	drug	175-183	mechanism

DDI-DrugBank.d752.s9	The difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate.
sedatives	group	102-110	methylphenidate	drug	178-192	false

DDI-DrugBank.d752.s10	The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.
VERSED Syrup	brand	23-34	narcotics	group	153-161	effect
VERSED Syrup	brand	23-34	morphine	drug	168-175	effect
VERSED Syrup	brand	23-34	meperidine	drug	178-187	effect
VERSED Syrup	brand	23-34	fentanyl	drug	193-200	effect
VERSED Syrup	brand	23-34	propofol	drug	204-211	effect
VERSED Syrup	brand	23-34	ketamine	drug	214-221	effect
VERSED Syrup	brand	23-34	nitrous oxide	drug	224-236	effect
VERSED Syrup	brand	23-34	secobarbital	drug	239-250	effect
VERSED Syrup	brand	23-34	droperidol	drug	256-265	effect
narcotics	group	153-161	morphine	drug	168-175	false
narcotics	group	153-161	meperidine	drug	178-187	false
narcotics	group	153-161	fentanyl	drug	193-200	false
narcotics	group	153-161	propofol	drug	204-211	false
narcotics	group	153-161	ketamine	drug	214-221	false
narcotics	group	153-161	nitrous oxide	drug	224-236	false
narcotics	group	153-161	secobarbital	drug	239-250	false
narcotics	group	153-161	droperidol	drug	256-265	false
morphine	drug	168-175	meperidine	drug	178-187	false
morphine	drug	168-175	fentanyl	drug	193-200	false
morphine	drug	168-175	propofol	drug	204-211	false
morphine	drug	168-175	ketamine	drug	214-221	false
morphine	drug	168-175	nitrous oxide	drug	224-236	false
morphine	drug	168-175	secobarbital	drug	239-250	false
morphine	drug	168-175	droperidol	drug	256-265	false
meperidine	drug	178-187	fentanyl	drug	193-200	false
meperidine	drug	178-187	propofol	drug	204-211	false
meperidine	drug	178-187	ketamine	drug	214-221	false
meperidine	drug	178-187	nitrous oxide	drug	224-236	false
meperidine	drug	178-187	secobarbital	drug	239-250	false
meperidine	drug	178-187	droperidol	drug	256-265	false
fentanyl	drug	193-200	propofol	drug	204-211	false
fentanyl	drug	193-200	ketamine	drug	214-221	false
fentanyl	drug	193-200	nitrous oxide	drug	224-236	false
fentanyl	drug	193-200	secobarbital	drug	239-250	false
fentanyl	drug	193-200	droperidol	drug	256-265	false
propofol	drug	204-211	ketamine	drug	214-221	false
propofol	drug	204-211	nitrous oxide	drug	224-236	false
propofol	drug	204-211	secobarbital	drug	239-250	false
propofol	drug	204-211	droperidol	drug	256-265	false
ketamine	drug	214-221	nitrous oxide	drug	224-236	false
ketamine	drug	214-221	secobarbital	drug	239-250	false
ketamine	drug	214-221	droperidol	drug	256-265	false
nitrous oxide	drug	224-236	secobarbital	drug	239-250	false
nitrous oxide	drug	224-236	droperidol	drug	256-265	false
secobarbital	drug	239-250	droperidol	drug	256-265	false

DDI-DrugBank.d752.s12	No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.
atropine	drug	72-79	scopolamine	drug	82-92	false
atropine	drug	72-79	glycopyrrolate	drug	95-108	false
atropine	drug	72-79	diazepam	drug	111-118	false
atropine	drug	72-79	hydroxyzine	drug	121-131	false
atropine	drug	72-79	muscle relaxants	group	144-159	false
atropine	drug	72-79	anesthetics	group	171-181	false
scopolamine	drug	82-92	glycopyrrolate	drug	95-108	false
scopolamine	drug	82-92	diazepam	drug	111-118	false
scopolamine	drug	82-92	hydroxyzine	drug	121-131	false
scopolamine	drug	82-92	muscle relaxants	group	144-159	false
scopolamine	drug	82-92	anesthetics	group	171-181	false
glycopyrrolate	drug	95-108	diazepam	drug	111-118	false
glycopyrrolate	drug	95-108	hydroxyzine	drug	121-131	false
glycopyrrolate	drug	95-108	muscle relaxants	group	144-159	false
glycopyrrolate	drug	95-108	anesthetics	group	171-181	false
diazepam	drug	111-118	hydroxyzine	drug	121-131	false
diazepam	drug	111-118	muscle relaxants	group	144-159	false
diazepam	drug	111-118	anesthetics	group	171-181	false
hydroxyzine	drug	121-131	muscle relaxants	group	144-159	false
hydroxyzine	drug	121-131	anesthetics	group	171-181	false
muscle relaxants	group	144-159	anesthetics	group	171-181	false

DDI-DrugBank.d784.s0	The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.
oxybutynin	drug	23-32	anticholinergic drugs	group	45-65	effect

DDI-DrugBank.d784.s3	Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor.
oxybutynin chloride	drug	5-23	DITROPAN XL	brand	85-95	false
oxybutynin chloride	drug	5-23	ketoconazole	drug	119-130	false
DITROPAN XL	brand	85-95	ketoconazole	drug	119-130	mechanism

DDI-DrugBank.d784.s4	Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).
antimycotic agents	group	67-84	itraconazole	drug	93-104	false
antimycotic agents	group	67-84	miconazole	drug	110-119	false
antimycotic agents	group	67-84	macrolide antibiotics	group	125-145	false
antimycotic agents	group	67-84	erythromycin	drug	154-165	false
antimycotic agents	group	67-84	clarithromycin	drug	171-184	false
antimycotic agents	group	67-84	oxybutynin	drug	198-207	mechanism
itraconazole	drug	93-104	miconazole	drug	110-119	false
itraconazole	drug	93-104	macrolide antibiotics	group	125-145	false
itraconazole	drug	93-104	erythromycin	drug	154-165	false
itraconazole	drug	93-104	clarithromycin	drug	171-184	false
itraconazole	drug	93-104	oxybutynin	drug	198-207	mechanism
miconazole	drug	110-119	macrolide antibiotics	group	125-145	false
miconazole	drug	110-119	erythromycin	drug	154-165	false
miconazole	drug	110-119	clarithromycin	drug	171-184	false
miconazole	drug	110-119	oxybutynin	drug	198-207	mechanism
macrolide antibiotics	group	125-145	erythromycin	drug	154-165	false
macrolide antibiotics	group	125-145	clarithromycin	drug	171-184	false
macrolide antibiotics	group	125-145	oxybutynin	drug	198-207	mechanism
erythromycin	drug	154-165	clarithromycin	drug	171-184	false
erythromycin	drug	154-165	oxybutynin	drug	198-207	mechanism
clarithromycin	drug	171-184	oxybutynin	drug	198-207	mechanism

DDI-DrugBank.d784.s7	Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.
antacid	group	24-30	antacid	group	42-48	false
antacid	group	24-30	aluminum hydroxide	drug	61-78	false
antacid	group	24-30	magnesium hydroxide	drug	81-99	false
antacid	group	24-30	simethicone	drug	106-116	false
antacid	group	24-30	oxybutynin	drug	164-173	false
antacid	group	24-30	desethyloxybutynin	drug_n	178-195	false
antacid	group	42-48	aluminum hydroxide	drug	61-78	false
antacid	group	42-48	magnesium hydroxide	drug	81-99	false
antacid	group	42-48	simethicone	drug	106-116	false
antacid	group	42-48	oxybutynin	drug	164-173	false
antacid	group	42-48	desethyloxybutynin	drug_n	178-195	false
aluminum hydroxide	drug	61-78	magnesium hydroxide	drug	81-99	false
aluminum hydroxide	drug	61-78	simethicone	drug	106-116	false
aluminum hydroxide	drug	61-78	oxybutynin	drug	164-173	false
aluminum hydroxide	drug	61-78	desethyloxybutynin	drug_n	178-195	false
magnesium hydroxide	drug	81-99	simethicone	drug	106-116	false
magnesium hydroxide	drug	81-99	oxybutynin	drug	164-173	false
magnesium hydroxide	drug	81-99	desethyloxybutynin	drug_n	178-195	false
simethicone	drug	106-116	oxybutynin	drug	164-173	false
simethicone	drug	106-116	desethyloxybutynin	drug_n	178-195	false
oxybutynin	drug	164-173	desethyloxybutynin	drug_n	178-195	false

DDI-DrugBank.d665.s0	Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.
bacteriostatic antibiotics	group	29-54	erythromycin	drug	63-74	false
bacteriostatic antibiotics	group	29-54	tetracycline	drug	77-88	false
bacteriostatic antibiotics	group	29-54	penicillins	group	132-142	effect
erythromycin	drug	63-74	tetracycline	drug	77-88	false
erythromycin	drug	63-74	penicillins	group	132-142	effect
tetracycline	drug	77-88	penicillins	group	132-142	effect

DDI-DrugBank.d665.s6	Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.
Penicillin	group	0-9	probenecid	drug	73-82	mechanism
Penicillin	group	0-9	penicillins	group	128-138	false
probenecid	drug	73-82	penicillins	group	128-138	false

DDI-DrugBank.d665.s7	Displacement of penicillin from plasma protein binding sites will elevate the level of free penicillin in the serum.
penicillin	group	16-25	penicillin	group	92-101	false

DDI-DrugBank.d671.s0	The interaction of CYLERT (pemoline) with other drugs has not been studied in humans.
CYLERT	brand	19-24	pemoline	drug	27-34	false

DDI-DrugBank.d671.s2	Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.
CYLERT	brand	68-73	antiepileptic medications	group	94-118	effect

DDI-DrugBank.d716.s0	You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.
mazindol	drug	16-23	monoamine oxidase inhibitor	group	45-71	advise
mazindol	drug	16-23	MAOI	group	74-77	advise
mazindol	drug	16-23	isocarboxazid	drug	88-100	advise
mazindol	drug	16-23	Marplan	brand	103-109	advise
mazindol	drug	16-23	tranylcypromine	drug	113-127	advise
mazindol	drug	16-23	Parnate	brand	130-136	advise
mazindol	drug	16-23	phenelzine	drug	143-152	advise
mazindol	drug	16-23	Nardil	brand	155-160	advise
monoamine oxidase inhibitor	group	45-71	MAOI	group	74-77	false
monoamine oxidase inhibitor	group	45-71	isocarboxazid	drug	88-100	false
monoamine oxidase inhibitor	group	45-71	Marplan	brand	103-109	false
monoamine oxidase inhibitor	group	45-71	tranylcypromine	drug	113-127	false
monoamine oxidase inhibitor	group	45-71	Parnate	brand	130-136	false
monoamine oxidase inhibitor	group	45-71	phenelzine	drug	143-152	false
monoamine oxidase inhibitor	group	45-71	Nardil	brand	155-160	false
MAOI	group	74-77	isocarboxazid	drug	88-100	false
MAOI	group	74-77	Marplan	brand	103-109	false
MAOI	group	74-77	tranylcypromine	drug	113-127	false
MAOI	group	74-77	Parnate	brand	130-136	false
MAOI	group	74-77	phenelzine	drug	143-152	false
MAOI	group	74-77	Nardil	brand	155-160	false
isocarboxazid	drug	88-100	Marplan	brand	103-109	false
isocarboxazid	drug	88-100	tranylcypromine	drug	113-127	false
isocarboxazid	drug	88-100	Parnate	brand	130-136	false
isocarboxazid	drug	88-100	phenelzine	drug	143-152	false
isocarboxazid	drug	88-100	Nardil	brand	155-160	false
Marplan	brand	103-109	tranylcypromine	drug	113-127	false
Marplan	brand	103-109	Parnate	brand	130-136	false
Marplan	brand	103-109	phenelzine	drug	143-152	false
Marplan	brand	103-109	Nardil	brand	155-160	false
tranylcypromine	drug	113-127	Parnate	brand	130-136	false
tranylcypromine	drug	113-127	phenelzine	drug	143-152	false
tranylcypromine	drug	113-127	Nardil	brand	155-160	false
Parnate	brand	130-136	phenelzine	drug	143-152	false
Parnate	brand	130-136	Nardil	brand	155-160	false
phenelzine	drug	143-152	Nardil	brand	155-160	false

DDI-DrugBank.d716.s1	Changes in insulin and other diabetes drug therapies may be necessary during treatment with mazindol.
insulin	drug	11-17	mazindol	drug	92-99	advise

DDI-DrugBank.d716.s2	Mazindol may reduce the effects of guanethidine (Ismelin).
Mazindol	drug	0-7	guanethidine	drug	35-46	effect
Mazindol	drug	0-7	Ismelin	brand	49-55	effect
guanethidine	drug	35-46	Ismelin	brand	49-55	false

DDI-DrugBank.d716.s5	Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).
tricyclic antidepressant	group	68-91	amitriptyline	drug	101-113	false
tricyclic antidepressant	group	68-91	Elavil	brand	116-121	false
tricyclic antidepressant	group	68-91	amoxapine	drug	125-133	false
tricyclic antidepressant	group	68-91	Asendin	brand	136-142	false
tricyclic antidepressant	group	68-91	doxepin	drug	146-152	false
tricyclic antidepressant	group	68-91	Sinequan	brand	155-162	false
tricyclic antidepressant	group	68-91	nortriptyline	drug	166-178	false
tricyclic antidepressant	group	68-91	Pamelor	brand	181-187	false
tricyclic antidepressant	group	68-91	imipramine	drug	191-200	false
tricyclic antidepressant	group	68-91	Tofranil	brand	203-210	false
tricyclic antidepressant	group	68-91	clomipramine	drug	214-225	false
tricyclic antidepressant	group	68-91	Anafranil	brand	228-236	false
tricyclic antidepressant	group	68-91	protriptyline	drug	240-252	false
tricyclic antidepressant	group	68-91	Vivactil	brand	255-262	false
tricyclic antidepressant	group	68-91	desipramine	drug	269-279	false
tricyclic antidepressant	group	68-91	Norpramin	brand	282-290	false
amitriptyline	drug	101-113	Elavil	brand	116-121	false
amitriptyline	drug	101-113	amoxapine	drug	125-133	false
amitriptyline	drug	101-113	Asendin	brand	136-142	false
amitriptyline	drug	101-113	doxepin	drug	146-152	false
amitriptyline	drug	101-113	Sinequan	brand	155-162	false
amitriptyline	drug	101-113	nortriptyline	drug	166-178	false
amitriptyline	drug	101-113	Pamelor	brand	181-187	false
amitriptyline	drug	101-113	imipramine	drug	191-200	false
amitriptyline	drug	101-113	Tofranil	brand	203-210	false
amitriptyline	drug	101-113	clomipramine	drug	214-225	false
amitriptyline	drug	101-113	Anafranil	brand	228-236	false
amitriptyline	drug	101-113	protriptyline	drug	240-252	false
amitriptyline	drug	101-113	Vivactil	brand	255-262	false
amitriptyline	drug	101-113	desipramine	drug	269-279	false
amitriptyline	drug	101-113	Norpramin	brand	282-290	false
Elavil	brand	116-121	amoxapine	drug	125-133	false
Elavil	brand	116-121	Asendin	brand	136-142	false
Elavil	brand	116-121	doxepin	drug	146-152	false
Elavil	brand	116-121	Sinequan	brand	155-162	false
Elavil	brand	116-121	nortriptyline	drug	166-178	false
Elavil	brand	116-121	Pamelor	brand	181-187	false
Elavil	brand	116-121	imipramine	drug	191-200	false
Elavil	brand	116-121	Tofranil	brand	203-210	false
Elavil	brand	116-121	clomipramine	drug	214-225	false
Elavil	brand	116-121	Anafranil	brand	228-236	false
Elavil	brand	116-121	protriptyline	drug	240-252	false
Elavil	brand	116-121	Vivactil	brand	255-262	false
Elavil	brand	116-121	desipramine	drug	269-279	false
Elavil	brand	116-121	Norpramin	brand	282-290	false
amoxapine	drug	125-133	Asendin	brand	136-142	false
amoxapine	drug	125-133	doxepin	drug	146-152	false
amoxapine	drug	125-133	Sinequan	brand	155-162	false
amoxapine	drug	125-133	nortriptyline	drug	166-178	false
amoxapine	drug	125-133	Pamelor	brand	181-187	false
amoxapine	drug	125-133	imipramine	drug	191-200	false
amoxapine	drug	125-133	Tofranil	brand	203-210	false
amoxapine	drug	125-133	clomipramine	drug	214-225	false
amoxapine	drug	125-133	Anafranil	brand	228-236	false
amoxapine	drug	125-133	protriptyline	drug	240-252	false
amoxapine	drug	125-133	Vivactil	brand	255-262	false
amoxapine	drug	125-133	desipramine	drug	269-279	false
amoxapine	drug	125-133	Norpramin	brand	282-290	false
Asendin	brand	136-142	doxepin	drug	146-152	false
Asendin	brand	136-142	Sinequan	brand	155-162	false
Asendin	brand	136-142	nortriptyline	drug	166-178	false
Asendin	brand	136-142	Pamelor	brand	181-187	false
Asendin	brand	136-142	imipramine	drug	191-200	false
Asendin	brand	136-142	Tofranil	brand	203-210	false
Asendin	brand	136-142	clomipramine	drug	214-225	false
Asendin	brand	136-142	Anafranil	brand	228-236	false
Asendin	brand	136-142	protriptyline	drug	240-252	false
Asendin	brand	136-142	Vivactil	brand	255-262	false
Asendin	brand	136-142	desipramine	drug	269-279	false
Asendin	brand	136-142	Norpramin	brand	282-290	false
doxepin	drug	146-152	Sinequan	brand	155-162	false
doxepin	drug	146-152	nortriptyline	drug	166-178	false
doxepin	drug	146-152	Pamelor	brand	181-187	false
doxepin	drug	146-152	imipramine	drug	191-200	false
doxepin	drug	146-152	Tofranil	brand	203-210	false
doxepin	drug	146-152	clomipramine	drug	214-225	false
doxepin	drug	146-152	Anafranil	brand	228-236	false
doxepin	drug	146-152	protriptyline	drug	240-252	false
doxepin	drug	146-152	Vivactil	brand	255-262	false
doxepin	drug	146-152	desipramine	drug	269-279	false
doxepin	drug	146-152	Norpramin	brand	282-290	false
Sinequan	brand	155-162	nortriptyline	drug	166-178	false
Sinequan	brand	155-162	Pamelor	brand	181-187	false
Sinequan	brand	155-162	imipramine	drug	191-200	false
Sinequan	brand	155-162	Tofranil	brand	203-210	false
Sinequan	brand	155-162	clomipramine	drug	214-225	false
Sinequan	brand	155-162	Anafranil	brand	228-236	false
Sinequan	brand	155-162	protriptyline	drug	240-252	false
Sinequan	brand	155-162	Vivactil	brand	255-262	false
Sinequan	brand	155-162	desipramine	drug	269-279	false
Sinequan	brand	155-162	Norpramin	brand	282-290	false
nortriptyline	drug	166-178	Pamelor	brand	181-187	false
nortriptyline	drug	166-178	imipramine	drug	191-200	false
nortriptyline	drug	166-178	Tofranil	brand	203-210	false
nortriptyline	drug	166-178	clomipramine	drug	214-225	false
nortriptyline	drug	166-178	Anafranil	brand	228-236	false
nortriptyline	drug	166-178	protriptyline	drug	240-252	false
nortriptyline	drug	166-178	Vivactil	brand	255-262	false
nortriptyline	drug	166-178	desipramine	drug	269-279	false
nortriptyline	drug	166-178	Norpramin	brand	282-290	false
Pamelor	brand	181-187	imipramine	drug	191-200	false
Pamelor	brand	181-187	Tofranil	brand	203-210	false
Pamelor	brand	181-187	clomipramine	drug	214-225	false
Pamelor	brand	181-187	Anafranil	brand	228-236	false
Pamelor	brand	181-187	protriptyline	drug	240-252	false
Pamelor	brand	181-187	Vivactil	brand	255-262	false
Pamelor	brand	181-187	desipramine	drug	269-279	false
Pamelor	brand	181-187	Norpramin	brand	282-290	false
imipramine	drug	191-200	Tofranil	brand	203-210	false
imipramine	drug	191-200	clomipramine	drug	214-225	false
imipramine	drug	191-200	Anafranil	brand	228-236	false
imipramine	drug	191-200	protriptyline	drug	240-252	false
imipramine	drug	191-200	Vivactil	brand	255-262	false
imipramine	drug	191-200	desipramine	drug	269-279	false
imipramine	drug	191-200	Norpramin	brand	282-290	false
Tofranil	brand	203-210	clomipramine	drug	214-225	false
Tofranil	brand	203-210	Anafranil	brand	228-236	false
Tofranil	brand	203-210	protriptyline	drug	240-252	false
Tofranil	brand	203-210	Vivactil	brand	255-262	false
Tofranil	brand	203-210	desipramine	drug	269-279	false
Tofranil	brand	203-210	Norpramin	brand	282-290	false
clomipramine	drug	214-225	Anafranil	brand	228-236	false
clomipramine	drug	214-225	protriptyline	drug	240-252	false
clomipramine	drug	214-225	Vivactil	brand	255-262	false
clomipramine	drug	214-225	desipramine	drug	269-279	false
clomipramine	drug	214-225	Norpramin	brand	282-290	false
Anafranil	brand	228-236	protriptyline	drug	240-252	false
Anafranil	brand	228-236	Vivactil	brand	255-262	false
Anafranil	brand	228-236	desipramine	drug	269-279	false
Anafranil	brand	228-236	Norpramin	brand	282-290	false
protriptyline	drug	240-252	Vivactil	brand	255-262	false
protriptyline	drug	240-252	desipramine	drug	269-279	false
protriptyline	drug	240-252	Norpramin	brand	282-290	false
Vivactil	brand	255-262	desipramine	drug	269-279	false
Vivactil	brand	255-262	Norpramin	brand	282-290	false
desipramine	drug	269-279	Norpramin	brand	282-290	false

DDI-DrugBank.d668.s0	Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).
mifepristone	drug	49-60	ketoconazole	drug	158-169	false
mifepristone	drug	49-60	itraconazole	drug	172-183	false
mifepristone	drug	49-60	erythromycin	drug	186-197	false
mifepristone	drug	49-60	mifepristone	drug	276-287	false
ketoconazole	drug	158-169	itraconazole	drug	172-183	false
ketoconazole	drug	158-169	erythromycin	drug	186-197	false
ketoconazole	drug	158-169	mifepristone	drug	276-287	mechanism
itraconazole	drug	172-183	erythromycin	drug	186-197	false
itraconazole	drug	172-183	mifepristone	drug	276-287	mechanism
erythromycin	drug	186-197	mifepristone	drug	276-287	mechanism

DDI-DrugBank.d668.s1	Furthermore, rifampin, dexamethasone, St.
rifampin	drug	13-20	dexamethasone	drug	23-35	false

DDI-DrugBank.d668.s2	John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).
anticonvulsants	group	27-41	phenytoin	drug	44-52	false
anticonvulsants	group	27-41	phenobarbital	drug	55-67	false
anticonvulsants	group	27-41	carbamazepine	drug	70-82	false
anticonvulsants	group	27-41	mifepristone	drug	96-107	mechanism
anticonvulsants	group	27-41	mifepristone	drug	146-157	false
phenytoin	drug	44-52	phenobarbital	drug	55-67	false
phenytoin	drug	44-52	carbamazepine	drug	70-82	false
phenytoin	drug	44-52	mifepristone	drug	96-107	mechanism
phenytoin	drug	44-52	mifepristone	drug	146-157	false
phenobarbital	drug	55-67	carbamazepine	drug	70-82	false
phenobarbital	drug	55-67	mifepristone	drug	96-107	mechanism
phenobarbital	drug	55-67	mifepristone	drug	146-157	false
carbamazepine	drug	70-82	mifepristone	drug	96-107	mechanism
carbamazepine	drug	70-82	mifepristone	drug	146-157	false
mifepristone	drug	96-107	mifepristone	drug	146-157	false

DDI-DrugBank.d735.s0	A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.
MYCAMINE	brand	140-147	mycophenolate mofetil	drug	153-173	false
MYCAMINE	brand	140-147	cyclosporine	drug	176-187	false
MYCAMINE	brand	140-147	tacrolimus	drug	190-199	false
MYCAMINE	brand	140-147	prednisolone	drug	202-213	false
MYCAMINE	brand	140-147	sirolimus	drug	216-224	false
MYCAMINE	brand	140-147	nifedipine	drug	227-236	false
MYCAMINE	brand	140-147	fluconazole	drug	239-249	false
MYCAMINE	brand	140-147	ritonavir	drug	252-260	false
MYCAMINE	brand	140-147	rifampin	drug	267-274	false
mycophenolate mofetil	drug	153-173	cyclosporine	drug	176-187	false
mycophenolate mofetil	drug	153-173	tacrolimus	drug	190-199	false
mycophenolate mofetil	drug	153-173	prednisolone	drug	202-213	false
mycophenolate mofetil	drug	153-173	sirolimus	drug	216-224	false
mycophenolate mofetil	drug	153-173	nifedipine	drug	227-236	false
mycophenolate mofetil	drug	153-173	fluconazole	drug	239-249	false
mycophenolate mofetil	drug	153-173	ritonavir	drug	252-260	false
mycophenolate mofetil	drug	153-173	rifampin	drug	267-274	false
cyclosporine	drug	176-187	tacrolimus	drug	190-199	false
cyclosporine	drug	176-187	prednisolone	drug	202-213	false
cyclosporine	drug	176-187	sirolimus	drug	216-224	false
cyclosporine	drug	176-187	nifedipine	drug	227-236	false
cyclosporine	drug	176-187	fluconazole	drug	239-249	false
cyclosporine	drug	176-187	ritonavir	drug	252-260	false
cyclosporine	drug	176-187	rifampin	drug	267-274	false
tacrolimus	drug	190-199	prednisolone	drug	202-213	false
tacrolimus	drug	190-199	sirolimus	drug	216-224	false
tacrolimus	drug	190-199	nifedipine	drug	227-236	false
tacrolimus	drug	190-199	fluconazole	drug	239-249	false
tacrolimus	drug	190-199	ritonavir	drug	252-260	false
tacrolimus	drug	190-199	rifampin	drug	267-274	false
prednisolone	drug	202-213	sirolimus	drug	216-224	false
prednisolone	drug	202-213	nifedipine	drug	227-236	false
prednisolone	drug	202-213	fluconazole	drug	239-249	false
prednisolone	drug	202-213	ritonavir	drug	252-260	false
prednisolone	drug	202-213	rifampin	drug	267-274	false
sirolimus	drug	216-224	nifedipine	drug	227-236	false
sirolimus	drug	216-224	fluconazole	drug	239-249	false
sirolimus	drug	216-224	ritonavir	drug	252-260	false
sirolimus	drug	216-224	rifampin	drug	267-274	false
nifedipine	drug	227-236	fluconazole	drug	239-249	false
nifedipine	drug	227-236	ritonavir	drug	252-260	false
nifedipine	drug	227-236	rifampin	drug	267-274	false
fluconazole	drug	239-249	ritonavir	drug	252-260	false
fluconazole	drug	239-249	rifampin	drug	267-274	false
ritonavir	drug	252-260	rifampin	drug	267-274	false

DDI-DrugBank.d735.s2	There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.
MYCAMINE	brand	58-65	mycophenolate mofetil	drug	70-90	false
MYCAMINE	brand	58-65	cyclosporine	drug	93-104	false
MYCAMINE	brand	58-65	tacrolimus	drug	107-116	false
MYCAMINE	brand	58-65	prednisolone	drug	119-130	false
MYCAMINE	brand	58-65	fluconazole	drug	137-147	false
mycophenolate mofetil	drug	70-90	cyclosporine	drug	93-104	false
mycophenolate mofetil	drug	70-90	tacrolimus	drug	107-116	false
mycophenolate mofetil	drug	70-90	prednisolone	drug	119-130	false
mycophenolate mofetil	drug	70-90	fluconazole	drug	137-147	false
cyclosporine	drug	93-104	tacrolimus	drug	107-116	false
cyclosporine	drug	93-104	prednisolone	drug	119-130	false
cyclosporine	drug	93-104	fluconazole	drug	137-147	false
tacrolimus	drug	107-116	prednisolone	drug	119-130	false
tacrolimus	drug	107-116	fluconazole	drug	137-147	false
prednisolone	drug	119-130	fluconazole	drug	137-147	false

DDI-DrugBank.d735.s3	Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone.
Sirolimus	drug	0-8	MYCAMINE	brand	90-97	mechanism
Sirolimus	drug	0-8	sirolimus	drug	113-121	false
MYCAMINE	brand	90-97	sirolimus	drug	113-121	false

DDI-DrugBank.d735.s4	Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone.
Nifedipine	drug	0-9	MYCAMINE	brand	101-108	mechanism
Nifedipine	drug	0-9	nifedipine	drug	124-133	false
MYCAMINE	brand	101-108	nifedipine	drug	124-133	false

DDI-DrugBank.d735.s5	Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.
sirolimus	drug	19-27	nifedipine	drug	32-41	false
sirolimus	drug	19-27	MYCAMINE	brand	63-70	advise
sirolimus	drug	19-27	sirolimus	drug	96-104	false
sirolimus	drug	19-27	nifedipine	drug	109-118	false
sirolimus	drug	19-27	sirolimus	drug	133-141	false
sirolimus	drug	19-27	nifedipine	drug	146-155	false
nifedipine	drug	32-41	MYCAMINE	brand	63-70	advise
nifedipine	drug	32-41	sirolimus	drug	96-104	false
nifedipine	drug	32-41	nifedipine	drug	109-118	false
nifedipine	drug	32-41	sirolimus	drug	133-141	false
nifedipine	drug	32-41	nifedipine	drug	146-155	false
MYCAMINE	brand	63-70	sirolimus	drug	96-104	false
MYCAMINE	brand	63-70	nifedipine	drug	109-118	false
MYCAMINE	brand	63-70	sirolimus	drug	133-141	false
MYCAMINE	brand	63-70	nifedipine	drug	146-155	false
sirolimus	drug	96-104	nifedipine	drug	109-118	false
sirolimus	drug	96-104	sirolimus	drug	133-141	false
sirolimus	drug	96-104	nifedipine	drug	146-155	false
nifedipine	drug	109-118	sirolimus	drug	133-141	false
nifedipine	drug	109-118	nifedipine	drug	146-155	false
sirolimus	drug	133-141	nifedipine	drug	146-155	false

DDI-DrugBank.d588.s0	Diuretics: Furosemide and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.
Diuretics	group	0-8	Furosemide	drug	11-20	false
Diuretics	group	0-8	loop diuretics	group	41-54	false
Diuretics	group	0-8	metolazone	drug	81-90	false
Furosemide	drug	11-20	loop diuretics	group	41-54	false
Furosemide	drug	11-20	metolazone	drug	81-90	effect
loop diuretics	group	41-54	metolazone	drug	81-90	effect

DDI-DrugBank.d588.s1	Other Antihypertensives: When MYKROX Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.
Antihypertensives	group	6-22	MYKROX	brand	30-35	false
Antihypertensives	group	6-22	antihypertensive drugs	group	65-86	false
MYKROX	brand	30-35	antihypertensive drugs	group	65-86	advise

DDI-DrugBank.d588.s3	Alcohol, Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.
Alcohol	drug	0-6	Barbiturates	group	9-20	false
Alcohol	drug	0-6	Narcotics	group	27-35	false
Alcohol	drug	0-6	metolazone	drug	150-159	false
Barbiturates	group	9-20	Narcotics	group	27-35	false
Barbiturates	group	9-20	metolazone	drug	150-159	false
Narcotics	group	27-35	metolazone	drug	150-159	false

DDI-DrugBank.d588.s4	Digitalis Glycosides: Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to digitalis.
Digitalis Glycosides	group	0-19	Diuretic	group	22-29	false
Digitalis Glycosides	group	0-19	digitalis	group	101-109	false
Diuretic	group	22-29	digitalis	group	101-109	effect

DDI-DrugBank.d588.s6	Corticosteroids or ACTH: May increase the risk of hypokalemia and increase salt and water retention.
Corticosteroids	group	0-14	ACTH	drug	19-22	false

DDI-DrugBank.d588.s7	Lithium: Serum lithium levels may increase.
Lithium	drug	0-6	lithium	drug	15-21	false

DDI-DrugBank.d588.s8	Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.
Curariform Drugs	group	0-15	Diuretic	group	18-25	false
Curariform Drugs	group	0-15	curariform drugs	group	93-108	false
Curariform Drugs	group	0-15	tubocurarine	drug	119-130	false
Diuretic	group	18-25	curariform drugs	group	93-108	effect
Diuretic	group	18-25	tubocurarine	drug	119-130	effect
curariform drugs	group	93-108	tubocurarine	drug	119-130	false

DDI-DrugBank.d588.s10	Salicylates and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of MYKROX Tablets.
Salicylates	group	0-10	Non-Steroidal Anti-Inflammatory Drugs	group	22-58	false
Salicylates	group	0-10	MYKROX	brand	106-111	effect
Non-Steroidal Anti-Inflammatory Drugs	group	22-58	MYKROX	brand	106-111	effect

DDI-DrugBank.d588.s11	Sympathomimetics: Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.
Sympathomimetics	group	0-15	Metolazone	drug	18-27	false
Sympathomimetics	group	0-15	norepinephrine	drug	69-82	false
Metolazone	drug	18-27	norepinephrine	drug	69-82	effect

DDI-DrugBank.d588.s12	Methenamine: Efficacy may be decreased due to urinary alkalizing effect of metolazone.
Methenamine	drug	0-10	metolazone	drug	75-84	effect

DDI-DrugBank.d588.s13	Anticoagulants: Metolazone, as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;
Anticoagulants	group	0-13	Metolazone	drug	16-25	false
Anticoagulants	group	0-13	thiazide-like diuretics	group	45-67	false
Anticoagulants	group	0-13	anticoagulants	group	117-130	false
Metolazone	drug	16-25	thiazide-like diuretics	group	45-67	false
Metolazone	drug	16-25	anticoagulants	group	117-130	effect
thiazide-like diuretics	group	45-67	anticoagulants	group	117-130	false

DDI-DrugBank.d765.s0	CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).
Ketoconazole	drug	19-30	tolterodine	drug	135-145	mechanism

DDI-DrugBank.d765.s1	For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.
ketoconazole	drug	23-34	azole antifungals	group	84-100	false
ketoconazole	drug	23-34	itraconazole	drug	107-118	false
ketoconazole	drug	23-34	miconazole	drug	121-130	false
ketoconazole	drug	23-34	macrolide antibiotics	group	136-156	false
ketoconazole	drug	23-34	erythromycin	drug	163-174	false
ketoconazole	drug	23-34	clarithromycin	drug	177-190	false
ketoconazole	drug	23-34	cyclosporine	drug	196-207	false
ketoconazole	drug	23-34	vinblastine	drug	212-222	false
ketoconazole	drug	23-34	DETROL LA	brand	249-257	advise
azole antifungals	group	84-100	itraconazole	drug	107-118	false
azole antifungals	group	84-100	miconazole	drug	121-130	false
azole antifungals	group	84-100	macrolide antibiotics	group	136-156	false
azole antifungals	group	84-100	erythromycin	drug	163-174	false
azole antifungals	group	84-100	clarithromycin	drug	177-190	false
azole antifungals	group	84-100	cyclosporine	drug	196-207	false
azole antifungals	group	84-100	vinblastine	drug	212-222	false
azole antifungals	group	84-100	DETROL LA	brand	249-257	advise
itraconazole	drug	107-118	miconazole	drug	121-130	false
itraconazole	drug	107-118	macrolide antibiotics	group	136-156	false
itraconazole	drug	107-118	erythromycin	drug	163-174	false
itraconazole	drug	107-118	clarithromycin	drug	177-190	false
itraconazole	drug	107-118	cyclosporine	drug	196-207	false
itraconazole	drug	107-118	vinblastine	drug	212-222	false
itraconazole	drug	107-118	DETROL LA	brand	249-257	advise
miconazole	drug	121-130	macrolide antibiotics	group	136-156	false
miconazole	drug	121-130	erythromycin	drug	163-174	false
miconazole	drug	121-130	clarithromycin	drug	177-190	false
miconazole	drug	121-130	cyclosporine	drug	196-207	false
miconazole	drug	121-130	vinblastine	drug	212-222	false
miconazole	drug	121-130	DETROL LA	brand	249-257	advise
macrolide antibiotics	group	136-156	erythromycin	drug	163-174	false
macrolide antibiotics	group	136-156	clarithromycin	drug	177-190	false
macrolide antibiotics	group	136-156	cyclosporine	drug	196-207	false
macrolide antibiotics	group	136-156	vinblastine	drug	212-222	false
macrolide antibiotics	group	136-156	DETROL LA	brand	249-257	advise
erythromycin	drug	163-174	clarithromycin	drug	177-190	false
erythromycin	drug	163-174	cyclosporine	drug	196-207	false
erythromycin	drug	163-174	vinblastine	drug	212-222	false
erythromycin	drug	163-174	DETROL LA	brand	249-257	advise
clarithromycin	drug	177-190	cyclosporine	drug	196-207	false
clarithromycin	drug	177-190	vinblastine	drug	212-222	false
clarithromycin	drug	177-190	DETROL LA	brand	249-257	advise
cyclosporine	drug	196-207	vinblastine	drug	212-222	false
cyclosporine	drug	196-207	DETROL LA	brand	249-257	advise
vinblastine	drug	212-222	DETROL LA	brand	249-257	advise

DDI-DrugBank.d607.s1	Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.
Leukine	brand	61-67	lithium	drug	78-84	effect
Leukine	brand	61-67	corticosteroids	group	90-104	effect
lithium	drug	78-84	corticosteroids	group	90-104	false

DDI-DrugBank.d647.s1	Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression;
Streptozocin	drug	0-11	doxorubicin	drug	71-81	mechanism

DDI-DrugBank.d647.s2	a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently.
doxorubicin	drug	19-29	ZANOSAR	brand	81-87	advise

DDI-DrugBank.d647.s3	The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.
streptozocin	drug	22-33	phenytoin	drug	39-47	effect
streptozocin	drug	22-33	streptozocin	drug	100-111	false
phenytoin	drug	39-47	streptozocin	drug	100-111	false

DDI-DrugBank.d636.s0	Some anticonvulsants may interact with Mephenytoin.
anticonvulsants	group	5-19	Mephenytoin	drug	39-49	int

DDI-DrugBank.d636.s2	Those anticonvulsants include divalproex sodium, valproic acid, and phenobarbital.
anticonvulsants	group	6-20	divalproex sodium	drug	30-46	false
anticonvulsants	group	6-20	valproic acid	drug	49-61	false
anticonvulsants	group	6-20	phenobarbital	drug	68-80	false
divalproex sodium	drug	30-46	valproic acid	drug	49-61	false
divalproex sodium	drug	30-46	phenobarbital	drug	68-80	false
valproic acid	drug	49-61	phenobarbital	drug	68-80	false

DDI-DrugBank.d636.s3	Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.
Mephenytoin	drug	0-10	steroid medications	group	75-93	effect
Mephenytoin	drug	0-10	warfarin	drug	96-103	effect
Mephenytoin	drug	0-10	anti-infective medicines	group	152-175	effect
Mephenytoin	drug	0-10	furosemide	drug	178-187	effect
Mephenytoin	drug	0-10	theophylline	drug	193-204	effect
Mephenytoin	drug	0-10	Mephenytoin	drug	223-233	false
steroid medications	group	75-93	warfarin	drug	96-103	false
steroid medications	group	75-93	anti-infective medicines	group	152-175	false
steroid medications	group	75-93	furosemide	drug	178-187	false
steroid medications	group	75-93	theophylline	drug	193-204	false
steroid medications	group	75-93	Mephenytoin	drug	223-233	false
warfarin	drug	96-103	anti-infective medicines	group	152-175	false
warfarin	drug	96-103	furosemide	drug	178-187	false
warfarin	drug	96-103	theophylline	drug	193-204	false
warfarin	drug	96-103	Mephenytoin	drug	223-233	false
anti-infective medicines	group	152-175	furosemide	drug	178-187	false
anti-infective medicines	group	152-175	theophylline	drug	193-204	false
anti-infective medicines	group	152-175	Mephenytoin	drug	223-233	false
furosemide	drug	178-187	theophylline	drug	193-204	false
furosemide	drug	178-187	Mephenytoin	drug	223-233	false
theophylline	drug	193-204	Mephenytoin	drug	223-233	false

DDI-DrugBank.d604.s0	Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine.
Thalidomide	drug	0-10	barbiturates	group	66-77	effect
Thalidomide	drug	0-10	alcohol	drug	80-86	false
Thalidomide	drug	0-10	chlorpromazine	drug	89-102	false
Thalidomide	drug	0-10	reserpine	drug	109-117	false
barbiturates	group	66-77	alcohol	drug	80-86	false
barbiturates	group	66-77	chlorpromazine	drug	89-102	false
barbiturates	group	66-77	reserpine	drug	109-117	false
alcohol	drug	80-86	chlorpromazine	drug	89-102	false
alcohol	drug	80-86	reserpine	drug	109-117	false
chlorpromazine	drug	89-102	reserpine	drug	109-117	false

DDI-DrugBank.d604.s2	Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied.
Contraceptives	group	5-18	norethindrone	drug	74-86	false
Contraceptives	group	5-18	ethinyl estradiol	drug	92-108	false
Contraceptives	group	5-18	norethindrone acetate	drug	173-193	false
Contraceptives	group	5-18	ethinyl estradiol	drug	210-226	false
norethindrone	drug	74-86	ethinyl estradiol	drug	92-108	false
norethindrone	drug	74-86	norethindrone acetate	drug	173-193	false
norethindrone	drug	74-86	ethinyl estradiol	drug	210-226	false
ethinyl estradiol	drug	92-108	norethindrone acetate	drug	173-193	false
ethinyl estradiol	drug	92-108	ethinyl estradiol	drug	210-226	false
norethindrone acetate	drug	173-193	ethinyl estradiol	drug	210-226	false

DDI-DrugBank.d604.s4	Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.
Thalidomide	drug	14-24	Hormonal Contraceptives	group	70-92	false
Thalidomide	drug	14-24	HIV-protease inhibitors	group	114-136	false
Thalidomide	drug	14-24	griseofulvin	drug	139-150	false
Thalidomide	drug	14-24	modafinil	drug	153-161	false
Thalidomide	drug	14-24	penicillins	group	164-174	false
Thalidomide	drug	14-24	rifampin	drug	177-184	false
Thalidomide	drug	14-24	rifabutin	drug	187-195	false
Thalidomide	drug	14-24	phenytoin	drug	198-206	false
Thalidomide	drug	14-24	carbamazepine	drug	209-221	false
Hormonal Contraceptives	group	70-92	HIV-protease inhibitors	group	114-136	false
Hormonal Contraceptives	group	70-92	griseofulvin	drug	139-150	false
Hormonal Contraceptives	group	70-92	modafinil	drug	153-161	false
Hormonal Contraceptives	group	70-92	penicillins	group	164-174	false
Hormonal Contraceptives	group	70-92	rifampin	drug	177-184	false
Hormonal Contraceptives	group	70-92	rifabutin	drug	187-195	false
Hormonal Contraceptives	group	70-92	phenytoin	drug	198-206	false
Hormonal Contraceptives	group	70-92	carbamazepine	drug	209-221	false
HIV-protease inhibitors	group	114-136	griseofulvin	drug	139-150	false
HIV-protease inhibitors	group	114-136	modafinil	drug	153-161	false
HIV-protease inhibitors	group	114-136	penicillins	group	164-174	false
HIV-protease inhibitors	group	114-136	rifampin	drug	177-184	false
HIV-protease inhibitors	group	114-136	rifabutin	drug	187-195	false
HIV-protease inhibitors	group	114-136	phenytoin	drug	198-206	false
HIV-protease inhibitors	group	114-136	carbamazepine	drug	209-221	false
griseofulvin	drug	139-150	modafinil	drug	153-161	false
griseofulvin	drug	139-150	penicillins	group	164-174	false
griseofulvin	drug	139-150	rifampin	drug	177-184	false
griseofulvin	drug	139-150	rifabutin	drug	187-195	false
griseofulvin	drug	139-150	phenytoin	drug	198-206	false
griseofulvin	drug	139-150	carbamazepine	drug	209-221	false
modafinil	drug	153-161	penicillins	group	164-174	false
modafinil	drug	153-161	rifampin	drug	177-184	false
modafinil	drug	153-161	rifabutin	drug	187-195	false
modafinil	drug	153-161	phenytoin	drug	198-206	false
modafinil	drug	153-161	carbamazepine	drug	209-221	false
penicillins	group	164-174	rifampin	drug	177-184	false
penicillins	group	164-174	rifabutin	drug	187-195	false
penicillins	group	164-174	phenytoin	drug	198-206	false
penicillins	group	164-174	carbamazepine	drug	209-221	false
rifampin	drug	177-184	rifabutin	drug	187-195	false
rifampin	drug	177-184	phenytoin	drug	198-206	false
rifampin	drug	177-184	carbamazepine	drug	209-221	false
rifabutin	drug	187-195	phenytoin	drug	198-206	false
rifabutin	drug	187-195	carbamazepine	drug	209-221	false
phenytoin	drug	198-206	carbamazepine	drug	209-221	false

DDI-DrugBank.d604.s5	John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.
John's Wort	drug_n	0-10	hormonal contraceptive agents	group	17-45	effect

DDI-DrugBank.d688.s0	Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs.
zidovudine	drug	104-113	rifabutin	drug	118-126	false
zidovudine	drug	104-113	megestrol acetate	drug	162-178	false
rifabutin	drug	118-126	megestrol acetate	drug	162-178	false

DDI-DrugBank.d688.s1	A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir.
megestrol acetate	drug	62-78	indinavir	drug	84-92	mechanism
megestrol acetate	drug	62-78	indinavir	drug	198-206	false
indinavir	drug	84-92	indinavir	drug	198-206	false

DDI-DrugBank.d688.s2	Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate.
indinavir	drug	35-43	megestrol acetate	drug	92-108	advise

DDI-DrugBank.d688.s3	The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.
indinavir	drug	15-23	zidovudine	drug	26-35	false
indinavir	drug	15-23	rifabutin	drug	40-48	false
indinavir	drug	15-23	megestrol acetate	drug	77-93	false
zidovudine	drug	26-35	rifabutin	drug	40-48	false
zidovudine	drug	26-35	megestrol acetate	drug	77-93	false
rifabutin	drug	40-48	megestrol acetate	drug	77-93	false

DDI-DrugBank.d700.s0	Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.
Antacids	group	0-7	Myfortic	brand	41-48	false
Antacids	group	0-7	magnesium	drug	133-141	false
Antacids	group	0-7	aluminum	drug	143-150	false
Antacids	group	0-7	antacids	group	163-170	false
Antacids	group	0-7	Myfortic	brand	271-278	false
Myfortic	brand	41-48	magnesium	drug	133-141	mechanism
Myfortic	brand	41-48	aluminum	drug	143-150	mechanism
Myfortic	brand	41-48	antacids	group	163-170	false
Myfortic	brand	41-48	Myfortic	brand	271-278	false
magnesium	drug	133-141	aluminum	drug	143-150	false
magnesium	drug	133-141	antacids	group	163-170	false
magnesium	drug	133-141	Myfortic	brand	271-278	false
aluminum	drug	143-150	antacids	group	163-170	false
aluminum	drug	143-150	Myfortic	brand	271-278	false
antacids	group	163-170	Myfortic	brand	271-278	false

DDI-DrugBank.d700.s1	It is recommended that Myfortic and antacids not be administered simultaneously.
Myfortic	drug	23-30	antacids	group	36-43	advise

DDI-DrugBank.d700.s2	Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic.
Cyclosporine	drug	0-11	cyclosporine	drug	64-75	false
Cyclosporine	drug	0-11	Myfortic	brand	152-159	false
cyclosporine	drug	64-75	Myfortic	brand	152-159	false

DDI-DrugBank.d700.s3	Acyclovir/Ganciclovir: may be taken with Myfortic;
Acyclovir	drug	0-8	Ganciclovir	drug	10-20	false
Acyclovir	drug	0-8	Myfortic	brand	41-48	false
Ganciclovir	drug	10-20	Myfortic	brand	41-48	false

DDI-DrugBank.d700.s5	Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.
acyclovir	drug	5-13	ganciclovir	drug	15-25	false
acyclovir	drug	5-13	MPAG	drug_n	31-34	false
ganciclovir	drug	15-25	MPAG	drug_n	31-34	false

DDI-DrugBank.d700.s6	Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.
Azathioprine	drug	0-11	Mycophenolate Mofetil	drug	13-33	false
Azathioprine	drug	0-11	azathioprine	drug	47-58	false
Azathioprine	drug	0-11	mycophenolate mofetil	drug	64-84	false
Azathioprine	drug	0-11	Myfortic	brand	136-143	false
Azathioprine	drug	0-11	azathioprine	drug	184-195	false
Azathioprine	drug	0-11	mycophenolate mofetil	drug	200-220	false
Mycophenolate Mofetil	drug	13-33	azathioprine	drug	47-58	false
Mycophenolate Mofetil	drug	13-33	mycophenolate mofetil	drug	64-84	false
Mycophenolate Mofetil	drug	13-33	Myfortic	brand	136-143	false
Mycophenolate Mofetil	drug	13-33	azathioprine	drug	184-195	false
Mycophenolate Mofetil	drug	13-33	mycophenolate mofetil	drug	200-220	false
azathioprine	drug	47-58	mycophenolate mofetil	drug	64-84	false
azathioprine	drug	47-58	Myfortic	brand	136-143	false
azathioprine	drug	47-58	azathioprine	drug	184-195	false
azathioprine	drug	47-58	mycophenolate mofetil	drug	200-220	false
mycophenolate mofetil	drug	64-84	Myfortic	brand	136-143	false
mycophenolate mofetil	drug	64-84	azathioprine	drug	184-195	false
mycophenolate mofetil	drug	64-84	mycophenolate mofetil	drug	200-220	false
Myfortic	brand	136-143	azathioprine	drug	184-195	advise
Myfortic	brand	136-143	mycophenolate mofetil	drug	200-220	advise
azathioprine	drug	184-195	mycophenolate mofetil	drug	200-220	false

DDI-DrugBank.d700.s7	Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil.
Cholestyramine	drug	0-13	MPA	drug_n	108-110	false
Cholestyramine	drug	0-13	mycophenolate mofetil	drug	146-166	false
MPA	drug_n	108-110	mycophenolate mofetil	drug	146-166	false

DDI-DrugBank.d700.s8	Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.
Myfortic	drug	29-36	cholestyramine	drug	43-56	advise
Myfortic	drug	29-36	activated charcoal	drug	204-221	advise
Myfortic	drug	29-36	Myfortic	brand	275-282	false
cholestyramine	drug	43-56	activated charcoal	drug	204-221	false
cholestyramine	drug	43-56	Myfortic	brand	275-282	false
activated charcoal	drug	204-221	Myfortic	brand	275-282	false

DDI-DrugBank.d700.s9	Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected.
Contraceptives	group	5-18	Myfortic	brand	55-62	false
Contraceptives	group	5-18	contraceptives	group	73-86	false
Myfortic	brand	55-62	contraceptives	group	73-86	false

DDI-DrugBank.d700.s10	However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil.
levonorgesterol	drug	48-62	mycophenolate mofetil	drug	114-134	mechanism

DDI-DrugBank.d700.s11	Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered.
contraceptives	group	39-52	Myfortic	brand	80-87	advise

DDI-DrugBank.d700.s12	Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.
Live Vaccines	group	0-12	Myfortic	drug	37-44	false
Live Vaccines	group	0-12	live attenuated vaccines	group	58-81	false
Myfortic	drug	37-44	live attenuated vaccines	group	58-81	advise

DDI-DrugBank.d700.s16	Interference of MPAG hydrolysis may lead to less MPA available for absorption.
MPAG	drug_n	16-19	MPA	drug_n	49-51	false

DDI-DrugBank.d711.s0	Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.
tetracyclines	group	8-20	anticoagulant	group	98-110	advise
tetracyclines	group	8-20	anticoagulant	group	161-173	false
anticoagulant	group	98-110	anticoagulant	group	161-173	false

DDI-DrugBank.d711.s1	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin.
penicillin	drug	73-82	tetracycline class drugs	group	117-140	false
penicillin	drug	73-82	penicillin	drug	162-171	false
tetracycline class drugs	group	117-140	penicillin	drug	162-171	advise

DDI-DrugBank.d711.s2	Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations.
tetracyclines	group	14-26	antacids	group	43-50	false
tetracyclines	group	14-26	aluminum	drug	63-70	mechanism
tetracyclines	group	14-26	calcium	drug	73-79	mechanism
tetracyclines	group	14-26	magnesium	drug	84-92	mechanism
tetracyclines	group	14-26	iron	drug	99-102	mechanism
antacids	group	43-50	aluminum	drug	63-70	false
antacids	group	43-50	calcium	drug	73-79	false
antacids	group	43-50	magnesium	drug	84-92	false
antacids	group	43-50	iron	drug	99-102	false
aluminum	drug	63-70	calcium	drug	73-79	false
aluminum	drug	63-70	magnesium	drug	84-92	false
aluminum	drug	63-70	iron	drug	99-102	false
calcium	drug	73-79	magnesium	drug	84-92	false
calcium	drug	73-79	iron	drug	99-102	false
magnesium	drug	84-92	iron	drug	99-102	false

DDI-DrugBank.d711.s3	The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity.
tetracycline	group	22-33	methoxyflurane	drug	39-52	effect

DDI-DrugBank.d711.s4	Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
tetracyclines	group	18-30	contraceptives	group	42-55	effect
tetracyclines	group	18-30	contraceptives	group	73-86	false
contraceptives	group	42-55	contraceptives	group	73-86	false

DDI-DrugBank.d713.s0	The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.
Sanctura	brand	23-30	anticholinergic agents	group	43-64	effect

DDI-DrugBank.d713.s2	Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).
Sanctura	brand	101-108	Sanctura	brand	135-142	false
Sanctura	brand	101-108	digoxin	drug	266-272	false
Sanctura	brand	101-108	procainamide	drug	275-286	false
Sanctura	brand	101-108	pancuronium	drug	289-299	false
Sanctura	brand	101-108	morphine	drug	302-309	false
Sanctura	brand	101-108	vancomycin	drug	312-321	false
Sanctura	brand	101-108	metformin	drug	324-332	false
Sanctura	brand	101-108	tenofovir	drug	338-346	false
Sanctura	brand	135-142	digoxin	drug	266-272	mechanism
Sanctura	brand	135-142	procainamide	drug	275-286	mechanism
Sanctura	brand	135-142	pancuronium	drug	289-299	mechanism
Sanctura	brand	135-142	morphine	drug	302-309	mechanism
Sanctura	brand	135-142	vancomycin	drug	312-321	mechanism
Sanctura	brand	135-142	metformin	drug	324-332	mechanism
Sanctura	brand	135-142	tenofovir	drug	338-346	mechanism
digoxin	drug	266-272	procainamide	drug	275-286	false
digoxin	drug	266-272	pancuronium	drug	289-299	false
digoxin	drug	266-272	morphine	drug	302-309	false
digoxin	drug	266-272	vancomycin	drug	312-321	false
digoxin	drug	266-272	metformin	drug	324-332	false
digoxin	drug	266-272	tenofovir	drug	338-346	false
procainamide	drug	275-286	pancuronium	drug	289-299	false
procainamide	drug	275-286	morphine	drug	302-309	false
procainamide	drug	275-286	vancomycin	drug	312-321	false
procainamide	drug	275-286	metformin	drug	324-332	false
procainamide	drug	275-286	tenofovir	drug	338-346	false
pancuronium	drug	289-299	morphine	drug	302-309	false
pancuronium	drug	289-299	vancomycin	drug	312-321	false
pancuronium	drug	289-299	metformin	drug	324-332	false
pancuronium	drug	289-299	tenofovir	drug	338-346	false
morphine	drug	302-309	vancomycin	drug	312-321	false
morphine	drug	302-309	metformin	drug	324-332	false
morphine	drug	302-309	tenofovir	drug	338-346	false
vancomycin	drug	312-321	metformin	drug	324-332	false
vancomycin	drug	312-321	tenofovir	drug	338-346	false
metformin	drug	324-332	tenofovir	drug	338-346	false

DDI-DrugBank.d713.s3	Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway.
Sanctura	brand	20-27	Sanctura	brand	134-141	false

DDI-DrugBank.d696.s0	Methysergide may reverse the analgesic activity of narcotic analgesics.
Methysergide	drug	0-11	narcotic analgesics	group	51-69	effect

DDI-DrugBank.d696.s1	Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.
vasoconstrictor agents	group	20-41	ergot alkaloids	group	53-67	false
vasoconstrictor agents	group	20-41	sumatriptan	drug	70-80	false
vasoconstrictor agents	group	20-41	nicotine	drug	87-94	false
ergot alkaloids	group	53-67	sumatriptan	drug	70-80	false
ergot alkaloids	group	53-67	nicotine	drug	87-94	false
sumatriptan	drug	70-80	nicotine	drug	87-94	false

DDI-DrugBank.d762.s0	Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem.
Probenecid	drug	0-9	meropenem	drug	25-33	mechanism
Probenecid	drug	0-9	meropenem	drug	105-113	false
meropenem	drug	25-33	meropenem	drug	105-113	false

DDI-DrugBank.d762.s2	Therefore, the coadministration of probenecid with meropenem is not recommended.
probenecid	drug	35-44	meropenem	drug	51-59	advise

DDI-DrugBank.d762.s3	There is evidence that meropenem may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total valproate).
meropenem	drug	23-31	valproic acid	drug	60-72	mechanism
meropenem	drug	23-31	valproate	drug	159-167	false
valproic acid	drug	60-72	valproate	drug	159-167	false

DDI-DrugBank.d609.s0	An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.
gemfibrozil	drug	32-42	rosiglitazone	drug	69-81	mechanism
gemfibrozil	drug	32-42	rifampin	drug	117-124	false
gemfibrozil	drug	32-42	rosiglitazone	drug	151-163	false
rosiglitazone	drug	69-81	rifampin	drug	117-124	false
rosiglitazone	drug	69-81	rosiglitazone	drug	151-163	false
rifampin	drug	117-124	rosiglitazone	drug	151-163	mechanism

DDI-DrugBank.d581.s2	patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.
lithium	drug	19-25	Neulasta	brand	31-38	advise

DDI-DrugBank.d739.s0	Montelukast at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline (predominantly a cytochrome P450 1A2 substrate).
Montelukast	drug	0-10	theophylline	drug	176-187	false

DDI-DrugBank.d739.s1	- did not change the pharmacokinetic profile of warfarin (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the INR (International Normalized Ratio).
warfarin	drug	48-55	warfarin	drug	158-165	false

DDI-DrugBank.d739.s3	- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily.
terfenadine	drug	53-63	fexofenadine	drug	105-116	false
terfenadine	drug	53-63	terfenadine	drug	218-228	false
fexofenadine	drug	105-116	terfenadine	drug	218-228	false

DDI-DrugBank.d739.s4	Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg.
Montelukast	drug	0-10	contraceptive	group	167-179	false
Montelukast	drug	0-10	norethindrone	drug	192-204	false
Montelukast	drug	0-10	estradiol	drug	219-227	false
contraceptive	group	167-179	norethindrone	drug	192-204	false
contraceptive	group	167-179	estradiol	drug	219-227	false
norethindrone	drug	192-204	estradiol	drug	219-227	false

DDI-DrugBank.d739.s5	- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.
prednisone	drug	72-81	prednisolone	drug	86-97	false
prednisone	drug	72-81	prednisone	drug	139-148	false
prednisone	drug	72-81	prednisolone	drug	165-176	false
prednisolone	drug	86-97	prednisone	drug	139-148	false
prednisolone	drug	86-97	prednisolone	drug	165-176	false
prednisone	drug	139-148	prednisolone	drug	165-176	false

DDI-DrugBank.d739.s6	Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast.
Phenobarbital	drug	0-12	montelukast	drug	70-80	false
Phenobarbital	drug	0-12	montelukast	drug	133-143	false
montelukast	drug	70-80	montelukast	drug	133-143	false

DDI-DrugBank.d739.s8	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
phenobarbital	drug	112-124	rifampin	drug	129-136	false
phenobarbital	drug	112-124	montelukast	drug	164-174	advise
rifampin	drug	129-136	montelukast	drug	164-174	advise

DDI-DrugBank.d739.s10	In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.
montelukast	drug	62-72	theophylline	drug	164-175	false
montelukast	drug	62-72	prednisone	drug	178-187	false
montelukast	drug	62-72	prednisolone	drug	190-201	false
montelukast	drug	62-72	contraceptives	group	209-222	false
montelukast	drug	62-72	norethindrone	drug	225-237	false
montelukast	drug	62-72	ethinyl estradiol	drug	244-260	false
montelukast	drug	62-72	terfenadine	drug	271-281	false
montelukast	drug	62-72	digoxin	drug	284-290	false
montelukast	drug	62-72	warfarin	drug	297-304	false
theophylline	drug	164-175	prednisone	drug	178-187	false
theophylline	drug	164-175	prednisolone	drug	190-201	false
theophylline	drug	164-175	contraceptives	group	209-222	false
theophylline	drug	164-175	norethindrone	drug	225-237	false
theophylline	drug	164-175	ethinyl estradiol	drug	244-260	false
theophylline	drug	164-175	terfenadine	drug	271-281	false
theophylline	drug	164-175	digoxin	drug	284-290	false
theophylline	drug	164-175	warfarin	drug	297-304	false
prednisone	drug	178-187	prednisolone	drug	190-201	false
prednisone	drug	178-187	contraceptives	group	209-222	false
prednisone	drug	178-187	norethindrone	drug	225-237	false
prednisone	drug	178-187	ethinyl estradiol	drug	244-260	false
prednisone	drug	178-187	terfenadine	drug	271-281	false
prednisone	drug	178-187	digoxin	drug	284-290	false
prednisone	drug	178-187	warfarin	drug	297-304	false
prednisolone	drug	190-201	contraceptives	group	209-222	false
prednisolone	drug	190-201	norethindrone	drug	225-237	false
prednisolone	drug	190-201	ethinyl estradiol	drug	244-260	false
prednisolone	drug	190-201	terfenadine	drug	271-281	false
prednisolone	drug	190-201	digoxin	drug	284-290	false
prednisolone	drug	190-201	warfarin	drug	297-304	false
contraceptives	group	209-222	norethindrone	drug	225-237	false
contraceptives	group	209-222	ethinyl estradiol	drug	244-260	false
contraceptives	group	209-222	terfenadine	drug	271-281	false
contraceptives	group	209-222	digoxin	drug	284-290	false
contraceptives	group	209-222	warfarin	drug	297-304	false
norethindrone	drug	225-237	ethinyl estradiol	drug	244-260	false
norethindrone	drug	225-237	terfenadine	drug	271-281	false
norethindrone	drug	225-237	digoxin	drug	284-290	false
norethindrone	drug	225-237	warfarin	drug	297-304	false
ethinyl estradiol	drug	244-260	terfenadine	drug	271-281	false
ethinyl estradiol	drug	244-260	digoxin	drug	284-290	false
ethinyl estradiol	drug	244-260	warfarin	drug	297-304	false
terfenadine	drug	271-281	digoxin	drug	284-290	false
terfenadine	drug	271-281	warfarin	drug	297-304	false
digoxin	drug	284-290	warfarin	drug	297-304	false

DDI-DrugBank.d739.s12	These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.
thyroid hormones	group	27-42	sedative hypnotics	group	45-62	false
thyroid hormones	group	27-42	non-steroidal anti-inflammatory agents	group	65-102	false
thyroid hormones	group	27-42	benzodiazepines	group	105-119	false
thyroid hormones	group	27-42	decongestants	group	126-138	false
sedative hypnotics	group	45-62	non-steroidal anti-inflammatory agents	group	65-102	false
sedative hypnotics	group	45-62	benzodiazepines	group	105-119	false
sedative hypnotics	group	45-62	decongestants	group	126-138	false
non-steroidal anti-inflammatory agents	group	65-102	benzodiazepines	group	105-119	false
non-steroidal anti-inflammatory agents	group	65-102	decongestants	group	126-138	false
benzodiazepines	group	105-119	decongestants	group	126-138	false

DDI-DrugBank.d739.s13	Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast.
Phenobarbital	drug	0-12	montelukast	drug	70-80	false
Phenobarbital	drug	0-12	montelukast	drug	133-143	false
montelukast	drug	70-80	montelukast	drug	133-143	false

DDI-DrugBank.d739.s15	It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.
phenobarbital	drug	112-124	rifampin	drug	129-136	false
phenobarbital	drug	112-124	montelukast	drug	164-174	advise
rifampin	drug	129-136	montelukast	drug	164-174	advise

DDI-DrugBank.d677.s0	Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)
Phenothiazines	group	0-13	CNS depressants	group	43-57	effect
Phenothiazines	group	0-13	barbiturates	group	66-77	effect
Phenothiazines	group	0-13	anesthetics	group	80-90	effect
Phenothiazines	group	0-13	opiates	group	93-99	effect
Phenothiazines	group	0-13	alcohol	drug	102-108	effect
CNS depressants	group	43-57	barbiturates	group	66-77	false
CNS depressants	group	43-57	anesthetics	group	80-90	false
CNS depressants	group	43-57	opiates	group	93-99	false
CNS depressants	group	43-57	alcohol	drug	102-108	false
barbiturates	group	66-77	anesthetics	group	80-90	false
barbiturates	group	66-77	opiates	group	93-99	false
barbiturates	group	66-77	alcohol	drug	102-108	false
anesthetics	group	80-90	opiates	group	93-99	false
anesthetics	group	80-90	alcohol	drug	102-108	false
opiates	group	93-99	alcohol	drug	102-108	false

DDI-DrugBank.d677.s1	as well as atropine and phosphorous insecticides.
atropine	drug	11-18	phosphorous insecticides	drug_n	24-47	false

DDI-DrugBank.d706.s0	Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents.
reserpine	drug	37-45	beta-blocking agents	group	92-111	effect

DDI-DrugBank.d658.s0	When administered concurrently, testolactone may increase the effects of oral anticoagulants;
testolactone	drug	32-43	anticoagulants	group	78-91	effect

DDI-DrugBank.d640.s0	Diuretics: Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started.
Diuretics	group	0-8	ACE inhibitors	group	97-110	false

DDI-DrugBank.d640.s1	The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced..
UNIVASC	brand	44-50	UNIVASC	brand	196-202	false
UNIVASC	brand	44-50	moexpril	drug	254-261	false
UNIVASC	brand	196-202	moexpril	drug	254-261	false

DDI-DrugBank.d640.s2	Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion.
Potassium	drug	0-8	Potassium-Sparing Diuretics	group	26-52	false
Potassium	drug	0-8	UNIVASC	brand	55-61	false
Potassium-Sparing Diuretics	group	26-52	UNIVASC	brand	55-61	false

DDI-DrugBank.d640.s3	Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.
potassium-sparing diuretics	group	7-33	spironolactone	drug	36-49	false
potassium-sparing diuretics	group	7-33	triamterene	drug	52-62	false
potassium-sparing diuretics	group	7-33	amiloride	drug	65-73	false
potassium-sparing diuretics	group	7-33	potassium	drug	79-87	false
potassium-sparing diuretics	group	7-33	ACE inhibitors	group	120-133	effect
spironolactone	drug	36-49	triamterene	drug	52-62	false
spironolactone	drug	36-49	amiloride	drug	65-73	false
spironolactone	drug	36-49	potassium	drug	79-87	false
spironolactone	drug	36-49	ACE inhibitors	group	120-133	effect
triamterene	drug	52-62	amiloride	drug	65-73	false
triamterene	drug	52-62	potassium	drug	79-87	false
triamterene	drug	52-62	ACE inhibitors	group	120-133	effect
amiloride	drug	65-73	potassium	drug	79-87	false
amiloride	drug	65-73	ACE inhibitors	group	120-133	effect
potassium	drug	79-87	ACE inhibitors	group	120-133	effect

DDI-DrugBank.d640.s5	Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.
Anticoagulants	group	5-18	warfarin	drug	46-53	false
Anticoagulants	group	5-18	anticoagulant	group	141-153	false
warfarin	drug	46-53	anticoagulant	group	141-153	false

DDI-DrugBank.d640.s6	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
Lithium	drug	0-6	lithium	drug	25-31	false
Lithium	drug	0-6	lithium	drug	56-62	false
Lithium	drug	0-6	ACE inhibitors	group	114-127	false
Lithium	drug	0-6	lithium	drug	149-155	false
lithium	drug	25-31	lithium	drug	56-62	false
lithium	drug	25-31	ACE inhibitors	group	114-127	false
lithium	drug	25-31	lithium	drug	149-155	false
lithium	drug	56-62	ACE inhibitors	group	114-127	false
lithium	drug	56-62	lithium	drug	149-155	false
ACE inhibitors	group	114-127	lithium	drug	149-155	effect

DDI-DrugBank.d640.s8	If a diuretic is also used, the risk of lithium toxicity may be increased.
diuretic	group	5-12	lithium	drug	40-46	effect

DDI-DrugBank.d640.s9	Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine.
UNIVASC	brand	81-87	hydrochlorothiazide	drug	128-146	false
UNIVASC	brand	81-87	digoxin	drug	149-155	false
UNIVASC	brand	81-87	cimetidine	drug	161-170	false
hydrochlorothiazide	drug	128-146	digoxin	drug	149-155	false
hydrochlorothiazide	drug	128-146	cimetidine	drug	161-170	false
digoxin	drug	149-155	cimetidine	drug	161-170	false

DDI-DrugBank.d640.s10	UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.
UNIVASC	brand	0-6	calcium-channel-blocking agents	group	63-93	false
UNIVASC	brand	0-6	diuretics	group	96-104	false
UNIVASC	brand	0-6	H2 blockers	group	107-117	false
UNIVASC	brand	0-6	digoxin	drug	120-126	false
UNIVASC	brand	0-6	hypoglycemic agents	group	134-152	false
calcium-channel-blocking agents	group	63-93	diuretics	group	96-104	false
calcium-channel-blocking agents	group	63-93	H2 blockers	group	107-117	false
calcium-channel-blocking agents	group	63-93	digoxin	drug	120-126	false
calcium-channel-blocking agents	group	63-93	hypoglycemic agents	group	134-152	false
diuretics	group	96-104	H2 blockers	group	107-117	false
diuretics	group	96-104	digoxin	drug	120-126	false
diuretics	group	96-104	hypoglycemic agents	group	134-152	false
H2 blockers	group	107-117	digoxin	drug	120-126	false
H2 blockers	group	107-117	hypoglycemic agents	group	134-152	false
digoxin	drug	120-126	hypoglycemic agents	group	134-152	false

DDI-DrugBank.d725.s0	Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.
Vasopressors	group	0-11	metaraminol	drug	27-37	false
Vasopressors	group	0-11	halothane	drug	85-93	effect
metaraminol	drug	27-37	halothane	drug	85-93	effect

DDI-DrugBank.d725.s1	MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).
MAO Inhibitors	group	0-13	sympathomimetic pressor amines	group	38-67	false
MAO Inhibitors	group	0-13	monoamine oxidase inhibitors	group	115-142	false
MAO Inhibitors	group	0-13	MAOI	group	145-148	false
sympathomimetic pressor amines	group	38-67	monoamine oxidase inhibitors	group	115-142	effect
sympathomimetic pressor amines	group	38-67	MAOI	group	145-148	effect
monoamine oxidase inhibitors	group	115-142	MAOI	group	145-148	false

DDI-DrugBank.d725.s3	The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.
adrenergic agents	group	24-40	tricyclic antidepressants	group	69-93	effect

DDI-DrugBank.d627.s0	Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances.
Pilocarpine	drug	0-10	beta adrenergic antagonists	group	67-93	advise

DDI-DrugBank.d627.s3	These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium).
atropine	drug	146-153	ipratropium	drug	164-174	false

DDI-DrugBank.d627.s4	While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.
acetylsalicylic acid	drug	179-198	calcium	drug	219-225	false
acetylsalicylic acid	drug	179-198	conjugated estrogens	drug	228-247	false
acetylsalicylic acid	drug	179-198	hydroxychloroquine sulfate	drug	250-275	false
acetylsalicylic acid	drug	179-198	ibuprofen	drug	278-286	false
acetylsalicylic acid	drug	179-198	levothyroxine sodium	drug	289-308	false
acetylsalicylic acid	drug	179-198	medroxyprogesterone acetate	drug	311-337	false
acetylsalicylic acid	drug	179-198	methotrexate	drug	340-351	false
acetylsalicylic acid	drug	179-198	multivitamins	group	354-366	false
acetylsalicylic acid	drug	179-198	naproxen	drug	369-376	false
acetylsalicylic acid	drug	179-198	omeprazole	drug	379-388	false
acetylsalicylic acid	drug	179-198	paracetamol	drug	391-401	false
acetylsalicylic acid	drug	179-198	prednisone	drug	408-417	false
calcium	drug	219-225	conjugated estrogens	drug	228-247	false
calcium	drug	219-225	hydroxychloroquine sulfate	drug	250-275	false
calcium	drug	219-225	ibuprofen	drug	278-286	false
calcium	drug	219-225	levothyroxine sodium	drug	289-308	false
calcium	drug	219-225	medroxyprogesterone acetate	drug	311-337	false
calcium	drug	219-225	methotrexate	drug	340-351	false
calcium	drug	219-225	multivitamins	group	354-366	false
calcium	drug	219-225	naproxen	drug	369-376	false
calcium	drug	219-225	omeprazole	drug	379-388	false
calcium	drug	219-225	paracetamol	drug	391-401	false
calcium	drug	219-225	prednisone	drug	408-417	false
conjugated estrogens	drug	228-247	hydroxychloroquine sulfate	drug	250-275	false
conjugated estrogens	drug	228-247	ibuprofen	drug	278-286	false
conjugated estrogens	drug	228-247	levothyroxine sodium	drug	289-308	false
conjugated estrogens	drug	228-247	medroxyprogesterone acetate	drug	311-337	false
conjugated estrogens	drug	228-247	methotrexate	drug	340-351	false
conjugated estrogens	drug	228-247	multivitamins	group	354-366	false
conjugated estrogens	drug	228-247	naproxen	drug	369-376	false
conjugated estrogens	drug	228-247	omeprazole	drug	379-388	false
conjugated estrogens	drug	228-247	paracetamol	drug	391-401	false
conjugated estrogens	drug	228-247	prednisone	drug	408-417	false
hydroxychloroquine sulfate	drug	250-275	ibuprofen	drug	278-286	false
hydroxychloroquine sulfate	drug	250-275	levothyroxine sodium	drug	289-308	false
hydroxychloroquine sulfate	drug	250-275	medroxyprogesterone acetate	drug	311-337	false
hydroxychloroquine sulfate	drug	250-275	methotrexate	drug	340-351	false
hydroxychloroquine sulfate	drug	250-275	multivitamins	group	354-366	false
hydroxychloroquine sulfate	drug	250-275	naproxen	drug	369-376	false
hydroxychloroquine sulfate	drug	250-275	omeprazole	drug	379-388	false
hydroxychloroquine sulfate	drug	250-275	paracetamol	drug	391-401	false
hydroxychloroquine sulfate	drug	250-275	prednisone	drug	408-417	false
ibuprofen	drug	278-286	levothyroxine sodium	drug	289-308	false
ibuprofen	drug	278-286	medroxyprogesterone acetate	drug	311-337	false
ibuprofen	drug	278-286	methotrexate	drug	340-351	false
ibuprofen	drug	278-286	multivitamins	group	354-366	false
ibuprofen	drug	278-286	naproxen	drug	369-376	false
ibuprofen	drug	278-286	omeprazole	drug	379-388	false
ibuprofen	drug	278-286	paracetamol	drug	391-401	false
ibuprofen	drug	278-286	prednisone	drug	408-417	false
levothyroxine sodium	drug	289-308	medroxyprogesterone acetate	drug	311-337	false
levothyroxine sodium	drug	289-308	methotrexate	drug	340-351	false
levothyroxine sodium	drug	289-308	multivitamins	group	354-366	false
levothyroxine sodium	drug	289-308	naproxen	drug	369-376	false
levothyroxine sodium	drug	289-308	omeprazole	drug	379-388	false
levothyroxine sodium	drug	289-308	paracetamol	drug	391-401	false
levothyroxine sodium	drug	289-308	prednisone	drug	408-417	false
medroxyprogesterone acetate	drug	311-337	methotrexate	drug	340-351	false
medroxyprogesterone acetate	drug	311-337	multivitamins	group	354-366	false
medroxyprogesterone acetate	drug	311-337	naproxen	drug	369-376	false
medroxyprogesterone acetate	drug	311-337	omeprazole	drug	379-388	false
medroxyprogesterone acetate	drug	311-337	paracetamol	drug	391-401	false
medroxyprogesterone acetate	drug	311-337	prednisone	drug	408-417	false
methotrexate	drug	340-351	multivitamins	group	354-366	false
methotrexate	drug	340-351	naproxen	drug	369-376	false
methotrexate	drug	340-351	omeprazole	drug	379-388	false
methotrexate	drug	340-351	paracetamol	drug	391-401	false
methotrexate	drug	340-351	prednisone	drug	408-417	false
multivitamins	group	354-366	naproxen	drug	369-376	false
multivitamins	group	354-366	omeprazole	drug	379-388	false
multivitamins	group	354-366	paracetamol	drug	391-401	false
multivitamins	group	354-366	prednisone	drug	408-417	false
naproxen	drug	369-376	omeprazole	drug	379-388	false
naproxen	drug	369-376	paracetamol	drug	391-401	false
naproxen	drug	369-376	prednisone	drug	408-417	false
omeprazole	drug	379-388	paracetamol	drug	391-401	false
omeprazole	drug	379-388	prednisone	drug	408-417	false
paracetamol	drug	391-401	prednisone	drug	408-417	false

DDI-DrugBank.d703.s0	Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).
Central Nervous System Depressants	group	23-56	MEPERIDINE	drug	59-68	false
Central Nervous System Depressants	group	23-56	NARCOTIC ANALGESICS	group	175-193	false
Central Nervous System Depressants	group	23-56	ANESTHETICS	group	204-214	false
Central Nervous System Depressants	group	23-56	PHENOTHIAZINES	group	217-230	false
Central Nervous System Depressants	group	23-56	TRANQUILIZERS	group	239-251	false
Central Nervous System Depressants	group	23-56	SEDATIVE-HYPNOTICS	group	254-271	false
Central Nervous System Depressants	group	23-56	BARBITURATES	group	284-295	false
Central Nervous System Depressants	group	23-56	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false
Central Nervous System Depressants	group	23-56	CNS DEPRESSANTS	group	335-349	false
Central Nervous System Depressants	group	23-56	ALCOHOL	drug	362-368	false
MEPERIDINE	drug	59-68	NARCOTIC ANALGESICS	group	175-193	advise
MEPERIDINE	drug	59-68	ANESTHETICS	group	204-214	advise
MEPERIDINE	drug	59-68	PHENOTHIAZINES	group	217-230	advise
MEPERIDINE	drug	59-68	TRANQUILIZERS	group	239-251	advise
MEPERIDINE	drug	59-68	SEDATIVE-HYPNOTICS	group	254-271	advise
MEPERIDINE	drug	59-68	BARBITURATES	group	284-295	advise
MEPERIDINE	drug	59-68	TRICYCLIC ANTIDEPRESSANTS	group	299-323	advise
MEPERIDINE	drug	59-68	CNS DEPRESSANTS	group	335-349	advise
MEPERIDINE	drug	59-68	ALCOHOL	drug	362-368	advise
NARCOTIC ANALGESICS	group	175-193	ANESTHETICS	group	204-214	false
NARCOTIC ANALGESICS	group	175-193	PHENOTHIAZINES	group	217-230	false
NARCOTIC ANALGESICS	group	175-193	TRANQUILIZERS	group	239-251	false
NARCOTIC ANALGESICS	group	175-193	SEDATIVE-HYPNOTICS	group	254-271	false
NARCOTIC ANALGESICS	group	175-193	BARBITURATES	group	284-295	false
NARCOTIC ANALGESICS	group	175-193	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false
NARCOTIC ANALGESICS	group	175-193	CNS DEPRESSANTS	group	335-349	false
NARCOTIC ANALGESICS	group	175-193	ALCOHOL	drug	362-368	false
ANESTHETICS	group	204-214	PHENOTHIAZINES	group	217-230	false
ANESTHETICS	group	204-214	TRANQUILIZERS	group	239-251	false
ANESTHETICS	group	204-214	SEDATIVE-HYPNOTICS	group	254-271	false
ANESTHETICS	group	204-214	BARBITURATES	group	284-295	false
ANESTHETICS	group	204-214	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false
ANESTHETICS	group	204-214	CNS DEPRESSANTS	group	335-349	false
ANESTHETICS	group	204-214	ALCOHOL	drug	362-368	false
PHENOTHIAZINES	group	217-230	TRANQUILIZERS	group	239-251	false
PHENOTHIAZINES	group	217-230	SEDATIVE-HYPNOTICS	group	254-271	false
PHENOTHIAZINES	group	217-230	BARBITURATES	group	284-295	false
PHENOTHIAZINES	group	217-230	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false
PHENOTHIAZINES	group	217-230	CNS DEPRESSANTS	group	335-349	false
PHENOTHIAZINES	group	217-230	ALCOHOL	drug	362-368	false
TRANQUILIZERS	group	239-251	SEDATIVE-HYPNOTICS	group	254-271	false
TRANQUILIZERS	group	239-251	BARBITURATES	group	284-295	false
TRANQUILIZERS	group	239-251	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false
TRANQUILIZERS	group	239-251	CNS DEPRESSANTS	group	335-349	false
TRANQUILIZERS	group	239-251	ALCOHOL	drug	362-368	false
SEDATIVE-HYPNOTICS	group	254-271	BARBITURATES	group	284-295	false
SEDATIVE-HYPNOTICS	group	254-271	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false
SEDATIVE-HYPNOTICS	group	254-271	CNS DEPRESSANTS	group	335-349	false
SEDATIVE-HYPNOTICS	group	254-271	ALCOHOL	drug	362-368	false
BARBITURATES	group	284-295	TRICYCLIC ANTIDEPRESSANTS	group	299-323	false
BARBITURATES	group	284-295	CNS DEPRESSANTS	group	335-349	false
BARBITURATES	group	284-295	ALCOHOL	drug	362-368	false
TRICYCLIC ANTIDEPRESSANTS	group	299-323	CNS DEPRESSANTS	group	335-349	false
TRICYCLIC ANTIDEPRESSANTS	group	299-323	ALCOHOL	drug	362-368	false
CNS DEPRESSANTS	group	335-349	ALCOHOL	drug	362-368	false

DDI-DrugBank.d726.s1	A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.
ketoconazole	drug	62-73	paricalcitol	drug	97-108	mechanism
ketoconazole	drug	62-73	paricalcitol	drug	126-137	false
ketoconazole	drug	62-73	ketoconazole	drug	177-188	false
ketoconazole	drug	62-73	paricalcitol	drug	291-302	false
ketoconazole	drug	62-73	ketoconazole	drug	309-320	false
ketoconazole	drug	62-73	atazanavir	drug	368-377	false
ketoconazole	drug	62-73	clarithromycin	drug	380-393	false
ketoconazole	drug	62-73	indinavir	drug	396-404	false
ketoconazole	drug	62-73	itraconazole	drug	407-418	false
ketoconazole	drug	62-73	nefazodone	drug	421-430	false
ketoconazole	drug	62-73	nelfinavir	drug	433-442	false
ketoconazole	drug	62-73	ritonavir	drug	445-453	false
ketoconazole	drug	62-73	saquinavir	drug	456-465	false
ketoconazole	drug	62-73	telithromycin	drug	468-480	false
ketoconazole	drug	62-73	voriconazole	drug	485-496	false
paricalcitol	drug	97-108	paricalcitol	drug	126-137	false
paricalcitol	drug	97-108	ketoconazole	drug	177-188	false
paricalcitol	drug	97-108	paricalcitol	drug	291-302	false
paricalcitol	drug	97-108	ketoconazole	drug	309-320	false
paricalcitol	drug	97-108	atazanavir	drug	368-377	false
paricalcitol	drug	97-108	clarithromycin	drug	380-393	false
paricalcitol	drug	97-108	indinavir	drug	396-404	false
paricalcitol	drug	97-108	itraconazole	drug	407-418	false
paricalcitol	drug	97-108	nefazodone	drug	421-430	false
paricalcitol	drug	97-108	nelfinavir	drug	433-442	false
paricalcitol	drug	97-108	ritonavir	drug	445-453	false
paricalcitol	drug	97-108	saquinavir	drug	456-465	false
paricalcitol	drug	97-108	telithromycin	drug	468-480	false
paricalcitol	drug	97-108	voriconazole	drug	485-496	false
paricalcitol	drug	126-137	ketoconazole	drug	177-188	false
paricalcitol	drug	126-137	paricalcitol	drug	291-302	false
paricalcitol	drug	126-137	ketoconazole	drug	309-320	false
paricalcitol	drug	126-137	atazanavir	drug	368-377	false
paricalcitol	drug	126-137	clarithromycin	drug	380-393	false
paricalcitol	drug	126-137	indinavir	drug	396-404	false
paricalcitol	drug	126-137	itraconazole	drug	407-418	false
paricalcitol	drug	126-137	nefazodone	drug	421-430	false
paricalcitol	drug	126-137	nelfinavir	drug	433-442	false
paricalcitol	drug	126-137	ritonavir	drug	445-453	false
paricalcitol	drug	126-137	saquinavir	drug	456-465	false
paricalcitol	drug	126-137	telithromycin	drug	468-480	false
paricalcitol	drug	126-137	voriconazole	drug	485-496	false
ketoconazole	drug	177-188	paricalcitol	drug	291-302	false
ketoconazole	drug	177-188	ketoconazole	drug	309-320	false
ketoconazole	drug	177-188	atazanavir	drug	368-377	false
ketoconazole	drug	177-188	clarithromycin	drug	380-393	false
ketoconazole	drug	177-188	indinavir	drug	396-404	false
ketoconazole	drug	177-188	itraconazole	drug	407-418	false
ketoconazole	drug	177-188	nefazodone	drug	421-430	false
ketoconazole	drug	177-188	nelfinavir	drug	433-442	false
ketoconazole	drug	177-188	ritonavir	drug	445-453	false
ketoconazole	drug	177-188	saquinavir	drug	456-465	false
ketoconazole	drug	177-188	telithromycin	drug	468-480	false
ketoconazole	drug	177-188	voriconazole	drug	485-496	false
paricalcitol	drug	291-302	ketoconazole	drug	309-320	advise
paricalcitol	drug	291-302	atazanavir	drug	368-377	advise
paricalcitol	drug	291-302	clarithromycin	drug	380-393	advise
paricalcitol	drug	291-302	indinavir	drug	396-404	advise
paricalcitol	drug	291-302	itraconazole	drug	407-418	advise
paricalcitol	drug	291-302	nefazodone	drug	421-430	advise
paricalcitol	drug	291-302	nelfinavir	drug	433-442	advise
paricalcitol	drug	291-302	ritonavir	drug	445-453	advise
paricalcitol	drug	291-302	saquinavir	drug	456-465	advise
paricalcitol	drug	291-302	telithromycin	drug	468-480	advise
paricalcitol	drug	291-302	voriconazole	drug	485-496	advise
ketoconazole	drug	309-320	atazanavir	drug	368-377	false
ketoconazole	drug	309-320	clarithromycin	drug	380-393	false
ketoconazole	drug	309-320	indinavir	drug	396-404	false
ketoconazole	drug	309-320	itraconazole	drug	407-418	false
ketoconazole	drug	309-320	nefazodone	drug	421-430	false
ketoconazole	drug	309-320	nelfinavir	drug	433-442	false
ketoconazole	drug	309-320	ritonavir	drug	445-453	false
ketoconazole	drug	309-320	saquinavir	drug	456-465	false
ketoconazole	drug	309-320	telithromycin	drug	468-480	false
ketoconazole	drug	309-320	voriconazole	drug	485-496	false
atazanavir	drug	368-377	clarithromycin	drug	380-393	false
atazanavir	drug	368-377	indinavir	drug	396-404	false
atazanavir	drug	368-377	itraconazole	drug	407-418	false
atazanavir	drug	368-377	nefazodone	drug	421-430	false
atazanavir	drug	368-377	nelfinavir	drug	433-442	false
atazanavir	drug	368-377	ritonavir	drug	445-453	false
atazanavir	drug	368-377	saquinavir	drug	456-465	false
atazanavir	drug	368-377	telithromycin	drug	468-480	false
atazanavir	drug	368-377	voriconazole	drug	485-496	false
clarithromycin	drug	380-393	indinavir	drug	396-404	false
clarithromycin	drug	380-393	itraconazole	drug	407-418	false
clarithromycin	drug	380-393	nefazodone	drug	421-430	false
clarithromycin	drug	380-393	nelfinavir	drug	433-442	false
clarithromycin	drug	380-393	ritonavir	drug	445-453	false
clarithromycin	drug	380-393	saquinavir	drug	456-465	false
clarithromycin	drug	380-393	telithromycin	drug	468-480	false
clarithromycin	drug	380-393	voriconazole	drug	485-496	false
indinavir	drug	396-404	itraconazole	drug	407-418	false
indinavir	drug	396-404	nefazodone	drug	421-430	false
indinavir	drug	396-404	nelfinavir	drug	433-442	false
indinavir	drug	396-404	ritonavir	drug	445-453	false
indinavir	drug	396-404	saquinavir	drug	456-465	false
indinavir	drug	396-404	telithromycin	drug	468-480	false
indinavir	drug	396-404	voriconazole	drug	485-496	false
itraconazole	drug	407-418	nefazodone	drug	421-430	false
itraconazole	drug	407-418	nelfinavir	drug	433-442	false
itraconazole	drug	407-418	ritonavir	drug	445-453	false
itraconazole	drug	407-418	saquinavir	drug	456-465	false
itraconazole	drug	407-418	telithromycin	drug	468-480	false
itraconazole	drug	407-418	voriconazole	drug	485-496	false
nefazodone	drug	421-430	nelfinavir	drug	433-442	false
nefazodone	drug	421-430	ritonavir	drug	445-453	false
nefazodone	drug	421-430	saquinavir	drug	456-465	false
nefazodone	drug	421-430	telithromycin	drug	468-480	false
nefazodone	drug	421-430	voriconazole	drug	485-496	false
nelfinavir	drug	433-442	ritonavir	drug	445-453	false
nelfinavir	drug	433-442	saquinavir	drug	456-465	false
nelfinavir	drug	433-442	telithromycin	drug	468-480	false
nelfinavir	drug	433-442	voriconazole	drug	485-496	false
ritonavir	drug	445-453	saquinavir	drug	456-465	false
ritonavir	drug	445-453	telithromycin	drug	468-480	false
ritonavir	drug	445-453	voriconazole	drug	485-496	false
saquinavir	drug	456-465	telithromycin	drug	468-480	false
saquinavir	drug	456-465	voriconazole	drug	485-496	false
telithromycin	drug	468-480	voriconazole	drug	485-496	false

DDI-DrugBank.d726.s2	Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole.
Zemplar	brand	19-25	ketoconazole	drug	209-220	advise

DDI-DrugBank.d726.s3	Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.
fat-soluble vitamins	group	43-62	cholestyramine	drug	73-86	mechanism
fat-soluble vitamins	group	43-62	Zemplar	brand	126-132	false
cholestyramine	drug	73-86	Zemplar	brand	126-132	mechanism

DDI-DrugBank.d652.s0	The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics.
metoclopramide	drug	15-28	anticholinergic drugs	group	78-98	effect
metoclopramide	drug	15-28	narcotic analgesics	group	104-122	effect
anticholinergic drugs	group	78-98	narcotic analgesics	group	104-122	false

DDI-DrugBank.d652.s1	Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers.
metoclopramide	drug	41-54	alcohol	drug	70-76	effect
metoclopramide	drug	41-54	sedatives	group	79-87	effect
metoclopramide	drug	41-54	hypnotics	group	90-98	effect
metoclopramide	drug	41-54	narcotics	group	101-109	effect
metoclopramide	drug	41-54	tranquilizers	group	115-127	effect
alcohol	drug	70-76	sedatives	group	79-87	false
alcohol	drug	70-76	hypnotics	group	90-98	false
alcohol	drug	70-76	narcotics	group	101-109	false
alcohol	drug	70-76	tranquilizers	group	115-127	false
sedatives	group	79-87	hypnotics	group	90-98	false
sedatives	group	79-87	narcotics	group	101-109	false
sedatives	group	79-87	tranquilizers	group	115-127	false
hypnotics	group	90-98	narcotics	group	101-109	false
hypnotics	group	90-98	tranquilizers	group	115-127	false
narcotics	group	101-109	tranquilizers	group	115-127	false

DDI-DrugBank.d652.s2	The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors.
metoclopramide	drug	17-30	monoamine oxi-dase inhibitors	group	173-201	advise

DDI-DrugBank.d652.s3	Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).
digoxin	drug	62-68	metoclopramide	drug	74-87	mechanism
digoxin	drug	62-68	acetaminophen	drug	189-201	false
digoxin	drug	62-68	tetracycline	drug	204-215	false
digoxin	drug	62-68	levodopa	drug	218-225	false
digoxin	drug	62-68	ethanol	drug	228-234	false
digoxin	drug	62-68	cyclosporine	drug	237-248	false
metoclopramide	drug	74-87	acetaminophen	drug	189-201	mechanism
metoclopramide	drug	74-87	tetracycline	drug	204-215	false
metoclopramide	drug	74-87	levodopa	drug	218-225	false
metoclopramide	drug	74-87	ethanol	drug	228-234	false
metoclopramide	drug	74-87	cyclosporine	drug	237-248	false
acetaminophen	drug	189-201	tetracycline	drug	204-215	false
acetaminophen	drug	189-201	levodopa	drug	218-225	false
acetaminophen	drug	189-201	ethanol	drug	228-234	false
acetaminophen	drug	189-201	cyclosporine	drug	237-248	false
tetracycline	drug	204-215	levodopa	drug	218-225	false
tetracycline	drug	204-215	ethanol	drug	228-234	false
tetracycline	drug	204-215	cyclosporine	drug	237-248	false
levodopa	drug	218-225	ethanol	drug	228-234	false
levodopa	drug	218-225	cyclosporine	drug	237-248	false
ethanol	drug	228-234	cyclosporine	drug	237-248	false

DDI-DrugBank.d652.s6	Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.
metoclopramide	drug	22-35	insulin	drug	124-130	advise

DDI-DrugBank.d630.s1	Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.
aspirin	brand	52-58	methazolamide	drug	64-76	advise
aspirin	brand	52-58	aspirin	brand	195-201	false
aspirin	brand	52-58	carbonic anhydrase inhibitors	group	207-235	false
methazolamide	drug	64-76	aspirin	brand	195-201	false
methazolamide	drug	64-76	carbonic anhydrase inhibitors	group	207-235	false
aspirin	brand	195-201	carbonic anhydrase inhibitors	group	207-235	effect

DDI-DrugBank.d727.s0	Zidovudine competitively inhibits the intracellular phosphorylation of stavudine.
Zidovudine	drug	0-9	stavudine	drug	71-79	effect

DDI-DrugBank.d727.s1	Therefore, use of zidovudine in combination with ZERIT should be avoided.
zidovudine	drug	18-27	ZERIT	brand	49-53	advise

DDI-DrugBank.d727.s2	In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin.
stavudine	drug	51-59	doxorubicin	drug	109-119	effect
stavudine	drug	51-59	ribavirin	drug	125-133	effect
doxorubicin	drug	109-119	ribavirin	drug	125-133	false

DDI-DrugBank.d771.s1	Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol.
Scopolamine	drug	0-10	sedatives	group	116-124	advise
Scopolamine	drug	0-10	tranquilizers	group	127-139	advise
Scopolamine	drug	0-10	alcohol	drug	145-151	advise
sedatives	group	116-124	tranquilizers	group	127-139	false
sedatives	group	116-124	alcohol	drug	145-151	false
tranquilizers	group	127-139	alcohol	drug	145-151	false

DDI-DrugBank.d771.s3	e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.
belladonna alkaloids	group	12-31	antihistamines	group	34-47	false
belladonna alkaloids	group	12-31	meclizine	drug	60-68	false
belladonna alkaloids	group	12-31	tricyclic antidepressants	group	72-96	false
belladonna alkaloids	group	12-31	muscle relaxants	group	103-118	false
antihistamines	group	34-47	meclizine	drug	60-68	false
antihistamines	group	34-47	tricyclic antidepressants	group	72-96	false
antihistamines	group	34-47	muscle relaxants	group	103-118	false
meclizine	drug	60-68	tricyclic antidepressants	group	72-96	false
meclizine	drug	60-68	muscle relaxants	group	103-118	false
tricyclic antidepressants	group	72-96	muscle relaxants	group	103-118	false

DDI-DrugBank.d613.s0	A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine.
vigabatrin	drug	37-46	carbamazepine	drug	115-127	mechanism

DDI-DrugBank.d613.s1	In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.
vigabatrin	drug	87-96	phenytoin	drug	103-111	mechanism
vigabatrin	drug	87-96	phenytoin	drug	131-139	false
phenytoin	drug	103-111	phenytoin	drug	131-139	false

DDI-DrugBank.d631.s0	Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics.
Pyrimethamine	drug	0-12	sulfonamides	group	31-42	false
Pyrimethamine	drug	0-12	quinine	drug	45-51	false
Pyrimethamine	drug	0-12	antimalarials	group	63-75	false
Pyrimethamine	drug	0-12	antibiotics	group	93-103	false
sulfonamides	group	31-42	quinine	drug	45-51	false
sulfonamides	group	31-42	antimalarials	group	63-75	false
sulfonamides	group	31-42	antibiotics	group	93-103	false
quinine	drug	45-51	antimalarials	group	63-75	false
quinine	drug	45-51	antibiotics	group	93-103	false
antimalarials	group	63-75	antibiotics	group	93-103	false

DDI-DrugBank.d631.s2	Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored.
Folinic acid	drug	0-11	leucovorin	drug	14-23	false

DDI-DrugBank.d631.s3	Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.
lorazepam	drug	60-68	pyrimethamine	drug	74-86	effect

DDI-DrugBank.d693.s0	Reduced absorption of folic acid and digoxin have been reported when those agents were administered concomitantly with sulfasalazine.
folic acid	drug	22-31	digoxin	drug	37-43	false
folic acid	drug	22-31	sulfasalazine	drug	119-131	mechanism
digoxin	drug	37-43	sulfasalazine	drug	119-131	mechanism

DDI-DrugBank.d693.s1	When daily doses of sulfasalazine 2 g and weekly doses of methotrexate 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.
sulfasalazine	drug	20-32	methotrexate	drug	58-69	false

DDI-DrugBank.d693.s2	Daily doses of sulfasalazine 2 g (maximum 3 g) and weekly doses of methotrexate 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies.
sulfasalazine	drug	15-27	methotrexate	drug	67-78	false

DDI-DrugBank.d751.s0	AGGRASTAT has been studied on a background of aspirin and heparin.
AGGRASTAT	brand	0-8	aspirin	brand	46-52	false
AGGRASTAT	brand	0-8	heparin	drug	58-64	false
aspirin	brand	46-52	heparin	drug	58-64	false

DDI-DrugBank.d751.s1	The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see
AGGRASTAT	brand	11-19	heparin	drug	42-48	effect
AGGRASTAT	brand	11-19	aspirin	brand	54-60	effect
AGGRASTAT	brand	11-19	heparin	drug	124-130	false
AGGRASTAT	brand	11-19	aspirin	drug	136-142	false
heparin	drug	42-48	aspirin	brand	54-60	false
heparin	drug	42-48	heparin	drug	124-130	false
heparin	drug	42-48	aspirin	drug	136-142	false
aspirin	brand	54-60	heparin	drug	124-130	false
aspirin	brand	54-60	aspirin	drug	136-142	false
heparin	drug	124-130	aspirin	drug	136-142	false

DDI-DrugBank.d756.s0	Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids.
opioids	group	38-44	levomepromazine	drug	95-109	effect
opioids	group	38-44	opioids	group	165-171	false
levomepromazine	drug	95-109	opioids	group	165-171	effect

DDI-DrugBank.d756.s1	Combination with tramadol (Ultram) is associated with increased risk of seizures.
tramadol	drug	17-24	Ultram	brand	27-32	false

DDI-DrugBank.d756.s2	Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates.
levomepromazine	drug	63-77	benzodiazepines	group	93-107	effect
levomepromazine	drug	63-77	barbiturates	group	112-123	effect
benzodiazepines	group	93-107	barbiturates	group	112-123	false

DDI-DrugBank.d756.s4	Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.
levomepromazine	drug	38-52	anticholinergic drugs	group	65-85	advise
levomepromazine	drug	38-52	tricyclic antidepressants	group	88-112	advise
levomepromazine	drug	38-52	antiparkinsonian-agents	group	118-140	advise
anticholinergic drugs	group	65-85	tricyclic antidepressants	group	88-112	false
anticholinergic drugs	group	65-85	antiparkinsonian-agents	group	118-140	false
tricyclic antidepressants	group	88-112	antiparkinsonian-agents	group	118-140	false

DDI-DrugBank.d756.s7	Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine.
Caffeine	drug	0-7	ephedrine	drug	35-43	false
Caffeine	drug	0-7	amphetamine	drug	45-55	false
Caffeine	drug	0-7	levomepromazine	drug	101-115	effect
ephedrine	drug	35-43	amphetamine	drug	45-55	false
ephedrine	drug	35-43	levomepromazine	drug	101-115	effect
amphetamine	drug	45-55	levomepromazine	drug	101-115	effect

DDI-DrugBank.d766.s0	Since trimetrexate is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter trimetrexate plasma concentrations.
trimetrexate	drug	6-17	trimetrexate	drug	184-195	false

DDI-DrugBank.d766.s1	Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and fluconazole.
trimetrexate	drug	41-52	erythromycin	drug	133-144	effect
trimetrexate	drug	41-52	rifampin	drug	147-154	effect
trimetrexate	drug	41-52	rifabutin	drug	157-165	effect
trimetrexate	drug	41-52	ketoconazole	drug	168-179	effect
trimetrexate	drug	41-52	fluconazole	drug	186-196	effect
erythromycin	drug	133-144	rifampin	drug	147-154	false
erythromycin	drug	133-144	rifabutin	drug	157-165	false
erythromycin	drug	133-144	ketoconazole	drug	168-179	false
erythromycin	drug	133-144	fluconazole	drug	186-196	false
rifampin	drug	147-154	rifabutin	drug	157-165	false
rifampin	drug	147-154	ketoconazole	drug	168-179	false
rifampin	drug	147-154	fluconazole	drug	186-196	false
rifabutin	drug	157-165	ketoconazole	drug	168-179	false
rifabutin	drug	157-165	fluconazole	drug	186-196	false
ketoconazole	drug	168-179	fluconazole	drug	186-196	false

DDI-DrugBank.d766.s2	In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in trimetrexate metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.
cimetidine	drug	56-65	trimetrexate	drug	101-112	mechanism
cimetidine	drug	56-65	acetaminophen	drug	134-146	false
trimetrexate	drug	101-112	acetaminophen	drug	134-146	false

DDI-DrugBank.d766.s3	Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.
imidazole drugs	group	59-73	clotrimazole	drug	76-87	false
imidazole drugs	group	59-73	ketoconazole	drug	90-101	false
imidazole drugs	group	59-73	miconazole	drug	104-113	false
imidazole drugs	group	59-73	trimetrexate	drug	159-170	mechanism
clotrimazole	drug	76-87	ketoconazole	drug	90-101	false
clotrimazole	drug	76-87	miconazole	drug	104-113	false
clotrimazole	drug	76-87	trimetrexate	drug	159-170	mechanism
ketoconazole	drug	90-101	miconazole	drug	104-113	false
ketoconazole	drug	90-101	trimetrexate	drug	159-170	mechanism
miconazole	drug	104-113	trimetrexate	drug	159-170	mechanism

DDI-DrugBank.d750.s0	Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.
alcohol	drug	19-25	phentermine hydrochloride	drug	32-56	int

DDI-DrugBank.d579.s0	Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.
antibiotics	group	19-29	sulfonamides	group	35-46	false
antibiotics	group	19-29	ganglion blockers	group	85-101	advise
sulfonamides	group	35-46	ganglion blockers	group	85-101	advise

DDI-DrugBank.d579.s1	The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.
Mecamylamine	drug	14-25	antihypertensive drugs	group	67-88	effect
Mecamylamine	drug	14-25	alcohol	drug	94-100	effect
antihypertensive drugs	group	67-88	alcohol	drug	94-100	false

DDI-DrugBank.d578.s1	Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone;
cyclosporin	drug	62-72	methylprednisolone	drug	78-95	mechanism

DDI-DrugBank.d578.s3	convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.
methylprednisolone	drug	54-71	cyclosporin	drug	77-87	effect

DDI-DrugBank.d578.s4	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.
phenobarbital	drug	42-54	phenytoin	drug	57-65	false
phenobarbital	drug	42-54	rifampin	drug	72-79	false
phenobarbital	drug	42-54	methylprednisolone	drug	111-128	mechanism
phenobarbital	drug	42-54	methylprednisolone	drug	159-176	advise
phenytoin	drug	57-65	rifampin	drug	72-79	false
phenytoin	drug	57-65	methylprednisolone	drug	111-128	mechanism
phenytoin	drug	57-65	methylprednisolone	drug	159-176	advise
rifampin	drug	72-79	methylprednisolone	drug	111-128	mechanism
rifampin	drug	72-79	methylprednisolone	drug	159-176	advise
methylprednisolone	drug	111-128	methylprednisolone	drug	159-176	false

DDI-DrugBank.d578.s5	Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance.
troleandomycin	drug	14-27	ketoconazole	drug	33-44	false
troleandomycin	drug	14-27	methylprednisolone	drug	76-93	mechanism
ketoconazole	drug	33-44	methylprednisolone	drug	76-93	mechanism

DDI-DrugBank.d578.s7	Methylprednisolone may increase the clearance of chronic high dose aspirin.
Methylprednisolone	drug	0-17	aspirin	brand	67-73	mechanism

DDI-DrugBank.d578.s8	This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn.
salicylate	group	29-38	salicylate	group	77-86	false
salicylate	group	29-38	methylprednisolone	drug	102-119	false
salicylate	group	77-86	methylprednisolone	drug	102-119	effect

DDI-DrugBank.d578.s9	Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia.
Aspirin	brand	0-6	corticosteroids	group	54-68	advise

DDI-DrugBank.d578.s10	The effect of methylprednisolone on oral anticoagulants is variable.
methylprednisolone	drug	14-31	anticoagulants	group	41-54	false

DDI-DrugBank.d578.s11	There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids.
anticoagulant	group	63-75	corticosteroids	group	106-120	effect

DDI-DrugBank.d641.s2	Concomitant administration of substances that are also tubularly secreted (e.g., probenecid) could potentially result in delayed clearance of ALIMTA.
probenecid	drug	81-90	ALIMTA	brand	142-147	mechanism

DDI-DrugBank.d641.s3	Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).
ibuprofen	drug	9-17	ALIMTA	brand	57-62	false
ibuprofen	drug	9-17	ibuprofen	drug	182-190	false
ibuprofen	drug	9-17	ALIMTA	brand	210-215	false
ALIMTA	brand	57-62	ibuprofen	drug	182-190	false
ALIMTA	brand	57-62	ALIMTA	brand	210-215	false
ibuprofen	drug	182-190	ALIMTA	brand	210-215	advise

DDI-DrugBank.d641.s4	Patients with mild to moderate renal insufficiency should avoid taking NSAIDs with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of ALIMTA.
NSAIDs	group	71-76	ALIMTA	brand	194-199	advise

DDI-DrugBank.d641.s5	In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.
ALIMTA	brand	63-68	NSAIDs	group	74-79	false
ALIMTA	brand	63-68	NSAIDs	group	131-136	false
ALIMTA	brand	63-68	ALIMTA	brand	223-228	false
NSAIDs	group	74-79	NSAIDs	group	131-136	false
NSAIDs	group	74-79	ALIMTA	brand	223-228	false
NSAIDs	group	131-136	ALIMTA	brand	223-228	advise

DDI-DrugBank.d590.s0	Coadministration of TRITEC with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).
TRITEC	brand	20-25	clarithromycin	drug	32-45	mechanism
TRITEC	brand	20-25	ranitidine	drug	76-85	false
TRITEC	brand	20-25	14- hydroxy- clarithromycin	drug_n	177-203	false
clarithromycin	drug	32-45	ranitidine	drug	76-85	false
clarithromycin	drug	32-45	14- hydroxy- clarithromycin	drug_n	177-203	false
ranitidine	drug	76-85	14- hydroxy- clarithromycin	drug_n	177-203	false

DDI-DrugBank.d590.s1	Coadministration with aspirin results in a slight decrease in the rate of salicylate absorption that is clinically unimportant.
aspirin	brand	22-28	salicylate	group	74-83	false

DDI-DrugBank.d590.s2	Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from TRITEC.
antacid	group	37-43	ranitidine	drug	109-118	mechanism
antacid	group	37-43	TRITEC	brand	175-180	mechanism
ranitidine	drug	109-118	TRITEC	brand	175-180	false

DDI-DrugBank.d590.s4	For information on drug interactions associated with ranitidine, refer to the ZANTAC     package insert.
ranitidine	drug	53-62	ZANTAC	brand	78-83	false

DDI-DrugBank.d642.s0	Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.
tigecycline	drug	79-89	warfarin	drug	112-119	advise

DDI-DrugBank.d642.s1	Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.
antibacterial drugs	group	18-36	contraceptives	group	48-61	effect
antibacterial drugs	group	18-36	contraceptives	group	79-92	false
contraceptives	group	48-61	contraceptives	group	79-92	false

DDI-DrugBank.d774.s0	Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).
Trilostane	drug	0-9	aminoglutethimide	drug	29-45	int
Trilostane	drug	0-9	mitotane	drug	50-57	int
aminoglutethimide	drug	29-45	mitotane	drug	50-57	false

DDI-DrugBank.d602.s0	Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan).
NEXAVAR	brand	42-48	irinotecan	drug	139-148	advise

DDI-DrugBank.d602.s1	Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin.
NEXAVAR	brand	27-33	doxorubicin	drug	76-86	mechanism

DDI-DrugBank.d602.s2	Caution is recommended when administering doxorubicin with NEXAVAR.
doxorubicin	drug	42-52	NEXAVAR	brand	59-65	advise

DDI-DrugBank.d715.s0	Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.
DEMSER	brand	44-49	phenothiazines	group	73-86	advise
DEMSER	brand	44-49	haloperidol	drug	91-101	advise
phenothiazines	group	73-86	haloperidol	drug	91-101	false

DDI-DrugBank.d715.s1	Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.
DEMSER	brand	18-23	alcohol	drug	30-36	effect
DEMSER	brand	18-23	CNS depressants	drug	47-61	effect
alcohol	drug	30-36	CNS depressants	drug	47-61	false

DDI-DrugBank.d611.s0	Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects.
beta adrenergic aerosol bronchodilators	group	6-44	Alupent	brand	84-90	advise
beta adrenergic aerosol bronchodilators	group	6-44	metaproterenol sulfate	drug	96-117	advise
Alupent	brand	84-90	metaproterenol sulfate	drug	96-117	false

DDI-DrugBank.d611.s1	Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.
Beta adrenergic agonists	group	0-23	monoamine oxidase inhibitors	group	92-119	advise
Beta adrenergic agonists	group	0-23	tricyclic antidepressants	group	124-148	advise
Beta adrenergic agonists	group	0-23	beta adrenergic agonists	group	171-194	false
monoamine oxidase inhibitors	group	92-119	tricyclic antidepressants	group	124-148	false
monoamine oxidase inhibitors	group	92-119	beta adrenergic agonists	group	171-194	false
tricyclic antidepressants	group	124-148	beta adrenergic agonists	group	171-194	false

DDI-DrugBank.d629.s0	Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time.
metronidazole	drug	5-17	coumarin	group	79-86	effect
metronidazole	drug	5-17	warfarin	drug	92-99	effect
coumarin	group	79-86	warfarin	drug	92-99	false

DDI-DrugBank.d629.s1	Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.
METROGEL	brand	46-53	metronidazole	drug	56-68	false
METROGEL	brand	46-53	metronidazole	drug	201-213	false
metronidazole	drug	56-68	metronidazole	drug	201-213	false

DDI-DrugBank.d670.s0	Potential for INVEGA    to Affect Other Drugs Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.
INVEGA	brand	14-19	Paliperidone	drug	46-57	false

DDI-DrugBank.d670.s6	Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol.
paliperidone	drug	33-44	INVEGA	brand	47-52	false
paliperidone	drug	33-44	centrally acting drugs	group	111-132	advise
paliperidone	drug	33-44	alcohol	drug	138-144	advise
INVEGA	brand	47-52	centrally acting drugs	group	111-132	advise
INVEGA	brand	47-52	alcohol	drug	138-144	advise
centrally acting drugs	group	111-132	alcohol	drug	138-144	false

DDI-DrugBank.d670.s7	Paliperidone may antagonize the effect of levodopa and other dopamine agonists.
Paliperidone	drug	0-11	levodopa	drug	42-49	effect
Paliperidone	drug	0-11	dopamine agonists	group	61-77	effect
levodopa	drug	42-49	dopamine agonists	group	61-77	false

DDI-DrugBank.d670.s9	Potential for Other Drugs to Affect INVEGA    Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.
INVEGA	brand	36-41	Paliperidone	drug	46-57	false

DDI-DrugBank.d622.s0	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.
atropine	drug	5-12	pralidoxime	drug	18-28	effect
atropine	drug	5-12	atropine	drug	189-196	false
pralidoxime	drug	18-28	atropine	drug	189-196	false

DDI-DrugBank.d622.s1	This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed.
atropine	drug	45-52	pralidoxime	drug	95-105	false

DDI-DrugBank.d622.s2	2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;
pralidoxime	drug	154-164	barbiturates	group	173-184	false
pralidoxime	drug	154-164	anticholinesterases	group	209-227	false
barbiturates	group	173-184	anticholinesterases	group	209-227	effect

DDI-DrugBank.d622.s3	morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.
morphine	drug	0-7	theophylline	drug	10-21	false
morphine	drug	0-7	aminophylline	drug	24-36	false
morphine	drug	0-7	succinylcholine	drug	39-53	false
morphine	drug	0-7	reserpine	drug	56-64	false
morphine	drug	0-7	phenothiazine-type tranquilizers	group	71-102	false
theophylline	drug	10-21	aminophylline	drug	24-36	false
theophylline	drug	10-21	succinylcholine	drug	39-53	false
theophylline	drug	10-21	reserpine	drug	56-64	false
theophylline	drug	10-21	phenothiazine-type tranquilizers	group	71-102	false
aminophylline	drug	24-36	succinylcholine	drug	39-53	false
aminophylline	drug	24-36	reserpine	drug	56-64	false
aminophylline	drug	24-36	phenothiazine-type tranquilizers	group	71-102	false
succinylcholine	drug	39-53	reserpine	drug	56-64	false
succinylcholine	drug	39-53	phenothiazine-type tranquilizers	group	71-102	false
reserpine	drug	56-64	phenothiazine-type tranquilizers	group	71-102	false

DDI-DrugBank.d720.s1	Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.
ergotamine	drug	80-89	ergot-type medications	group	105-126	false
ergotamine	drug	80-89	dihydroergotamine	drug	134-150	false
ergotamine	drug	80-89	methysergide	drug	155-166	false
ergotamine	drug	80-89	sumatriptan	drug	173-183	advise
ergot-type medications	group	105-126	dihydroergotamine	drug	134-150	false
ergot-type medications	group	105-126	methysergide	drug	155-166	false
ergot-type medications	group	105-126	sumatriptan	drug	173-183	advise
dihydroergotamine	drug	134-150	methysergide	drug	155-166	false
dihydroergotamine	drug	134-150	sumatriptan	drug	173-183	advise
methysergide	drug	155-166	sumatriptan	drug	173-183	advise

DDI-DrugBank.d720.s2	MAO-A inhibitors reduce sumatriptan clearance, significantly increasing systemic exposure.
MAO-A inhibitors	group	0-15	sumatriptan	drug	24-34	mechanism

DDI-DrugBank.d720.s3	Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.
sumatriptan succinate	drug	22-42	MAO-A inhibitors	group	74-89	advise
sumatriptan succinate	drug	22-42	Selective serotonin reuptake inhibitors	group	112-150	false
sumatriptan succinate	drug	22-42	SSRIs	group	153-157	false
sumatriptan succinate	drug	22-42	fluoxetine	drug	167-176	false
sumatriptan succinate	drug	22-42	fluvoxamine	drug	179-189	false
sumatriptan succinate	drug	22-42	paroxetine	drug	192-201	false
sumatriptan succinate	drug	22-42	sertraline	drug	204-213	false
sumatriptan succinate	drug	22-42	sumatriptan	drug	322-332	false
MAO-A inhibitors	group	74-89	Selective serotonin reuptake inhibitors	group	112-150	false
MAO-A inhibitors	group	74-89	SSRIs	group	153-157	false
MAO-A inhibitors	group	74-89	fluoxetine	drug	167-176	false
MAO-A inhibitors	group	74-89	fluvoxamine	drug	179-189	false
MAO-A inhibitors	group	74-89	paroxetine	drug	192-201	false
MAO-A inhibitors	group	74-89	sertraline	drug	204-213	false
MAO-A inhibitors	group	74-89	sumatriptan	drug	322-332	false
Selective serotonin reuptake inhibitors	group	112-150	SSRIs	group	153-157	false
Selective serotonin reuptake inhibitors	group	112-150	fluoxetine	drug	167-176	false
Selective serotonin reuptake inhibitors	group	112-150	fluvoxamine	drug	179-189	false
Selective serotonin reuptake inhibitors	group	112-150	paroxetine	drug	192-201	false
Selective serotonin reuptake inhibitors	group	112-150	sertraline	drug	204-213	false
Selective serotonin reuptake inhibitors	group	112-150	sumatriptan	drug	322-332	effect
SSRIs	group	153-157	fluoxetine	drug	167-176	false
SSRIs	group	153-157	fluvoxamine	drug	179-189	false
SSRIs	group	153-157	paroxetine	drug	192-201	false
SSRIs	group	153-157	sertraline	drug	204-213	false
SSRIs	group	153-157	sumatriptan	drug	322-332	effect
fluoxetine	drug	167-176	fluvoxamine	drug	179-189	false
fluoxetine	drug	167-176	paroxetine	drug	192-201	false
fluoxetine	drug	167-176	sertraline	drug	204-213	false
fluoxetine	drug	167-176	sumatriptan	drug	322-332	effect
fluvoxamine	drug	179-189	paroxetine	drug	192-201	false
fluvoxamine	drug	179-189	sertraline	drug	204-213	false
fluvoxamine	drug	179-189	sumatriptan	drug	322-332	effect
paroxetine	drug	192-201	sertraline	drug	204-213	false
paroxetine	drug	192-201	sumatriptan	drug	322-332	effect
sertraline	drug	204-213	sumatriptan	drug	322-332	effect

DDI-DrugBank.d720.s4	If concomitant treatment with sumatriptan and an SSRI is clinically warranted, appropriate observation of the patient is advised.
sumatriptan	drug	30-40	SSRI	group	49-52	advise

DDI-DrugBank.d773.s1	Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin.
TNKase	brand	39-44	heparin	drug	74-80	false
TNKase	brand	39-44	aspirin	brand	86-92	false
heparin	drug	74-80	aspirin	brand	86-92	false

DDI-DrugBank.d773.s2	Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.
Anticoagulants	group	0-13	heparin	drug	24-30	false
Anticoagulants	group	0-13	vitamin K antagonists	group	36-56	false
Anticoagulants	group	0-13	acetylsalicylic acid	drug	107-126	false
Anticoagulants	group	0-13	dipyridamole	drug	129-140	false
Anticoagulants	group	0-13	TNKase	brand	248-253	effect
heparin	drug	24-30	vitamin K antagonists	group	36-56	false
heparin	drug	24-30	acetylsalicylic acid	drug	107-126	false
heparin	drug	24-30	dipyridamole	drug	129-140	false
heparin	drug	24-30	TNKase	brand	248-253	effect
vitamin K antagonists	group	36-56	acetylsalicylic acid	drug	107-126	false
vitamin K antagonists	group	36-56	dipyridamole	drug	129-140	false
vitamin K antagonists	group	36-56	TNKase	brand	248-253	effect
acetylsalicylic acid	drug	107-126	dipyridamole	drug	129-140	false
acetylsalicylic acid	drug	107-126	TNKase	brand	248-253	effect
dipyridamole	drug	129-140	TNKase	brand	248-253	effect

DDI-DrugBank.d584.s0	Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants.
Anticoagulants	group	0-13	Anabolic steroids	group	15-31	false
Anticoagulants	group	0-13	anticoagulants	group	66-79	false
Anabolic steroids	group	15-31	anticoagulants	group	66-79	effect

DDI-DrugBank.d584.s3	Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.
Warfarin	drug	0-7	oxandrolone	drug	31-41	false
Warfarin	drug	0-7	warfarin	drug	117-124	false
Warfarin	drug	0-7	S-warfarin	drug	158-167	false
Warfarin	drug	0-7	R-warfarin	drug	257-266	false
oxandrolone	drug	31-41	warfarin	drug	117-124	mechanism
oxandrolone	drug	31-41	S-warfarin	drug	158-167	false
oxandrolone	drug	31-41	R-warfarin	drug	257-266	false
warfarin	drug	117-124	S-warfarin	drug	158-167	false
warfarin	drug	117-124	R-warfarin	drug	257-266	false
S-warfarin	drug	158-167	R-warfarin	drug	257-266	false

DDI-DrugBank.d584.s5	A 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of warfarin dose), was necessary to maintain a target INR of 1.5.
warfarin	drug	32-39	warfarin	drug	113-120	false

DDI-DrugBank.d584.s6	When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.
oxandrolone	drug	5-15	warfarin	drug	84-91	advise
oxandrolone	drug	5-15	warfarin	drug	171-178	false
warfarin	drug	84-91	warfarin	drug	171-178	false

DDI-DrugBank.d584.s7	Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued.
warfarin	drug	106-113	oxandrolone	drug	160-170	advise

DDI-DrugBank.d584.s9	Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents.
hypoglycemic agents	group	5-23	Oxandrolone	drug	25-35	false
hypoglycemic agents	group	5-23	hypoglycemic agents	group	72-90	false
Oxandrolone	drug	25-35	hypoglycemic agents	group	72-90	mechanism

DDI-DrugBank.d584.s10	Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.
Adrenal steroids	group	0-15	ACTH	drug	20-23	false
Adrenal steroids	group	0-15	adrenal cortical steroids	group	81-105	false
Adrenal steroids	group	0-15	ACTH	drug	110-113	false
ACTH	drug	20-23	adrenal cortical steroids	group	81-105	false
ACTH	drug	20-23	ACTH	drug	110-113	false
adrenal cortical steroids	group	81-105	ACTH	drug	110-113	false

DDI-DrugBank.d573.s0	Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.
Guanethidine	drug	17-28	minoxidil	drug	40-48	false
Guanethidine	drug	17-28	guanethidine	drug	146-157	false
minoxidil	drug	40-48	guanethidine	drug	146-157	effect

DDI-DrugBank.d573.s1	If at all possible guanethidine should be discontinued well before minoxidil is begun.
guanethidine	drug	19-30	minoxidil	drug	67-75	advise

DDI-DrugBank.d595.s1	norepinephrine and dobutamine are incompatible with sodium bicarbonate solution.
norepinephrine	drug	0-13	dobutamine	drug	19-28	false
norepinephrine	drug	0-13	sodium bicarbonate	drug	52-69	int
dobutamine	drug	19-28	sodium bicarbonate	drug	52-69	int

DDI-DrugBank.d595.s2	The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established.
sodium bicarbonate	drug	16-33	calcium	drug	70-76	false

DDI-DrugBank.d682.s0	Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics.
Sulfoxone	drug	0-8	barbiturates	group	38-49	effect
Sulfoxone	drug	0-8	tolbutamide	drug	52-62	effect
Sulfoxone	drug	0-8	uricosurics	group	69-79	effect
barbiturates	group	38-49	tolbutamide	drug	52-62	false
barbiturates	group	38-49	uricosurics	group	69-79	false
tolbutamide	drug	52-62	uricosurics	group	69-79	false

DDI-DrugBank.d682.s1	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
thiazides	group	26-34	cyclosporine	drug	66-77	false
thiazides	group	26-34	sulfonylurea agents	group	107-125	false
thiazides	group	26-34	warfarin	drug	162-169	false
thiazides	group	26-34	methotrexate	drug	205-216	false
thiazides	group	26-34	methotrexate	drug	248-259	false
thiazides	group	26-34	phenytoin	drug	263-271	false
thiazides	group	26-34	phenytoin	drug	305-313	false
cyclosporine	drug	66-77	sulfonylurea agents	group	107-125	false
cyclosporine	drug	66-77	warfarin	drug	162-169	false
cyclosporine	drug	66-77	methotrexate	drug	205-216	false
cyclosporine	drug	66-77	methotrexate	drug	248-259	false
cyclosporine	drug	66-77	phenytoin	drug	263-271	false
cyclosporine	drug	66-77	phenytoin	drug	305-313	false
sulfonylurea agents	group	107-125	warfarin	drug	162-169	false
sulfonylurea agents	group	107-125	methotrexate	drug	205-216	false
sulfonylurea agents	group	107-125	methotrexate	drug	248-259	false
sulfonylurea agents	group	107-125	phenytoin	drug	263-271	false
sulfonylurea agents	group	107-125	phenytoin	drug	305-313	false
warfarin	drug	162-169	methotrexate	drug	205-216	false
warfarin	drug	162-169	methotrexate	drug	248-259	false
warfarin	drug	162-169	phenytoin	drug	263-271	false
warfarin	drug	162-169	phenytoin	drug	305-313	false
methotrexate	drug	205-216	methotrexate	drug	248-259	false
methotrexate	drug	205-216	phenytoin	drug	263-271	false
methotrexate	drug	205-216	phenytoin	drug	305-313	false
methotrexate	drug	248-259	phenytoin	drug	263-271	false
methotrexate	drug	248-259	phenytoin	drug	305-313	false
phenytoin	drug	263-271	phenytoin	drug	305-313	false

DDI-DrugBank.d605.s0	SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.
SKELAXIN	brand	0-7	alcohol	drug	36-42	effect
SKELAXIN	brand	0-7	barbiturates	group	45-56	effect
SKELAXIN	brand	0-7	CNS depressants	group	68-82	effect
alcohol	drug	36-42	barbiturates	group	45-56	false
alcohol	drug	36-42	CNS depressants	group	68-82	false
barbiturates	group	45-56	CNS depressants	group	68-82	false

DDI-DrugBank.d694.s0	Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days.
Digoxin	drug	0-6	digoxin	drug	124-130	false
Digoxin	drug	0-6	sitagliptin	drug	169-179	false
digoxin	drug	124-130	sitagliptin	drug	169-179	mechanism

DDI-DrugBank.d694.s2	No dosage adjustment of digoxin or JANUVIA is recommended.
digoxin	drug	24-30	JANUVIA	brand	35-41	false

DDI-DrugBank.d675.s0	CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
Macrolide Antibiotics	group	25-45	Protease Inhibitors	group	51-69	false
Macrolide Antibiotics	group	25-45	ergot alkaloid drugs	group	178-197	false
Macrolide Antibiotics	group	25-45	dihydroergotamine	drug	205-221	false
Macrolide Antibiotics	group	25-45	ergotamine	drug	227-236	false
Protease Inhibitors	group	51-69	ergot alkaloid drugs	group	178-197	false
Protease Inhibitors	group	51-69	dihydroergotamine	drug	205-221	false
Protease Inhibitors	group	51-69	ergotamine	drug	227-236	false
ergot alkaloid drugs	group	178-197	dihydroergotamine	drug	205-221	false
ergot alkaloid drugs	group	178-197	ergotamine	drug	227-236	false
dihydroergotamine	drug	205-221	ergotamine	drug	227-236	false

DDI-DrugBank.d675.s2	Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).
macrolide antibiotics	group	63-83	erythromycin	drug	92-103	false
macrolide antibiotics	group	63-83	troleandomycin	drug	106-119	false
macrolide antibiotics	group	63-83	clarithromycin	drug	122-135	false
macrolide antibiotics	group	63-83	HIV protease inhibitors	group	139-150;177-186	false
macrolide antibiotics	group	63-83	reverse transcriptase inhibitors	group	155-186	false
macrolide antibiotics	group	63-83	ritonavir	drug	195-203	false
macrolide antibiotics	group	63-83	indinavir	drug	206-214	false
macrolide antibiotics	group	63-83	nelfinavir	drug	217-226	false
macrolide antibiotics	group	63-83	delavirdine	drug	229-239	false
macrolide antibiotics	group	63-83	azole antifungals	group	245-261	false
macrolide antibiotics	group	63-83	ketoconazole	drug	270-281	false
macrolide antibiotics	group	63-83	itraconazole	drug	284-295	false
macrolide antibiotics	group	63-83	voriconazole	drug	298-309	false
erythromycin	drug	92-103	troleandomycin	drug	106-119	false
erythromycin	drug	92-103	clarithromycin	drug	122-135	false
erythromycin	drug	92-103	HIV protease inhibitors	group	139-150;177-186	false
erythromycin	drug	92-103	reverse transcriptase inhibitors	group	155-186	false
erythromycin	drug	92-103	ritonavir	drug	195-203	false
erythromycin	drug	92-103	indinavir	drug	206-214	false
erythromycin	drug	92-103	nelfinavir	drug	217-226	false
erythromycin	drug	92-103	delavirdine	drug	229-239	false
erythromycin	drug	92-103	azole antifungals	group	245-261	false
erythromycin	drug	92-103	ketoconazole	drug	270-281	false
erythromycin	drug	92-103	itraconazole	drug	284-295	false
erythromycin	drug	92-103	voriconazole	drug	298-309	false
troleandomycin	drug	106-119	clarithromycin	drug	122-135	false
troleandomycin	drug	106-119	HIV protease inhibitors	group	139-150;177-186	false
troleandomycin	drug	106-119	reverse transcriptase inhibitors	group	155-186	false
troleandomycin	drug	106-119	ritonavir	drug	195-203	false
troleandomycin	drug	106-119	indinavir	drug	206-214	false
troleandomycin	drug	106-119	nelfinavir	drug	217-226	false
troleandomycin	drug	106-119	delavirdine	drug	229-239	false
troleandomycin	drug	106-119	azole antifungals	group	245-261	false
troleandomycin	drug	106-119	ketoconazole	drug	270-281	false
troleandomycin	drug	106-119	itraconazole	drug	284-295	false
troleandomycin	drug	106-119	voriconazole	drug	298-309	false
clarithromycin	drug	122-135	HIV protease inhibitors	group	139-150;177-186	false
clarithromycin	drug	122-135	reverse transcriptase inhibitors	group	155-186	false
clarithromycin	drug	122-135	ritonavir	drug	195-203	false
clarithromycin	drug	122-135	indinavir	drug	206-214	false
clarithromycin	drug	122-135	nelfinavir	drug	217-226	false
clarithromycin	drug	122-135	delavirdine	drug	229-239	false
clarithromycin	drug	122-135	azole antifungals	group	245-261	false
clarithromycin	drug	122-135	ketoconazole	drug	270-281	false
clarithromycin	drug	122-135	itraconazole	drug	284-295	false
clarithromycin	drug	122-135	voriconazole	drug	298-309	false
HIV protease inhibitors	group	139-150;177-186	reverse transcriptase inhibitors	group	155-186	false
HIV protease inhibitors	group	139-150;177-186	ritonavir	drug	195-203	false
HIV protease inhibitors	group	139-150;177-186	indinavir	drug	206-214	false
HIV protease inhibitors	group	139-150;177-186	nelfinavir	drug	217-226	false
HIV protease inhibitors	group	139-150;177-186	delavirdine	drug	229-239	false
HIV protease inhibitors	group	139-150;177-186	azole antifungals	group	245-261	false
HIV protease inhibitors	group	139-150;177-186	ketoconazole	drug	270-281	false
HIV protease inhibitors	group	139-150;177-186	itraconazole	drug	284-295	false
HIV protease inhibitors	group	139-150;177-186	voriconazole	drug	298-309	false
reverse transcriptase inhibitors	group	155-186	ritonavir	drug	195-203	false
reverse transcriptase inhibitors	group	155-186	indinavir	drug	206-214	false
reverse transcriptase inhibitors	group	155-186	nelfinavir	drug	217-226	false
reverse transcriptase inhibitors	group	155-186	delavirdine	drug	229-239	false
reverse transcriptase inhibitors	group	155-186	azole antifungals	group	245-261	false
reverse transcriptase inhibitors	group	155-186	ketoconazole	drug	270-281	false
reverse transcriptase inhibitors	group	155-186	itraconazole	drug	284-295	false
reverse transcriptase inhibitors	group	155-186	voriconazole	drug	298-309	false
ritonavir	drug	195-203	indinavir	drug	206-214	false
ritonavir	drug	195-203	nelfinavir	drug	217-226	false
ritonavir	drug	195-203	delavirdine	drug	229-239	false
ritonavir	drug	195-203	azole antifungals	group	245-261	false
ritonavir	drug	195-203	ketoconazole	drug	270-281	false
ritonavir	drug	195-203	itraconazole	drug	284-295	false
ritonavir	drug	195-203	voriconazole	drug	298-309	false
indinavir	drug	206-214	nelfinavir	drug	217-226	false
indinavir	drug	206-214	delavirdine	drug	229-239	false
indinavir	drug	206-214	azole antifungals	group	245-261	false
indinavir	drug	206-214	ketoconazole	drug	270-281	false
indinavir	drug	206-214	itraconazole	drug	284-295	false
indinavir	drug	206-214	voriconazole	drug	298-309	false
nelfinavir	drug	217-226	delavirdine	drug	229-239	false
nelfinavir	drug	217-226	azole antifungals	group	245-261	false
nelfinavir	drug	217-226	ketoconazole	drug	270-281	false
nelfinavir	drug	217-226	itraconazole	drug	284-295	false
nelfinavir	drug	217-226	voriconazole	drug	298-309	false
delavirdine	drug	229-239	azole antifungals	group	245-261	false
delavirdine	drug	229-239	ketoconazole	drug	270-281	false
delavirdine	drug	229-239	itraconazole	drug	284-295	false
delavirdine	drug	229-239	voriconazole	drug	298-309	false
azole antifungals	group	245-261	ketoconazole	drug	270-281	false
azole antifungals	group	245-261	itraconazole	drug	284-295	false
azole antifungals	group	245-261	voriconazole	drug	298-309	false
ketoconazole	drug	270-281	itraconazole	drug	284-295	false
ketoconazole	drug	270-281	voriconazole	drug	298-309	false
itraconazole	drug	284-295	voriconazole	drug	298-309	false

DDI-DrugBank.d675.s4	Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.
saquinavir	drug	31-40	nefazodone	drug	43-52	false
saquinavir	drug	31-40	fluconazole	drug	55-65	false
saquinavir	drug	31-40	fluoxetine	drug	86-95	false
saquinavir	drug	31-40	fluvoxamine	drug	98-108	false
saquinavir	drug	31-40	zileuton	drug	111-118	false
saquinavir	drug	31-40	clotrimazole	drug	125-136	false
nefazodone	drug	43-52	fluconazole	drug	55-65	false
nefazodone	drug	43-52	fluoxetine	drug	86-95	false
nefazodone	drug	43-52	fluvoxamine	drug	98-108	false
nefazodone	drug	43-52	zileuton	drug	111-118	false
nefazodone	drug	43-52	clotrimazole	drug	125-136	false
fluconazole	drug	55-65	fluoxetine	drug	86-95	false
fluconazole	drug	55-65	fluvoxamine	drug	98-108	false
fluconazole	drug	55-65	zileuton	drug	111-118	false
fluconazole	drug	55-65	clotrimazole	drug	125-136	false
fluoxetine	drug	86-95	fluvoxamine	drug	98-108	false
fluoxetine	drug	86-95	zileuton	drug	111-118	false
fluoxetine	drug	86-95	clotrimazole	drug	125-136	false
fluvoxamine	drug	98-108	zileuton	drug	111-118	false
fluvoxamine	drug	98-108	clotrimazole	drug	125-136	false
zileuton	drug	111-118	clotrimazole	drug	125-136	false

DDI-DrugBank.d675.s7	Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.
Methergine	brand	33-42	methylergonovine maleate	drug	48-71	false
Methergine	brand	33-42	vasoconstrictors	group	106-121	advise
Methergine	brand	33-42	ergot alkaloids	group	126-140	advise
methylergonovine maleate	drug	48-71	vasoconstrictors	group	106-121	advise
methylergonovine maleate	drug	48-71	ergot alkaloids	group	126-140	false
vasoconstrictors	group	106-121	ergot alkaloids	group	126-140	false

DDI-DrugBank.d610.s0	Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine.
abacavir	drug	30-37	lamivudine	drug	82-91	false
abacavir	drug	30-37	zidovudine	drug	96-105	false
abacavir	drug	30-37	lamivudine	drug	129-138	false
abacavir	drug	30-37	zidovudine	drug	144-153	false
lamivudine	drug	82-91	zidovudine	drug	96-105	false
lamivudine	drug	82-91	lamivudine	drug	129-138	false
lamivudine	drug	82-91	zidovudine	drug	144-153	false
zidovudine	drug	96-105	lamivudine	drug	129-138	false
zidovudine	drug	96-105	zidovudine	drug	144-153	false
lamivudine	drug	129-138	zidovudine	drug	144-153	false

DDI-DrugBank.d610.s1	No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir.
lamivudine	drug	37-46	zidovudine	drug	51-60	false
lamivudine	drug	37-46	abacavir	drug	133-140	false
zidovudine	drug	51-60	abacavir	drug	133-140	false

DDI-DrugBank.d610.s2	Abacavir has no effect on the pharmacokinetic properties of ethanol.
Abacavir	drug	0-7	ethanol	drug	60-66	false

DDI-DrugBank.d610.s3	Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.
Ethanol	drug	0-6	abacavir	drug	37-44	mechanism
Ethanol	drug	0-6	methadone	drug	104-112	false
Ethanol	drug	0-6	abacavir	drug	188-195	false
abacavir	drug	37-44	methadone	drug	104-112	false
abacavir	drug	37-44	abacavir	drug	188-195	false
methadone	drug	104-112	abacavir	drug	188-195	false

DDI-DrugBank.d610.s4	In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).
methadone	drug	49-57	ZIAGEN	brand	118-123	mechanism
methadone	drug	49-57	methadone	drug	182-190	false
ZIAGEN	brand	118-123	methadone	drug	182-190	false

DDI-DrugBank.d757.s0	Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.
Alcohol	drug	11-17	alcohol	drug	80-86	false
Alcohol	drug	11-17	pentazocine	drug	156-166	false
alcohol	drug	80-86	pentazocine	drug	156-166	advise

DDI-DrugBank.d615.s0	Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.
Triprolidine	drug	0-11	central nervous system depressants	group	49-82	effect
Triprolidine	drug	0-11	alcohol	drug	94-100	effect
Triprolidine	drug	0-11	barbiturates	group	103-114	effect
Triprolidine	drug	0-11	hypnotics	group	117-125	effect
Triprolidine	drug	0-11	narcotic analgesics	group	128-146	effect
Triprolidine	drug	0-11	sedatives	group	149-157	effect
Triprolidine	drug	0-11	tranquillisers	group	164-177	effect
central nervous system depressants	group	49-82	alcohol	drug	94-100	false
central nervous system depressants	group	49-82	barbiturates	group	103-114	false
central nervous system depressants	group	49-82	hypnotics	group	117-125	false
central nervous system depressants	group	49-82	narcotic analgesics	group	128-146	false
central nervous system depressants	group	49-82	sedatives	group	149-157	false
central nervous system depressants	group	49-82	tranquillisers	group	164-177	false
alcohol	drug	94-100	barbiturates	group	103-114	false
alcohol	drug	94-100	hypnotics	group	117-125	false
alcohol	drug	94-100	narcotic analgesics	group	128-146	false
alcohol	drug	94-100	sedatives	group	149-157	false
alcohol	drug	94-100	tranquillisers	group	164-177	false
barbiturates	group	103-114	hypnotics	group	117-125	false
barbiturates	group	103-114	narcotic analgesics	group	128-146	false
barbiturates	group	103-114	sedatives	group	149-157	false
barbiturates	group	103-114	tranquillisers	group	164-177	false
hypnotics	group	117-125	narcotic analgesics	group	128-146	false
hypnotics	group	117-125	sedatives	group	149-157	false
hypnotics	group	117-125	tranquillisers	group	164-177	false
narcotic analgesics	group	128-146	sedatives	group	149-157	false
narcotic analgesics	group	128-146	tranquillisers	group	164-177	false
sedatives	group	149-157	tranquillisers	group	164-177	false

DDI-DrugBank.d615.s1	The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.
anticholinergic drugs	group	15-35	atropine	drug	46-53	false
anticholinergic drugs	group	15-35	tricyclic antidepressants	group	59-83	false
anticholinergic drugs	group	15-35	triprolidine	drug	138-149	effect
atropine	drug	46-53	tricyclic antidepressants	group	59-83	false
atropine	drug	46-53	triprolidine	drug	138-149	effect
tricyclic antidepressants	group	59-83	triprolidine	drug	138-149	effect

DDI-DrugBank.d596.s0	Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases.
Exelon	brand	33-38	rivastigmine tartrate	drug	44-64	false
Exelon	brand	33-38	Rivastigmine	drug	101-112	false
rivastigmine tartrate	drug	44-64	Rivastigmine	drug	101-112	false

DDI-DrugBank.d596.s3	No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers.
rivastigmine	drug	52-63	digoxin	drug	69-75	false
rivastigmine	drug	52-63	warfarin	drug	78-85	false
rivastigmine	drug	52-63	diazepam	drug	88-95	false
rivastigmine	drug	52-63	fluoxetine	drug	101-110	false
digoxin	drug	69-75	warfarin	drug	78-85	false
digoxin	drug	69-75	diazepam	drug	88-95	false
digoxin	drug	69-75	fluoxetine	drug	101-110	false
warfarin	drug	78-85	diazepam	drug	88-95	false
warfarin	drug	78-85	fluoxetine	drug	101-110	false
diazepam	drug	88-95	fluoxetine	drug	101-110	false

DDI-DrugBank.d596.s4	The elevation of prothrombin time induced by warfarin is not affected by administration of Exelon.
warfarin	drug	45-52	Exelon	brand	91-96	false

DDI-DrugBank.d596.s5	Effect of Other Drugs on the Metabolism of Exelon: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine.
Exelon	brand	43-48	rivastigmine	drug	142-153	false

DDI-DrugBank.d596.s6	Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine.
rivastigmine	drug	72-83	digoxin	drug	147-153	false
rivastigmine	drug	72-83	warfarin	drug	156-163	false
rivastigmine	drug	72-83	diazepam	drug	166-173	false
rivastigmine	drug	72-83	fluoxetine	drug	179-188	false
digoxin	drug	147-153	warfarin	drug	156-163	false
digoxin	drug	147-153	diazepam	drug	166-173	false
digoxin	drug	147-153	fluoxetine	drug	179-188	false
warfarin	drug	156-163	diazepam	drug	166-173	false
warfarin	drug	156-163	fluoxetine	drug	179-188	false
diazepam	drug	166-173	fluoxetine	drug	179-188	false

DDI-DrugBank.d596.s7	Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).
rivastigmine	drug	91-102	antacids	group	167-174	false
rivastigmine	drug	91-102	antihypertensives	group	184-200	false
rivastigmine	drug	91-102	calcium channel blockers	group	210-233	false
rivastigmine	drug	91-102	antidiabetics	group	243-255	false
rivastigmine	drug	91-102	nonsteroidal anti-inflammatory drugs	group	265-300	false
rivastigmine	drug	91-102	estrogens	group	310-318	false
rivastigmine	drug	91-102	salicylate analgesics	group	328-348	false
rivastigmine	drug	91-102	antianginals	group	359-370	false
rivastigmine	drug	91-102	antihistamines	group	384-397	false
antacids	group	167-174	antihypertensives	group	184-200	false
antacids	group	167-174	calcium channel blockers	group	210-233	false
antacids	group	167-174	antidiabetics	group	243-255	false
antacids	group	167-174	nonsteroidal anti-inflammatory drugs	group	265-300	false
antacids	group	167-174	estrogens	group	310-318	false
antacids	group	167-174	salicylate analgesics	group	328-348	false
antacids	group	167-174	antianginals	group	359-370	false
antacids	group	167-174	antihistamines	group	384-397	false
antihypertensives	group	184-200	calcium channel blockers	group	210-233	false
antihypertensives	group	184-200	antidiabetics	group	243-255	false
antihypertensives	group	184-200	nonsteroidal anti-inflammatory drugs	group	265-300	false
antihypertensives	group	184-200	estrogens	group	310-318	false
antihypertensives	group	184-200	salicylate analgesics	group	328-348	false
antihypertensives	group	184-200	antianginals	group	359-370	false
antihypertensives	group	184-200	antihistamines	group	384-397	false
calcium channel blockers	group	210-233	antidiabetics	group	243-255	false
calcium channel blockers	group	210-233	nonsteroidal anti-inflammatory drugs	group	265-300	false
calcium channel blockers	group	210-233	estrogens	group	310-318	false
calcium channel blockers	group	210-233	salicylate analgesics	group	328-348	false
calcium channel blockers	group	210-233	antianginals	group	359-370	false
calcium channel blockers	group	210-233	antihistamines	group	384-397	false
antidiabetics	group	243-255	nonsteroidal anti-inflammatory drugs	group	265-300	false
antidiabetics	group	243-255	estrogens	group	310-318	false
antidiabetics	group	243-255	salicylate analgesics	group	328-348	false
antidiabetics	group	243-255	antianginals	group	359-370	false
antidiabetics	group	243-255	antihistamines	group	384-397	false
nonsteroidal anti-inflammatory drugs	group	265-300	estrogens	group	310-318	false
nonsteroidal anti-inflammatory drugs	group	265-300	salicylate analgesics	group	328-348	false
nonsteroidal anti-inflammatory drugs	group	265-300	antianginals	group	359-370	false
nonsteroidal anti-inflammatory drugs	group	265-300	antihistamines	group	384-397	false
estrogens	group	310-318	salicylate analgesics	group	328-348	false
estrogens	group	310-318	antianginals	group	359-370	false
estrogens	group	310-318	antihistamines	group	384-397	false
salicylate analgesics	group	328-348	antianginals	group	359-370	false
salicylate analgesics	group	328-348	antihistamines	group	384-397	false
antianginals	group	359-370	antihistamines	group	384-397	false

DDI-DrugBank.d596.s8	Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications.
Anticholinergics	group	9-24	cholinesterase inhibitors	group	65-89	false
Anticholinergics	group	9-24	anticholinergic medications	group	144-170	false
cholinesterase inhibitors	group	65-89	anticholinergic medications	group	144-170	int

DDI-DrugBank.d596.s9	Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.
Cholinomimetics	group	9-23	Cholinesterase Inhibitors	group	35-59	false
Cholinomimetics	group	9-23	cholinesterase inhibitors	group	104-128	false
Cholinomimetics	group	9-23	succinylcholine	drug	158-172	false
Cholinomimetics	group	9-23	neuromuscular blocking agents	group	183-211	false
Cholinomimetics	group	9-23	cholinergic agonists	group	216-235	false
Cholinomimetics	group	9-23	bethanechol	drug	245-255	false
Cholinesterase Inhibitors	group	35-59	cholinesterase inhibitors	group	104-128	false
Cholinesterase Inhibitors	group	35-59	succinylcholine	drug	158-172	false
Cholinesterase Inhibitors	group	35-59	neuromuscular blocking agents	group	183-211	false
Cholinesterase Inhibitors	group	35-59	cholinergic agonists	group	216-235	false
Cholinesterase Inhibitors	group	35-59	bethanechol	drug	245-255	false
cholinesterase inhibitors	group	104-128	succinylcholine	drug	158-172	effect
cholinesterase inhibitors	group	104-128	neuromuscular blocking agents	group	183-211	effect
cholinesterase inhibitors	group	104-128	cholinergic agonists	group	216-235	effect
cholinesterase inhibitors	group	104-128	bethanechol	drug	245-255	effect
succinylcholine	drug	158-172	neuromuscular blocking agents	group	183-211	false
succinylcholine	drug	158-172	cholinergic agonists	group	216-235	false
succinylcholine	drug	158-172	bethanechol	drug	245-255	false
neuromuscular blocking agents	group	183-211	cholinergic agonists	group	216-235	false
neuromuscular blocking agents	group	183-211	bethanechol	drug	245-255	false
cholinergic agonists	group	216-235	bethanechol	drug	245-255	false

DDI-DrugBank.d743.s0	Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g.
Ketoconazole	drug	0-11	ketoconazole	drug	82-93	false
Ketoconazole	drug	0-11	terfenadine	drug	121-131	false
ketoconazole	drug	82-93	terfenadine	drug	121-131	effect

DDI-DrugBank.d743.s2	Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels.
ketoconazole	drug	35-46	terfenadine	drug	84-94	mechanism
ketoconazole	drug	35-46	terfenadine	drug	126-136	false
terfenadine	drug	84-94	terfenadine	drug	126-136	false

DDI-DrugBank.d743.s4	Concomitant administration of ketoconazole and terfenadine is contraindicated.
ketoconazole	drug	30-41	terfenadine	drug	47-57	advise

DDI-DrugBank.d743.s5	Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.
Itraconazole	drug	0-11	terfenadine	drug	54-64	false
Itraconazole	drug	0-11	terfenadine	drug	118-128	false
Itraconazole	drug	0-11	itraconazole	drug	134-145	false
Itraconazole	drug	0-11	itraconazole	drug	169-180	false
terfenadine	drug	54-64	terfenadine	drug	118-128	false
terfenadine	drug	54-64	itraconazole	drug	134-145	false
terfenadine	drug	54-64	itraconazole	drug	169-180	false
terfenadine	drug	118-128	itraconazole	drug	134-145	mechanism
terfenadine	drug	118-128	itraconazole	drug	169-180	false
itraconazole	drug	134-145	itraconazole	drug	169-180	false

DDI-DrugBank.d743.s7	Concomitant administration of itraconazole and terfenadine is contraindicated.
itraconazole	drug	30-41	terfenadine	drug	47-57	advise

DDI-DrugBank.d743.s8	Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.
azole-type antifungal agents	group	40-67	fluconazole	drug	80-90	false
azole-type antifungal agents	group	40-67	metronidazole	drug	93-105	false
azole-type antifungal agents	group	40-67	miconazole	drug	112-121	false
azole-type antifungal agents	group	40-67	ketoconazole	drug	127-138	false
azole-type antifungal agents	group	40-67	itraconazole	drug	145-156	false
azole-type antifungal agents	group	40-67	terfenadine	drug	198-208	advise
fluconazole	drug	80-90	metronidazole	drug	93-105	false
fluconazole	drug	80-90	miconazole	drug	112-121	false
fluconazole	drug	80-90	ketoconazole	drug	127-138	false
fluconazole	drug	80-90	itraconazole	drug	145-156	false
fluconazole	drug	80-90	terfenadine	drug	198-208	advise
metronidazole	drug	93-105	miconazole	drug	112-121	false
metronidazole	drug	93-105	ketoconazole	drug	127-138	false
metronidazole	drug	93-105	itraconazole	drug	145-156	false
metronidazole	drug	93-105	terfenadine	drug	198-208	advise
miconazole	drug	112-121	ketoconazole	drug	127-138	false
miconazole	drug	112-121	itraconazole	drug	145-156	false
miconazole	drug	112-121	terfenadine	drug	198-208	advise
ketoconazole	drug	127-138	itraconazole	drug	145-156	false
ketoconazole	drug	127-138	terfenadine	drug	198-208	false
itraconazole	drug	145-156	terfenadine	drug	198-208	false

DDI-DrugBank.d743.s9	Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.
Macrolides	group	0-9	erythromycin	drug	60-71	false
Macrolides	group	0-9	clarithromycin	drug	77-90	false
Macrolides	group	0-9	terfenadine	drug	115-125	false
Macrolides	group	0-9	ketoconazole	drug	185-196	false
erythromycin	drug	60-71	clarithromycin	drug	77-90	false
erythromycin	drug	60-71	terfenadine	drug	115-125	mechanism
erythromycin	drug	60-71	ketoconazole	drug	185-196	false
clarithromycin	drug	77-90	terfenadine	drug	115-125	mechanism
clarithromycin	drug	77-90	ketoconazole	drug	185-196	false
terfenadine	drug	115-125	ketoconazole	drug	185-196	false

DDI-DrugBank.d743.s11	A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin.
erythromycin	drug	155-166	troleandomycin	drug	171-184	false

DDI-DrugBank.d743.s12	Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.
terfenadine	drug	30-40	clarithromycin	drug	47-60	advise
terfenadine	drug	30-40	erythromycin	drug	63-74	advise
terfenadine	drug	30-40	troleandomycin	drug	80-93	advise
terfenadine	drug	30-40	terfenadine	drug	202-212	false
terfenadine	drug	30-40	macrolide antibiotics	group	225-245	false
terfenadine	drug	30-40	azithromycin	drug	258-269	false
clarithromycin	drug	47-60	erythromycin	drug	63-74	false
clarithromycin	drug	47-60	troleandomycin	drug	80-93	false
clarithromycin	drug	47-60	terfenadine	drug	202-212	false
clarithromycin	drug	47-60	macrolide antibiotics	group	225-245	false
clarithromycin	drug	47-60	azithromycin	drug	258-269	false
erythromycin	drug	63-74	troleandomycin	drug	80-93	false
erythromycin	drug	63-74	terfenadine	drug	202-212	false
erythromycin	drug	63-74	macrolide antibiotics	group	225-245	false
erythromycin	drug	63-74	azithromycin	drug	258-269	false
troleandomycin	drug	80-93	terfenadine	drug	202-212	false
troleandomycin	drug	80-93	macrolide antibiotics	group	225-245	false
troleandomycin	drug	80-93	azithromycin	drug	258-269	false
terfenadine	drug	202-212	macrolide antibiotics	group	225-245	advise
terfenadine	drug	202-212	azithromycin	drug	258-269	advise
macrolide antibiotics	group	225-245	azithromycin	drug	258-269	false

DDI-DrugBank.d743.s13	Studies to evaluate potential interactions of terfenadine with azithromycin are in progress.
terfenadine	drug	46-56	azithromycin	drug	63-74	false

DDI-DrugBank.d736.s1	Hypokalemia may develop during concomitant use of steroids or ACTH.
steroids	group	50-57	ACTH	drug	62-65	false

DDI-DrugBank.d736.s3	Thiazides may decrease arterial responsiveness to norepinephrine.
Thiazides	group	0-8	norepinephrine	drug	50-63	effect

DDI-DrugBank.d736.s5	Thiazide drugs may increase the responsiveness of tubocurarine.
Thiazide drugs	group	0-13	tubocurarine	drug	50-61	effect

DDI-DrugBank.d736.s6	Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity.
Lithium	drug	0-6	thiazides	group	38-46	mechanism
Lithium	drug	0-6	lithium	drug	72-78	false
thiazides	group	38-46	lithium	drug	72-78	false

DDI-DrugBank.d736.s7	Thiazides may add to or potentiate the action of other antihypertensive drugs.
Thiazides	group	0-8	antihypertensive drugs	group	55-76	effect

DDI-DrugBank.d736.s8	Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
ganglionic adrenergic blocking drugs	group	25-34;50-74	peripheral adrenergic blocking drugs	group	39-74	false

DDI-DrugBank.d721.s0	The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.
SKELID	brand	23-28	calcium	drug	50-56	mechanism
SKELID	brand	23-28	calcium	drug	64-70	false
SKELID	brand	23-28	SKELID	brand	76-81	false
SKELID	brand	23-28	aluminum	drug	134-141	false
SKELID	brand	23-28	magnesium	drug	147-155	false
SKELID	brand	23-28	antacids	drug	168-175	false
SKELID	brand	23-28	SKELID	brand	210-215	false
calcium	drug	50-56	calcium	drug	64-70	false
calcium	drug	50-56	SKELID	brand	76-81	false
calcium	drug	50-56	aluminum	drug	134-141	false
calcium	drug	50-56	magnesium	drug	147-155	false
calcium	drug	50-56	antacids	drug	168-175	false
calcium	drug	50-56	SKELID	brand	210-215	false
calcium	drug	64-70	SKELID	brand	76-81	false
calcium	drug	64-70	aluminum	drug	134-141	false
calcium	drug	64-70	magnesium	drug	147-155	false
calcium	drug	64-70	antacids	drug	168-175	false
calcium	drug	64-70	SKELID	brand	210-215	false
SKELID	brand	76-81	aluminum	drug	134-141	false
SKELID	brand	76-81	magnesium	drug	147-155	false
SKELID	brand	76-81	antacids	drug	168-175	false
SKELID	brand	76-81	SKELID	brand	210-215	false
aluminum	drug	134-141	magnesium	drug	147-155	false
aluminum	drug	134-141	antacids	drug	168-175	false
aluminum	drug	134-141	SKELID	brand	210-215	mechanism
magnesium	drug	147-155	antacids	drug	168-175	false
magnesium	drug	147-155	SKELID	brand	210-215	mechanism
antacids	drug	168-175	SKELID	brand	210-215	false

DDI-DrugBank.d721.s1	Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID.
Aspirin	brand	0-6	SKELID	brand	40-45	mechanism
Aspirin	brand	0-6	SKELID	brand	85-90	false
SKELID	brand	40-45	SKELID	brand	85-90	false

DDI-DrugBank.d721.s2	The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac.
SKELID	brand	23-28	indomethacin	drug	55-66	mechanism
SKELID	brand	23-28	diclofenac	drug	124-133	false
indomethacin	drug	55-66	diclofenac	drug	124-133	false

DDI-DrugBank.d721.s3	The pharmacokinetic parameters of digoxin are not significantly modified by SKELID coadministration.
digoxin	drug	34-40	SKELID	brand	76-81	false

DDI-DrugBank.d721.s4	In vitro studies show that tiludronate does not displace warfarin from its binding site on protein.
tiludronate	drug	27-37	warfarin	drug	57-64	false

DDI-DrugBank.d769.s0	Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving ZOLINZA concomitantly with coumarin-derivative anticoagulants.
Coumarin-Derivative Anticoagulants	group	0-33	ZOLINZA	brand	151-157	false
Coumarin-Derivative Anticoagulants	group	0-33	coumarin-derivative anticoagulants	group	178-211	false
ZOLINZA	brand	151-157	coumarin-derivative anticoagulants	group	178-211	effect

DDI-DrugBank.d769.s1	Physicians should carefully monitor PT and INR in patients concurrently administered ZOLINZA and coumarin derivatives.
ZOLINZA	brand	85-91	coumarin derivatives	group	97-116	advise

DDI-DrugBank.d769.s2	Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., valproic acid).
HDAC Inhibitors	group	6-20	ZOLINZA	brand	119-125	false
HDAC Inhibitors	group	6-20	HDAC inhibitors	group	137-151	false
HDAC Inhibitors	group	6-20	valproic acid	drug	160-172	false
ZOLINZA	brand	119-125	HDAC inhibitors	group	137-151	effect
ZOLINZA	brand	119-125	valproic acid	drug	160-172	effect
HDAC inhibitors	group	137-151	valproic acid	drug	160-172	false

DDI-DrugBank.d649.s0	Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics.
Sulfamethizole	drug	0-13	barbiturates	group	43-54	effect
Sulfamethizole	drug	0-13	tolbutamide	drug	57-67	effect
Sulfamethizole	drug	0-13	uricosurics	group	74-84	effect
barbiturates	group	43-54	tolbutamide	drug	57-67	false
barbiturates	group	43-54	uricosurics	group	74-84	false
tolbutamide	drug	57-67	uricosurics	group	74-84	false

DDI-DrugBank.d649.s1	It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).
thiazides	group	26-34	cyclosporine	drug	66-77	false
thiazides	group	26-34	sulfonylurea agents	group	107-125	false
thiazides	group	26-34	warfarin	drug	162-169	false
thiazides	group	26-34	methotrexate	drug	205-216	false
thiazides	group	26-34	methotrexate	drug	248-259	false
thiazides	group	26-34	phenytoin	drug	263-271	false
thiazides	group	26-34	phenytoin	drug	305-313	false
cyclosporine	drug	66-77	sulfonylurea agents	group	107-125	false
cyclosporine	drug	66-77	warfarin	drug	162-169	false
cyclosporine	drug	66-77	methotrexate	drug	205-216	false
cyclosporine	drug	66-77	methotrexate	drug	248-259	false
cyclosporine	drug	66-77	phenytoin	drug	263-271	false
cyclosporine	drug	66-77	phenytoin	drug	305-313	false
sulfonylurea agents	group	107-125	warfarin	drug	162-169	false
sulfonylurea agents	group	107-125	methotrexate	drug	205-216	false
sulfonylurea agents	group	107-125	methotrexate	drug	248-259	false
sulfonylurea agents	group	107-125	phenytoin	drug	263-271	false
sulfonylurea agents	group	107-125	phenytoin	drug	305-313	false
warfarin	drug	162-169	methotrexate	drug	205-216	false
warfarin	drug	162-169	methotrexate	drug	248-259	false
warfarin	drug	162-169	phenytoin	drug	263-271	false
warfarin	drug	162-169	phenytoin	drug	305-313	false
methotrexate	drug	205-216	methotrexate	drug	248-259	false
methotrexate	drug	205-216	phenytoin	drug	263-271	false
methotrexate	drug	205-216	phenytoin	drug	305-313	false
methotrexate	drug	248-259	phenytoin	drug	263-271	false
methotrexate	drug	248-259	phenytoin	drug	305-313	false
phenytoin	drug	263-271	phenytoin	drug	305-313	false

DDI-DrugBank.d687.s0	Administration of valproic acid decreases oral clearance of temozolomide by about 5%.
valproic acid	drug	18-30	temozolomide	drug	60-71	mechanism

DDI-DrugBank.d695.s0	While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme.
ZAVESCA	brand	27-33	Cerezyme	brand	76-83	mechanism
ZAVESCA	brand	27-33	Cerezyme	brand	218-225	false
Cerezyme	brand	76-83	Cerezyme	brand	218-225	false

DDI-DrugBank.d695.s1	Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.
Cerezyme	brand	25-32	imiglucerase	drug	38-49	false
Cerezyme	brand	25-32	ZAVESCA	brand	56-62	advise
imiglucerase	drug	38-49	ZAVESCA	brand	56-62	advise

DDI-DrugBank.d645.s0	In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine.
terbinafine	drug	57-67	tolbutamide	drug	104-114	false
terbinafine	drug	57-67	ethinylestradiol	drug	117-132	false
terbinafine	drug	57-67	ethoxycoumarin	drug_n	135-148	false
terbinafine	drug	57-67	cyclosporine	drug	155-166	false
tolbutamide	drug	104-114	ethinylestradiol	drug	117-132	false
tolbutamide	drug	104-114	ethoxycoumarin	drug_n	135-148	false
tolbutamide	drug	104-114	cyclosporine	drug	155-166	false
ethinylestradiol	drug	117-132	ethoxycoumarin	drug_n	135-148	false
ethinylestradiol	drug	117-132	cyclosporine	drug	155-166	false
ethoxycoumarin	drug_n	135-148	cyclosporine	drug	155-166	false

DDI-DrugBank.d645.s2	This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.
tricyclic antidepressants	group	98-122	selective serotonin reuptake inhibitors	group	139-177	false
tricyclic antidepressants	group	98-122	SSRIs	group	180-184	false
tricyclic antidepressants	group	98-122	monoamine oxidase inhibitors (MAO-Is) Type B	group	192-235	false
selective serotonin reuptake inhibitors	group	139-177	SSRIs	group	180-184	false
selective serotonin reuptake inhibitors	group	139-177	monoamine oxidase inhibitors (MAO-Is) Type B	group	192-235	false
SSRIs	group	180-184	monoamine oxidase inhibitors (MAO-Is) Type B	group	192-235	false

DDI-DrugBank.d645.s3	In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin.
terbinafine	drug	89-99	antipyrine	drug	134-143	false
terbinafine	drug	89-99	digoxin	drug	148-154	false
antipyrine	drug	134-143	digoxin	drug	148-154	false

DDI-DrugBank.d645.s4	Terbinafine decreases the clearance of caffeine by 19%.
Terbinafine	drug	0-10	caffeine	drug	39-46	mechanism

DDI-DrugBank.d645.s5	Terbinafine increases the clearance of cyclosporine by 15%.
Terbinafine	drug	0-10	cyclosporine	drug	39-50	mechanism

DDI-DrugBank.d645.s6	There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established.
terbinafine	drug	119-129	warfarin	drug	135-142	effect
terbinafine	drug	119-129	LAMISIL	brand	184-190	false
warfarin	drug	135-142	LAMISIL	brand	184-190	false

DDI-DrugBank.d645.s7	Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.
Terbinafine	drug	0-10	rifampin	drug	43-50	mechanism
Terbinafine	drug	0-10	cimetidine	drug	99-108	mechanism
rifampin	drug	43-50	cimetidine	drug	99-108	false

DDI-DrugBank.d645.s8	Terbinafine clearance is unaffected by cyclosporine.
Terbinafine	drug	0-10	cyclosporine	drug	39-50	false

DDI-DrugBank.d645.s9	There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.
contraceptives	group	120-133	hypoglycemics	group	167-179	false
contraceptives	group	120-133	theophyllines	drug	182-194	false
contraceptives	group	120-133	phenytoins	drug	197-206	false
contraceptives	group	120-133	thiazide diuretics	group	209-226	false
contraceptives	group	120-133	beta blockers	group	229-241	false
contraceptives	group	120-133	calcium channel blockers	group	248-271	false
hypoglycemics	group	167-179	theophyllines	drug	182-194	false
hypoglycemics	group	167-179	phenytoins	drug	197-206	false
hypoglycemics	group	167-179	thiazide diuretics	group	209-226	false
hypoglycemics	group	167-179	beta blockers	group	229-241	false
hypoglycemics	group	167-179	calcium channel blockers	group	248-271	false
theophyllines	drug	182-194	phenytoins	drug	197-206	false
theophyllines	drug	182-194	thiazide diuretics	group	209-226	false
theophyllines	drug	182-194	beta blockers	group	229-241	false
theophyllines	drug	182-194	calcium channel blockers	group	248-271	false
phenytoins	drug	197-206	thiazide diuretics	group	209-226	false
phenytoins	drug	197-206	beta blockers	group	229-241	false
phenytoins	drug	197-206	calcium channel blockers	group	248-271	false
thiazide diuretics	group	209-226	beta blockers	group	229-241	false
thiazide diuretics	group	209-226	calcium channel blockers	group	248-271	false
beta blockers	group	229-241	calcium channel blockers	group	248-271	false

DDI-DrugBank.d680.s1	Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.
pantoprazole	drug	53-64	theophylline	drug	154-165	false
pantoprazole	drug	53-64	cisapride	drug	168-176	false
pantoprazole	drug	53-64	antipyrine	drug	179-188	false
pantoprazole	drug	53-64	caffeine	drug	191-198	false
pantoprazole	drug	53-64	carbamazepine	drug	201-213	false
pantoprazole	drug	53-64	diazepam	drug	216-223	false
pantoprazole	drug	53-64	desmethyldiazepam	drug_n	253-269	false
pantoprazole	drug	53-64	diclofenac	drug	273-282	false
pantoprazole	drug	53-64	naproxen	drug	285-292	false
pantoprazole	drug	53-64	piroxicam	drug	295-303	false
pantoprazole	drug	53-64	digoxin	drug	306-312	false
pantoprazole	drug	53-64	ethanol	drug	315-321	false
pantoprazole	drug	53-64	glyburide	drug	324-332	false
pantoprazole	drug	53-64	contraceptive	group	343-355	false
pantoprazole	drug	53-64	levonorgestrel	drug	358-371	false
pantoprazole	drug	53-64	ethinyl estradiol	drug	373-389	false
pantoprazole	drug	53-64	metoprolol	drug	393-402	false
pantoprazole	drug	53-64	nifedipine	drug	405-414	false
pantoprazole	drug	53-64	phenytoin	drug	417-425	false
pantoprazole	drug	53-64	warfarin	drug	428-435	false
pantoprazole	drug	53-64	midazolam	drug	438-446	false
pantoprazole	drug	53-64	clarithromycin	drug	449-462	false
pantoprazole	drug	53-64	metronidazole	drug	465-477	false
pantoprazole	drug	53-64	amoxicillin	drug	483-493	false
theophylline	drug	154-165	cisapride	drug	168-176	false
theophylline	drug	154-165	antipyrine	drug	179-188	false
theophylline	drug	154-165	caffeine	drug	191-198	false
theophylline	drug	154-165	carbamazepine	drug	201-213	false
theophylline	drug	154-165	diazepam	drug	216-223	false
theophylline	drug	154-165	desmethyldiazepam	drug_n	253-269	false
theophylline	drug	154-165	diclofenac	drug	273-282	false
theophylline	drug	154-165	naproxen	drug	285-292	false
theophylline	drug	154-165	piroxicam	drug	295-303	false
theophylline	drug	154-165	digoxin	drug	306-312	false
theophylline	drug	154-165	ethanol	drug	315-321	false
theophylline	drug	154-165	glyburide	drug	324-332	false
theophylline	drug	154-165	contraceptive	group	343-355	false
theophylline	drug	154-165	levonorgestrel	drug	358-371	false
theophylline	drug	154-165	ethinyl estradiol	drug	373-389	false
theophylline	drug	154-165	metoprolol	drug	393-402	false
theophylline	drug	154-165	nifedipine	drug	405-414	false
theophylline	drug	154-165	phenytoin	drug	417-425	false
theophylline	drug	154-165	warfarin	drug	428-435	false
theophylline	drug	154-165	midazolam	drug	438-446	false
theophylline	drug	154-165	clarithromycin	drug	449-462	false
theophylline	drug	154-165	metronidazole	drug	465-477	false
theophylline	drug	154-165	amoxicillin	drug	483-493	false
cisapride	drug	168-176	antipyrine	drug	179-188	false
cisapride	drug	168-176	caffeine	drug	191-198	false
cisapride	drug	168-176	carbamazepine	drug	201-213	false
cisapride	drug	168-176	diazepam	drug	216-223	false
cisapride	drug	168-176	desmethyldiazepam	drug_n	253-269	false
cisapride	drug	168-176	diclofenac	drug	273-282	false
cisapride	drug	168-176	naproxen	drug	285-292	false
cisapride	drug	168-176	piroxicam	drug	295-303	false
cisapride	drug	168-176	digoxin	drug	306-312	false
cisapride	drug	168-176	ethanol	drug	315-321	false
cisapride	drug	168-176	glyburide	drug	324-332	false
cisapride	drug	168-176	contraceptive	group	343-355	false
cisapride	drug	168-176	levonorgestrel	drug	358-371	false
cisapride	drug	168-176	ethinyl estradiol	drug	373-389	false
cisapride	drug	168-176	metoprolol	drug	393-402	false
cisapride	drug	168-176	nifedipine	drug	405-414	false
cisapride	drug	168-176	phenytoin	drug	417-425	false
cisapride	drug	168-176	warfarin	drug	428-435	false
cisapride	drug	168-176	midazolam	drug	438-446	false
cisapride	drug	168-176	clarithromycin	drug	449-462	false
cisapride	drug	168-176	metronidazole	drug	465-477	false
cisapride	drug	168-176	amoxicillin	drug	483-493	false
antipyrine	drug	179-188	caffeine	drug	191-198	false
antipyrine	drug	179-188	carbamazepine	drug	201-213	false
antipyrine	drug	179-188	diazepam	drug	216-223	false
antipyrine	drug	179-188	desmethyldiazepam	drug_n	253-269	false
antipyrine	drug	179-188	diclofenac	drug	273-282	false
antipyrine	drug	179-188	naproxen	drug	285-292	false
antipyrine	drug	179-188	piroxicam	drug	295-303	false
antipyrine	drug	179-188	digoxin	drug	306-312	false
antipyrine	drug	179-188	ethanol	drug	315-321	false
antipyrine	drug	179-188	glyburide	drug	324-332	false
antipyrine	drug	179-188	contraceptive	group	343-355	false
antipyrine	drug	179-188	levonorgestrel	drug	358-371	false
antipyrine	drug	179-188	ethinyl estradiol	drug	373-389	false
antipyrine	drug	179-188	metoprolol	drug	393-402	false
antipyrine	drug	179-188	nifedipine	drug	405-414	false
antipyrine	drug	179-188	phenytoin	drug	417-425	false
antipyrine	drug	179-188	warfarin	drug	428-435	false
antipyrine	drug	179-188	midazolam	drug	438-446	false
antipyrine	drug	179-188	clarithromycin	drug	449-462	false
antipyrine	drug	179-188	metronidazole	drug	465-477	false
antipyrine	drug	179-188	amoxicillin	drug	483-493	false
caffeine	drug	191-198	carbamazepine	drug	201-213	false
caffeine	drug	191-198	diazepam	drug	216-223	false
caffeine	drug	191-198	desmethyldiazepam	drug_n	253-269	false
caffeine	drug	191-198	diclofenac	drug	273-282	false
caffeine	drug	191-198	naproxen	drug	285-292	false
caffeine	drug	191-198	piroxicam	drug	295-303	false
caffeine	drug	191-198	digoxin	drug	306-312	false
caffeine	drug	191-198	ethanol	drug	315-321	false
caffeine	drug	191-198	glyburide	drug	324-332	false
caffeine	drug	191-198	contraceptive	group	343-355	false
caffeine	drug	191-198	levonorgestrel	drug	358-371	false
caffeine	drug	191-198	ethinyl estradiol	drug	373-389	false
caffeine	drug	191-198	metoprolol	drug	393-402	false
caffeine	drug	191-198	nifedipine	drug	405-414	false
caffeine	drug	191-198	phenytoin	drug	417-425	false
caffeine	drug	191-198	warfarin	drug	428-435	false
caffeine	drug	191-198	midazolam	drug	438-446	false
caffeine	drug	191-198	clarithromycin	drug	449-462	false
caffeine	drug	191-198	metronidazole	drug	465-477	false
caffeine	drug	191-198	amoxicillin	drug	483-493	false
carbamazepine	drug	201-213	diazepam	drug	216-223	false
carbamazepine	drug	201-213	desmethyldiazepam	drug_n	253-269	false
carbamazepine	drug	201-213	diclofenac	drug	273-282	false
carbamazepine	drug	201-213	naproxen	drug	285-292	false
carbamazepine	drug	201-213	piroxicam	drug	295-303	false
carbamazepine	drug	201-213	digoxin	drug	306-312	false
carbamazepine	drug	201-213	ethanol	drug	315-321	false
carbamazepine	drug	201-213	glyburide	drug	324-332	false
carbamazepine	drug	201-213	contraceptive	group	343-355	false
carbamazepine	drug	201-213	levonorgestrel	drug	358-371	false
carbamazepine	drug	201-213	ethinyl estradiol	drug	373-389	false
carbamazepine	drug	201-213	metoprolol	drug	393-402	false
carbamazepine	drug	201-213	nifedipine	drug	405-414	false
carbamazepine	drug	201-213	phenytoin	drug	417-425	false
carbamazepine	drug	201-213	warfarin	drug	428-435	false
carbamazepine	drug	201-213	midazolam	drug	438-446	false
carbamazepine	drug	201-213	clarithromycin	drug	449-462	false
carbamazepine	drug	201-213	metronidazole	drug	465-477	false
carbamazepine	drug	201-213	amoxicillin	drug	483-493	false
diazepam	drug	216-223	desmethyldiazepam	drug_n	253-269	false
diazepam	drug	216-223	diclofenac	drug	273-282	false
diazepam	drug	216-223	naproxen	drug	285-292	false
diazepam	drug	216-223	piroxicam	drug	295-303	false
diazepam	drug	216-223	digoxin	drug	306-312	false
diazepam	drug	216-223	ethanol	drug	315-321	false
diazepam	drug	216-223	glyburide	drug	324-332	false
diazepam	drug	216-223	contraceptive	group	343-355	false
diazepam	drug	216-223	levonorgestrel	drug	358-371	false
diazepam	drug	216-223	ethinyl estradiol	drug	373-389	false
diazepam	drug	216-223	metoprolol	drug	393-402	false
diazepam	drug	216-223	nifedipine	drug	405-414	false
diazepam	drug	216-223	phenytoin	drug	417-425	false
diazepam	drug	216-223	warfarin	drug	428-435	false
diazepam	drug	216-223	midazolam	drug	438-446	false
diazepam	drug	216-223	clarithromycin	drug	449-462	false
diazepam	drug	216-223	metronidazole	drug	465-477	false
diazepam	drug	216-223	amoxicillin	drug	483-493	false
desmethyldiazepam	drug_n	253-269	diclofenac	drug	273-282	false
desmethyldiazepam	drug_n	253-269	naproxen	drug	285-292	false
desmethyldiazepam	drug_n	253-269	piroxicam	drug	295-303	false
desmethyldiazepam	drug_n	253-269	digoxin	drug	306-312	false
desmethyldiazepam	drug_n	253-269	ethanol	drug	315-321	false
desmethyldiazepam	drug_n	253-269	glyburide	drug	324-332	false
desmethyldiazepam	drug_n	253-269	contraceptive	group	343-355	false
desmethyldiazepam	drug_n	253-269	levonorgestrel	drug	358-371	false
desmethyldiazepam	drug_n	253-269	ethinyl estradiol	drug	373-389	false
desmethyldiazepam	drug_n	253-269	metoprolol	drug	393-402	false
desmethyldiazepam	drug_n	253-269	nifedipine	drug	405-414	false
desmethyldiazepam	drug_n	253-269	phenytoin	drug	417-425	false
desmethyldiazepam	drug_n	253-269	warfarin	drug	428-435	false
desmethyldiazepam	drug_n	253-269	midazolam	drug	438-446	false
desmethyldiazepam	drug_n	253-269	clarithromycin	drug	449-462	false
desmethyldiazepam	drug_n	253-269	metronidazole	drug	465-477	false
desmethyldiazepam	drug_n	253-269	amoxicillin	drug	483-493	false
diclofenac	drug	273-282	naproxen	drug	285-292	false
diclofenac	drug	273-282	piroxicam	drug	295-303	false
diclofenac	drug	273-282	digoxin	drug	306-312	false
diclofenac	drug	273-282	ethanol	drug	315-321	false
diclofenac	drug	273-282	glyburide	drug	324-332	false
diclofenac	drug	273-282	contraceptive	group	343-355	false
diclofenac	drug	273-282	levonorgestrel	drug	358-371	false
diclofenac	drug	273-282	ethinyl estradiol	drug	373-389	false
diclofenac	drug	273-282	metoprolol	drug	393-402	false
diclofenac	drug	273-282	nifedipine	drug	405-414	false
diclofenac	drug	273-282	phenytoin	drug	417-425	false
diclofenac	drug	273-282	warfarin	drug	428-435	false
diclofenac	drug	273-282	midazolam	drug	438-446	false
diclofenac	drug	273-282	clarithromycin	drug	449-462	false
diclofenac	drug	273-282	metronidazole	drug	465-477	false
diclofenac	drug	273-282	amoxicillin	drug	483-493	false
naproxen	drug	285-292	piroxicam	drug	295-303	false
naproxen	drug	285-292	digoxin	drug	306-312	false
naproxen	drug	285-292	ethanol	drug	315-321	false
naproxen	drug	285-292	glyburide	drug	324-332	false
naproxen	drug	285-292	contraceptive	group	343-355	false
naproxen	drug	285-292	levonorgestrel	drug	358-371	false
naproxen	drug	285-292	ethinyl estradiol	drug	373-389	false
naproxen	drug	285-292	metoprolol	drug	393-402	false
naproxen	drug	285-292	nifedipine	drug	405-414	false
naproxen	drug	285-292	phenytoin	drug	417-425	false
naproxen	drug	285-292	warfarin	drug	428-435	false
naproxen	drug	285-292	midazolam	drug	438-446	false
naproxen	drug	285-292	clarithromycin	drug	449-462	false
naproxen	drug	285-292	metronidazole	drug	465-477	false
naproxen	drug	285-292	amoxicillin	drug	483-493	false
piroxicam	drug	295-303	digoxin	drug	306-312	false
piroxicam	drug	295-303	ethanol	drug	315-321	false
piroxicam	drug	295-303	glyburide	drug	324-332	false
piroxicam	drug	295-303	contraceptive	group	343-355	false
piroxicam	drug	295-303	levonorgestrel	drug	358-371	false
piroxicam	drug	295-303	ethinyl estradiol	drug	373-389	false
piroxicam	drug	295-303	metoprolol	drug	393-402	false
piroxicam	drug	295-303	nifedipine	drug	405-414	false
piroxicam	drug	295-303	phenytoin	drug	417-425	false
piroxicam	drug	295-303	warfarin	drug	428-435	false
piroxicam	drug	295-303	midazolam	drug	438-446	false
piroxicam	drug	295-303	clarithromycin	drug	449-462	false
piroxicam	drug	295-303	metronidazole	drug	465-477	false
piroxicam	drug	295-303	amoxicillin	drug	483-493	false
digoxin	drug	306-312	ethanol	drug	315-321	false
digoxin	drug	306-312	glyburide	drug	324-332	false
digoxin	drug	306-312	contraceptive	group	343-355	false
digoxin	drug	306-312	levonorgestrel	drug	358-371	false
digoxin	drug	306-312	ethinyl estradiol	drug	373-389	false
digoxin	drug	306-312	metoprolol	drug	393-402	false
digoxin	drug	306-312	nifedipine	drug	405-414	false
digoxin	drug	306-312	phenytoin	drug	417-425	false
digoxin	drug	306-312	warfarin	drug	428-435	false
digoxin	drug	306-312	midazolam	drug	438-446	false
digoxin	drug	306-312	clarithromycin	drug	449-462	false
digoxin	drug	306-312	metronidazole	drug	465-477	false
digoxin	drug	306-312	amoxicillin	drug	483-493	false
ethanol	drug	315-321	glyburide	drug	324-332	false
ethanol	drug	315-321	contraceptive	group	343-355	false
ethanol	drug	315-321	levonorgestrel	drug	358-371	false
ethanol	drug	315-321	ethinyl estradiol	drug	373-389	false
ethanol	drug	315-321	metoprolol	drug	393-402	false
ethanol	drug	315-321	nifedipine	drug	405-414	false
ethanol	drug	315-321	phenytoin	drug	417-425	false
ethanol	drug	315-321	warfarin	drug	428-435	false
ethanol	drug	315-321	midazolam	drug	438-446	false
ethanol	drug	315-321	clarithromycin	drug	449-462	false
ethanol	drug	315-321	metronidazole	drug	465-477	false
ethanol	drug	315-321	amoxicillin	drug	483-493	false
glyburide	drug	324-332	contraceptive	group	343-355	false
glyburide	drug	324-332	levonorgestrel	drug	358-371	false
glyburide	drug	324-332	ethinyl estradiol	drug	373-389	false
glyburide	drug	324-332	metoprolol	drug	393-402	false
glyburide	drug	324-332	nifedipine	drug	405-414	false
glyburide	drug	324-332	phenytoin	drug	417-425	false
glyburide	drug	324-332	warfarin	drug	428-435	false
glyburide	drug	324-332	midazolam	drug	438-446	false
glyburide	drug	324-332	clarithromycin	drug	449-462	false
glyburide	drug	324-332	metronidazole	drug	465-477	false
glyburide	drug	324-332	amoxicillin	drug	483-493	false
contraceptive	group	343-355	levonorgestrel	drug	358-371	false
contraceptive	group	343-355	ethinyl estradiol	drug	373-389	false
contraceptive	group	343-355	metoprolol	drug	393-402	false
contraceptive	group	343-355	nifedipine	drug	405-414	false
contraceptive	group	343-355	phenytoin	drug	417-425	false
contraceptive	group	343-355	warfarin	drug	428-435	false
contraceptive	group	343-355	midazolam	drug	438-446	false
contraceptive	group	343-355	clarithromycin	drug	449-462	false
contraceptive	group	343-355	metronidazole	drug	465-477	false
contraceptive	group	343-355	amoxicillin	drug	483-493	false
levonorgestrel	drug	358-371	ethinyl estradiol	drug	373-389	false
levonorgestrel	drug	358-371	metoprolol	drug	393-402	false
levonorgestrel	drug	358-371	nifedipine	drug	405-414	false
levonorgestrel	drug	358-371	phenytoin	drug	417-425	false
levonorgestrel	drug	358-371	warfarin	drug	428-435	false
levonorgestrel	drug	358-371	midazolam	drug	438-446	false
levonorgestrel	drug	358-371	clarithromycin	drug	449-462	false
levonorgestrel	drug	358-371	metronidazole	drug	465-477	false
levonorgestrel	drug	358-371	amoxicillin	drug	483-493	false
ethinyl estradiol	drug	373-389	metoprolol	drug	393-402	false
ethinyl estradiol	drug	373-389	nifedipine	drug	405-414	false
ethinyl estradiol	drug	373-389	phenytoin	drug	417-425	false
ethinyl estradiol	drug	373-389	warfarin	drug	428-435	false
ethinyl estradiol	drug	373-389	midazolam	drug	438-446	false
ethinyl estradiol	drug	373-389	clarithromycin	drug	449-462	false
ethinyl estradiol	drug	373-389	metronidazole	drug	465-477	false
ethinyl estradiol	drug	373-389	amoxicillin	drug	483-493	false
metoprolol	drug	393-402	nifedipine	drug	405-414	false
metoprolol	drug	393-402	phenytoin	drug	417-425	false
metoprolol	drug	393-402	warfarin	drug	428-435	false
metoprolol	drug	393-402	midazolam	drug	438-446	false
metoprolol	drug	393-402	clarithromycin	drug	449-462	false
metoprolol	drug	393-402	metronidazole	drug	465-477	false
metoprolol	drug	393-402	amoxicillin	drug	483-493	false
nifedipine	drug	405-414	phenytoin	drug	417-425	false
nifedipine	drug	405-414	warfarin	drug	428-435	false
nifedipine	drug	405-414	midazolam	drug	438-446	false
nifedipine	drug	405-414	clarithromycin	drug	449-462	false
nifedipine	drug	405-414	metronidazole	drug	465-477	false
nifedipine	drug	405-414	amoxicillin	drug	483-493	false
phenytoin	drug	417-425	warfarin	drug	428-435	false
phenytoin	drug	417-425	midazolam	drug	438-446	false
phenytoin	drug	417-425	clarithromycin	drug	449-462	false
phenytoin	drug	417-425	metronidazole	drug	465-477	false
phenytoin	drug	417-425	amoxicillin	drug	483-493	false
warfarin	drug	428-435	midazolam	drug	438-446	false
warfarin	drug	428-435	clarithromycin	drug	449-462	false
warfarin	drug	428-435	metronidazole	drug	465-477	false
warfarin	drug	428-435	amoxicillin	drug	483-493	false
midazolam	drug	438-446	clarithromycin	drug	449-462	false
midazolam	drug	438-446	metronidazole	drug	465-477	false
midazolam	drug	438-446	amoxicillin	drug	483-493	false
clarithromycin	drug	449-462	metronidazole	drug	465-477	false
clarithromycin	drug	449-462	amoxicillin	drug	483-493	false
metronidazole	drug	465-477	amoxicillin	drug	483-493	false

DDI-DrugBank.d680.s3	Therefore, when coadministered with pantoprazole, adjustment of the dosage of pantoprazole or of such drugs may not be necessary.
pantoprazole	drug	36-47	pantoprazole	drug	78-89	false

DDI-DrugBank.d680.s5	There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly.
proton pump inhibitors	group	98-119	pantoprazole	drug	132-143	false
proton pump inhibitors	group	98-119	warfarin	drug	150-157	effect
pantoprazole	drug	132-143	warfarin	drug	150-157	effect

DDI-DrugBank.d680.s7	Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time.
proton pump inhibitors	group	22-43	warfarin	drug	49-56	advise

DDI-DrugBank.d680.s8	Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts).
pantoprazole	drug	75-86	ketoconazole	drug	202-213	mechanism
pantoprazole	drug	75-86	ampicillin	drug	216-225	mechanism
pantoprazole	drug	75-86	iron	drug	239-242	mechanism
ketoconazole	drug	202-213	ampicillin	drug	216-225	false
ketoconazole	drug	202-213	iron	drug	239-242	false
ampicillin	drug	216-225	iron	drug	239-242	false

DDI-DrugBank.d680.s9	Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole.
tetrahydrocannabinol	drug	85-104	THC	drug	107-109	false
tetrahydrocannabinol	drug	85-104	proton pump inhibitors	group	139-160	false
tetrahydrocannabinol	drug	85-104	pantoprazole	drug	173-184	false
THC	drug	107-109	proton pump inhibitors	group	139-160	false
THC	drug	107-109	pantoprazole	drug	173-184	false
proton pump inhibitors	group	139-160	pantoprazole	drug	173-184	false

DDI-DrugBank.d648.s0	Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA.
Cholestyramine	drug	0-13	Cholestyramine	drug	16-29	false
Cholestyramine	drug	0-13	raloxifene	drug	101-110	false
Cholestyramine	drug	0-13	EVISTA	brand	150-155	false
Cholestyramine	drug	16-29	raloxifene	drug	101-110	mechanism
Cholestyramine	drug	16-29	EVISTA	brand	150-155	advise
raloxifene	drug	101-110	EVISTA	brand	150-155	false

DDI-DrugBank.d648.s1	Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions.
Warfarin	drug	0-7	EVISTA	brand	34-39	false
Warfarin	drug	0-7	warfarin	drug	45-52	false
EVISTA	brand	34-39	warfarin	drug	45-52	false

DDI-DrugBank.d648.s3	If EVISTA is given concurrently with warfarin, prothrombin time should be monitored.
EVISTA	brand	3-8	warfarin	drug	37-44	advise

DDI-DrugBank.d648.s5	In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen.
raloxifene	drug	10-19	warfarin	drug	51-58	false
raloxifene	drug	10-19	phenytoin	drug	61-69	false
raloxifene	drug	10-19	tamoxifen	drug	75-83	false
warfarin	drug	51-58	phenytoin	drug	61-69	false
warfarin	drug	51-58	tamoxifen	drug	75-83	false
phenytoin	drug	61-69	tamoxifen	drug	75-83	false

DDI-DrugBank.d648.s6	Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.
EVISTA	brand	28-33	clofibrate	drug	100-109	advise
EVISTA	brand	28-33	indomethacin	drug	112-123	advise
EVISTA	brand	28-33	naproxen	drug	126-133	advise
EVISTA	brand	28-33	ibuprofen	drug	136-144	advise
EVISTA	brand	28-33	diazepam	drug	147-154	advise
EVISTA	brand	28-33	diazoxide	drug	161-169	advise
clofibrate	drug	100-109	indomethacin	drug	112-123	false
clofibrate	drug	100-109	naproxen	drug	126-133	false
clofibrate	drug	100-109	ibuprofen	drug	136-144	false
clofibrate	drug	100-109	diazepam	drug	147-154	false
clofibrate	drug	100-109	diazoxide	drug	161-169	false
indomethacin	drug	112-123	naproxen	drug	126-133	false
indomethacin	drug	112-123	ibuprofen	drug	136-144	false
indomethacin	drug	112-123	diazepam	drug	147-154	false
indomethacin	drug	112-123	diazoxide	drug	161-169	false
naproxen	drug	126-133	ibuprofen	drug	136-144	false
naproxen	drug	126-133	diazepam	drug	147-154	false
naproxen	drug	126-133	diazoxide	drug	161-169	false
ibuprofen	drug	136-144	diazepam	drug	147-154	false
ibuprofen	drug	136-144	diazoxide	drug	161-169	false
diazepam	drug	147-154	diazoxide	drug	161-169	false

DDI-DrugBank.d746.s0	ARAMINE should be used with caution in digitalized patients, since the combination of digitalis and sympathomimetic amines may cause ectopic arrhythmias.
ARAMINE	brand	0-6	digitalis	group	86-94	false
ARAMINE	brand	0-6	sympathomimetic amines	group	100-121	false
digitalis	group	86-94	sympathomimetic amines	group	100-121	effect

DDI-DrugBank.d746.s1	Monoamine oxidase inhibitors or tricyclic antidepressants may potentiate the action of sympathomimetic amines.
Monoamine oxidase inhibitors	group	0-27	tricyclic antidepressants	group	32-56	false
Monoamine oxidase inhibitors	group	0-27	sympathomimetic amines	group	87-108	effect
tricyclic antidepressants	group	32-56	sympathomimetic amines	group	87-108	effect

DDI-DrugBank.d734.s0	Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines.
Thiazide diuretics	group	0-17	phenothiazines	group	82-95	effect

DDI-DrugBank.d734.s1	Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly.
guanethidine	drug	28-39	phenothiazines	group	88-101	effect

DDI-DrugBank.d734.s2	Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.
propranolol	drug	30-40	phenothiazines	group	47-60	mechanism

DDI-DrugBank.d717.s0	Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.
Mitotane	drug	0-7	warfarin	drug	59-66	mechanism
Mitotane	drug	0-7	warfarin	drug	175-182	false
warfarin	drug	59-66	warfarin	drug	175-182	false

DDI-DrugBank.d717.s1	Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants.
anticoagulant	group	70-82	Mitotane	drug	123-130	false
anticoagulant	group	70-82	coumarin-type anticoagulants	group	147-174	false
Mitotane	drug	123-130	coumarin-type anticoagulants	group	147-174	advise

DDI-DrugBank.d780.s0	Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.
Anticholinesterases	group	0-18	procaine hydrochloride	drug	39-60	false
Anticholinesterases	group	0-18	anticholinesterase agents	group	66-90	false
Anticholinesterases	group	0-18	anticholinesterases	group	140-158	false
Anticholinesterases	group	0-18	procaine hydrochloride	drug	185-206	false
procaine hydrochloride	drug	39-60	anticholinesterase agents	group	66-90	effect
procaine hydrochloride	drug	39-60	anticholinesterases	group	140-158	false
procaine hydrochloride	drug	39-60	procaine hydrochloride	drug	185-206	false
anticholinesterase agents	group	66-90	anticholinesterases	group	140-158	false
anticholinesterase agents	group	66-90	procaine hydrochloride	drug	185-206	false
anticholinesterases	group	140-158	procaine hydrochloride	drug	185-206	mechanism

DDI-DrugBank.d780.s4	CNS depressant medications: Concurrent use of procaine hydrochloride and CNS depressant medications may result in additive depressant effects.
CNS depressant	group	0-13	procaine hydrochloride	drug	46-67	false
CNS depressant	group	0-13	CNS depressant medications	group	73-98	false
procaine hydrochloride	drug	46-67	CNS depressant medications	group	73-98	effect

DDI-DrugBank.d780.s5	Hyaluronidase: Hyaluronidase may increase the diffusion rate of procaine hydrochloride, resulting in a decreased time of onset, but an increase in systemic toxicity.
Hyaluronidase	drug	0-12	Hyaluronidase	drug	15-27	false
Hyaluronidase	drug	0-12	procaine hydrochloride	drug	64-85	false
Hyaluronidase	drug	15-27	procaine hydrochloride	drug	64-85	mechanism

DDI-DrugBank.d780.s6	Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.
Neuromuscular blocking agents	group	0-28	suxamethonium chloride	drug	39-60	false
Neuromuscular blocking agents	group	0-28	procaine hydrochloride	drug	82-103	false
Neuromuscular blocking agents	group	0-28	neuromuscular blocking agents	group	109-137	false
suxamethonium chloride	drug	39-60	procaine hydrochloride	drug	82-103	false
suxamethonium chloride	drug	39-60	neuromuscular blocking agents	group	109-137	false
procaine hydrochloride	drug	82-103	neuromuscular blocking agents	group	109-137	effect

DDI-DrugBank.d780.s7	Sulfonamides: Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.
Sulfonamides	group	0-11	procaine hydrochloride	drug	32-53	false
Sulfonamides	group	0-11	sulfonamides	group	59-70	false
Sulfonamides	group	0-11	sulfonamide	group	133-143	false
procaine hydrochloride	drug	32-53	sulfonamides	group	59-70	effect
procaine hydrochloride	drug	32-53	sulfonamide	group	133-143	false
sulfonamides	group	59-70	sulfonamide	group	133-143	false

DDI-DrugBank.d780.s8	Acetazolamide: Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of procaine.
Acetazolamide	drug	0-12	acetazolamide	drug	33-45	false
Acetazolamide	drug	0-12	procaine hydrochloride	drug	51-72	false
Acetazolamide	drug	0-12	procaine	drug	109-116	false
acetazolamide	drug	33-45	procaine hydrochloride	drug	51-72	mechanism
acetazolamide	drug	33-45	procaine	drug	109-116	false
procaine hydrochloride	drug	51-72	procaine	drug	109-116	false

DDI-DrugBank.d728.s1	No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks.
ELOXATIN	brand	48-55	5-FU	drug	72-75	false

DDI-DrugBank.d728.s2	Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks.
5-FU	drug	13-16	ELOXATIN	brand	104-111	mechanism

DDI-DrugBank.d753.s0	The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.
CNS depressants	group	29-43	sedatives	group	55-63	false
CNS depressants	group	29-43	hypnotics	group	66-74	false
CNS depressants	group	29-43	tranquilizers	group	77-89	false
CNS depressants	group	29-43	anesthetics	group	100-110	false
CNS depressants	group	29-43	phenothiazines	group	113-126	false
CNS depressants	group	29-43	opioids	group	135-141	false
CNS depressants	group	29-43	tricyclic antidepressants	group	144-168	false
CNS depressants	group	29-43	monoamine oxidase (MAO) inhibitors	group	171-204	false
CNS depressants	group	29-43	alcohol	drug	211-217	false
sedatives	group	55-63	hypnotics	group	66-74	false
sedatives	group	55-63	tranquilizers	group	77-89	false
sedatives	group	55-63	anesthetics	group	100-110	false
sedatives	group	55-63	phenothiazines	group	113-126	false
sedatives	group	55-63	opioids	group	135-141	false
sedatives	group	55-63	tricyclic antidepressants	group	144-168	false
sedatives	group	55-63	monoamine oxidase (MAO) inhibitors	group	171-204	false
sedatives	group	55-63	alcohol	drug	211-217	false
hypnotics	group	66-74	tranquilizers	group	77-89	false
hypnotics	group	66-74	anesthetics	group	100-110	false
hypnotics	group	66-74	phenothiazines	group	113-126	false
hypnotics	group	66-74	opioids	group	135-141	false
hypnotics	group	66-74	tricyclic antidepressants	group	144-168	false
hypnotics	group	66-74	monoamine oxidase (MAO) inhibitors	group	171-204	false
hypnotics	group	66-74	alcohol	drug	211-217	false
tranquilizers	group	77-89	anesthetics	group	100-110	false
tranquilizers	group	77-89	phenothiazines	group	113-126	false
tranquilizers	group	77-89	opioids	group	135-141	false
tranquilizers	group	77-89	tricyclic antidepressants	group	144-168	false
tranquilizers	group	77-89	monoamine oxidase (MAO) inhibitors	group	171-204	false
tranquilizers	group	77-89	alcohol	drug	211-217	false
anesthetics	group	100-110	phenothiazines	group	113-126	false
anesthetics	group	100-110	opioids	group	135-141	false
anesthetics	group	100-110	tricyclic antidepressants	group	144-168	false
anesthetics	group	100-110	monoamine oxidase (MAO) inhibitors	group	171-204	false
anesthetics	group	100-110	alcohol	drug	211-217	false
phenothiazines	group	113-126	opioids	group	135-141	false
phenothiazines	group	113-126	tricyclic antidepressants	group	144-168	false
phenothiazines	group	113-126	monoamine oxidase (MAO) inhibitors	group	171-204	false
phenothiazines	group	113-126	alcohol	drug	211-217	false
opioids	group	135-141	tricyclic antidepressants	group	144-168	false
opioids	group	135-141	monoamine oxidase (MAO) inhibitors	group	171-204	false
opioids	group	135-141	alcohol	drug	211-217	false
tricyclic antidepressants	group	144-168	monoamine oxidase (MAO) inhibitors	group	171-204	false
tricyclic antidepressants	group	144-168	alcohol	drug	211-217	false
monoamine oxidase (MAO) inhibitors	group	171-204	alcohol	drug	211-217	false

DDI-DrugBank.d753.s2	Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.
Anticholinergics	group	0-15	opioid analgesics	group	96-112	effect

DDI-DrugBank.d753.s3	It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia.
oxymorphone	drug	74-84	propofol	drug	104-111	effect

DDI-DrugBank.d753.s4	In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics;
cimetidine	drug	143-152	opioid analgesics	group	159-175	effect

DDI-DrugBank.d655.s0	Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).
Methscopolamine	drug	0-14	antidepressants	group	34-48	false
Methscopolamine	drug	0-14	tricyclic	group	51-59	int
Methscopolamine	drug	0-14	MAO inhibitors	group	68-81	int
Methscopolamine	drug	0-14	phenelzine	drug	90-99	int
Methscopolamine	drug	0-14	linezolid	drug	102-110	int
Methscopolamine	drug	0-14	tranylcypromine	drug	113-127	int
Methscopolamine	drug	0-14	isocarboxazid	drug	130-142	int
Methscopolamine	drug	0-14	selegiline	drug	145-154	int
Methscopolamine	drug	0-14	furazolidone	drug	157-168	int
Methscopolamine	drug	0-14	quinidine	drug	172-180	int
Methscopolamine	drug	0-14	amantadine	drug	183-192	int
Methscopolamine	drug	0-14	antihistamines	group	195-208	int
Methscopolamine	drug	0-14	diphenhydramine	drug	217-231	int
Methscopolamine	drug	0-14	anticholinergics	group	241-256	int
Methscopolamine	drug	0-14	potassium chloride	drug	259-276	int
Methscopolamine	drug	0-14	antacids	group	291-298	int
Methscopolamine	drug	0-14	absorbent-type anti-diarrhea medicines	group	301-338	int
Methscopolamine	drug	0-14	kaolin	drug	347-352	int
Methscopolamine	drug	0-14	pectin	drug	354-359	int
Methscopolamine	drug	0-14	phenothiazines	group	363-376	int
Methscopolamine	drug	0-14	chlorpromazine	drug	385-398	int
Methscopolamine	drug	0-14	promethazine	drug	401-412	int
antidepressants	group	34-48	tricyclic	group	51-59	false
antidepressants	group	34-48	MAO inhibitors	group	68-81	false
antidepressants	group	34-48	phenelzine	drug	90-99	false
antidepressants	group	34-48	linezolid	drug	102-110	false
antidepressants	group	34-48	tranylcypromine	drug	113-127	false
antidepressants	group	34-48	isocarboxazid	drug	130-142	false
antidepressants	group	34-48	selegiline	drug	145-154	false
antidepressants	group	34-48	furazolidone	drug	157-168	false
antidepressants	group	34-48	quinidine	drug	172-180	false
antidepressants	group	34-48	amantadine	drug	183-192	false
antidepressants	group	34-48	antihistamines	group	195-208	false
antidepressants	group	34-48	diphenhydramine	drug	217-231	false
antidepressants	group	34-48	anticholinergics	group	241-256	false
antidepressants	group	34-48	potassium chloride	drug	259-276	false
antidepressants	group	34-48	antacids	group	291-298	false
antidepressants	group	34-48	absorbent-type anti-diarrhea medicines	group	301-338	false
antidepressants	group	34-48	kaolin	drug	347-352	false
antidepressants	group	34-48	pectin	drug	354-359	false
antidepressants	group	34-48	phenothiazines	group	363-376	false
antidepressants	group	34-48	chlorpromazine	drug	385-398	false
antidepressants	group	34-48	promethazine	drug	401-412	false
tricyclic	group	51-59	MAO inhibitors	group	68-81	false
tricyclic	group	51-59	phenelzine	drug	90-99	false
tricyclic	group	51-59	linezolid	drug	102-110	false
tricyclic	group	51-59	tranylcypromine	drug	113-127	false
tricyclic	group	51-59	isocarboxazid	drug	130-142	false
tricyclic	group	51-59	selegiline	drug	145-154	false
tricyclic	group	51-59	furazolidone	drug	157-168	false
tricyclic	group	51-59	quinidine	drug	172-180	false
tricyclic	group	51-59	amantadine	drug	183-192	false
tricyclic	group	51-59	antihistamines	group	195-208	false
tricyclic	group	51-59	diphenhydramine	drug	217-231	false
tricyclic	group	51-59	anticholinergics	group	241-256	false
tricyclic	group	51-59	potassium chloride	drug	259-276	false
tricyclic	group	51-59	antacids	group	291-298	false
tricyclic	group	51-59	absorbent-type anti-diarrhea medicines	group	301-338	false
tricyclic	group	51-59	kaolin	drug	347-352	false
tricyclic	group	51-59	pectin	drug	354-359	false
tricyclic	group	51-59	phenothiazines	group	363-376	false
tricyclic	group	51-59	chlorpromazine	drug	385-398	false
tricyclic	group	51-59	promethazine	drug	401-412	false
MAO inhibitors	group	68-81	phenelzine	drug	90-99	false
MAO inhibitors	group	68-81	linezolid	drug	102-110	false
MAO inhibitors	group	68-81	tranylcypromine	drug	113-127	false
MAO inhibitors	group	68-81	isocarboxazid	drug	130-142	false
MAO inhibitors	group	68-81	selegiline	drug	145-154	false
MAO inhibitors	group	68-81	furazolidone	drug	157-168	false
MAO inhibitors	group	68-81	quinidine	drug	172-180	false
MAO inhibitors	group	68-81	amantadine	drug	183-192	false
MAO inhibitors	group	68-81	antihistamines	group	195-208	false
MAO inhibitors	group	68-81	diphenhydramine	drug	217-231	false
MAO inhibitors	group	68-81	anticholinergics	group	241-256	false
MAO inhibitors	group	68-81	potassium chloride	drug	259-276	false
MAO inhibitors	group	68-81	antacids	group	291-298	false
MAO inhibitors	group	68-81	absorbent-type anti-diarrhea medicines	group	301-338	false
MAO inhibitors	group	68-81	kaolin	drug	347-352	false
MAO inhibitors	group	68-81	pectin	drug	354-359	false
MAO inhibitors	group	68-81	phenothiazines	group	363-376	false
MAO inhibitors	group	68-81	chlorpromazine	drug	385-398	false
MAO inhibitors	group	68-81	promethazine	drug	401-412	false
phenelzine	drug	90-99	linezolid	drug	102-110	false
phenelzine	drug	90-99	tranylcypromine	drug	113-127	false
phenelzine	drug	90-99	isocarboxazid	drug	130-142	false
phenelzine	drug	90-99	selegiline	drug	145-154	false
phenelzine	drug	90-99	furazolidone	drug	157-168	false
phenelzine	drug	90-99	quinidine	drug	172-180	false
phenelzine	drug	90-99	amantadine	drug	183-192	false
phenelzine	drug	90-99	antihistamines	group	195-208	false
phenelzine	drug	90-99	diphenhydramine	drug	217-231	false
phenelzine	drug	90-99	anticholinergics	group	241-256	false
phenelzine	drug	90-99	potassium chloride	drug	259-276	false
phenelzine	drug	90-99	antacids	group	291-298	false
phenelzine	drug	90-99	absorbent-type anti-diarrhea medicines	group	301-338	false
phenelzine	drug	90-99	kaolin	drug	347-352	false
phenelzine	drug	90-99	pectin	drug	354-359	false
phenelzine	drug	90-99	phenothiazines	group	363-376	false
phenelzine	drug	90-99	chlorpromazine	drug	385-398	false
phenelzine	drug	90-99	promethazine	drug	401-412	false
linezolid	drug	102-110	tranylcypromine	drug	113-127	false
linezolid	drug	102-110	isocarboxazid	drug	130-142	false
linezolid	drug	102-110	selegiline	drug	145-154	false
linezolid	drug	102-110	furazolidone	drug	157-168	false
linezolid	drug	102-110	quinidine	drug	172-180	false
linezolid	drug	102-110	amantadine	drug	183-192	false
linezolid	drug	102-110	antihistamines	group	195-208	false
linezolid	drug	102-110	diphenhydramine	drug	217-231	false
linezolid	drug	102-110	anticholinergics	group	241-256	false
linezolid	drug	102-110	potassium chloride	drug	259-276	false
linezolid	drug	102-110	antacids	group	291-298	false
linezolid	drug	102-110	absorbent-type anti-diarrhea medicines	group	301-338	false
linezolid	drug	102-110	kaolin	drug	347-352	false
linezolid	drug	102-110	pectin	drug	354-359	false
linezolid	drug	102-110	phenothiazines	group	363-376	false
linezolid	drug	102-110	chlorpromazine	drug	385-398	false
linezolid	drug	102-110	promethazine	drug	401-412	false
tranylcypromine	drug	113-127	isocarboxazid	drug	130-142	false
tranylcypromine	drug	113-127	selegiline	drug	145-154	false
tranylcypromine	drug	113-127	furazolidone	drug	157-168	false
tranylcypromine	drug	113-127	quinidine	drug	172-180	false
tranylcypromine	drug	113-127	amantadine	drug	183-192	false
tranylcypromine	drug	113-127	antihistamines	group	195-208	false
tranylcypromine	drug	113-127	diphenhydramine	drug	217-231	false
tranylcypromine	drug	113-127	anticholinergics	group	241-256	false
tranylcypromine	drug	113-127	potassium chloride	drug	259-276	false
tranylcypromine	drug	113-127	antacids	group	291-298	false
tranylcypromine	drug	113-127	absorbent-type anti-diarrhea medicines	group	301-338	false
tranylcypromine	drug	113-127	kaolin	drug	347-352	false
tranylcypromine	drug	113-127	pectin	drug	354-359	false
tranylcypromine	drug	113-127	phenothiazines	group	363-376	false
tranylcypromine	drug	113-127	chlorpromazine	drug	385-398	false
tranylcypromine	drug	113-127	promethazine	drug	401-412	false
isocarboxazid	drug	130-142	selegiline	drug	145-154	false
isocarboxazid	drug	130-142	furazolidone	drug	157-168	false
isocarboxazid	drug	130-142	quinidine	drug	172-180	false
isocarboxazid	drug	130-142	amantadine	drug	183-192	false
isocarboxazid	drug	130-142	antihistamines	group	195-208	false
isocarboxazid	drug	130-142	diphenhydramine	drug	217-231	false
isocarboxazid	drug	130-142	anticholinergics	group	241-256	false
isocarboxazid	drug	130-142	potassium chloride	drug	259-276	false
isocarboxazid	drug	130-142	antacids	group	291-298	false
isocarboxazid	drug	130-142	absorbent-type anti-diarrhea medicines	group	301-338	false
isocarboxazid	drug	130-142	kaolin	drug	347-352	false
isocarboxazid	drug	130-142	pectin	drug	354-359	false
isocarboxazid	drug	130-142	phenothiazines	group	363-376	false
isocarboxazid	drug	130-142	chlorpromazine	drug	385-398	false
isocarboxazid	drug	130-142	promethazine	drug	401-412	false
selegiline	drug	145-154	furazolidone	drug	157-168	false
selegiline	drug	145-154	quinidine	drug	172-180	false
selegiline	drug	145-154	amantadine	drug	183-192	false
selegiline	drug	145-154	antihistamines	group	195-208	false
selegiline	drug	145-154	diphenhydramine	drug	217-231	false
selegiline	drug	145-154	anticholinergics	group	241-256	false
selegiline	drug	145-154	potassium chloride	drug	259-276	false
selegiline	drug	145-154	antacids	group	291-298	false
selegiline	drug	145-154	absorbent-type anti-diarrhea medicines	group	301-338	false
selegiline	drug	145-154	kaolin	drug	347-352	false
selegiline	drug	145-154	pectin	drug	354-359	false
selegiline	drug	145-154	phenothiazines	group	363-376	false
selegiline	drug	145-154	chlorpromazine	drug	385-398	false
selegiline	drug	145-154	promethazine	drug	401-412	false
furazolidone	drug	157-168	quinidine	drug	172-180	false
furazolidone	drug	157-168	amantadine	drug	183-192	false
furazolidone	drug	157-168	antihistamines	group	195-208	false
furazolidone	drug	157-168	diphenhydramine	drug	217-231	false
furazolidone	drug	157-168	anticholinergics	group	241-256	false
furazolidone	drug	157-168	potassium chloride	drug	259-276	false
furazolidone	drug	157-168	antacids	group	291-298	false
furazolidone	drug	157-168	absorbent-type anti-diarrhea medicines	group	301-338	false
furazolidone	drug	157-168	kaolin	drug	347-352	false
furazolidone	drug	157-168	pectin	drug	354-359	false
furazolidone	drug	157-168	phenothiazines	group	363-376	false
furazolidone	drug	157-168	chlorpromazine	drug	385-398	false
furazolidone	drug	157-168	promethazine	drug	401-412	false
quinidine	drug	172-180	amantadine	drug	183-192	false
quinidine	drug	172-180	antihistamines	group	195-208	false
quinidine	drug	172-180	diphenhydramine	drug	217-231	false
quinidine	drug	172-180	anticholinergics	group	241-256	false
quinidine	drug	172-180	potassium chloride	drug	259-276	false
quinidine	drug	172-180	antacids	group	291-298	false
quinidine	drug	172-180	absorbent-type anti-diarrhea medicines	group	301-338	false
quinidine	drug	172-180	kaolin	drug	347-352	false
quinidine	drug	172-180	pectin	drug	354-359	false
quinidine	drug	172-180	phenothiazines	group	363-376	false
quinidine	drug	172-180	chlorpromazine	drug	385-398	false
quinidine	drug	172-180	promethazine	drug	401-412	false
amantadine	drug	183-192	antihistamines	group	195-208	false
amantadine	drug	183-192	diphenhydramine	drug	217-231	false
amantadine	drug	183-192	anticholinergics	group	241-256	false
amantadine	drug	183-192	potassium chloride	drug	259-276	false
amantadine	drug	183-192	antacids	group	291-298	false
amantadine	drug	183-192	absorbent-type anti-diarrhea medicines	group	301-338	false
amantadine	drug	183-192	kaolin	drug	347-352	false
amantadine	drug	183-192	pectin	drug	354-359	false
amantadine	drug	183-192	phenothiazines	group	363-376	false
amantadine	drug	183-192	chlorpromazine	drug	385-398	false
amantadine	drug	183-192	promethazine	drug	401-412	false
antihistamines	group	195-208	diphenhydramine	drug	217-231	false
antihistamines	group	195-208	anticholinergics	group	241-256	false
antihistamines	group	195-208	potassium chloride	drug	259-276	false
antihistamines	group	195-208	antacids	group	291-298	false
antihistamines	group	195-208	absorbent-type anti-diarrhea medicines	group	301-338	false
antihistamines	group	195-208	kaolin	drug	347-352	false
antihistamines	group	195-208	pectin	drug	354-359	false
antihistamines	group	195-208	phenothiazines	group	363-376	false
antihistamines	group	195-208	chlorpromazine	drug	385-398	false
antihistamines	group	195-208	promethazine	drug	401-412	false
diphenhydramine	drug	217-231	anticholinergics	group	241-256	false
diphenhydramine	drug	217-231	potassium chloride	drug	259-276	false
diphenhydramine	drug	217-231	antacids	group	291-298	false
diphenhydramine	drug	217-231	absorbent-type anti-diarrhea medicines	group	301-338	false
diphenhydramine	drug	217-231	kaolin	drug	347-352	false
diphenhydramine	drug	217-231	pectin	drug	354-359	false
diphenhydramine	drug	217-231	phenothiazines	group	363-376	false
diphenhydramine	drug	217-231	chlorpromazine	drug	385-398	false
diphenhydramine	drug	217-231	promethazine	drug	401-412	false
anticholinergics	group	241-256	potassium chloride	drug	259-276	false
anticholinergics	group	241-256	antacids	group	291-298	false
anticholinergics	group	241-256	absorbent-type anti-diarrhea medicines	group	301-338	false
anticholinergics	group	241-256	kaolin	drug	347-352	false
anticholinergics	group	241-256	pectin	drug	354-359	false
anticholinergics	group	241-256	phenothiazines	group	363-376	false
anticholinergics	group	241-256	chlorpromazine	drug	385-398	false
anticholinergics	group	241-256	promethazine	drug	401-412	false
potassium chloride	drug	259-276	antacids	group	291-298	false
potassium chloride	drug	259-276	absorbent-type anti-diarrhea medicines	group	301-338	false
potassium chloride	drug	259-276	kaolin	drug	347-352	false
potassium chloride	drug	259-276	pectin	drug	354-359	false
potassium chloride	drug	259-276	phenothiazines	group	363-376	false
potassium chloride	drug	259-276	chlorpromazine	drug	385-398	false
potassium chloride	drug	259-276	promethazine	drug	401-412	false
antacids	group	291-298	absorbent-type anti-diarrhea medicines	group	301-338	false
antacids	group	291-298	kaolin	drug	347-352	false
antacids	group	291-298	pectin	drug	354-359	false
antacids	group	291-298	phenothiazines	group	363-376	false
antacids	group	291-298	chlorpromazine	drug	385-398	false
antacids	group	291-298	promethazine	drug	401-412	false
absorbent-type anti-diarrhea medicines	group	301-338	kaolin	drug	347-352	false
absorbent-type anti-diarrhea medicines	group	301-338	pectin	drug	354-359	false
absorbent-type anti-diarrhea medicines	group	301-338	phenothiazines	group	363-376	false
absorbent-type anti-diarrhea medicines	group	301-338	chlorpromazine	drug	385-398	false
absorbent-type anti-diarrhea medicines	group	301-338	promethazine	drug	401-412	false
kaolin	drug	347-352	pectin	drug	354-359	false
kaolin	drug	347-352	phenothiazines	group	363-376	false
kaolin	drug	347-352	chlorpromazine	drug	385-398	false
kaolin	drug	347-352	promethazine	drug	401-412	false
pectin	drug	354-359	phenothiazines	group	363-376	false
pectin	drug	354-359	chlorpromazine	drug	385-398	false
pectin	drug	354-359	promethazine	drug	401-412	false
phenothiazines	group	363-376	chlorpromazine	drug	385-398	false
phenothiazines	group	363-376	promethazine	drug	401-412	false
chlorpromazine	drug	385-398	promethazine	drug	401-412	false

DDI-DrugBank.d572.s0	Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%.
Cholestyramine	drug	0-13	cholestyramine	drug	28-41	false
Cholestyramine	drug	0-13	ezetimibe	drug	90-98	false
cholestyramine	drug	28-41	ezetimibe	drug	90-98	mechanism

DDI-DrugBank.d572.s1	The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction.
ezetimibe	drug	46-54	cholestyramine	drug	59-72	effect

DDI-DrugBank.d572.s2	Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established.
Fibrates	group	0-7	ezetimibe	drug	42-50	false
Fibrates	group	0-7	fibrates	group	70-77	false
ezetimibe	drug	42-50	fibrates	group	70-77	false

DDI-DrugBank.d572.s5	Co-administration of ZETIA with fibrates is not recommended until use in patients is studied.
ZETIA	brand	21-25	fibrates	group	32-39	advise

DDI-DrugBank.d572.s6	Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold.
Fenofibrate	drug	0-10	fenofibrate	drug	53-63	false
Fenofibrate	drug	0-10	ezetimibe	drug	96-104	false
fenofibrate	drug	53-63	ezetimibe	drug	96-104	mechanism

DDI-DrugBank.d572.s7	Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold.
Gemfibrozil	drug	0-10	gemfibrozil	drug	53-63	false
Gemfibrozil	drug	0-10	ezetimibe	drug	96-104	false
gemfibrozil	drug	53-63	ezetimibe	drug	96-104	false

DDI-DrugBank.d572.s8	HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.
HMG-CoA reductase inhibitors	group	0-27	ezetimibe	drug	100-108	false
HMG-CoA reductase inhibitors	group	0-27	atorvastatin	drug	135-146	false
HMG-CoA reductase inhibitors	group	0-27	simvastatin	drug	149-159	false
HMG-CoA reductase inhibitors	group	0-27	pravastatin	drug	162-172	false
HMG-CoA reductase inhibitors	group	0-27	lovastatin	drug	175-184	false
HMG-CoA reductase inhibitors	group	0-27	fluvastatin	drug	190-200	false
ezetimibe	drug	100-108	atorvastatin	drug	135-146	false
ezetimibe	drug	100-108	simvastatin	drug	149-159	false
ezetimibe	drug	100-108	pravastatin	drug	162-172	false
ezetimibe	drug	100-108	lovastatin	drug	175-184	false
ezetimibe	drug	100-108	fluvastatin	drug	190-200	false
atorvastatin	drug	135-146	simvastatin	drug	149-159	false
atorvastatin	drug	135-146	pravastatin	drug	162-172	false
atorvastatin	drug	135-146	lovastatin	drug	175-184	false
atorvastatin	drug	135-146	fluvastatin	drug	190-200	false
simvastatin	drug	149-159	pravastatin	drug	162-172	false
simvastatin	drug	149-159	lovastatin	drug	175-184	false
simvastatin	drug	149-159	fluvastatin	drug	190-200	false
pravastatin	drug	162-172	lovastatin	drug	175-184	false
pravastatin	drug	162-172	fluvastatin	drug	190-200	false
lovastatin	drug	175-184	fluvastatin	drug	190-200	false

DDI-DrugBank.d572.s9	Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.
Cyclosporine	drug	0-11	ezetimibe	drug	24-32	false
Cyclosporine	drug	0-11	cyclosporine	drug	132-143	false
ezetimibe	drug	24-32	cyclosporine	drug	132-143	mechanism

DDI-DrugBank.d572.s10	Patients who take both ezetimibe and cyclosporine should be carefully monitored.
ezetimibe	drug	23-31	cyclosporine	drug	37-48	advise

DDI-DrugBank.d572.s11	Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
ezetimibe	drug	99-107	ezetimibe	drug	271-279	false

DDI-DrugBank.d572.s12	A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
ezetimibe	drug	46-54	ezetimibe	drug	187-195	false

DDI-DrugBank.d572.s17	In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
ezetimibe	drug	38-46	ezetimibe	drug	240-248	false

DDI-DrugBank.d572.s22	In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
ezetimibe	drug	24-32	ezetimibe	drug	186-194	false

DDI-DrugBank.d572.s24	Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.
ezetimibe	drug	25-33	HMG-CoA reductase inhibitors	group	61-88	false
ezetimibe	drug	25-33	statins	group	91-97	false
ezetimibe	drug	25-33	ezetimibe	drug	158-166	false
HMG-CoA reductase inhibitors	group	61-88	statins	group	91-97	false
HMG-CoA reductase inhibitors	group	61-88	ezetimibe	drug	158-166	false
statins	group	91-97	ezetimibe	drug	158-166	false

DDI-DrugBank.d572.s27	When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor.
ZETIA	brand	5-9	HMG-CoA reductase inhibitor	group	35-61	false
ZETIA	brand	5-9	HMG-CoA reductase inhibitor	drug	162-188	false
HMG-CoA reductase inhibitor	group	35-61	HMG-CoA reductase inhibitor	drug	162-188	false

